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Early detection of breast cancer combined with targeted therapy offers the best 
outcome for breast cancer patients. The development of low-dose screen-film 
mammography made the early detection of breast cancer a reality. This technology 
was successfully implemented in the population-based screening trials, which proved 
that the early detection of breast cancer through mammography screening can prevent 
at least 40% of the deaths from breast cancer in participating women. Additionally, 
these smaller and less advanced cancers do not need as extensive therapy as the larger, 
palpable cancers.  
The heterogeneity of benign and malignant breast diseases has necessitated the 
development of supplementary imaging methods for their improved detection and 
differential diagnosis. The optimum preoperative diagnosis and mapping of the full 
disease extent has become an important prerequisite for adequate management of the 
disease. This volume deal with a wide range of new technical innovations for 
improving breast cancer detection, diagnosis and therapy. There is a special focus on 
improvements in mammographic image quality, image analysis, magnetic resonance 
imaging of the breast and molecular imaging. A chapter on targeted therapy explores 
the option of less radical postoperative therapy for women with early, screen-detected 
breast cancers. 
Laszlo Tabar, M.D., F.A.C.R. 
Department of Mammography 
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Magnetic Resonance Imaging of the Breast 
Marc Lobbes and Carla Boetes 
Maastricht University Medical Center 
The Netherlands 
1. Introduction 
Magnetic resonance imaging (MRI) of the breast was first performed in the late 1980s. At 
first, differentiation between benign and malignant breast lesions was primarily based on 
their differences in T1 and T2 relaxations times (Rausch et al., 2006). Due to the large overlap 
in T1 and T2 relaxation times in benign and malignant breast lesions, it became apparent 
that contrast administration was mandatory for reliable breast MRI. Heywang et al. 
demonstrated that breast carcinomas showed significant enhancement within 5 minutes 
after contrast administration (Heywang et al., 1989).  
Since then, increasing field strengths, dedicated breast  coil designs, and improvements in 
sequence protocols have led to a large improvement in diagnostic accuracy of breast MRI. 
Currently, the sensitivity of contrast-enhanced MRI for detecting breast cancer reaches 88%, 
with a specificity of 68%. The positive predictive value is reported to be 72%, with a 
negative predictive value of 85% (Bluemke et al., 2004). The reported sensitivity and 
specificity may vary in different publications due to differences in study populations, and 
technical and diagnostic criteria used. Reported sensitivities therefore vary from 83-100%, 
with reported specificities varying from 29-100% (Rausch et al., 2006). 
These numbers are superior to mammography and ultrasound, and are independent of 
factors such as tumor histology, breast density, and hormonal therapy use. They also show 
that breast MRI is highly accurate for detecting breast cancer. However, due to the rather 
limited specificity, false-positive results are frequently observed, requiring additional 
imaging or (MR guided) biopsy, in turn causing patient anxiety and discomfort. 
In this chapter, the technical aspects and proper indications of breast MRI are discussed. In 
addition, a systematic approach to the image interpretation of breast MRI is proposed. 
2. Performing magnetic resonance imaging of the breast 
2.1 Patient handling 
Before performing breast MRI, it is important to instruct the patient thoroughly. It is 
important to inform the patient that lying comfortly and motionless is important for 
succesfull imaging of the breast. They should be instructed that administration of the 
contrast agent can result in various physical sensations, which may cause patient anxiety 
(and motion) when not properly instructed.  
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A dedicated breast coil should be used for breast MRI. These coils usually consist of a 
multichannel coil (nowadays up to 32-channel) with two loops in which the breasts are 
placed while the patient is lying in prone position. The breasts should be placed as deep as 
possible in the coil loops, with the nipples pointing downward if possible. To further reduce 
motion artefacts, the breasts can be gently fixated using cushions. Excessive compression 
should be avoided, as this might influence breast perfusion, and thus contrast enhancement 
pharmacokinetics. 
In premenopausal women, the enhancement of the fibroglandular tissue after contrast 
administration is dependent of the menstrual cycle. MR imaging of the breast in the wrong 
phase of the menstrual cycle can result in strong glandular enhancement, complicating the 
interpretation of the images. Elective breast MRI is ideally performed in the first phase of 
the menstrual cycle, i.e. days 3-14, with day 1 being the first day of menstruation (Delille et 
al., 2005). In patients with proven breast cancer who undergo breast MRI as part of their 
preoperative staging, MRI should be performed at the earliest opportunity. In these cases, 
rapid presurgical patient work-up is preferred over optimal MR image quality.  
2.2 Technical aspects 
2.2.1 Field strengths 
Increasing field strengths are associated with increased signal-to-noise (SNR) ratios. In order 
to acquire sufficient spatial resolution for accurate assessment of lesion morphology, it is 
generally accepted that field strengths of more than 1.5 Tesla are recommended for breast 
MRI (Weinstein et al., 2010). Theoretically, a higher field strength (e.g. 3 Tesla) increases the 
SNR for breast MRI. At a similar temporal resolution, this increased SNR might be used to 
increase spatial resolution, and thus improve lesion morphology evaluation and diagnostic 
accuracy.  
In a proof-of-concept study, Kuhl et al. compared the accuracy of both 1.5 and 3.0 Tesla 
breast MRI in the same patients. Although the study population was small (n=37, total of 53 
breast lesions, both malignant and benign), they demonstrated that the overall image quality 
scores for the dynamic contrast-enhanced series were higher (p<0.01). They also 
demonstrated that at 3.0 Tesla, the differential diagnosis of enhancing lesions was possible 
with a higher diagnostic confidence, as reflected by a larger area under the ROC-curve 
(Kuhl et al., 2006).  
In another proof-of-concept study by Pinker et al., contrast-enhanced breast MRI was 
performed on a 3 Tesla MRI scanner in 34 patients (having 55 breast lesions). Their imaging 
protocol enabled accurate detection and assessment of breast lesions, with a sensitivity of 
100% (95% confidence interval 90.6-100.0%. The specificity was 72.2%, with a 95% 
confidence interval of 49.1-87.5% (Pinker et al., 2009). Although these preliminary results are  
promising, there is no strong evidence to date of the superiority of 3.0 over 1.5 Tesla breast 
MR imaging. 
2.2.2 Imaging planes 
In the past, breast MR imaging was usually performed in a sagittal plane. The advantage of 
this imaging plane was that a relatively small field-of-view could be selected to cover the 
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breast, resulting in an improved spatial resolution. However, simultaneous contralateral 
breast cancer can be detected in 3% of the cases (Lehman et al., 2007), indicating that 
bilateral breast imaging is strongly recommended. Bilateral sagittal imaging of the breast 
can lead to decrease of SNR and spatial resolution (Kuhl, 2007). Therefore, current bilateral 
imaging protocols use the transverse or coronal plane. Coronal imaging of the breast tends 
to give more respiratory motion artifacts. Also, nipple and chest wall involvement is more 
difficult to detect on coronal images. Therefore, the transverse imaging plane is preferred 
when bilateral breast imaging is performed (Kuhl, 2007). 
2.2.3 Spatial and temporal resolution 
Breast MRI needs to be performed with adequate spatial resolution in order to assess lesion 
morphology accurately. It is widely adopted that an optimal breast MRI should have a 
minimum size threshold for detection of lesions of 5 mm. Therefore, a voxel size of at least  
2.5 mm in any direction should be used (Mann et al., 2008). However, higher in-plane spatial 
resolution results in more accurate lesion morphology assessment. Therefore, the minimal 
in-plane spatial resolution as recommended by the American College of Radiology is < 1 
mm (Weinstein et al., 2010).  
2.2.4 Temporal resolution and contrast-enhanced dynamic T1 weighted imaging 
sequences 
Gadolinium (Gd, atom number 64) is a chemical that belongs to the element category of the 
lanthanides. Due to it’s  paramagnetic properties, it is often used as an intravenous contrast 
agent in MRI. However, free Gd-atoms are highly toxic and as a result, gadolinium-based 
contrast agents consist of a chelated Gd-complex to render it non-toxic. Gd-based contrast 
agents lower T1, T2, and T2* relaxation times. Since the decrease is highest for T1 relaxation 
times, contrast-enhanced MR imaging sequences are mostly T1-weighted. 
The contrast agent is administered intravenously with an automated injector to ensure a 
continuous inflow of contrast. Although the optimal dose is unknown, a dose of 0.1-0.2 
mmol per kilogram of body weight and a flow rate of 3 mL/second is generally accepted 
(Kuhl, 2007, Rausch et al., 2006). The administration is followed by a saline flush to ensure 
complete administration of the dose. 
After intravenous administration, the contrast agent leaks through immature (‘leaky’) 
microvessels that were formed by tumor angiogenesis (Carmeliet et al., 2000, Hashizume et 
al., 2000, Jansen et al., 2009). As a result, breast lesions tend to demonstrate a peak 
enhancement between 90-120 seconds. In order to assess the pharmacokinetic enhancement 
curves (see paragraph 4 on ‘Image interpretation’), a minimum of three different time points 
should be included: first, a non-enhanced scan; second, a scan which captures the peak 
enhancement of the lesion, and third, a scan with shows the delayed enhancement 
characteristics of the lesion. In order to capture the peak enhancement of the lesion, 
temporal resolution of the acquisitions performed should be in the order of 60-120 seconds, 
but they should not compromise the in-plane spatial resolution (which must be used for 
lesion morphology). In order to acquire a reliable measurement of the delayed enhancement 
characteristics, it is recommended to continue imaging until approximately 8 minutes after 
contrast administration (Weinstein et al., 2010). 
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2.2.5 T2-weighted imaging sequences 
This sequence is often used as ‘problem solver’ sequence, since it provides additional 
relevant information on different breast lesions, narrowing down the differential diagnostic 
considerations. 
For example, breast cysts (when inflammed) can show rim enhancement after 
administration of contrast agent. In these cases, signal intensity of the cyst is often slightly 
increased on the non-enhanced T1-weighted image due to the proteinacious content of the 
cyst. Due to the high water content and, consequently, the longer T2 relaxation times, cysts 
show a very high signal intensity on T2-weighted images, and can thus be distinguished (in 
combination with their sharp margins) from malignant breast lesions (Figure 1). 
In 1999, Kuhl et al. demonstrated the additional value of T2-weighted imaging in breast MRI 
by examining 205 benign and malignant tumors. By means of visual assessment of the lesion 
appearance on T2-weighted fast spin echo images, they were able to distinguish between 
fibroadenomas and breast cancers, with a respective (age-dependent) sensitivity, specificity, 
positive predictive value, and negative predictive value for patients over 50 years of age of 
89%, 62%, 85%, and 68% (Kuhl et al., 1999a).  
In another recent study, Baltzer et al. evaluated 316 patients, of which 65 showed nonmass 
like enhancement on breast MRI. BI-RADS predictors could not discriminate between 
benign and malignant lesions with respect to nonmass like enhancement. However, the 
signal intensity of T2-weighted images and the presence of cysts improved the diagnostic 
accuracy, with a sensitivity of 91% and a specificity of 65% (Baltzer et al., 2011). 
 
Fig. 1. Example of the added value of T2-weighted breast imaging. (A) shows the primary 
metaplastic tumor in the right breast. At MRI, a suspicious lesion was observed in the 
contralateral breast (B), with a corresponding high signal intensity on T2-weighted imaging 
(C). Second look ultrasound demonstrated a small simple cyst at this site, which was 
subsequently aspirated (D). 
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However, both benign and malignant breast lesions may show increased signal intensity on 
T2-weighted images. In a review of the histopathologic findings in such a group of lesions, 
Santamaria et al. stated that MR signal hyperintensity is most likely to be associated with 
the following conditions: extensive necrosis, (micro)cysts, fatty or sebaceous components, 
mucinous stroma, loose myxoid stroma, edema or hemorrhage (Santamaria et al., 2010). But 
also other benign entities, such as myxoid fibroadenomas, oil cysts, and intramammary 
lymph nodes are known to show an increased signal intensity on these sequences (Kuhl, 
2007). In addition, some malignant lesions might also demonstrate an increased signal 
intensity on T2-weighted images, especially mucinous carcinomas due to their mucinous 
content (Santamaria et al., 2010). 
3. Indications for breast MRI 
Breast MRI can be used for a variety of diagnostic problems. Proper indications for 
performing breast MRI (as supported by the European Society of Breast Cancer Specialists 
and the European Society of Breast Imaging) are: inconclusive findings in conventional 
imaging, preoperative staging, unknown primary cancer, evaluation of therapy response in 
neoadjuvant chemotherapy, imaging of the breast after conservative therapy, screening of 
the high risk patient, breast implant imaging, and MR-guided interventions, such as biopsy 
and lesion localization (Mann et al., 2008, Sardanelli et al., 2010, Yeh, 2010). 
3.1 Inconclusive findings in conventional imaging 
In a study by Berg et al., 177 malignant lesions in 121 breast were evaluated with 
mammography, ultrasound, and MRI. They showed that the sensitivity for detecting tumors 
decreased from 100% in fatty breasts, to only 45% in extremely dense breasts. The sensitivity 
of mammography was highest for invasive ductal carcinoma (89%), versus 55% for ductal 
carcinoma in situ, and only 34% for invasive lobular carcinoma. Ultrasound demonstrated a 
higher sensitivity for both invasive ductal (94%) and invasive lobular carcinoma (86%). 
Sensitivity for detecting ductal carcinoma in situ was worse for ultrasound (47%), 
presumably owing to the fine microcalcifications associated with ductal carcinoma in situ, 
which are much better visualized on mammography. However, MRI was superior to all 
other modalities and for all tumor types: it detected 95% of the cases of invasive ductal 
carcinoma, 96% of the cases of invasive lobular carcinoma, and 89% of the cases of ductal 
carcinoma in situ (Berg et al., 2004). Due to this superior ability to detect breast cancer, MRI 
can be used as a problem-solving modality, when inconclusive findings in conventional 
imaging are encountered. For example, patients can be reffered from the mammography 
screening programm with abnormalities owing to a presumable superposition of 
fibroglandular tissue. These patients can undergo a single breast MRI to exclude possible 
underlying malignancies. Also, if there are discrepancies between clinical examination, 
mammography, and/or ultrasound, MRI can serve as a powerful problem-solving entity. 
This was demonstrated by Moy et al., who retrospectively reviewed all MRI examinations 
(n=115) of the breast that were performed for inconclusive findings at mammography. They 
found no suspicious correlate on MRI in 87% of the cases. In the remaining 15 cases (13%), 6 
malignancies were found. However, 18 incidental lesions were also observed on these 
examinations (Moy et al., 2009). Similar results were observed by Yau et al., who reviewed 
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Fig. 1. Example of the added value of T2-weighted breast imaging. (A) shows the primary 
metaplastic tumor in the right breast. At MRI, a suspicious lesion was observed in the 
contralateral breast (B), with a corresponding high signal intensity on T2-weighted imaging 
(C). Second look ultrasound demonstrated a small simple cyst at this site, which was 
subsequently aspirated (D). 
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However, both benign and malignant breast lesions may show increased signal intensity on 
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3001 MRI exams and found 204 MRI exams that were performed for ‘problem solving’. Of 
these 204 exams, 42 were graded as BI-RADS category 4 or 5 (see also paragraph 4.4).  
Malignant lesions were found in 14 cases, whereas benign findings or follow-up imaging 
encompassed the remaining 28 cases. 162 exams were graded as BI-RADS category 0, 1, 2, or 
3. In this group, biopsy was performed in 28 cases, revealing 1 malignant lesions. In the 
remaining 134 cases, no biopsy was performed within the following 12 months (Yau et al., 
2011). Both studies concluded that MRI is a valuable tool for evaluation of inconclusive 
mammography findings, but patient selection criteria should be strict because of the high 
incidence of incidental lesions seen on MRI. 
3.2 Preoperative staging 
The assessment of tumor size and additional tumor foci is essential for establishing the 
proper surgical and post-surgical treatment of each individual patient.  
Recently, Uetmatsu et al. compared the ability to assess breast cancer extension for 
mammography, ultrasound, breast MRI, and even multidetector row computed 
tomography (MDCT). In this study of 210 breast tumors, they showed that the accuracy for 
establish the tumor extent (compared to histopathological results) was highest for breast 
MRI: 76%. The accuracy of establishing the tumor extent was lower for the other modalities: 
MDCT 71%, ultrasound 56%, and mammography 52%. However, they showed that MRI and 
ultrasound had a substantial risk of overestimating the tumor size. With respect to ductal 
carcinoma in situ extent, their study showed that the accuracy of breast MRI was also 
highest: 89% (followed by MDCT (72%), ultrasound (61%), and mammography (22%)). They 
concluded that breast MRI had the highest accuracy for assessing the true breast cancer 
extent, but emphasize that there is a risk of overestimation, which should be considered in 
pre-surgical planning (Uematsu et al. 2008). In line with these results, the superiority of 
assessing the proper breast tumor extension was also demonstrated by several other studies 
(Mann et al., 2008, 2008b). 
Also, MRI can be helpful for detecting additional tumor foci (Figure 2). In a study of 969 
patients by Lehman et al., simultaneous contralateral breast cancer was detected by breast 
MRI in 3% of the cases (Lehman et al., 2007). 
Tumor multifocality or multicentricity can also be accurately assessed by MRI (Figure 3). For 
instance, this was demonstrated by Drew et al. in their study of 334 women, with 178 
confirmed cancer cases. With preoperative breast MRI, multifocal or multicentric breast 
cancers was suggested in 38% of the cases. In this particular group, histology eventually 
demonstrated multifocality or multicentricity in 74% of the cases. Unifocal breast cancer was 
found in 22% of the cases, benign breast disease in 4%. Their observations resulted in a 
sensitivity of breast MRI for detecting multifocal/multicentric cancer of 100%, with 
corresponding specificity, positive predictive value, and negative predictive value of 86%, 
73%, and 100%, respectively (Drew et al., 1999).  
Although these results seem promising, the effectiveness of performing pre-operative breast 
MRI was not evaluated until recently. In 2010, the COMICE trial, by Turnbull et al., 
randomly assigned a total of 1623 patients to undergo either pre-operative breast MRI 
(n=816) or no breast MRI (n=807). They demonstrated that next to the conventional triple  
 




Fig. 2. Detection of contralateral breast cancer by breast MRI. (A) shows the primary index 
tumor in the right breast, presenting as an irregular mass with rim enhancement. The tumor 
shows a surrounding area of nonmass-like enhancement, with skin enhancement (open 
arrow) and pectoral muscle ingrowth (arrow head). (B) shows an additional small 
enhancing mass in the left breast (arrow), which corresponded with a small hypoechoic 
mass on second look targeted ultrasound (C). Histologic biopsy of this small mass revealed 
invasive ductal carcinoma, similar to the primary mass in the right breast. 
assessment performed in breast cancer, addition of a pre-operative breast MRI did not result 
in a significantly reduced re-operation rate (odds ratio 0.96, 95% confidence interval 0.75-
1.24, p=0.77, Turnbull et al., 2010).  
In another (randomized controlled) trial of 418 patients (the MONET trial), Peters et al. 
allocated 207 patients to preoperative stageing with MRI, and 21 patients to the control 
group (no preoperative MRI). They found that the number of re-excisions performed 
because of positive resection margins after primary breast conserving therapy was increased 
in the MRI group: 34% in the MRI group versus 12% in the control group (p=0.008). The 
number of conversions to mastectomy were similar (Peters et al., 2011). 
 
Fig. 3. Detection of tumor multifocality and/or multicentricity by breast MRI. (A) shows the 
index tumor in the lateral side of the left breast (*), with additional tumor deposits in the 
medial part of the breast (arrows), resulting in a multifocal, multicentric malignancy. (B) 
shows the index tumor in the lateral side of the left breast (*), with an additional tumor 
deposit in the same quadrant (arrow), resulting in a multifocal malignancy. Both cancers 
proved to be invasive ductal carcinomas at biopsy. 
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However, both studies have some limitations. For example, the COMICE trial recruited 
patients from 45 centres, resulting in a large variation of radiologic experience when 
evaluating the breast MRI exams. The MONET trial only evaluated non-palpable breast 
tumors and a subanalysis of their results showed that the volume of the lumpectomy 
specimen was significantly larger in the control group than in the group which was assigned 
to preoperative breast MRI.  
3.3 Unknown primary cancer 
This indication refers to the group of patients who are diagnosed with metastases, but in 
who a primary tumor cannot be identified. Schorn et al. demonstrated that MRI was helpful 
in patients with an unknown primary cancer and a negative mammography and ultrasound 
of the breasts. Breast cancer was detected by MRI in almost 50% of the cases. However, it 
should be mentioned that this study only consisted of 14 patients (Schorn et al. 1999). When 
looking only at axillary lymph node metastasis, Orel et al. demonstrated in a study of 38 
patients that breast MRI could detect the previously unknow breast cancer in even 86% of 
the cases (Orel et al. 1999). Therefore, in patients diagnosed with metastasis and negative 
mammography and ultrasound, breast MRI should be strongly considered. 
3.4 Evaluation of therapy respons in neoadjuvant chemotherapy 
In a study by Yeh et al., 31 women who underwent neoadjuvant therapy for palpable breast 
cancer were included. Agreements with the therapy respons rate as measured by clinical 
examination, mammography, ultrasound, and breast MRI (as compared with pathology 
results) were 19%, 26%, 35%, and 71%, respectively. Of these four modalities, MRI agreed 
with the pathology results significantly more often: p<0.002 for all three comparisons with 
MRI (Yeh et al., 2005).  
 
Fig. 4. Evaluation of tumor respons after neoadjuvant chemotherapy. (A) shows the initial 
(large) tumor (invasive lobular carcinoma at biopsy) in the right breast, presenting as a large 
area of regional nonmass like enhancement. (B) shows significant reduction in tumor size 
and enhancing volume after three gifts of chemotherapy. Thus, adequate chemotherapy 
respons was proven and continued in this patient. 
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In another study, Shin et al. prospectively included 43 patients with locally advanced or 
inflammatory breast cancer who underwent neoadjuvant therapy. The assessment of 
therapy respons was evaluated for clinical examination, mammography, ultrasound, and 
breast MRI. The intraclass correlation coefficients between predicted tumor size (as assessed 
by the different modalities) and the pathologically determined tumor size were calculated. 
The values were highest for breast MRI (0.97), followed by ultrasound (0.78), 
mammography (0.69), and clinical examination (0.65). Agreement between the prediction of 
final therapy respons and the respons assessed by pathology were expressed as the Kappa-
value and were highest for MRI (0.82), followed by ultrasound (0.50), mammography (0.44), 
and clinical examination (0.43, Shin et al., 2010). 
These results show that breast MRI is the most suitable imaging modality to assess 
chemotherapy respons (Figure 4). In addition, it is significantly more accurate in assessing 
the respons than non-imaging techniques, such as clinical examination. 
3.5 Imaging of the breast after conservative therapy 
There are three important reasons to perform breast MRI after breast conserving therapy: 1) 
an evaluation tool for detecting residual disease after positive tumor margins, 2) evaluation 
when recurrence is suspected, and 3) screening for patients that underwent breast 
conservative therapy in the past (Mann et al., 2008).  
Due to the strong enhancement of the breast tissue immediately after surgery (which can 
last for more than a year), the interpretation of breast MR images for residual disease is 
hampered (Orel et al., 1997). Lee et al. concluded that the evaluation of MRI for residual 
disease in patients with close or positive margins is limited due to overlap in the 
appearances of benign and malignant lesions (Lee et al., 2004). Image interpretation can also 
be hampered by post-radiation enhancement of the breast, which is known to occur up to 
three months after the last irradiation of the breast. Nonetheless, Morakkabati et al. 
demonstrated that the detection and characterization of breast lesions can be performed 
with comparible diagnostic accuracies in irradiated breasts (when compared with non-
irradiated breasts, Morakkabati et al., 2003). 
Finally, the risk of local recurrence is dependent on the age of the patient at the time of the 
diagnosis (Mann et al., 2008). Even with additional booster radiation therapy, these patients 
still have a life-time risk of developing breast cancer of probably more than 20%, which is 
equal to the life-time risk for breast MRI screening for the high risk patient, as discussed in 
paragraph 3.6. Therefore, annual MRI screening can be considered for patients that 
underwent breast conservative surgery for primary breast cancer, but large trials are needed 
to confirm this assumption. 
3.6 Screening of the high risk patient 
The first non-randomised studies to determine the additional value of breast MRI to 
conventional mammography in women who were BRCA1 or -2 gene mutation carriers, or 
who had a lifetime risk of at least 20-25% for developing breast cancer were published in the 
1990s. Based on these studies initiated in the Netherlands, the United Kingdom, the United 
States, Canada, Italy, and Germany, the American Cancer Society (ACS) and European 
Society of Breast Imaging (EUSOBI)  recommended annual MR evaluation of the breasts for 
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all women with a lifetime risk for breast cancer of more than 20-25% (Saslow et al., 2007, 
Mann et al., 2008). These women include known BRCA gene mutation carriers, first-degree 
untested relatives of a BRCA gene mutation carrier, women with radiation to the chest wall 
between ages 10 and 30 years, Li-Fraumeni syndrome and first degree relatives, and 
Cowden syndrome with first degree relatives (Boetes, 2010). 
3.7 Breast implant imaging 
Past publications have shown that breast MRI can be an excellent modality to assess breast 
implant integrity. The sensitivity of MRI for detecting implant rupture can be as high as 80 
to 90%, with a specificity of over 90% (Brown et al., 2000, Cher et al., 2001, Hölmich et al., 
2005). However, specific sequences have to be used to optimize the visualisation of silicone 
and to provide concurrent suppression of water signal. Depending on the reason the study 
was requested, these prothesis-specific sequences can replace, or can be added to the 
previously discussed dynamic, contrast-enhanced breast MR imaging protocol. It is the 
authors’ opinion, however, that a more eloborate description on the technical aspects and 
interpretation of images in breast implant imaging is beyond the scope of this chapter. An  
instructive pictorial essay on breast implant rupture was recently published by Colombo et 
al. (Colombo et al., 2011). 
3.8 MR guided interventions 
Despite the high sensitivity of breast MRI, it’s specificity is relatively low. In practice, this 
leads to many false-positive findings, which require additional tissue sampling to exclude 
malignancy. In 2009, an interdisciplinary European committee established a consensus on 
the uses and technique of MR-guided vacuum-assisted breast biopsies (Heywang-
Köbrunner et al., 2009). Although an elaborate discussion on the indications and techniques 
of MR guided breast interventions is beyond the scope of this chapter, the authors wish to 
emphasize some essential recommendations of this consensus meeting 
Before performing any kind of MR guided breast intervention, a full imaging work-up 
should be completed. It must be absolutely certain that the culprit lesion can only be 
visualized by breast MRI. Patients should not have any kind of contra-indication for MRI or 
contrast administration. Relative contra-indications are lesions close to the chest wall who 
are estimated to be unfeasible or unsafe, patients with coagulation disorders, and patients 
with breast implants. When these criteria are met, MR guided biopsy of a breast lesion 
should be performed using a vacuum-assisted breast biopsy system (core needle biopsies 
are not recommended). Minimum probe size should be 11 Gauge, and the average number 
of cores taken should be 24 or more (or an equivalent volume if a larger probe is used). The 
intervention does not stop with acquiring the samples: proper correlation between 
histopathologic results and MR findings should be performed, preferably in a 
multidisciplinary setting. If the correlation is uncertain, re-biopsy or short-term follow-up 
should be considered (Heywang-Köbrunner et al., 2009). 
4. Image interpretation 
According to the Breast Imaging Reporting and Data System (BI-RADS), the interpretation 
of breast MR images should start with the analysis of the type of enhancement observed. 
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Three categories of enhancement can be observed: focal, mass-, and nonmass-like 
enhancement (Figure 5, Molleran et al., 2010).  
Subsequently, shapes and margins of the lesions should be assessed in the case of masslike 
enhancement. In the case of nonmass-like enhancement, it should be assessed whether this 
enhancement pattern is linear,  ductal, regional, or segmental. In addition, the reader should 
assess if the nonmass-like enhancement is clumped, in other words beaded or 
cobblestonelike.  
 
Fig. 5. Examples of focus (A), mass (B), and segmental (clumped) nonmass-like 
enhancement (C). 
Finally, the enhancement characteristics of the lesion should be assessed by looking at both 
the internal enhancement characteristics and the signal intensity time curves. Internal 
enhancement characteristics can be described as homogeneous, heterogeneous, rim 
enhancement, or dark internal septations (American College of Radiology, 2003). Lesions 
can demonstrate slow, intermediate, or rapid contrast enhancement in the initial 
enhancement phase. In general, this initial enhancement phase can be followed by three 
different types of enhancement curves in the delayed phase: persistent enhancement, 
plateau phase, or wash-out. The enhancement characteristics of lesions can be indicative for 
their benign or malignant character. 
By combining the findings of these different analyses, the radiologist estimates the 
likelihood of a lesion being benign or malignant. This estimation can be expressed in the 
final conclusion of the report as the BI-RADS classification, and should be the basis for 
management recommendations (i.e. biopsy or follow-up). 
4.1 Focal, mass-, and nonmass-like enhancement 
Focal enhancement can be described as small (less than 5 mm) area of enhancement that 
cannot be specified otherwise. A mass is a lesion that is visible in three dimensions and 
which occupies a space. Masses can be round, oval, lobulated, or irregular, and may have 
smooth, irregular, or spiculated margins. Nonmass-like enhancement is an area of 
enhancement that does not belong to a three dimensional mass or that has no distinct mass 
characteristics (American College of Radiology, 2003, Erguvan-Dogan et al., 2006). 
Nonmass-like enhancement patterns can be divided in linear, ductal, segmental, and 
regional enhancement (Figures 5 and 6). 
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and to provide concurrent suppression of water signal. Depending on the reason the study 
was requested, these prothesis-specific sequences can replace, or can be added to the 
previously discussed dynamic, contrast-enhanced breast MR imaging protocol. It is the 
authors’ opinion, however, that a more eloborate description on the technical aspects and 
interpretation of images in breast implant imaging is beyond the scope of this chapter. An  
instructive pictorial essay on breast implant rupture was recently published by Colombo et 
al. (Colombo et al., 2011). 
3.8 MR guided interventions 
Despite the high sensitivity of breast MRI, it’s specificity is relatively low. In practice, this 
leads to many false-positive findings, which require additional tissue sampling to exclude 
malignancy. In 2009, an interdisciplinary European committee established a consensus on 
the uses and technique of MR-guided vacuum-assisted breast biopsies (Heywang-
Köbrunner et al., 2009). Although an elaborate discussion on the indications and techniques 
of MR guided breast interventions is beyond the scope of this chapter, the authors wish to 
emphasize some essential recommendations of this consensus meeting 
Before performing any kind of MR guided breast intervention, a full imaging work-up 
should be completed. It must be absolutely certain that the culprit lesion can only be 
visualized by breast MRI. Patients should not have any kind of contra-indication for MRI or 
contrast administration. Relative contra-indications are lesions close to the chest wall who 
are estimated to be unfeasible or unsafe, patients with coagulation disorders, and patients 
with breast implants. When these criteria are met, MR guided biopsy of a breast lesion 
should be performed using a vacuum-assisted breast biopsy system (core needle biopsies 
are not recommended). Minimum probe size should be 11 Gauge, and the average number 
of cores taken should be 24 or more (or an equivalent volume if a larger probe is used). The 
intervention does not stop with acquiring the samples: proper correlation between 
histopathologic results and MR findings should be performed, preferably in a 
multidisciplinary setting. If the correlation is uncertain, re-biopsy or short-term follow-up 
should be considered (Heywang-Köbrunner et al., 2009). 
4. Image interpretation 
According to the Breast Imaging Reporting and Data System (BI-RADS), the interpretation 
of breast MR images should start with the analysis of the type of enhancement observed. 
 
Magnetic Resonance Imaging of the Breast 
 
13 
Three categories of enhancement can be observed: focal, mass-, and nonmass-like 
enhancement (Figure 5, Molleran et al., 2010).  
Subsequently, shapes and margins of the lesions should be assessed in the case of masslike 
enhancement. In the case of nonmass-like enhancement, it should be assessed whether this 
enhancement pattern is linear,  ductal, regional, or segmental. In addition, the reader should 
assess if the nonmass-like enhancement is clumped, in other words beaded or 
cobblestonelike.  
 
Fig. 5. Examples of focus (A), mass (B), and segmental (clumped) nonmass-like 
enhancement (C). 
Finally, the enhancement characteristics of the lesion should be assessed by looking at both 
the internal enhancement characteristics and the signal intensity time curves. Internal 
enhancement characteristics can be described as homogeneous, heterogeneous, rim 
enhancement, or dark internal septations (American College of Radiology, 2003). Lesions 
can demonstrate slow, intermediate, or rapid contrast enhancement in the initial 
enhancement phase. In general, this initial enhancement phase can be followed by three 
different types of enhancement curves in the delayed phase: persistent enhancement, 
plateau phase, or wash-out. The enhancement characteristics of lesions can be indicative for 
their benign or malignant character. 
By combining the findings of these different analyses, the radiologist estimates the 
likelihood of a lesion being benign or malignant. This estimation can be expressed in the 
final conclusion of the report as the BI-RADS classification, and should be the basis for 
management recommendations (i.e. biopsy or follow-up). 
4.1 Focal, mass-, and nonmass-like enhancement 
Focal enhancement can be described as small (less than 5 mm) area of enhancement that 
cannot be specified otherwise. A mass is a lesion that is visible in three dimensions and 
which occupies a space. Masses can be round, oval, lobulated, or irregular, and may have 
smooth, irregular, or spiculated margins. Nonmass-like enhancement is an area of 
enhancement that does not belong to a three dimensional mass or that has no distinct mass 
characteristics (American College of Radiology, 2003, Erguvan-Dogan et al., 2006). 
Nonmass-like enhancement patterns can be divided in linear, ductal, segmental, and 
regional enhancement (Figures 5 and 6). 
 




Fig. 6. Proper terminology (according to the BI-RADS lexicon) for enhancement patterns, 
shapes, margins, and nonmass-like enhancement distributions. 
Linear nonmass-like enhancement is defined according to the BI-RADS lexicon of the 
American College of Radiology as ‘enhancement in a line that is not definitely in a duct’. 
Ductal enhancement can be defined as ‘enhancement in a line that points towards the 
nipple, and may have branching, conforming to a duct’. Segmental enhancement can be 
defined as ‘a triangular region or cone of enhancement, with the apex pointing towards the 
nipple’. Finally, regional enhancement can be defined as ‘enhancement in a large volume of 
tissue  not conforming to a ductal distribution’ (American College of Radiology, 2003). 
Jansen et al. recently investigated the pathology and kinetics of mass, nonmass, and focal 
enhancement in a retrospective study using dynamic contrast-enhanced breast MRI. They 
analyzed a total of 852 breast lesions (histologically proven) in 697 patients. Of the lesions 
demonstrating mass-like enhancement (n=552), 71.7% proved to be malignant. Of the lesions 
demonstrating nonmass-like enhancement (n=261), 81.2% proved to be malignant. The 
remaining lesions demonstrated focal enhancement (n=30), which were usually benign 
(76.9%). Malignant mass- and nonmass-like enhancing lesions differed significantly in their 
pathology (p<0.0001), with mass-like enhancing lesions usually consisting of invasive ductal 
carcinoma and nonmass-like enhancement usually consisting of ductal carcinoma in situ. 
Similarly, benign mass- and nonmass-like enhancing lesions differed significantly in their 
pathology (p<0.002), with the former usually consisting of fibroadenomas and the latter 
usually presenting fibrocystic changes. Finally, the predominant pathology of focal 
enhancing lesions was fibrocystic changes (Jansen et al., 2011). 
4.2 Morphologic descriptors in masslike- and nonmass-like enhancement 
Margins of masses can be described as smooth (or sharp), irregular, or spiculated. Similar 
to mammography, some morphologic features of a lesion are more associated with 
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malignancy than others (Liberman et al., 1998). Past studies showed that spiculated 
margins,  irregular shapes, and linear/ductal nonmass-like enhancement had the highest 
positive predictive values for malignancy (Nunes et al., 1997, 2001). However, these 
studies included patients with mammographic or palpable findings, creating a potential 
bias in the study population. 
Therefore, Liberman et al. performed a retrospective review of 100 consecutive solitary MR 
imaging-detected lesions. For mass-like enhancement, margins and shape were evaluated. 
With respect to lesion margins, spiculated margins had the highest positive predictive value 
for malignancy (80%), much higher than irregular (22%) and smooth (17%) margins. With 
respect to lesion shapes, irregular shapes had the highest positive predictive value for 
malignancy (32%), lobular shapes had a positive predictive value for malignancy of only 
13% (Liberman et al., 2002).  
In the same study, the pattern of nonmass-like enhancement was evaluated. With respect to 
linear or ductal enhancement, clumped enhancement (or beadlike enhancement) had a 
positive predictive value for malignancy of 31%. Smooth linear enhancement was not 
observed in malignant lesions. Clumped regional enhancement had a positive predictive 
value of 67%, whereas clumped segmental enhancement had a positive predictive value of 
67% too (Liberman et al., 2002). 
In addition, Siegmann et al. looked at lesion size as a additional descriptor for the 
assessment of malignancy. They showed in a study of 51 lesions (in 45 patients) that lesions 
with a diameter of more than 10 mm have a higher positive predictive value (45.5%) than 
lesions smaller than 10 mm (27.6%, Siegmann et al., 2002).  
To summarize, features that have the highest positive predictive value for malignancy are 
spiculated (ill-defined) margins and irregular shapes (based on morphology alone and in the 
case of masslike enhancement). For nonmass-like enhancement, features that have the 
highest positive predicitive value are clumped linear, segmental or regional enhancement. 
Lesions larger than 10 mm have a higher positive predictive value for being malignant than 
lesions < 10 mm (Tse et al., 2007). 
4.3 Kinetic analysis of the signal intensity time curves 
Lesion enhancement is described as homogeneous, heterogeneous, rim enhancement, or 
enhancement with dark internal septations (American College of Radiology, 2003, Figure 7).  
In a landmark paper by Kuhl et al., the value of signal intensity time curves was evaluated 
with respect to the differential diagnosis of enhancing breast lesions. A total of 266 breast 
lesions (101 malignant, 165 benign) were examined using a dynamic contrast-enhanced 
breast imaging protocol. The relative enhancement of breast lesions was assessed by 
drawing a region-of-interest in the lesion itself. The enhancement was then calculated 
according to the following formula: 
 Relative signal enhancement (%) = (SIpost – SIpre) / SIpre x 100  
In this formula, SIpre and SIpost represent pre-contrast and post-contrast signal intensities, 
respectively. By calculating the signal intensity time curves, it was demonstrated that 
enhancement patterns can be divided into two phases: early enhancement (from contrast 
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malignancy than others (Liberman et al., 1998). Past studies showed that spiculated 
margins,  irregular shapes, and linear/ductal nonmass-like enhancement had the highest 
positive predictive values for malignancy (Nunes et al., 1997, 2001). However, these 
studies included patients with mammographic or palpable findings, creating a potential 
bias in the study population. 
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imaging-detected lesions. For mass-like enhancement, margins and shape were evaluated. 
With respect to lesion margins, spiculated margins had the highest positive predictive value 
for malignancy (80%), much higher than irregular (22%) and smooth (17%) margins. With 
respect to lesion shapes, irregular shapes had the highest positive predictive value for 
malignancy (32%), lobular shapes had a positive predictive value for malignancy of only 
13% (Liberman et al., 2002).  
In the same study, the pattern of nonmass-like enhancement was evaluated. With respect to 
linear or ductal enhancement, clumped enhancement (or beadlike enhancement) had a 
positive predictive value for malignancy of 31%. Smooth linear enhancement was not 
observed in malignant lesions. Clumped regional enhancement had a positive predictive 
value of 67%, whereas clumped segmental enhancement had a positive predictive value of 
67% too (Liberman et al., 2002). 
In addition, Siegmann et al. looked at lesion size as a additional descriptor for the 
assessment of malignancy. They showed in a study of 51 lesions (in 45 patients) that lesions 
with a diameter of more than 10 mm have a higher positive predictive value (45.5%) than 
lesions smaller than 10 mm (27.6%, Siegmann et al., 2002).  
To summarize, features that have the highest positive predictive value for malignancy are 
spiculated (ill-defined) margins and irregular shapes (based on morphology alone and in the 
case of masslike enhancement). For nonmass-like enhancement, features that have the 
highest positive predicitive value are clumped linear, segmental or regional enhancement. 
Lesions larger than 10 mm have a higher positive predictive value for being malignant than 
lesions < 10 mm (Tse et al., 2007). 
4.3 Kinetic analysis of the signal intensity time curves 
Lesion enhancement is described as homogeneous, heterogeneous, rim enhancement, or 
enhancement with dark internal septations (American College of Radiology, 2003, Figure 7).  
In a landmark paper by Kuhl et al., the value of signal intensity time curves was evaluated 
with respect to the differential diagnosis of enhancing breast lesions. A total of 266 breast 
lesions (101 malignant, 165 benign) were examined using a dynamic contrast-enhanced 
breast imaging protocol. The relative enhancement of breast lesions was assessed by 
drawing a region-of-interest in the lesion itself. The enhancement was then calculated 
according to the following formula: 
 Relative signal enhancement (%) = (SIpost – SIpre) / SIpre x 100  
In this formula, SIpre and SIpost represent pre-contrast and post-contrast signal intensities, 
respectively. By calculating the signal intensity time curves, it was demonstrated that 
enhancement patterns can be divided into two phases: early enhancement (from contrast 
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administration to approximately two minutes post-contrast, or when the curve starts to 
change), followed by the delayed enhancement. 
 
Fig. 7. Proper terminology (according to the BI-RADS lexicon for lesions enhancement 
patterns) homogeneous, heterogeneous, rim enhancement, and enhancement with dark 
internal septa. 
For the early enhancement phase, it was assumed that benign lesions had a (slow) 
enhancement of 60% or less. Indeterminate lesions were assumed to have an (intermediate) 
enhancement of more than 60%, but less than 80%. Finally, malignant lesions were assumed 
to have a (strong) enhancement of more than 80%. For these assumptions, the diagnostic 
accuracies in this study were: sensitivity 91%, specificity 37%, positive predictive value 47%, 
negative predictive value 87%, diagnostic accuracy 58%. Mean peak enhancement was 
significantly higher for malignant lesions than for benign lesions: mean enhancement 104% 
versus 72%, p<0.001 (Kuhl et al., 1999b). 
For the delayed phase, three different type of signal intensity curves were defined. A type I 
curve was characterized by a persistent increase in signal intensity over time. A type II 
curve was characterized by a plateau in signal intensity values over time. Finally, a type III 
curve was characterized by a so-called washout, i.e. the signal intensity decreases in time 
after the initial upslope in the early enhancement phase (Figure 8). 
For benign lesions, a type I curve was observed in 83.0% of the cases. A type II curve was 
observed in 11.5% of the cases, whereas a type III curve was hardly seen in benign lesions: 
5.5% of the cases. For malignant lesions, a type III curve was most frequently observed: 
57.4% of the cases. A type II curve was observed in 33.6% of the cases, whereas a type I 
curve was infrequently seen in these cases: 8.9%. The assessment of the signal intensity time 
curves had an excellent interreader agreement with a Kappa-value of 0.849, p<0.001 (Kuhl et 
al., 1999b).  
 




Fig. 8. Possible enhancement characteristics that can be observed in dynamic contrast-
enhanced breast MRI.  
In the past, Jansen et al. demonstrated that analysis of the signal intensity time curve can 
help distinguish between benign and malignant mass lesions effectively, but the analysis is 
not that useful in discriminating between benign and malignant nonmass-like lesions. 
Although their pilotstudy only consisted of a total of 108 breast lesions with 70 observed 
masses, 44 of which were malignant and 26 benign. There were 38 nonmass-like lesions 
observed, of which 31 were malignant and 7 benign. Despite these relatively small numbers, 
they showed that analysis of the signal intensity time curve was helpful in distinguishing 
between benign and malignant masses on MRI. However, it could not be used to accurately 
distinguish between benign and malignant nonmass-like lesions. Therefore, they suggested 
that analysis of the signal intensity time curves of nonmass-like enhancement is not very 
useful and that morphology analysis should be favored (Jansen et al., 2008).  
In summary, it is advised by the BI-RADS MRI lexicon that the signal intensity curve of a 
lesion should be described qualitatively. A proper region-of-interest should at least contain 
3 pixels and if this enhancement of the lesion is heterogeneous, the most suspicious 
enhancement curve should be mentioned in the final report. Initial enhancement can be 
slow, moderate, or rapid, while the delayed enhancement can show a persistent, plateau, or 
wash-out curve (American College of Radiology, 2003). A strong early enhancement is 
suggestive of malignancy, whereas a slow signal intensity increase is suggestive of a benign 
entity. More importantly, type I signal intensity curves are suggestive of benign breast 
lesions, whereas type III curves are suggestive of malignancy. The indeterminate type II 
curve scan be observed in both benign and malignant breast lesions, albeit slightly more 
suggestive of malignancy (in a ratio of 2:3, Kuhl et al., 1999b). 
It should be emphasized that kinetic analysis of contrast enhancement is no substitute for 
morphology analysis. It should be used as an aid in further narrowing the differential 
diagnosis. With this respect, several recommendations can be made: 
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suggestive of malignancy, whereas a slow signal intensity increase is suggestive of a benign 
entity. More importantly, type I signal intensity curves are suggestive of benign breast 
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First, it is recommended to perform the kinetic analysis after morphologic analysis of a 
lesion. When the morphology is highly suggestive of malignancy, kinetic analysis should be 
skipped, and the lesion should be biopsied. Kinetic analysis should be performed in lesions 
with indeterminate or benign morphologies. 
Second, lesions with a type III enhancement curve should always be biopsied, even if 
morphology is suggestive of a benign lesion. In contrast, the absence of a clear wash-out 
phase in the signal intensity time curve cannot rule out malignancy. 
Third, when lesion morphology is indeterminate and a type I curve is observed, follow-up 
of the lesion might be considered to reduce false-positive biopsy findings. 
4.4 What the clinicians need to know: report organization 
The pre-surgical planning and post-surgical treatment is dependent not only on tumor type, 
but also on it’s corresponding TNM-classification. The most recent TNM-classification, 
edition 7, was recently published in 2010. (Edge et al., 2010). For a proper TNM-
classification, several issues need to be adressed in the final report of any breast MRI. 
For a proper T-classification of breast cancer, the maximum diameter of the culprit mass 
should be mentioned in the report, including any suspicious nonmass-like enhancement 
that can be associated with an extensive intraductal component. In addition, the relationship 
of the tumor to the skin, pectoral muscle and thoracic wall must be accurately described. 
Enhancement of the pectoral muscle or skin is one of the most reliable signs for the 
assesment of tumor invasion in these structures. Although inflammatory breast cancer is 
clinical diagnosis, it can be suggested in MRI when strong enhancement of the breast is 
observed, together with diffuse skin thickening and enhancement. 
Many authors have tried to developed accurate criteria for the assessment of axillary lymph 
node status on MRI. In a study of 65 patients, Kvistad et al. demonstrated a significant 
correlation between flow kinetics and axillary lymph node status (Kvistad et al., 2000). 
Murray et al. demonstrated a correlation between nodal enhancement and nodal area and 
axillary lymph node status in a study encompassing 47 patients (Murray et al., 2002). More 
recently, Mortellaro et al. stated in their study of 56 patients that the presence of any axillary 
lymph node without a fatty hilum and the number of nodes without a fatty hilum correlated 
significantly with axillary lymph node positivity for metastases (Mortellaro et al., 2009). In 
summary, study results on MRI of axillary lymph node status vary in study design, study 
population, and outcome. Until now, there are no reliable criteria for the evaluation of 
axillary lymph node positivity. However, it is the authors’ opinion that analysis of the 
axillae is an important part of the total breast MRI evaluation. Patients with suspicious 
axillary lymph nodes on MRI should be considered for (re)evaluation with (second look) 
ultrasound. 
With respect to a proper M-classification, it should be emphasized that other imaging 
modalities, such as (PET-)CT, need to be performed. However, extramammary findings on 
breast MRI should be noted and reported. In a retrospective review of 1535 breast MRI 
examinations, Rinaldi et al. observed 285 patients with extramammary (incidental) findings. 
Most incidental findings occured in the liver (51.9%). Other sites were lung (11.2%), bone 
(7%), and mediastinum (4.2%). Pleural or pericardial effusions were observed in 15.4% of 
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the cases. Of all these incidental findings, 20.4% proved to be malignant (Rinaldi et al. 2011). 
Therefore, the occurence of extramammary findings is a non-negligible phenomenon. 
Finally, the radiologst should construct a comprehensible report of all findings observed on 
breast MRI. By analyzing morphology, enhancement, and signal intensity time curves, the 
probability of malignancy should be estimated. The maximum diameter of suspicious 
lesions should be provided, together with their location within the breast and their 
relationship with the skin, pectoral muscle, or thoracic wall. Together with an assessment of 
the axillary lymph node morphology and incidental extra-mammary findings, the 
radiologist should finish the report with the appropriate BI-RADS classification and possible  
management recommendations (Americal College of Radiology, 2003): 
BI-RADS 1:  Additional imaging is needed (i.e. failure of equipment, severe artefacts) 
 
BI-RADS 1: Normal, there is nothing to comment on 
 
BI-RADS 2: Benign findings 
 
BI-RADS 3: Probably benign findings; the probability of malignancy is less than 2%. 
  Short-term follow-up is recommended 
 
BI-RADS 4: Suspicious findings; the probability of malignancy is 2-95%. Biopsy should 
  be considered 
 
BI-RADS 5: Highly suggestive of malignancy; the probability of malignancy is higher 
  than 95%. Appropriate action should be taken 
 
BI-RADS 6: Proven malignancy (through histopathologic results) 
In conclusion, dynamic, contrast-enhanced breast MRI can be a powerful adjuvant imaging 
modality for the detection of breast cancer. It can be of help when inconclusive findings are 
encountered on conventional imaging or in the case of an unknown primary cancer. The 
evaluation of neoadjuvant chemotherapy respons can be evaluated with breast MRI, and it can 
aid in the assessment of the postoperative breast. Breast MRI is advised in screening certain 
populations with high risk of developing breast cancer, breast implants can be accurately 
analyzed with MRI, and it can aid in MR guided breast interventions. One of the most 
important indications of breast MRI is preoperative planning, and it’s superiority compared to 
other breast imaging modalities to evaluate disease extent, multifocality or multicentricity, and 
the presence of (occult) contralateral malignancy. However, due to it’s limited specificity, false-
positive findings are frequently observed. Therefore, patient selection should be performed 
with care and the proper indications for breast MRI should be observed. 
This chapter is dedicated to professor Carla Boetes (1949-2011). 
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First, it is recommended to perform the kinetic analysis after morphologic analysis of a 
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ultrasound. 
With respect to a proper M-classification, it should be emphasized that other imaging 
modalities, such as (PET-)CT, need to be performed. However, extramammary findings on 
breast MRI should be noted and reported. In a retrospective review of 1535 breast MRI 
examinations, Rinaldi et al. observed 285 patients with extramammary (incidental) findings. 
Most incidental findings occured in the liver (51.9%). Other sites were lung (11.2%), bone 
(7%), and mediastinum (4.2%). Pleural or pericardial effusions were observed in 15.4% of 
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the cases. Of all these incidental findings, 20.4% proved to be malignant (Rinaldi et al. 2011). 
Therefore, the occurence of extramammary findings is a non-negligible phenomenon. 
Finally, the radiologst should construct a comprehensible report of all findings observed on 
breast MRI. By analyzing morphology, enhancement, and signal intensity time curves, the 
probability of malignancy should be estimated. The maximum diameter of suspicious 
lesions should be provided, together with their location within the breast and their 
relationship with the skin, pectoral muscle, or thoracic wall. Together with an assessment of 
the axillary lymph node morphology and incidental extra-mammary findings, the 
radiologist should finish the report with the appropriate BI-RADS classification and possible  
management recommendations (Americal College of Radiology, 2003): 
BI-RADS 1:  Additional imaging is needed (i.e. failure of equipment, severe artefacts) 
 
BI-RADS 1: Normal, there is nothing to comment on 
 
BI-RADS 2: Benign findings 
 
BI-RADS 3: Probably benign findings; the probability of malignancy is less than 2%. 
  Short-term follow-up is recommended 
 
BI-RADS 4: Suspicious findings; the probability of malignancy is 2-95%. Biopsy should 
  be considered 
 
BI-RADS 5: Highly suggestive of malignancy; the probability of malignancy is higher 
  than 95%. Appropriate action should be taken 
 
BI-RADS 6: Proven malignancy (through histopathologic results) 
In conclusion, dynamic, contrast-enhanced breast MRI can be a powerful adjuvant imaging 
modality for the detection of breast cancer. It can be of help when inconclusive findings are 
encountered on conventional imaging or in the case of an unknown primary cancer. The 
evaluation of neoadjuvant chemotherapy respons can be evaluated with breast MRI, and it can 
aid in the assessment of the postoperative breast. Breast MRI is advised in screening certain 
populations with high risk of developing breast cancer, breast implants can be accurately 
analyzed with MRI, and it can aid in MR guided breast interventions. One of the most 
important indications of breast MRI is preoperative planning, and it’s superiority compared to 
other breast imaging modalities to evaluate disease extent, multifocality or multicentricity, and 
the presence of (occult) contralateral malignancy. However, due to it’s limited specificity, false-
positive findings are frequently observed. Therefore, patient selection should be performed 
with care and the proper indications for breast MRI should be observed. 
This chapter is dedicated to professor Carla Boetes (1949-2011). 
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1. Introduction 
1.1 Increase incidence of breast cancer in Taiwan and Asia 
Although the incidence of breast cancer is lower in Asian countries, the cause-specific 
mortality in most Asian countries is much higher as compared to western countries 
(Agarwal et al., 2007; Shibuya et al., 2002). Although the overall picture of breast cancer is 
variable among different Asian countries and in different ethnic groups within individual 
countries, breast cancer has emerged as the largest cancer problem in Asian women. Breast 
cancer is also the largest cause of cancer-related deaths. It remains the second commonest 
malignancy in women in the rural areas of developing Asian countries (Agarwal et al., 
2007). Breast cancer is gradually become one of the major public health problem and the 
most important issue to concern in order to decrease cancer mortality. 
Base on the data from the Bureau of Health Promotion, Department of Health, Executive 
Yuan, Taiwan, indicate that the incidence of breast cancer in Taiwan increased from 27.9 to 
49.2 per 100,000 women in the decade from 1995 to 2005, which is an annual increase of 
approximately 7%. As the decrease incidence of cervical cancer in the meanwhile, breast 
cancer is already the highest new number of malignancy diagnosis in Taiwan. Moreover, 
according to the data released from the World Health Organization, an incidence of 
Taiwanese breast cancer is reported as 52.8 per 100,000 women in 2008, which is the second 
place in Asia, only slightly lower than that seen in Singapore. 
2. Characteristics and difficulty of early detection of breast tumor in Asian 
women 
There are higher proportions of breast cancer patients in developing Asian countries are 
younger than patients in developed Asian and western countries (Agarwal et al., 2007; Amr 
et al., 1995). Given the huge population in the developing Asian nations, and the fact that up 
to 25% of all breast cancer patients in Asian countries are young, and also, young age by 
itself is a known indicator of poor prognosis in breast cancer patients (Agarwal et al., 2007; 
Amr et al., 1995). The first nation-wide mammographic screening program in Asia was 
started in Singapore during 2002 (Chuwa et al., 2009). By 2009, there is still no significant 
survival benefit could be demonstrated in the country, in the meanwhile, rapid increase of 
breast cancer incidence was reported. Singapore government choose for longer period of 
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1. Introduction 
1.1 Increase incidence of breast cancer in Taiwan and Asia 
Although the incidence of breast cancer is lower in Asian countries, the cause-specific 
mortality in most Asian countries is much higher as compared to western countries 
(Agarwal et al., 2007; Shibuya et al., 2002). Although the overall picture of breast cancer is 
variable among different Asian countries and in different ethnic groups within individual 
countries, breast cancer has emerged as the largest cancer problem in Asian women. Breast 
cancer is also the largest cause of cancer-related deaths. It remains the second commonest 
malignancy in women in the rural areas of developing Asian countries (Agarwal et al., 
2007). Breast cancer is gradually become one of the major public health problem and the 
most important issue to concern in order to decrease cancer mortality. 
Base on the data from the Bureau of Health Promotion, Department of Health, Executive 
Yuan, Taiwan, indicate that the incidence of breast cancer in Taiwan increased from 27.9 to 
49.2 per 100,000 women in the decade from 1995 to 2005, which is an annual increase of 
approximately 7%. As the decrease incidence of cervical cancer in the meanwhile, breast 
cancer is already the highest new number of malignancy diagnosis in Taiwan. Moreover, 
according to the data released from the World Health Organization, an incidence of 
Taiwanese breast cancer is reported as 52.8 per 100,000 women in 2008, which is the second 
place in Asia, only slightly lower than that seen in Singapore. 
2. Characteristics and difficulty of early detection of breast tumor in Asian 
women 
There are higher proportions of breast cancer patients in developing Asian countries are 
younger than patients in developed Asian and western countries (Agarwal et al., 2007; Amr 
et al., 1995). Given the huge population in the developing Asian nations, and the fact that up 
to 25% of all breast cancer patients in Asian countries are young, and also, young age by 
itself is a known indicator of poor prognosis in breast cancer patients (Agarwal et al., 2007; 
Amr et al., 1995). The first nation-wide mammographic screening program in Asia was 
started in Singapore during 2002 (Chuwa et al., 2009). By 2009, there is still no significant 
survival benefit could be demonstrated in the country, in the meanwhile, rapid increase of 
breast cancer incidence was reported. Singapore government choose for longer period of 
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follow-up, expect for the benefit of mortality reduction in the population resulted from their 
mass mammography screening program (Chuwa et al., 2009). As we know, many 
therapeutic options for early detected breast cancer with small tumor size, the success rate of 
therapy for early stage cancer is higher than advanced stage disease. 
In Taiwan, a national project of 2-year interval screening mammograms for 45- to 70-year-
old women has detected significantly more early breast cancers (Chen et al., 2008). 
However, the major source of breast cancer detection is not arise from this screening 
program. The overall average detection size of breast cancer tumors in Taiwan is over 2 cm, 
which is larger than that detectable with the diagnostic capabilities in Europe and North 
America (Ng et al., 1998; Shen et al., 2005). The median age at diagnosis of breast cancer is 
45–49 years in Taiwan, and this age group is more likely to present with a dense breast 
parenchyma pattern (DBPP). This median age is significantly lower than that of Caucasian 
women in Western countries, where breast cancer peaks between the ages of 70 and 74 
years, and this older age group is more likely to present with a non-dense parenchyma 
pattern (NDBPP) (Huang et al., 2001; Shen et al., 2005). Breast cancer in this age group is 
reportedly more aggressive (Kwong et al., 2008). This pathological pattern is also commonly 
seen in our clinical practice in Taiwan (Leung et al., 2010b). Previous study have 
demonstrated that the prevalence of NDBPP (ACR types 1 and 2; ACR: American College of 
Radiology classification of breast parenchymal density in digital mammography) could be 
as high as 78%, compared with 22% for DBPP (ACR types 3 and 4), which is representative 
of most Western countries (Table 1) (Van Gils et al., 1999). The ratio of NDBPP to DBPP is 
reversed compared with their previous results. Although the case number is small, we 
believe that the results are representative of developed Asian countries such as Taiwan, 
Hong Kong, South Korea, Singapore, and Japan.  
 
Breast pattern according to 
mammography 
NDBPP DBPP 
Prevalence (%) in Taiwan 
(Leung et al in Taipei Medical 
university Hospital)  
20.8 79.2 
Prevalence (%) in 
Western countries  
78 22 
Table 1. Analysis of the prevalence of breast pattern in Taiwan and Western countries 
(Leung et al., 2010b; Van Gils et al., 1999). 
Breast density is a major factor influencing the incidence of breast malignancy, and has been 
discussed extensively in the past two decades. In a normal woman, mammographic 
densities correspond to different amounts of fat and connective and epithelial tissue. Fat 
appears radiographically dark on film-screen mammograms, and radiographically opaque 
areas represent epithelial and connective tissues (Gram et al., 1997). Most cases of high 
mammographic density are not abnormalities, but varied distributions in healthy breast 
tissue. It was also found that high mammographic density may be related to a fourfold 
increased risk of developing breast cancer. It was found that the diagnostic sensitivity of 
mammography in women with a fatty breast pattern is 98% (Boyd et al., 1998; Kolb et al., 
2002). Women with high mammographic breast densities are at higher risk of breast cancer; 
the incidence of breast cancer in NDBPP was 26.4% versus 73.4% in DBPP. It was discussed 
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and investigated whether the women with DBPP should receive more frequent screening or 
screening with alternative techniques that increase the length of the preclinical detectable 
phase to reduce breast cancer mortality (Van Gils et al., 1999). 
Data collected in Japan showed the successful result of a mass screening program using 
mammography on asymptomatic women over 50 years of age. The program had a 0.84 % 
cancer detection rate. The breast cancer cases screened from the program had not been 
detected by physical examination (Morimoto et al., 1994). The detection rates were higher in 
the sixth and seventh decades of life.  
In a study of Japanese women, mammography missed 16 % of breast cancer occurrences 
(Uchida et al., 2008). Breast density was also confirmed as a significant determinant of breast 
cancer risk. They quantitatively measured the mammographic density, and found that a 
higher risk was associated with a larger breast size and with a higher proportion of 
glandular density, especially for extreme densities (Nagata et al., 2005). A study in 
Singapore showed an increased risk of breast cancer associated with a higher-density 
pattern with extensive nodular characteristics, and linear densities with a nodular size larger 
than normal lobules (Jakes et al., 2000). 
Although breast cancer is the most common female cancer in South Korea, its early 
detection rate is low compared to developed Western countries (Ryu et al., 2008). The 
clinical characteristics of Korean breast cancer patients showed a pattern of a younger age (< 
50 years old) and increasing early stage and asymptomatic cases. This finding reflects the 
need for more effective breast screening programs for young Korean women (Son et al., 
2006). 
Increased breast parenchyma density correlates with breast cancer risk and obscures the 
detection with the mammography of early stage, small-sized breast tumors. Asian women 
have smaller breasts and are affected by breast cancer at a younger age; both factors that are 
associated with DBPP (Leung et al., 2010b). 
3. Limitation of conventional mammography in detecting early tumors in 
young Asian women with dense breast parenchyma pattern  
In Western countries, mammography has been proven to detect breast cancer at an early 
stage and, when followed up with appropriate diagnosis and treatment, to reduce the 
mortality rate caused by breast cancer (Saslow et al., 2007). 
Asian women have higher breast densities than Caucasian women, in addition, 
mammography is not a perfect screening tool for Asian women with DBPP. Mammography 
has lower sensitivity for invasive ductal carcinoma of breasts in patients with DBPP (Kolb et 
al., 2002).  
The percentage of dense tissue to breast volume of both Chinese and Japanese women 
appeared to be higher than that in Caucasian women (Maskarineca et al., 2001). Despite the 
considerably smaller proportion of non-dense areas, the overall proportion of dense breast 
tissue in the breasts of Chinese and Japanese women is 20 % higher than in Caucasian 
women in the same age group (Huang et al., 2001; Maskarineca et al., 2001). Irrespective of 
race, women with lower mammographic densities have a lower risk of breast cancer.  
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women in the same age group (Huang et al., 2001; Maskarineca et al., 2001). Irrespective of 
race, women with lower mammographic densities have a lower risk of breast cancer.  
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Whether the presence of many dense areas in the breasts corresponds to a higher cancer risk 
is unclear (Boyd et al., 2005; Kolb et al., 2002; Maskarineca et al., 2001; Tseng et al., 2006). In 
fact, mammographic density usually reflects the opacity of epithelial and stromal tissue in 
the breast within the lucent background of non-dense fatty tissue. Ductal carcinoma in situ 
and infiltrative ductal carcinomas originate in epithelial cells, and therefore, areas of 
fibroglandular tissue with a greater number of cells are at a higher risk during increased 
epithelial proliferation (McCormack & Santos et al., 2006). The masking hypothesis 
proposed by Egan and Mosteller (1977) may also explain why radiographically dense 
patterns are associated with an increased risk of breast cancer. They found that breast cancer 
was easy to detect using mammography in breasts with non-dense glandular parenchyma, 
though it was unreliable for detecting cancer in dense glandular parenchyma. Cases of 
missed cancer detection during a first mammographic examination due to the masking 
effect of dense glandular tissue of the breast may be detected in subsequent mammographic 
examinations. The apparent excess of cancers detected in this specific group, with initial 
masking of the tumor in dense breasts, can cause the group to appear to be at a higher risk 
than those with non-dense breast tissue (Leung et al., 2010). Conventional mammography is 
also lower sensitivity to detect enlarged axillary and have no information on internal 
mammary chain. Probably due to some additional reasons, such as the screening program 
may cause call-back anxiety, psychological trauma by false positive results and radiation 
exposure (Leung et al., 2002), Hong Kong and most regions of mainland China currently 
have no mass screening programs for any age group. 
Although some limitations of mammographic screening on DBPP women in Asia, we need 
give applause to health policy planners in the majority of developed Asian countries, such 
as Japan, Singapore, Taiwan, and South Korea, are believed helping us to bring early breast 
cancer awareness and provide cost-effective screening to prevent delay diagnosis of Asian 
breast cancer.  
4. Application of breast MRI on Asian women and the dense breast 
parenchyma pattern  
Digital mammography is reliable as a screening or diagnostic tool for Asian women with 
NDBPP. Mammography can reliably image microcalcifications and solid tumors with 
good contrast from the fatty background tissue of the breast. The aim of image production 
during mammography is to separate fatty tissue from glandular breast tissue of low 
contrast density based on different X-ray absorption characteristics. Mammographic 
density estimation is based on a single two-dimensional projection of the breast. In 
contrast, breast MRI distinguishes different tissue types based on their signal production 
after radiofrequency stimulation within a strong magnetic field. MRI evaluation of the 
breast is three-dimensional, and the image analysis is assisted by a post-enhanced kinetic 
curve, and subtraction techniques only allow contrast-enhanced lesions to be depicted 
(Figures 1&2). 
Figure 1 presents a representative case in the NDBPP group showing that a large tumor and 
cluster of microcalcifications could be easily detected with both mammography and breast 
MRI. Figure 2, in contrast, shows a representative case from the DBPP group. The 
mammograms of the left breast under cranial-caudal and medial-oblique views show 
diffuse faint nodular shadows without major architectural distortion. The finding of 
 
The Application of Breast MRI on Asian Women (Dense Breast Pattern) 
 
27 
malignancy could not be concluded due to a dense breast parenchyma background. 
However, breast MRI with a subtraction image demonstrated an enhanced tumor mass.  
 
      






Fig. 1. (a) Mammogram of the non-dense parenchyma pattern group shows a large tumor 
and cluster of microcalcifications (thin white arrow) at the superior left breast with enlarged 
lymph nodes (thick white arrow), which was diagnosed as advanced infiltrative ductal 
carcinoma and lymph node metastasis. (b) The corresponding breast magnetic resonance 
imaging subtracted image of ESP (white arrow) matched the mammographic interpretation. 
(c) It shows a characteristic “wash-out” enhancing curve pattern, which is more likely to 
appear in malignancy. 
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Fig. 2. Mammograms of the left breast under (a) cranial-caudal and (b) medial-oblique views 
of the dense parenchyma pattern group show diffuse faint nodular shadows without major 
architectural distortion. The finding of malignancy could not be concluded due to a dense 
breast parenchyma background. (c) However, follow-up breast magnetic resonance imaging 
with a subtraction image of ESP demonstrated an enhanced tumor mass (white arrow) at the 
medial aspect. (d) The corresponding enhanced curve analysis revealed a characteristic 
“wash-out” pattern. 
Because the image is processed by subtraction of all the background tissue, a possible lesion 
can only be identified in the presence of extremely dense glandular tissue, different types of 
implantation, or fibrotic changes after chemotherapy with BRMRI (Thompson et al., 2009). 
Previous study conducted by Kuhl et al (2010), have indicated that breast MRI is 
significantly more sensitive than mammography, sonography, and a combination of both. 
Breast MRI and mammography are more specific than sonography alone or in combination. 
In addition, the positive predictive value of breast MRI was 48%, higher than 39% of 
mammography and 36% of ultrasound. 
 
The Application of Breast MRI on Asian Women (Dense Breast Pattern) 
 
29 
5. MRI acts as a screening tool in a population of asymptomatic women 
Mammography has well-recognized limitations for early breast cancer detection, especially 
for Asian women with DBPP. In the United States, MRI is provided as an adjunctive 
screening tool, mainly for women who may be at increased risk for the development of 
breast cancer. The Society of Breast Imaging and the Breast Imaging Commission of the ACR 
issue these recommendations to provide guidance to patients and clinicians on the use of 
imaging to screen for breast cancer. The recommendations are based on available evidence, 
or based on consensus opinions of professionals and experts from the executive committee 
of the Society of Breast Imaging and the members of the Breast Imaging Commission of the 
ACR. These recommendations are intended to suggest appropriate utilization of breast MRI 
for screening high-risk groups. They are not intended to replace sound clinical judgment 
and are not to be construed as representing the standard of care. Mammography should be 
remembered to be the only imaging modality that has been proven to decrease mortality 
from breast cancer. Before using breast MRI, the potential benefits, limitations, and harm 
from this additional screening modality should be reviewed (Lee et al., 2010; Saslow et al., 
2007).  
Similar to Western countries, a higher proportion of Asian women with breast cancer have 
at least one relative with breast cancer. This risk can be almost double that of the general 
population. However, the gene correlated with this is different from that found in Western 
countries. In addition, gene screening programs and services are poorly developed, even in 
the wealthiest Asian countries. To define the high-risk group in the population, the national 
screening mammography program in Taiwan provides services for women aged between 
40-45 years with a family history of breast cancer. Considering the low sensitivity of 
mammography in young women, a more aggressive breast MRI screening at this age or 
lower is recommended. Adjuvant breast MRI screening should also be considered for 
women with lymphoma (Hodgkin’s disease), women who received radiation treatment 
between the ages of 10 to 30 years, women with lobular carcinoma in situ (LCIS), atypical 
lobular hyperplasia (ALH), and atypical ductal hyperplasia (ADH), which may range from 
normal ductal hyperplasia to ductal carcinoma in situ (DCIS). Specifically, women with a 
personal history of breast cancer, including DCIS, should be included. As previously 
mentioned, DBPP has been shown to be an independent risk factor for breast cancer. 
Women with the highest breast density were found to have a 4- to 6-fold increased risk 
compared with women with the least dense breasts. In addition, malignant tumors of the 
breast are more likely to arise in the areas of greatest mammographic density than in fattier 
areas of the breast. Although the ACS recommendations for Breast MRI Screening as an 
adjunct to mammography are more detailed, the most suitable indications for Asian women 
are provided in the following table (Table 2; Lee et al., 2010; Saslow et al., 2007) 
6. The value of breast MRI as an adjunct in the diagnosis of breast diseases  
Breast MRI can be used as an adjunct in the diagnosis of breast diseases when inconclusive 
findings in conventional imaging exist, such as with mammography and sonography (BI-
RADS 0). Therefore, MRI can be used as a problem-solving modality (Mann et al., 2008). 
Generally, breast MRI provides a relatively higher negative predictive value for excluding 
malignancy (Dorrius et al., 2009; Dorrius et al., 2010). 
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lobular hyperplasia (ALH), and atypical ductal hyperplasia (ADH), which may range from 
normal ductal hyperplasia to ductal carcinoma in situ (DCIS). Specifically, women with a 
personal history of breast cancer, including DCIS, should be included. As previously 
mentioned, DBPP has been shown to be an independent risk factor for breast cancer. 
Women with the highest breast density were found to have a 4- to 6-fold increased risk 
compared with women with the least dense breasts. In addition, malignant tumors of the 
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adjunct to mammography are more detailed, the most suitable indications for Asian women 
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Breast MRI can be used as an adjunct in the diagnosis of breast diseases when inconclusive 
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Breast MRI Screening as an adjunct to mammography is advised for women with a 
family history that may suggest a genetic predisposition to breast cancer  (Lee et al., 2010; 
Saslow et al., 2007) 
Breast MRI Screening recommendations for who received radiation therapy to the chest 
in their 2nd or 3rd decade (Saslow et al., 2007) 
Breast MRI Screening recommendations for patients with lobular carcinoma in situ 
(LCIS) , atypical lobular hyperplasia (ALH), or atypical ductal hyperplasia (ADH) 
(Saslow et al., 2007) 
Breast MRI Screening recommendations for heterogeneously or extremely dense breast 
tissue, disabling the mammograph from interpretation (Lee et al., 2010; Saslow et al., 
2007) 
Breast MRI Screening recommendations for personal history of breast cancer, including 
ductal carcinoma in situ (DCIS) (Lee et al., 2010; Saslow et al., 2007) 
Table 2. MRI acts as a screening tool in a population of asymptomatic women with 
preselection is listed. 
MRI is the most reliable imaging technique for measuring the tumor size, and it detects 
additional foci of the tumor in the ipsilateral breast in 10–30 % of patients (Mann et al., 
2008). The sensitivity of breast MRI is, in the setting of preoperational evaluation, close to 
100 %. MRI may be considered after breast-conserving therapy (BCT) as an evaluation tool 
for residual disease after positive tumor margins. Thus, breast MRI acts as a diagnostic tool 
for all patients who undergo BCT. Breast MRI is superior for evaluating suspected 
recurrence compared to clinical examination, mammography, or sonography (Kuhl et al., 
2010). Postradiation changes usually occur up to 3 months after radiation therapy and do 
not reduce the accuracy of MRI for identifying residual or recurrent tumors. The presence of 
an implant does not seem to decrease the sensitivity of breast MRI. MRI is the most accurate 
modality in the evaluation of implant integrity. Its sensitivity for rupture is between 80 % 
and 90 %, and its specificity is approximately 90 %, whereas the sensitivity of 
mammography is approximately 25 %. MRI may aid explanation surgery as it documents 
the presence and extent of silicone leakage better than any other imaging modality. In 
patients with prosthesis and prior breast cancer, MRI may be used to evaluate suspected 
recurrent disease or as a postoperative screening modality (Mann et al., 2008). Although 
most MRI-detected lesions can be found (and biopsied) with a second sonography, many 
cannot. The specificity of MRI in a previous study was 88 %; a biopsy was recommended on 
the basis of a positive MRI in 13.9 % of the women, and 24.8 % of the biopsies resulted in a 
diagnosis of breast cancer (Lehman et al., 2007a). MRI resulted in 8.2 % of women 
undergoing biopsy compared with 2.3 % for mammography and 2.3 % for sonography 
(Lehman et al., 2007b). The Positve Predictive Values (PPVs) of biopsies obtained by using 
MRI (43 %) and mammography (50 %) were higher than those of the United States (25 %). 
Of the cancers identified by MRI alone, approximately 75 % were targeted under 
sonographic guidance. However, approximately 25 % were removed for biopsy under MRI 
guidance because only MRI demonstrated the accurate location (Lehman et al., 2007b). In 
addition, breast MRI identified high-grade DCIS and high-risk lesions that were missed by 
mammography (Hartman et al., 2004). The call-back and biopsy rates of MRI are higher than 
for mammography in high-risk populations, while the increased sensitivity of MRI leads to 
a higher call-back rate and a higher number of cancers detected (Saslow et al., 2007). Women 
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at risk for familial breast cancer have shown an increased detection rate using this modality 
than with mammographic screening (Lee et al., 2010). Table 3 summarizes these values. 
 
Backup for inconclusive findings and for more detail to evaluate the lesion 
characterization: Breast MRI may be indicated when other imaging examinations 
(sonography and mammography) and physical examinations are inconclusive for the 
presence of breast cancer (Figure 14). 
Occluded images: Certain conditions that may impair conventional breast imaging, such 
as silicone augmentation or radiographically dense breasts, may warrant breast MRI 
depending on clinical findings (Figures 13,19). 
Contralateral breast with breast malignancy: MRI can detect unsuspected disease in the 
contralateral breast (coincidence positive rate at 4-5% of breast cancer patients), which 
often provides false negative findings on mammography or sonography (Figure 2). 
To differentiate scars from real malignant mass: Breast MRI can help distinguish 
postoperative scarring or radiation scarring from recurrent cancer. 
Suspect of breast cancer recurrence: Breast MRI may be indicated in women with a past 
history of breast cancer. 
Metastatic adenopathy: MRI provides a full field of view in a single position and an 
image acquisition that covers major positions of the bilateral axillary lymph nodes and 
internal mammary chains, which may be missed by mammographic or physical findings 
(Figure 4,5,12). 
Determining true tumor extension: Breast MRI can locate the primary area of breast 
cancer and define the extent of the disease for definitive therapy. A negative breast MRI 
may exclude the breast as a potential primary site of cancer and avoid a mastectomy or 
help minimize the invasive procedure (Figure 9,10,11). 
For metastasis: Breast MRI helps evaluate the breasts in case of metastases of an 
unknown primary carcinoma. 
For chemotherapy: Breast MRI helps evaluate therapy response in patients treated with 
neoadjuvant chemotherapy (Figure 7-8). 
Silicone and nonsilicone breast augmentation: Breast MRI is useful in the evaluation of 
patients with silicone implants and silicon injections, in which sonography and 
mammography are usually inconclusive in defining tumor mass, silicoma, granuloma, 
and intracapsular or extracapsular implant ruptures (Figure 13,19). 
Table 3. The value of breast MRI as an adjunct in the diagnosis of breast diseases (Mann et 
al., 2008). 
7. Ability of MRI to describe multifocality and the extent of the disease 
For women with newly diagnosed breast cancer, a single round of screening of the 
contralateral breast with MRI at the time of diagnosis might detect otherwise occult 
malignancy in approximately 3 % to 9 % of cases (Lee et al., 2010) (Figure 4). 
MRI has been found to be more accurate in assessing tumor extent and multifocality in 
patients with dense breasts. MRI can improve the detection of cancer in the contralateral 
breast when added to a thorough clinical breast examination and mammographic 
evaluation at the time of the initial diagnosis of breast cancer. The increased rate of cancer 
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Breast MRI Screening as an adjunct to mammography is advised for women with a 
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at risk for familial breast cancer have shown an increased detection rate using this modality 
than with mammographic screening (Lee et al., 2010). Table 3 summarizes these values. 
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detection comes with a false positive rate of 10.9 % and a relatively low risk of detecting 
benign disease on biopsy (9.4 %) (Lehman et al., 2007a).  
8. Limitations of the breast MRI technique for screening in its current form  
MRI is inappropriate for women at a low lifetime risk for breast cancer. Breast MRI is not 
meant to replace mammography (Lee et al., 2010). Under rare circumstances, such as DCIS 
with typical microcalcification clusters, mammography is superior to MRI for interpretation 
malignancy, which produces an image that is faint or equivocal (Lee et al., 2010).  
The lesion-detecting specificity of MRI is highly influenced by reacted inflammation within 
a month after surgery. Thus, a time period should elapse post-surgery before an MRI (Mann 
et al., 2008). In addition, the dynamic breast MRI is highly influenced by hormonal 
fluctuations during the menstrual cycle, which may cause interpretative difficulties related 
to the uptake of gadolinium in normal breast tissue (Delille et al., 2005; Kriege et al., 2006). 
The call-back and biopsy rates of MRI are higher than for mammography in high-risk 
populations. This is because of the increased sensitivity of MRI. The net harm, benefits, and 
psychological impact of higher cancer detection rates should be considered (Saslow et al., 
2007). Breast MRI screening is almost 10 times more expensive than mammographic 
screening, and generates higher diagnostic costs (Plevritis et al., 2006). Asian countries 
adopting unlimited breast MRI can face a heavy financial burden. Some concern exists 
regarding the clinical safety of the intravenous gadolinium-based contrast media used 
during breast MRI. In Hong Kong, the adverse reaction rate is reported at 0.48 %, and the 
incidence of severe anaphylactoid reaction is approximately 0.01 %. Although most of the 
symptoms are mild and transient, these adverse reactions must be documented and 
managed accurately (Li et al., 2006). 
9. Advantages of a dedicated breast MRI (DBMRI) system with parameters of 
dynamic scan, 3D representation, and post processing techniques 
The recent recommended standard for assessing MRIs to differentiate malignancies from 
benign lesions is the fourth edition of a breast MR lexicon (Morphological interpretation of 
BRMRI images using standards of the American College of Radiology’s (ACR) BI-RADS-
MRI lexicon for malignancy grading) (American College of Radiology, 2003; Erguvan-
Dogan et al., 2006), which is a classification scheme used for the interpretation of breast 
cancer. Although universal standards for integrating different MRI systems and 
manufacturers are lacking, overall, characteristics based on BIRADS scoring of MRI 
descriptions depend on certain parameters. This is a report on my experience with a specific 
MRI system and pulse sequence.  
The DBMRI system with a Spiral RODEO pulse sequence of a 1.5 T dedicated spiral breast 
MRI system (Aurora System; Aurora Imaging Technology Inc., North Andover, MA, USA, 
using the Spiral RODEO pulse sequence) is equipped with different post-processing 
techniques, including early subtracted phase (ESP), post-contrast kinetic curve, and MPR 
with ductal orientation, which can be independently applied in a DBMRI system (Leung et 
al., 2010a; Leung et al., 2010b; Leung et al., 2010c; Leung et al., in press). Axial and sagittal 
gradient echo T1 acquisitions were performed for both breasts with a bilateral breast coil. 
Sequences were performed before and after the infusion of 0.2 mmol/kg gadolinium, 
administrated as a bolus dose with a power injector followed by a 20 mL saline flush.  
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10. Lesion analysis using ESP image, kinetic curve patterns, color mapping, 
and morphology 
In the DBMRI, for cases suspected of being malignant, an ESP image was obtained based on 
subtraction of the post-enhanced phase of images from 90 s non-enhanced images. Lesions 
that could be subtracted in the ESP (by subtraction of the post enhanced image at 90 s from 
the pre-contrast phase) were almost completely excluded from the possibility of being 
malignant (Figure 1b). Therefore, the lesions that could not be subtracted in the ESP 
required further analysis to assess the risk of malignancy. 
Using the mean percentage calculation and comparing pre- and post-contrast kinetic data 
(calculated from 0 s, 90 s, and 4.5 min), the threshold point for lesion enhancement was 
displayed. According to the diagnostic observations of Dr. Christane Kuhl (1999), curved 
patterns of the plateau and washout with bound protein water and free water represent 
possible lesions. A stabilized enhancement without change in signal intensity between 90 s 
and 4.5 min was termed a “plateau” pattern. A “washout” pattern was indicated by a 
decline in signal intensity between 90 s and 4.5 min after the injection of contrast. Each 
lesion was characterized according to the strongest enhancement pattern visible over the 
entire lesion. Figures 1c show magnetic resonance imaging for differentiating lesions that 
are normal, benign, or display a washout pattern. 
 
Fig. 3. In normal tissue, the contrast medium equally permeates in and out through the 
normal gaps in the vascular endothelial cells and interstitial space. In benign neoplasms, 
contrast does not permeate out of the microvessel to interstitial space, and the progressive 
accumulate increases the concentration which manifests itself in a progressively increased 
MRI signal.  
The washout curve represents the initial increase in contrast concentration in the interstitial 
space and then a decrease, as it reverse permeates back through the abnormal gaps in the 
vascular endothelial cells. A final decreased contrast concentration in the tumor interstitial 
space can be detected. 
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A color mapping method was also adopted to assess the possibility of a malignancy. This 
reflects the overall curved patterns of the persistent-plateau (yellow color) and plateau-
washout (red color), which is depends on the permeability of contrast medium through the 
capillary vessel of the neoplasm (Figure 3). This provided a tool for the subtle distinction of 
different grades of contrast-enhanced percentages so that the kinetic curve analysis of the 
region of interest (ROI) would be more convenient (Figure 1,2). 
Morphological interpretation of BRMRI images uses standards of the American College of 
Radiology’s (ACR) BI-RADS-MRI lexicon for malignancy grading (x). In this study, MRI 
studies were interpreted in conjunction with clinical history, family history of breast cancer, 
age, and menstrual status. Referring MRI-detected lesions for biopsy depended on 
characteristics of the ESP image, post-enhanced curve pattern, color mapping, and tumor 
morphology, such as spiculation, irregular margins, architectural distortion, and ductal or 
segmental enhancement (Figure 4). The lesion configuration was classified as focal mass 
enhancement or non-mass-like enhancement. The morphological parameters of focal mass 
enhancement were evaluated by its lesion shape and mass margin. Lesion shape was 
classified as round, oval, lobular, and irregular. Mass margins were classified as smooth, 
irregular, and spiculated. Non-mass-like enhancement included linear, ductal, regional, and 
segmental enhancement (Figure 4). 
Morphological characteristics were considered the most important determining factor for 
benign or malignant masses. Any suspicious MR-enhanced lesions were described based on 
lesion shape, borders, distribution, kinetics, and internal architecture. The final MR assessment 
was classified on a six-point scale, which is summarized in the following table (Table 4). 
 
Category  Interpretation and the suggestion 
I Negative for malignancy 
II Benign findings or benign lesions 
IIIa Probable benign lesion, suggest 6 months follow up with sonography 
focused on the MRI indicated position or in the other breast 
IIIb Probable benign lesion, suggest 3 months follow up with sonography 
focused on the MRI indicated position or in the other breast  
IV Could not rule out the possibility of malignancy, suggest biopsy 
V Malignancy is strongly suggested.  Tumor staging and therapeutic 
planning suggested. 
VI Malignancy. Further treatment, including surgery, adjuvant chemical 
therapy, or radiation therapy is suggested. 
Table 4. MRI is believed to be the most sensitive and accurate screening tool for breast 
cancer in Asian women. Thus, no Category 0 exists in the interpretation of breast MRI, 
which differs from mammography or sonography.  
Examinations that provided an initial assessment of incomplete or 0 received a final MR 
assessment of Category I-V, based on the results of follow-up procedures. A lesion was 
identified as suspicious if a focal mass existed with irregular or speculated margins, if 
enhancement had a ductal distribution, if a solid lesion showed rim enhancement, or if there 
was intense regional enhancement in less than one quadrant. Benign lesions were identified 
as having smooth or lobulated margins (Lehman et al., 2007b).  
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A lesion of < 5 mm of enhancement, even with a washout curve or mixed washout/plateau 
kinetic curve and reddish color mapping, was not automatically referred for biopsy. This 
was because a tiny spot of enhancement of < 5 mm is known as a ‘focus,’ as described by the 
ACR Breast MRI Lexicon, and has a very low possibility of being a malignancy, and is, 
therefore, suitable for a short-interval follow-up (Liberman et al., 2006). MRI-guided biopsy, 
MRI-guided localization for an excisional biopsy, sono-guided biopsy, or surgical excision 
biopsy is employed in cases suggestive of or strongly suspected of being a malignancy. 
The interpretation of breast MRI images using early phase subtraction, kinetic curve 
patterns, color mapping (based on the summing up of kinetic curve data from 
corresponding areas), and the morphology of the MR image, is helpful in differentiating 
malignancies from benign lesions. Dedicated breast MRI with ESP, kinetic curve, and 
morphology analysis was found to have an over 95% negative predictive value of ruling out 
malignancy and was helpful in identifying the characteristics of early-stage malignant 
lesions.  








Fig. 4. (a) 
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Fig. 4. (a) Digital mammography of an Asian women with DBPP showed two indistinct ill 
defined dense shadows noted at superior lateral of right breast. There is no enlarged axillary 
lymph node could be demonstrated. (b) Breast MRI simultaneously showed an enlarged 
right side axillary lymphadenopathy (long white arrow); first right superior mass (black 
arrow) and second right superior mass (white curve arrow). (c) Breast MRI with post 
processing software for analysis shows the first right superior mass remains high signal 
under ESP and exhibits ‘washout’ curve pattern. Pathological report indicate a small 
invasive ductal carcinoma. (d) It shows the second right superior mass remains high signal 
under ESP but exhibits a ‘persistent’ curve pattern. Pathological report as benign 
fibroadenoma. 
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Fig. 5. (a) Digital mammography showed an ill defined hyperdense mass (thin arrow) locate 
at superior right breast, but it could not demonstrate ipsilateral axillary lymph node. (b) 
Breast MRI with 3D MIP (maximum intensity projection) shows the first right superior mass 
remains high signal under ESP and exhibits ‘washout’ curve pattern. Pathological report 
indicates a small invasive ductal carcinoma. 
 
   
Fig. 6. Breast MRI image of an Asian woman with bloody discharge with clinical diagnosis 
as malignancy, it shows high signal intensity content within intraductal appearance under 
3D MIP (a: with circle); but the signal being almost subtracted under ESP (b: arrow). 
Pathological report indicates benign papilloma. 
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        (c)             (d) 
Fig. 7. Breast MRI has the merit on the clinical response assessment for chemotherapy. (a)(b) 
A patient with a huge size tumor of IDC at the left breast; after five cycles of chemotherapy, 
the tumor was shrinkage. (c)(d) In another patient, a similar huge size IDC mass in right 
breast, is finally almost completely regress after adjuvant and targeting chemotherapy. 
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Fig. 8. By using color mapping of post processing breast MRI technique, more lively to 
demonstrate initial result of chemotherapy, even though the tumor size is not remarkable 
shrinkage. (a)(b) Red color area (represent active viable malignant cell with ‘washout’ 
contrast enhanced kinetic curve pattern) occupy the major part of the IDC tumor, in the 
right breast. (c)(d) After two cycles of chemotherapy, the red color shrinkage to less than 
20% area of the tumor. This result encouraged both clinician and patient to continue this 
effective protocol of chemotherapy. 
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Fig. 9. Breast MRI adjunct the conventional breast modality with no limitation of breast size 
and breast dense pattern. (a) In this Breast MRI image of Asian woman, a 1.5 cm IDC tumor 
showed on left breast by all axial, sagittal and coronal views and associate ‘washout’ kinetic 
curve pattern. (b) As we retrospectively to review the digital mammography of this patient 
(both CC & MLO views), the mentioned mass is not capable to demonstrate due to the deep 
location and dense parenchyma occult effect of the breast. 
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(c) 
Fig. 10. (a)(b) An Asian woman with DBPP who received digital mammography, it shows 
suspicious mass locate at deep superior of left breast under MLO view (white arrow), but 
the CC view  could not demonstrate the tumor location. (c) Breast MRI (oblique view of 3D 
MIP) is more clearly to demonstrate multiple foci of malignant masses by different tumor 
location and tumor sizes . Pathological proved as IDC and DCIS. 
 






         (b)                 (c) 
Fig. 11. (a) Breast MRI have the merit on the describing multifocality and the detection of 
asymptomatic cancer on the contralateral breast. In this Asian patient, digital 
mammography shows a single isodense palpable mass at superior of left breast (white 
arrow with metal beam). (b)(c)The follow up breast MRI shows another two enhanced 
tumor masses, with ill defined margin at superior lateral of right breast (long white arrow), 
which was proved as IDC. There is also a well defined enhanced mass with smooth margin, 
locate at paramedial aspect of left breast (black thick arrow), which was proved as 
fibroadenoma. Besides, the stronger enhancement of left axillary lymph nodes (circle on 11b) 
indicate the metastasis, compared with the weaker enhancement of right axillary lymph 
nodes (circle on 11c). 
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      (a)               (b)  
Fig. 12. (a) Breast MRI shows suspect enlarged lymph node at left side internal mammary 
chain (white arrows), (b) which proven by PET scan (black arrows). 
     
         (a)                 (b)          (c) 
Fig. 13. Free silicon injection with silicoma and calcified granuloma formations usually 
occult the possible tumor growth on mammography (a); MRI with sagittal T2 plus fat 
saturation (b) and post enhanced subtracted image (c) provide a satisfactory detective rate 
on cancer on this group of patient. 
 






           (b)              (c) 
Fig. 14. Breast MRI may decrease unnecessary biopsy base on interpretation of screening 
mammography. In this Asian patient, digital mammography with spot compression view on 
left breast (a) demonstrate some cluster of faint microcalcifications. However, the follow up 
breast MRI shows no enhanced lesion in both 3D MIP (b) and subtracted image (c), thus, the 
schedule of call-back mammographic guide biopsy was cancelled. 
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11. Using a dedicated breast MRI system with the application of 
postprocessing techniques for multiplanar reformation (MPR) on mammary 
ductal orientation, for three-dimensional (3D) anatomical demonstration  
Surgeons are required to localize accurately malignant tumors of the breast. Preoperative 
evaluation using DCIS or IDC is helpful for determining the surgical method and the 
necessity of lymphadectomy or preoperative chemotherapy. Compared to mammography 
and sonography, magnetic resonance imaging (MRI) is the most sensitive tool for breast 
cancer detection. Its ability for 3D anatomical representation has also become more 
important for pre-surgical evaluation. 
Although the incidence of DCIS of the breast seems to be gradually increasing in Taiwan 
and other Asian countries, the proportion of small tumors detected is lower than in Western 
countries (Leung et al., 2010c; Huang et al., 2001; Shen et al., 2005). 
The early stage of ductal carcinoma in situ (DCIS) appears as a spread-out distribution 
pattern, extending toward the nipple and is occasionally seen in the breast tissue peripheral 
to the infiltrating carcinoma. Only 3D imagery demonstrates the correlation of image and 
pathology. Sonography and mammography are incapable of showing the anatomical and 
spatial relationship between the lesion and the ductal structures within the breast (Figure 
15) (Leung et al., 2010c). 
 
 
Fig. 15. shows the relationship between the mammary duct, the glandular tissue, and the 
nipple (Leung et al., 2010c).  
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The following figures demonstrate the application of DBMRI with the MPR technique, 
based on the AurorCad 4.0’s oblique display protocol (Aurora System; Aurora Imaging 
Technology Inc., North Andover, MA, USA). The 3D maximum intensity projection (MIP) 
image outputs the selected plane of orientation as an oblique MPR on side-by-side display 
windows. The user controls the rotation of the 3D MIP from any angle, and the MPR pane is 
updated to match the slice, while having the same orientation as the MIP (Figures 16a & 
16b). 
  
      (a)             (b) 
Fig. 16. While controlling the rotation of the 3D MIP (Maximum Intensity Projection) (a) 
from any angle of rotation, the MPR (multi-planar reformation) pane updates to match the 
slice in the same orientation as the new orientation of the MIP (b).  
Ductal carcinoma in situ (DCIS) is a preinvasive condition that appears as tumor lesions of 
the ducts with severe atypical proliferation of epithelial cells. DCIS shows different grades 
of malignant potential, and certain subtypes of DCIS are more likely to recur. 
Approximately 60 % of women with DCIS will progress to invasive ductal carcinoma (IDC) 
over an 8–10-year period, and poor prognostic outcomes are likely when IDC develops. 
Thus, the early detection of DCIS through imaging studies that permit accurate assessment 
of size and distribution is important. 
Breast MRI is a useful tool for staging invasive cancers like IDC. However, traditional breast 
MRI systems have limitations in the analysis of early DCIS using the sagittal and coronal 
planes. Although MRI provides a 3D representation of the enhanced tissues, the borders 
between DCIS and its surrounding benign processes are often indistinguishable, especially 
when DCIS is sparsely scattered. The actual size is also difficult to measure accurately 
during pathological examinations. This is because of the anatomy of the breast ducts are 
distributed in three dimensions and histological sections show only two. Measuring 
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scattered and widely distributed DCIS is difficult, which is one possible explanation for the 
frequent mismatch between MRI and pathological findings.  
Screening for cases with ductogram appearance were performed to find if a significant 
correlation between DCIS and ductograms exists. The term ‘ductogram’ was used for image 
phenomenon that occurred when peri-ductal infiltration in the tissues immediately adjacent 
to the mammary duct was observed. The ductogram image shows non-contrast ductal 
structures differing from the enhanced periductal tumor infiltration if the ductal orientation 
is in phase using multiplanar reformation (MPR) (Leung et al., 2010c) (Figure 17). 
 
Fig. 17. (a) A characteristic ductogram appearance (long arrow) is visualized in case 1. (b) A 
characteristic ductogram appearance (long arrow) is visualized in case 2. (c) Case 3 shows 
characteristics of a ductogram pattern along the lactiferous sinus and duct to the areola, 
within a background of stripping and non-mass signal intensity. (d) Case 4 shows that pure 
DCIS is an intermediate grade of malignancy with delayed surgical treatment, in which the 
ductogram appearance is preserved. The MPR for ductal orientation is visualized by a non-
mass with strip appearance, and lesion cross-over glandular tissue. (e) Case 5 shows pure 
DCIS visualized by its non-mass like intensity (curved arrow) and ductogram appearance. 
(f) Case 6 shows pure DCIS appearing with non-mass of intensity (arrow is the true DICIS 
area). The MRI overestimates tumor size over pathological size by over 200% (the curved 
arrow shows the false area).  
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Non-DCIS early ductal lesions, including intraductal papilloma, ductal hyperplasia, and 
early focal IDC, can be visualized using MPR with ductal orientation. Although certain 
characteristics of the lesion morphology (Figure 18) are similar to the pictures in terms of 
tumor size and the spreading along glandular tissue, not all lesions exhibit a ductogram 
appearance. However, additional analysis using early subtracted image and a post-contrast 
kinetic curve may further confirm the image diagnosis.  
 
Fig. 18. Three types of non-DCIS lesions, both benign and malignant, under MPR with 
ductal orientation. (a) MPR shows enhanced thick strip-like intensity with an irregular 
contour, which spreads along the intraductal structure (arrow) and within the network 
(intraductal papilloma). (b) MPR shows an enhanced and well-defined smooth nodular 
lesion with a tadpole morphology, which occupies the intraductal area of the non-dilated 
side (ductal hyperplasia; arrow). (c) MPR shows a focal lesion with enhancement (arrow), 
which crosses over the ducts of the surrounding glandular structures and is not continuous 
with the ductal structures (early focal intraductal carcinoma). 
A traditional MRI system can provide coronal, sagittal, and coronal images of the whole 
breast and is capable of visualizing lesions (Menellet et al., 2005). However, the borders 
between DCIS and its surrounding benign processes are often indistinguishable, especially 
when DCIS is sparsely scattered. The actual size, based on the pathologic examination, is 
also difficult to accurately measure. This is because the anatomy of the breast ducts is 
distributed in three dimensions, while histological sections are in two dimensions. 
Measuring scattered and widely distributed DCIS is difficult, which is one possible 
explanation for the frequent mismatch between MRI and pathologically determined tumor 
size. In addition, heterogeneous DCIS lesions more often exist alongside benign active tissue 
or lesions, such as adenosis, sclerosing adenosis, inflammation, and proliferative fibrocystic 
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changes. Therefore, the image size acquired in DBMRI is usually overestimated and larger 
than the actual pathological size of the lesion. MPR with a ductal orientation for anatomical 
localization and 3D demonstration was found to be a useful technique for increasing the 
detection rate for early stage DCIS. Detection is performed using characteristic findings that 
include a strip morphology, the spreading along glandular tissue, and a ductogram 
appearance. Moreover, MPR is excellent for visualizing the anatomical pattern of spreading 
early intraductal carcinoma which extends towards the nipple. In addition, MPR can show 
the spatial relationship between the carcinoma and the surrounding breast tissue. These 
findings should be considered for surgical strategy in segmental resections or partial 
mastectomy. Breast MRI with MPR for ductal orientation improves the early detection rate 
and exhibits higher specificity because of improved anatomical interpretation of mammary 
ducts. However, the existence of adenosis, fibroadenomas, and some specific benign 
proliferative processes may still interfere with the characteristic pattern of the MRI findings. 
This can lead to an overestimation of the true size and scope of the distribution (Viehweg et 
al., 2000). For cases of IDC with a DCIS component, distinguishing the DCIS from the IDC 
region is difficult. Some pitfalls exist when matching the three-dimensional DCIS 
distribution with the routine two-dimensional histology sectioning. Using a DBMRI system 
with Spiral Rodeo pulse sequence, those lesions that could be subtracted in the ESP were 
almost completely excluded from the possibility of being a malignancy (Figure 6b).  
To improve the correlation between image diagnosis of tumor size and pathological size, the 
pathologist should be notified of the MRI findings, the estimated lesion size, and the 
mammary ductal orientation before planning sectioning of a specimen that is scheduled for 
microscopic study. In the future, better integration of radiologists, surgeons, and 
pathologists to propose working guidelines would create an environment for better 
correlation of imaging studies and pathology. The accumulation of experience will provide a 
more accurate estimation of the DCIS volume and improve preoperative image assessment 
(Mariano et al., 2005; Neubauer et al., 2003).  
12. Probably benign interpretations of Breast MRI and False positive biopsy 
results base on MRI interpretation 
Breast MRI is a very sensitive modality for breast lesion, but the specificity for real 
malignancy is the issue that long been concerned. People may think breast MRI can pick up 
a lot of things, but these things are not necessarily abnormal. Besides malignant lesions, 
Breast MRI may also highlight fibrocysts, fibroadenomas, and other benign conditions. 
Breast MRI reported to have false positive rate, range from 13% to 83% (Hoogerbrugge et al., 
2008), which means that it may misdiagnosis for lesions that not cancer. Breast MRI reading 
radiologists have the responsibility, through restlessly of receiving new MRI knowledge and 
collecting clinical experience, to achieve higher specificity of tumor differentiation and 
image diagnosis. By our self assessment in Taipei Medical University hospital, benign 
lesions reported by pathology accounted for 15.2%, which were initially suspected of being 
malignancy based on the MRI. In our experience, the pathological results of those false 
positive MRI interpretations are included atypical ductal hyperplasia, adenosis/apocrine 
metaplasia, radial scar, sclerosing adenosis, phylloides tumor, infectious mastitis and fat 
necrosis with hemorrhage.  
In both North America and in Asia, the frequency of benign proliferative breast lesions, 
particularly among women under 40 years of age, is progressively increasing (Schnitt et al., 
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1993). Breast neoplasm is a developing disease, and initially the possible risk cannot be 
precisely determined by a single biopsy result. A study conducted by Liberman el al. 
demonstrated that 24% of all breast MRI cases studied were interpreted as ‘probably benign’ 
in the initial readings. Within seven months, however, nearly 10% of them were 
subsequently proven to be malignancies (Buadu et al., 1996). One study based on over 
120,000 individual cases collected in ten years that received breast biopsies, had been 
diagnosed as benign disease. However, 50% of the lesions were associated proliferative 
changes, of which nearly 10% had atypical ductal hyperplasia. Within this latter group, 15% 
eventually developed invasive carcinoma (London et al., 1992). Atypical hyperplasia and 
other benign results at the first time of biopsied, is significantly increased risk of breast 
cancer (London et al., 1992). In another study, about 2% of cases interpreted as probably 
benign were subsequently identified as malignancies (Liberman et al., 2003). 
Accordingly, we cannot negate the possibility to those probably benign lesions or suspected 
malignant lesions that based on MRI’s interpretation that initially proven to be benign(as 
false positive lesions) may further malignant development, although it is not yet to have a 
precise predictive percentage value. Thus, of the proven benign cases, it is essential to have 
long-term imaging follow-up. To our limited knowledge, not able to explain the possible 
reasons of false positive interpretation of MRI, there is still lack of study on direct 
biomolecular correlation with MRI images. In the future, we believe that further 
understanding of tumor transformation will improve our interpretation of dynamically 
enhanced breast MRI, according to the kinetic curve analysis. This will help in evaluating 
lesions as well as identifying angiogenesis, microvessel density, and microvascular 
endothelial permeabilities. The investigation should also include image-pathology 
correlations of tumor behavior, biological activity, nuclear pleomorphism, mitotic count, 
and histological grading (Bone et al., 1998; Mussurakis et al., 1997; Narisada et al., 2006; 
Szabo et al., 2003).  
13. Screening by DBMRI with breast augmentations 
DBMRI can differentiate breast glandular tissue and pathological lesions from 
silicone/saline bag implants. It can also better visualize intracapsular rupture of breast 
implantation. Breast augmentation has become popular among different age groups in 
Asia, especially in the developed countries. In our breast image center, over 30% of breast 
MRI candidates have received at least one or two different types of breast implant 
surgery. Silicon can cause major complications. Silicone compounds primarily consist of 
fluids, gels, rubbers, sponges, foams, and resins (Ojo-Amaize et al., 1994). Although 
silicone is relatively inert and biocompatible with biological tissue, it is polymeric, has 
hydrophobic characteristics, and possesses electrostatic charges. The organic side groups 
have potentially immunogenic factors, especially over the long-term. Silicone induces 
inflammatory responses in women with breast implants who have several types of 
autoantibodies against different self-antigens (Van Gilset al., 1999). The symptoms and 
signs of preoperative diagnosis for breast implant rupturing based on physical 
examination are usually vague, especially when the fibrous capsule encloses the rupture. 
This situation may become complicated when active inflammation and malignancy are 
suspected. Image studies are, then, necessary for localization and preoperative 
differentiation (Scaranelo et al., 2004).  
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al., 2000). For cases of IDC with a DCIS component, distinguishing the DCIS from the IDC 
region is difficult. Some pitfalls exist when matching the three-dimensional DCIS 
distribution with the routine two-dimensional histology sectioning. Using a DBMRI system 
with Spiral Rodeo pulse sequence, those lesions that could be subtracted in the ESP were 
almost completely excluded from the possibility of being a malignancy (Figure 6b).  
To improve the correlation between image diagnosis of tumor size and pathological size, the 
pathologist should be notified of the MRI findings, the estimated lesion size, and the 
mammary ductal orientation before planning sectioning of a specimen that is scheduled for 
microscopic study. In the future, better integration of radiologists, surgeons, and 
pathologists to propose working guidelines would create an environment for better 
correlation of imaging studies and pathology. The accumulation of experience will provide a 
more accurate estimation of the DCIS volume and improve preoperative image assessment 
(Mariano et al., 2005; Neubauer et al., 2003).  
12. Probably benign interpretations of Breast MRI and False positive biopsy 
results base on MRI interpretation 
Breast MRI is a very sensitive modality for breast lesion, but the specificity for real 
malignancy is the issue that long been concerned. People may think breast MRI can pick up 
a lot of things, but these things are not necessarily abnormal. Besides malignant lesions, 
Breast MRI may also highlight fibrocysts, fibroadenomas, and other benign conditions. 
Breast MRI reported to have false positive rate, range from 13% to 83% (Hoogerbrugge et al., 
2008), which means that it may misdiagnosis for lesions that not cancer. Breast MRI reading 
radiologists have the responsibility, through restlessly of receiving new MRI knowledge and 
collecting clinical experience, to achieve higher specificity of tumor differentiation and 
image diagnosis. By our self assessment in Taipei Medical University hospital, benign 
lesions reported by pathology accounted for 15.2%, which were initially suspected of being 
malignancy based on the MRI. In our experience, the pathological results of those false 
positive MRI interpretations are included atypical ductal hyperplasia, adenosis/apocrine 
metaplasia, radial scar, sclerosing adenosis, phylloides tumor, infectious mastitis and fat 
necrosis with hemorrhage.  
In both North America and in Asia, the frequency of benign proliferative breast lesions, 
particularly among women under 40 years of age, is progressively increasing (Schnitt et al., 
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1993). Breast neoplasm is a developing disease, and initially the possible risk cannot be 
precisely determined by a single biopsy result. A study conducted by Liberman el al. 
demonstrated that 24% of all breast MRI cases studied were interpreted as ‘probably benign’ 
in the initial readings. Within seven months, however, nearly 10% of them were 
subsequently proven to be malignancies (Buadu et al., 1996). One study based on over 
120,000 individual cases collected in ten years that received breast biopsies, had been 
diagnosed as benign disease. However, 50% of the lesions were associated proliferative 
changes, of which nearly 10% had atypical ductal hyperplasia. Within this latter group, 15% 
eventually developed invasive carcinoma (London et al., 1992). Atypical hyperplasia and 
other benign results at the first time of biopsied, is significantly increased risk of breast 
cancer (London et al., 1992). In another study, about 2% of cases interpreted as probably 
benign were subsequently identified as malignancies (Liberman et al., 2003). 
Accordingly, we cannot negate the possibility to those probably benign lesions or suspected 
malignant lesions that based on MRI’s interpretation that initially proven to be benign(as 
false positive lesions) may further malignant development, although it is not yet to have a 
precise predictive percentage value. Thus, of the proven benign cases, it is essential to have 
long-term imaging follow-up. To our limited knowledge, not able to explain the possible 
reasons of false positive interpretation of MRI, there is still lack of study on direct 
biomolecular correlation with MRI images. In the future, we believe that further 
understanding of tumor transformation will improve our interpretation of dynamically 
enhanced breast MRI, according to the kinetic curve analysis. This will help in evaluating 
lesions as well as identifying angiogenesis, microvessel density, and microvascular 
endothelial permeabilities. The investigation should also include image-pathology 
correlations of tumor behavior, biological activity, nuclear pleomorphism, mitotic count, 
and histological grading (Bone et al., 1998; Mussurakis et al., 1997; Narisada et al., 2006; 
Szabo et al., 2003).  
13. Screening by DBMRI with breast augmentations 
DBMRI can differentiate breast glandular tissue and pathological lesions from 
silicone/saline bag implants. It can also better visualize intracapsular rupture of breast 
implantation. Breast augmentation has become popular among different age groups in 
Asia, especially in the developed countries. In our breast image center, over 30% of breast 
MRI candidates have received at least one or two different types of breast implant 
surgery. Silicon can cause major complications. Silicone compounds primarily consist of 
fluids, gels, rubbers, sponges, foams, and resins (Ojo-Amaize et al., 1994). Although 
silicone is relatively inert and biocompatible with biological tissue, it is polymeric, has 
hydrophobic characteristics, and possesses electrostatic charges. The organic side groups 
have potentially immunogenic factors, especially over the long-term. Silicone induces 
inflammatory responses in women with breast implants who have several types of 
autoantibodies against different self-antigens (Van Gilset al., 1999). The symptoms and 
signs of preoperative diagnosis for breast implant rupturing based on physical 
examination are usually vague, especially when the fibrous capsule encloses the rupture. 
This situation may become complicated when active inflammation and malignancy are 
suspected. Image studies are, then, necessary for localization and preoperative 
differentiation (Scaranelo et al., 2004).  
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Intense images followed up with sonography may find minor changes in implanted breast 
pathology. However, in most situations, breast sonography provided no definite way to 
differentiate benign from malignant conditions. When mammography is arranged, well-
trained radiological technicians may help provide good quality pictures as the implantation 
is being compressed and differentiate the implant from normal breast glandular tissue, in 
order to detect possible lesions. Poor technique for patients with breast implants are increase 
the risk of iatrogenic ruptures. In this situation, sonographic guided or mammographic 
guided biopsy may be indicated. If DBMRI is available, further analysis with noninvasive 
techniques is preferred before a biopsy is suggested.  
In our center, a breast MRI with a dedicated breast acquisition system was arranged using 
the Aurora Spiral Rodeo pulse sequence (Figure 19). The Silicone and water Rodeo image 
mode was adopted to subtract implanted silicone and water bag material as low signal 
intensity background before and after contrast injection. Post processing of the images could 
be performed using silicon and water material subtraction techniques followed by the 
AurorCad 4.0’s color mapping display protocol. The same procedure may also apply to 
other breast augmentation material, such as hyaluronic acid (HA) and an individual’s own 
breast tissue.  
Although it is difficult to identify the malignancies when the rupture of implants was 
coexisted, MRI is considered the most accurate modality for detecting breast cancer in the 
presence of silicone (Azavedo & Bone, 1999). The MR images of ruptured implants usually 
showed low-signal-intensity bands, linguine appearance, and a mass within the gel of the 
implants, while of malignancies were irregular margin and showed reddish of color 
mapping. However, free silicone may be hypothesized to induce a foreign body reaction 
with dense fibrosis and granulomatous formations. In this situation, distinction of 
inflammation areas and malignancies remains problematic. 
In case of rupture, silicone from an implant can leak out into the space around the implant. 
An intracapsular rupture (silicone contained within the fibrous capsule) can progress to the 
outside of the, becoming an extracapasular rupture (silicone present outside the fibrous 
capsule) (Everson et al., 1994). These conditions indicate the need for removal of the 
implant. Previous study results establish a rupture rate of 8.0 percent at 11 years for silicone 
breast implants (Hedén et al., 1994). If clinical examination by a skillful surgeon is the only 
diagnostic tool for identifying implant rupture, it is not reliable, and neither the sensitivity 
nor the specificity is acceptable (Holmich et al., 2005). Physical examination is inadequate to 
evaluate a suspected rupture, as experienced plastic surgeons accurately detect only 30% of 
ruptures in asymptomatic patients, compared to 86% detected by MRI (Hedén et al., 1994). 
Mammography is a highly sensitive and specific modality for diagnosing extracapasular 
silicone rupture, and it can detect silicone gel migration through the glandular parenchyma. 
On the other hand, the diagnosis of intracapsular rupture is difficult to detect via 
mammography (Gorczyca et al., 1994; Scaranelo et al., 1994). A change in implant shape is 
the most important mammographic pattern (Gorczyca et al., 1994). Breast sonography has 
been used in breast implant integrity evaluation for several years. A great variety of 
sonography signs detect anywhere from 10% to 17% of ruptured implants (Scaranelo et al., 
1994). Breast sonography can be the first test in the assessment of breast implants in 
asymptomatic patients, followed by mammography. This is because breast sonography has 
greater ability to detect intracapsular rupture than mammography does (Chung et al., 1996; 
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Harris et al., 1993; Venta et al., 1996). There is limitation for sonogram to rule out 
extracapsular rupture, but accurate diagnosis requires magnetic resonance imaging (Chung 
et al., 1996; Harris et al., 1993; Venta et al., 1996). As a result, the FDA has recommended that 
MRIs be considered for use in screening for silent ruptures starting at three years after 
implantation, and every two years thereafter (Allergan, 2006; FDA, 2004). The following 
figures show a special case with initially neither breast sonography nor mammography was 
able to detect the intracapsular rupture of the implant. Although mammography reveals 
microcalcifications that might be malignancy, but the final suggestion for surgery is based 
on MRI images. In our opinion, MRI should be a first-line diagnostic tool for implant 
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Fig. 19. (a) The breast MRI showed an ill-defined, non-mass enhanced area with red under 
color mapping, located in the deep superior anterior portion of the left breast (region1); the 
silicon implantation is showed by white arrow. (b) The breast MRI showed an enhanced 
focus with heterogenous red and yellow color mapping (marked by blue circle) at about 9 
o’clock from the nipple of the left breast (region2); Blue area (by curved arrow) respresents 
intracapsular rupture within the implanted silicon bag (white arrow). (c) The mass (region1) 
of irregular red and yellow by color mapping (by white arrow) showed by DBMRI is 
corresponding to the excised specimen and is palpable as firm mass by surgeon (by white 
arrow). (d) Pathological results revealed a mass of invasive ductal carcinoma (IDC) on the 
region 1. (e) Pathological results also showed extensive high-grade ductal carcinoma in situ 
(DCIS) on region 2. 
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1. Introduction 
Breast cancer is the most common non-skin cancer and the second leading cause of cancer 
death in women. Despite advances in the adjuvant treatment of early stage disease, many 
women will have breast cancer relapse that often is not amenable to complete surgical 
excision [Eubank et al., 2005]. There are 40,000 women per year dying of breast cancer in the 
United States, and most breast cancer victims die of progressive metastatic disease.  
Currently, the detection and staging of breast cancer involves physical examination, fine 
needle aspiration (FNA) biopsy and imaging methods, namely mammography, 
ultrasonography, breast magnetic resonance imaging (MRI) and scintimammography. 
Screening mammography is widely available and evaluates patients with low cost, yet it 
bears a sensitivity ranging from 45% to 90% and low specificity, especially in cases of dense 
breasts, fibrocystic change and scars. Ultrasonography differentiates cystic from solid 
masses. Scintimammography by the use of various common radiotracers such as 
technetium-99m hexakis 2-methoxyisobutyl isonitrile (99mTc-sestamibi), 99mTc-6,9-bis (2-
ethoxyethyl)-3, 12-dioxo-6, 9-diphosphatetradecane (99mTc-tetrofosmin), thallium-201 
chloride (201TlCl), 99mTc-methylene diphosphonate (99mTc-MDP) and pentavalent 99mTc-
dimercaptosuccinic acid [99mTc(V)-DMSA], constitutes not only a complementary modality, 
but a significant method of choice in particular clinical settings, as summarized in Table 1. 
Nuclear medicine methods enormously contribute to breast cancer clinical management due 
to the following reasons: (a) the recent technological advance in the detection and 
processing systems. Single photon emission computed tomography (SPECT) is 
progressively used more often in parallel with traditional planar scintigraphy with 
considerable improvement of the resolution and sensitivity of the scintigraphic image, 
mainly pertaining to lymph node involvement. The detection limit regarding malignant 
lesions approaches the corresponding one obtained by traditional radiological methods. 
Another important innovative improvement is positron emission tomography (ΡΕΤ), a 
technique which is based on the use of precursor metabolites (amino acids, hormones, 
monosaccharites), which are labelled with isotopes with very short half life that emit 
positrons. The pioneer characteristics of this technique enable the study of tumor biology 
accurately and non-invasively, providing interesting perspectives for research and clinical 
applications. PET is gradually used more extensively in oncology and seems to have 
particular value in breast cancer; (b) the introduction of new radiotracers has allowed the 
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acquisition of images reflecting on biological and functional parameters that can 
characterize specific tumor features, like perfusion, mitotic and metabolic activity and 
receptor status. The significance of these parameters lies upon the fact that apart from 
defining the extent of the disease, they could also be regarded as prognostic indices of 
response to treatment and tumor behavior, and thus have major impact on designing and 
monitoring local and systemic therapy. Among the developed radiopharmaceuticals, the 
tracers described in Table 2 may play significant role in investigating breast cancer, with 
particular detection accuracy. 
 
Traditional established indications 
High-risk patients with difficult mammographic evaluation  
(dense breasts, breast structural abnormalities, implants) 
Patients with multiple suspicious lesions or calcifications 
Lobular carcinoma  
Scars from previous biopsy visible on mammography 
Palpable breast mass, not detectable by mammography or ultrasound staging 
Evaluation of response to pre-operative chemotherapy 
Detection of residual disease following mastectomy 
Patients with palpable axillary lymph nodes with unknown primary focus 
Novel clinical applications for 99mTc(V)-DMSA [Papantoniou et al., 2006-2011] 
Patients with potentially premalignant mammary conditions (pre- and post-
chemopreventive treatment) 
Patients with increased serum CGRP  
Selection of patients with metastatic breast cancer for treatment with 188Re(V)-DMSA   
Table 1. Indications for scintimammography 
 
Nuclear medicine modality Radiopharmaceuticals
Scintimammography: tumor-seeking tracers 
with specific metabolic features 
99mTc-sestamibi, 99mTc-tetrofosmin, 
201ΤlCl 
Scintimammography: tumor-seeking tracer 
with proliferation-seeking properties 
99mTc(V)-DMSA [Papantoniou et al., 
Denoyer et al., Al Scheidauer et al.] 
Hydroxyapatite crystals/amorphous calcium 
phosphate-seeking scintigraphy  
99mTc-MDP 
Lymphoscintigraphy 99mTc-labelled nanocolloids 
Radioimmunoscintigraphy Labelled monoclonal antibodies 
Receptor scintigraphy  Labelled peptides with affinity for 
specific receptors 
PET 18F-FDG* 
*18F-FDG: fluorine-18 fluorodeoxyglucose 
Table 2. Synopsis of nuclear medicine exams and tracers applied in breast cancer 
Furthermore, during the past few years the scintigraphic recognition of mammary lesions 
retaining a considerable potential to progress to breast cancer has been introduced in 
association with risk factors  involved in the carcinogenic process such as breast density 
(BD) and calcitonin gene-related peptide (CGRP) [Papantoniou et al. 2010b, 2011]. 
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Specifically, 99mTc(V)-DMSA scintimammography in combination with mammography may 
substantially contribute toward the visualization of these lesions [Papantoniou et al. 2005-
2007, 2010, 2011]. 
Considering that besides cytotoxic chemotherapy, various systemic options including 
hormonal and other biologically targeted therapies are now available, the detection 
potential of the imaging modalities currently employed at such early premalignant stages, is 
limited.  Therefore, this review focuses on current and future applications of traditional 
scintimammography (planar and SPECT) and PET to breast cancer, highlighting the 
significant advantages, the clinically crucial role and the perspectives of molecular imaging 
by 99mTc(V)-DMSA scintimammography. 
2. Scintimammography - molecular imaging 
2.1 Scintimammography with γ-emitting tumor-avid agents 
99mTc-sestamibi and 99mTc-tetrofosmin are lipophilic cations which accumulate in the cell and 
in mitochondria due to the negative transmembrane potential. This happens mainly in cells 
with high-energy metabolism (and hence rich in mitochondria), including neoplastic cells. 
99mTc-sestamibi imaging of breast cancer was first reported in a patient under investigation 
due to myocardial infarction  [Chiti A et al., 1994]. As opposed to 99mTc-sestamibi, 99mTc-
tetrofosmin mostly localizes within the cytosol, with only a fraction passing into the 
mitochondria. Nevertheless, considering that both tracers pass through an intact cell 
membrane, their cellular uptake and retention mainly reflects on the viability of lesion cells, 
their perfusion and their metabolic status, including cellular proliferative activity as a major 
driving force. Moreover, scintimammography using 99mTc-sestamibi/tetrofosmin is not 
influenced by mammographic limitations, like dense breast and scars. The method 
demonstrates 85-95% sensitivity and specificity regarding primary tumor imaging, although 
somewhat lower values are expected for non-palpable lesions and axillary lymph node 
invasion. In general, these two tracers present greater sensitivity than 201TlCl. The method 
can help the surgeon localize the tumor during planning biopsy or surgery. In addition, 
sestamibi is associated with prognostic significance due to the correlation between 
radiopharmaceutical uptake and tumor angiogenesis or, most importantly, between tumor 
uptake and tissue P-glycoprotein expression, which is encoded by the multi-drug resistance 
(MDR) gene. P-glycoprotein is a membrane protein that acts as an ATP-dependent drug 
efflux pump, excreting anticancer pharmaceuticals and radiopharmaceutical imaging agents 
outside the tumor cell. Thus, prediction of P-glycoprotein-mediated response to anticancer 
agents is identified in vivo by sestamibi retention or efflux. 
According to the scintimammographic protocol, the patient is asked to accommodate at 
prone position, in order for anterior, lateral and 30o posterior oblique images to be obtained. 
The latter projection is helpful for distinguishing lesions localized at the posterior breast 
segment from the ones at the thoracic wall and for axillary lesions. The planar images 
(10min/image) are acquired at 5-10 min and 60 min after intravenous (IV) injection of 740 
MBq of radiotracer activity. 
201TlCl exhibits kinetic behavior as a potassium-analogue tracer and shows intense uptake in 
all proliferating cases with increased cell number. Planar scintigraphy, including anterior 
and lateral images, takes place 3 h post IV injection of 111 MBq of the tracer. This 
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radioligand is indicated in women bearing benign or malignant breast lesions, since it 
demonstrates a sensitivity of 80-96%. Its specificity varies from relatively poor, with a false-
positive rate of 23% due to adenomas, to high (96%) in benign fibrocystic disease, which 
shows no 201TlCl uptake. Unfortunately, the tracer appears weak in detecting axillary 
metastases with a reported sensitivity of only 57%. The study seems more suitable in the 
differential diagnosis of palpable lesions, providing useful indications for the selection of 
patients for biopsy, rather than pre-operative staging [Waxmann AD et al., 1989, Lee VW et 
al., 1993]. Of note are the unfavorable radiation characteristics of this tracer when compared 
to 99mTc-labelled compounds, with increased radiation burden to the patient and inferior 
image quality. 
99mTc-methylene diphosphonate (MDP) is another radioligand applied in breast lesions and was 
first proposed by Piccolo S et al. (1995) reporting that a) in a portion of breast lesions MDP 
uptake with optimal tumor-to-background (T/Bg) ratio occurs a little after the 
radiopharmaceutical administration. This phenomenon could be attributed to the 
particularly increased tumor perfusion due to neo-angiogenesis and c) this it could be useful 
in the differential diagnosis of mammographically equivocal lesions, or in the diagnosis of 
lesions in dense breasts, in which mammography shows limited value. Protocol guidelines 
include image acquisition at anterior and posterior positions at 4 min, 10–20 min and 2 h 
post IV injection of 740 MBq of the tracer. Ninety-two percent of breast cancer lesions 
appear as a focus of 99mTc-MDP uptake in the 10–20 min-image, with mean T/Bg ratio: ~4.3, 
as opposed to the 2 h-image which is positive in 38% of cases. In addition, the method 
provides prognostic information by the traditional whole-body study identifying skeletal 
metastases. 
2.1.1 99mTc(V)-DMSA scintimammography 
99mTc(V)-DMSA is a well-known tumor–seeking radiotracer with affinity for neuroendocrine 
and soft tissue tumors, such as medullary thyroid carcinoma and lung, breast, brain, and 
metastatic bone lesions [Ohta et al., 1984, Babbar et al., 1991, Kashyap et al., 1992, Hirano et 
al., 1995, Atasever et al., 1997, Lam et al., 1997, Kiratli et al., 1998, Papantoniou et al., 2002, 
2004-2007, 2010, 2011, Denoyer et al., 2004, 2005, Tsiouris et al., 2007, Al-Saeedi, 2007]. These 
tumor-seeking properties have lead to the use of 99mTc(V)-DMSA in scintimammographic 
studies. In our studies the radiotracer is prepared using a domestically available kit 
(DMS(V)/Demoscan, National Center of Physical Sciences, Institute of Radioisotopes and 
Radiodiagnostics “Demokritos”, Athens, Greece) labelled with 99mTc within our 
Department. Scintimammography is performed on a single-head gamma camera 
(Sophycamera DS7, Sopha Medical Vision International, Buc Cedex, France) equipped with 
a high-resolution, parallel-hole collimator and connected to a dedicated computer (Sophy 
NxT, Sopha Medical Vision International). The matrix is set at 256 x 256 pixels, and the 
photopeak centered at 140 keV, with a symmetric 10% window. Lateral and anterior prone 
early and late planar images (at approximately 10–20 and 60–70 minutes, respectively) are 
acquired after IV administration of 925 to 1,100 MBq tracer activity. Acquisitions are 
obtained using a special positioning pad (PBI-2 Scintimammography Pad Set, Pinestar 
Technology Inc., Greenville, PA). Breast radiotracer uptake in early and late images is first 
evaluated visually. Any focally increased accumulation is regarded as associated with 
invasive pathology, whereas any other pattern of a more widespread diffuse uptake has 
been found to correspond to pre-invasive lesions (ductal carcinoma in situ (DCIS), epithelial 
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hyperplasia) [Papantoniou et al., 2005a, 2006a]. Semiquantitative analysis is also performed. 
Radiotracer uptake area is calculated at the late (60-minute) images by drawing regions of 
interest (ROI) encompassing the total breast and the area of focally and/or diffusely 
increased tracer uptake in the lateral view; then the number of pixels within these two 
regions is divided. The aforementioned procedure is repeated in the anterior scintigraphic 
image, and the average tracer uptake area of these two views is considered the tracer uptake 
area of the breast under investigation. 
Our research over the last two decades has been increasingly focused on the behavior, 
kinetics and properties of 99mTc(V)-DMSA in a variety of breast lesions, based on the 
postulation that breast cancer is the end-result of a continuum, i.e. a pathway leading to 
malignant transformation upon which intervention possibilities may emerge and early 
avoid disease development and progression. Therefore this research was initially limited on 
evaluating invasive ductal carcinoma (IDC) and was continued backwards through the 
pathway of malignant transformation, i.e. to include DCIS and to reach even some cases of 
the early stages of epithelial hyperplasia, occasionally representing a state of a so-called 
“activated” normal epithelium, which could eventually progress to a premalignant state and 
eventulally to malignant transformation, though lacking such evidence or suspicion on any 
available imaging modality or even biopsy. Based on in vivo scintigraphic studies, we 
advocated that its cellular uptake mechanism is closely related to cellular proliferation, as 
expressed by the Ki-67 immunohistologic index [Papantoniou et al., 2004-2006] and at the 
same time is independent from estrogen receptor (ER) status [Babbar et al., 1991, Kashyap et 
al., 1992]. It has been further demonstrated that the uptake of 99mTc(V)-DMSA is related to 
cell proliferation, focal adhesion kinase (FAK) activation, neo-angiogenesis and 
overexpression of several growth factors, including CGRP and platelet-derived growth 
factor (PDGF) [Papantoniou et al., 2005-2007, 2010, 2011]. Denoyer and colleagues elucidated 
the exact mechanisms; notably, the tracer reflects phosphate ion (Pi) transport and 
metabolism, entering cancer cells specifically via the type III Na/Pi co-transporter, this 
uptake being driven by the cellular levels of phosphorylated (i.e. activated) FAK, a keystone 
of accelerated proliferation [Denoyer et al., 2004, 2005]. 
With reference to the scintimammographic diagnostic yield, we have demonstrated that in 
cases of clinical and/or mammographic suspicion, both 99mTc-sestamibi and 99mTc(V)-DMSA 
exhibit high sensitivity (88.4%), specificity (93.3%), positive predictive value (PPV) (95%), 
negative predictive value (NPV) (82% & 80%), and accuracy for the primary lesion (90 & 
89%, respectively). Notably, in lesions of less than 1 cm in diameter, the planar imaging 
sensitivity drops to ~75%, a percentage which is considerably improved by SPECT. 
Regarding lymph node involvement, the tracers have been reported to show 78.9% 
sensitivity and 86.3% specificity. Pre-invasive lesions, like DCIS and lobular carcinoma in 
situ (LCIS) are detected with high sensitivity by 99mTc(V)-DMSA, whereas with high 
specificity by 99mTc-sestamibi [Papantoniou et al., 2001, 2002]. 
Moreover, in breast cancer we have determined tumor size and Ki-67 as independent 
parameters of 99mTc-sestamibi and 99mTc(V)-DMSA uptake, respectively; hence tumors 
which accumulate 99mTc(V)-DMSA sustain increased cell proliferation and are in fact more 
aggressive [Papantoniou et al. 2002]. 
Relatively recent in vivo and in vitro studies have demonstrated that 99mTc(V)-DMSA 
possesses the potential to depict increased cellular proliferation, compatible with increased 
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Ki-67 expression, not only in IDC (Figure 1) but also in some cases of epithelial hyperplasia 
of the usual type and in pre-invasive mammary lesions like DCIS, independently of the 
presence of estrogen or progesterone receptors [Boyd et al., 1998, Papantoniou et al., 2004-
2007, Denoyer et al., 2004, 2005, Tamimi et al., 2007]. Characteristic diffuse and intense 
99mTc(V)-DMSA uptake is depicted in a case of usual ductal breast hyperplasia in Figure 2 
(a) & (b), though no corresponding findings are observed by 99mTc-sestamibi (Figure 2 (c) & 
(d)). 
 
Fig. 1. 99mTc(V)-DMSA scintimammography (lateral projections) in a 58-year-old woman 
bearing a 2.5-cm, grade III, left-sided IDC with a coexistent 5-cm DCIS, both diagnosed 
histologically. A. The round-shaped focal tracer accumulation (arrow) corresponds to the 
invasive lesion and is noticeable since the early (10-minute) acquisition. Anterior to it lies a 
restricted, hardly visible region of diffuse tracer uptake (arrowhead). B. On the contralateral 
breast, there is also a rather faint extended area of diffuse uptake (arrowheads). C. In the late 
(55-minute) image, the focal 99mTc(V)-DMSA accumulation intensifies and its margins 
expand and become less sharply demarcated from the surrounding breast (arrow). The 
diffuse tracer uptake, corresponding to the in situ component, substantially increases and 
extends above and anterior to the invasive lesion, occupying an area of the gland seemingly 
normal on early imaging. D. Likewise, the inhomogeneous diffuse uptake area on the 
normal right breast becomes clearer and expands over time. No biopsy for histologic 
confirmation was performed on this breast; nonetheless, based on our experience from 
similar histologically-verified scintimammographic patterns, the finding is suspicious of 
representing a widespread pre-invasive lesion (DCIS and/or epithelial hyperplasia) 
[Papantoniou et al., 2007]. 
At the same time, our continuing research shed light to the intensified CGRP expression and 
neoangiogenesis in IDC with a coexistent in situ and/or hyperplastic component, in 
association with the tendency of the proliferation depicter 99mTc(V)-DMSA to image pre-
invasive breast pathologies. The CGRP/99mTc(V)-DMSA correlation could be indicative of 
 




Fig. 2. Dual-tracer study in usual breast hyperplasia. Usual ductal hyperplasia of the right 
breast in a 68-year-old woman. Scintimammography, right lateral projection; 99mTc(V)-DMSA 
at (a) 10 min and (b) 70 min. Diffusely increased tracer uptake in the area corresponding to the 
lesion is observed, barely visible during early acquisition (arrowheads), but clearly perceptible 
at 70 min (lesion-to-background ratios: L/Bearly =1.32 and L/Blate=1.83). 99mTc-sestamibi at (c) 
10 min and (d) 65 min. No increased tracer activity is identified in the corresponding area 
throughout the study (L/Bearly=1.12 and L/Blate =1.14). [Papantoniou et al., 2006b]. As a cell 
proliferation tracer, 99mTc(V)DMSA evaluates the invasive potential in a case of usual ductal 
breast hyperplasia, i.e. identifies mammary tissue with increased cellular proliferation, a state 
of so-called “activated” epithelium, which is related to Ki-67 expression and thus could 
provide some indication of its probability to progress towards atypical ductal hyperplasia, 
DCIS and IDC, i.e. the malignant transformation pathway upon which intervention 
possibilities may aid in early avoidance of disease development and progression. 
an additional proliferative role for CGRP, possibly exerted through the PDGF/PDGF-
receptor system. In this study, the preferential CGRP expression in low- rather than in high-
grade IDC added support to the hypothesis of its precocious role primarily during the early 
stages of mammary malignant transformation [Papantoniou et al., 2007]. 
Furthermore, in a recent retrospective study we aimed at identifying a possible relationship 
between mammographic BD and scintimammographic 99mTc(V)-DMSA uptake in various 
breast histologies. We also investigated whether women with dense breasts, possibly 
expressing a proliferative potential, could be discriminated visually or on the basis of 
semiquantitative analysis of 99mTc(V)-DMSA uptake intensity and benefit from biopsy and 
possible proper chemoprophylactic treatment. Our findings support that increased BD 
correlates with the presence of florid epithelial hyperplasia and mixed DCIS+IDC but not 
with pure IDC or mild epithelial hyperplasia. Its close relationship to the proliferation-
seeking 99mTc(V)-DMSA, which also showed an affinity to florid epithelial hyperplasia, 
indicates that stromal microenvironment may constitute a specific substrate leading to 
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progression to different subtypes of cancerous lesions (i.e. DCIS+IDC) that are totally 
different from pure IDC originating from particular pathways. 
In another prospective study of ours enrolling women with breast epithelial hyperplastic 
lesions, a relatively short (4-week) scheme of daily oral intake of the non-steroidal anti-
inflammatory drug (NSAID) ibuprofen (400 mg) resulted in the reduction of diffuse 
99mTc(V)-DMSA uptake (Figure 3) [Papantoniou et al., 2010]. Other recent studies have 
shown that cyclo-oxygenase-2 (COX-2) inhibitors may reduce the risk of breast cancer 
[Harris et al., 2006]. The biokinetic characteristics of 99mTc(V)-DMSA support our suggestion 
that the observed reduction in its uptake could be attributable to ibuprofen-induced COX 
inhibition and may indicate a “switch off” mechanism on activated FAK, rather than a 
slowing down of the proliferation rate per se. 99mTc(V)-DMSA cellular uptake is linked to 
FAK activation and cell proliferation, which is a precocious stage of malignant 
transformation [Papantoniou et al. 2004, Le Jeune et al. 2005, Al-Saeedi, 2007]. Compared to 
invasive lesions, the exact mechanism of 99mTc-(V)DMSA accumulation in benign 
proliferating diseases and in some non-proliferating diseases with higher lesion-to-
background tracer uptake ratios is not yet clear [Papantoniou et al. 2004, 2006b]. 
Nevertheless, based on the imaging properties and biokinetic characteristics of 99mTc(V)-
DMSA in relation to mammographic density and its ability to visualize potentially pre-
invasive lesions, the clinical impact of various chemopreventive agents may be evaluated by 
quantifying their effect on 99mTc(V)-DMSA breast uptake. 
 
Fig. 3. Early (A) and late (B) images of 99mTc(V)-DMSA breast distribution at baseline and 
corresponding acquisitions after a monthly oral course of ibuprofen (C and D, respectively). 
After the NSAID treatment the diffuse tracer uptake is notably diminished on both early 
and late imaging [Papantoniou et al., 2010] 
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We also studied prospectively the variation of the serum neo-angiogenic neuropeptide 
CGRP levels in women bearing histologically confirmed benign and malignant breast 
lesions and evaluated its possible correlation with mammographic BD. Among the various 
lesions, including mild, florid and atypical epithelial hyperplasia as well as DCIS and pure 
IDC, women suffering from mixed DCIS+IDC demonstrated significantly higher serum 
CGRP levels, which also correlated with BD. These findings further support that DCIS+IDC 
represents a discrete pathological entity which is evoked by an interdependent mechanism 
between BD and serum CGRP expression. In addition, in the near future serum CGRP levels 
could constitute a useful pre-operative index regarding the nature and type of a 
mammographically suspicious lesion, in order for the proper therapeutic scheme to be 
planned, and potentially for the challenging innovative perspective of introducing 
adjunctive therapeutic administration of anti-CGRP peptides. 
Finally, in advanced breast cancer stages, 99mTc(V)-DMSA uptake in metastatic lesions may 
guide therapeutic 188Re(V)-DMSA administration, as propounded by Papantoniou and 
colleagues. Currently this protocol has just started being processed in collaboration with 
Djokic and colleagues (Vince Institute of Nuclear Sciences, Belgrade, Serbia). 
2.2 Lymphoscintigraphy and lymphoimmunoscintigraphy 
The development of distant metastases and breast cancer patient survival appear to be 
related to lymphoscintigraphic positivity [Casara et al., 1992, Uren et al., 1995]. Based on the 
used radiotracers, the following techniques have been applied:  
i. Lymphoscintigraphy using labelled colloids. The used radiolabelled particles are 10-30 
nm in size, pass through the extracellular space into the lymph capillaries and are then 
transferred by the lymph to the regional lymph nodes, to be recruited by macrophages. 
The colloids used are labelled with 99mTc and include antimony/sulphur/colloids, b) 
rhenium/sulphur/microcolloids and c) albumin nanocolloids. 
Protocol guidelines indicate injection of ~37 MBq radioactivity in the extracellular space 
(intradermal, subcutaneous or submucosal) and the injection site depends on the lymph 
node region under investigation. In breast cancer, the tracer is usually injected in the 
interdigital spaces of the hand when examining axillary lymph nodes, at the periareolar 
zone when intramammary lymph nodes are studied, parasternally by the xiphoid 
process in order for the internal mammary chain to be investigated, or intercostally or 
close to the tumor. 
For over the past decade the strategic importance of the pre-operative determination of 
lymph node invasion at the mammary region has encouraged the application of 
lymphoscintigraphy using colloids for lymphatic mapping and detection of the sentinel 
lymph node (SLN) (100% PPV and 96% NPV). Lymphoscintigraphy can be successfully 
applied in breast cancer management, if conducted intra-operatively by the use of γ-
probe and in combination with blue dye; this technique can identify axillary lymph 
node invasion and through SLN detection may allow planning strategy and extent of 
the surgical operation [Krag et al., 1993, De Cicco et al., 1997]. Unfortunately, the 
method lacks adequate specificity. Therefore, particular attention has been paid to 
alternative methods:  
 
Imaging of the Breast – Technical Aspects and Clinical Implication 
 
68
progression to different subtypes of cancerous lesions (i.e. DCIS+IDC) that are totally 
different from pure IDC originating from particular pathways. 
In another prospective study of ours enrolling women with breast epithelial hyperplastic 
lesions, a relatively short (4-week) scheme of daily oral intake of the non-steroidal anti-
inflammatory drug (NSAID) ibuprofen (400 mg) resulted in the reduction of diffuse 
99mTc(V)-DMSA uptake (Figure 3) [Papantoniou et al., 2010]. Other recent studies have 
shown that cyclo-oxygenase-2 (COX-2) inhibitors may reduce the risk of breast cancer 
[Harris et al., 2006]. The biokinetic characteristics of 99mTc(V)-DMSA support our suggestion 
that the observed reduction in its uptake could be attributable to ibuprofen-induced COX 
inhibition and may indicate a “switch off” mechanism on activated FAK, rather than a 
slowing down of the proliferation rate per se. 99mTc(V)-DMSA cellular uptake is linked to 
FAK activation and cell proliferation, which is a precocious stage of malignant 
transformation [Papantoniou et al. 2004, Le Jeune et al. 2005, Al-Saeedi, 2007]. Compared to 
invasive lesions, the exact mechanism of 99mTc-(V)DMSA accumulation in benign 
proliferating diseases and in some non-proliferating diseases with higher lesion-to-
background tracer uptake ratios is not yet clear [Papantoniou et al. 2004, 2006b]. 
Nevertheless, based on the imaging properties and biokinetic characteristics of 99mTc(V)-
DMSA in relation to mammographic density and its ability to visualize potentially pre-
invasive lesions, the clinical impact of various chemopreventive agents may be evaluated by 
quantifying their effect on 99mTc(V)-DMSA breast uptake. 
 
Fig. 3. Early (A) and late (B) images of 99mTc(V)-DMSA breast distribution at baseline and 
corresponding acquisitions after a monthly oral course of ibuprofen (C and D, respectively). 
After the NSAID treatment the diffuse tracer uptake is notably diminished on both early 
and late imaging [Papantoniou et al., 2010] 
 
Scintimammography - Molecular Imaging: Value and New Perspectives with 99mTc(V)-DMSA 
 
69 
We also studied prospectively the variation of the serum neo-angiogenic neuropeptide 
CGRP levels in women bearing histologically confirmed benign and malignant breast 
lesions and evaluated its possible correlation with mammographic BD. Among the various 
lesions, including mild, florid and atypical epithelial hyperplasia as well as DCIS and pure 
IDC, women suffering from mixed DCIS+IDC demonstrated significantly higher serum 
CGRP levels, which also correlated with BD. These findings further support that DCIS+IDC 
represents a discrete pathological entity which is evoked by an interdependent mechanism 
between BD and serum CGRP expression. In addition, in the near future serum CGRP levels 
could constitute a useful pre-operative index regarding the nature and type of a 
mammographically suspicious lesion, in order for the proper therapeutic scheme to be 
planned, and potentially for the challenging innovative perspective of introducing 
adjunctive therapeutic administration of anti-CGRP peptides. 
Finally, in advanced breast cancer stages, 99mTc(V)-DMSA uptake in metastatic lesions may 
guide therapeutic 188Re(V)-DMSA administration, as propounded by Papantoniou and 
colleagues. Currently this protocol has just started being processed in collaboration with 
Djokic and colleagues (Vince Institute of Nuclear Sciences, Belgrade, Serbia). 
2.2 Lymphoscintigraphy and lymphoimmunoscintigraphy 
The development of distant metastases and breast cancer patient survival appear to be 
related to lymphoscintigraphic positivity [Casara et al., 1992, Uren et al., 1995]. Based on the 
used radiotracers, the following techniques have been applied:  
i. Lymphoscintigraphy using labelled colloids. The used radiolabelled particles are 10-30 
nm in size, pass through the extracellular space into the lymph capillaries and are then 
transferred by the lymph to the regional lymph nodes, to be recruited by macrophages. 
The colloids used are labelled with 99mTc and include antimony/sulphur/colloids, b) 
rhenium/sulphur/microcolloids and c) albumin nanocolloids. 
Protocol guidelines indicate injection of ~37 MBq radioactivity in the extracellular space 
(intradermal, subcutaneous or submucosal) and the injection site depends on the lymph 
node region under investigation. In breast cancer, the tracer is usually injected in the 
interdigital spaces of the hand when examining axillary lymph nodes, at the periareolar 
zone when intramammary lymph nodes are studied, parasternally by the xiphoid 
process in order for the internal mammary chain to be investigated, or intercostally or 
close to the tumor. 
For over the past decade the strategic importance of the pre-operative determination of 
lymph node invasion at the mammary region has encouraged the application of 
lymphoscintigraphy using colloids for lymphatic mapping and detection of the sentinel 
lymph node (SLN) (100% PPV and 96% NPV). Lymphoscintigraphy can be successfully 
applied in breast cancer management, if conducted intra-operatively by the use of γ-
probe and in combination with blue dye; this technique can identify axillary lymph 
node invasion and through SLN detection may allow planning strategy and extent of 
the surgical operation [Krag et al., 1993, De Cicco et al., 1997]. Unfortunately, the 
method lacks adequate specificity. Therefore, particular attention has been paid to 
alternative methods:  
 
Imaging of the Breast – Technical Aspects and Clinical Implication 
 
70
ii. Lymphoscintigraphy using tumor-seeking tracers that can localize neoplastic tissue, like 
99mTc-sestamibi, which localizes invaded lymph nodes with 80% PPV and NPV; and 
iii. Lymphoimmunoscintigraphy using monoclonal antibodies (MAbs) administered 
IV, subcutaneously or directly into lymphatics [Khalkhali et al., 2001]. The first 
lymphoimmunoscintigraphic studies were performed in 1984 and since then 
various 123/131I, 111In or 99mTc-labelled MAbs have been applied, including anti-
breast MAb (131I-RCC-1), MAbs raised against human milk fat globulins (131I-anti-
HMFG1, anti-HMFG2) and anti-carcinoembryonic antigen MAbs (99mTc- or 131I-
labelled anti-CEA, 99mTc-BW 431/26) [Thompson et al., 1984, Athanassiou et al., 
1988, Kairemo., 1990]. MAbs approved by the United States Food and Drug 
Administration (FDA) include the anti-CEA and B72.3, prepared against the tumor-
associated glycoprotein- TAG-72. In most cases, breast cancer cell lines produce 
CEA, although only a slight increase of serum CEA levels above normal may 
appear [Lind et al., 1991]. Regarding the detection of lymph node breast cancer 
metastases by arcitumomab, the commercially applied kit of anti-CEA MAb (CEA-
Scan, Immunomedics, Morris Plains, NJ, USA), it has achieved 75% sensitivity, 83% 
specificity, 80% accuracy, 75% PPV and 83% NPV [Nabi, 1997, Goldenberg et al., 
1999]. The method has not gained access into routine clinical practice though, 
because false-positive results are frequent due to tracer uptake by inflammatory 
lymph nodes, the technique is relatively complex owing to the slow tracer kinetics 
and biodistribution and the radiolabelled MAbs can hardly be obtained. 
Nevertheless the inherent biologic property of MAbs to accumulate selectively in 
the tumor as well as in metastases could be useful in both imaging and treatment of 
breast cancer. Specifically, “cold” or “hot” monoclonal antibodies may be applied 
therapeutically, with or without chemotherapeutic agents, thereby propounding 
significant changes in overall breast cancer management and survival [Stipsanelli et 
al., 2005]. Hence, further research may assist in most effectively applying 
lymphoimmunoscintigraphy to aid decision upon conservative or surgical 
approach, monitoring response to treatment and evaluating treatment regimes. 
2.3 Radioimmunoscintigraphy 
Radioimmunoscintigraphy may play a major role in the diagnosis of multifocal breast 
cancer by revealing residual or recurrent tumors, and also occult metastases. Several 
labelled MAbs, already mentioned above, have been hitherto used in breast cancer and new 
immuno-substrates continue to be proposed. The c-erbB-2 (also known as HER2) oncogene 
receptor is overexpressed in 25%-30% of breast cancer cell lines and is associated with poor 
prognosis. The expression of the products of HER2 oncogene in malignant mammary tissue 
and lymph node metastases has been studied in vivo by radioimmunoscintigraphy using 
anti-c-erbB-2 oncoprotein MAb labelled with 99mTc and has been targeted by “cold” or “hot” 
synthetic therapeutic immuno-agents. Specifically, the recombinant humanized “cold” anti-
HER2 MAb (or trastuzumab) has been widely used in the United States to treat breast 
cancer, either alone or combined with chemotherapy. Moreover, radioimmunotherapy 
comprises systemically administered MAbs, linked to high-energy, beta-emitting 
radionuclides, such as yttrium-90 (90Y-BrE-3, 90Y-m170) and 131I- or 90Y-labelled L6 antibody, 
yielding partial or rarely complete responses. Adjuvant peripheral blood stem cells 
transfusion prevents myelotoxicity. 
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Scintigraphic protocol guidelines suggest planar or SPECT imaging following tracer 
administration in the extracellular space or more often IV and rarely via an alternative route 
(e.g. intraperitoneally).  
The higher PPV and NPV for anti-CEA-MAb SPECT as compared to mammography (100% 
vs 91% and 78%-80% vs 25%, respectively) allows for prompt biopsy or lumpectomy in 
MAb-positive lesions. High scintigraphic yield has also been reported for 99mTc- or 111In-
labelled m170 with 90% sensitivity, 93% specificity and 92% accuracy concerning the 
detection of both primary and metastatic breast cancer lesions measuring less than 1 cm in 
diameter [McEwan et al., 1994]. Similar results for breast cancer detection have been shown 
by the use of satumomab (OncoScint, Cytogen Corp, Princeton, NJ USA), which consists of 2 
mg of B72.3 MAb labelled with 111In [Nabi., 1997, Khalkhali I et al., 2001]. 
Overall, suggested applications of the technique do not mainly aim at diagnosing the 
primary tumor, but at identifying regional lymph node spread and distant metastases (bone 
and soft tissue), which are not otherwise visualized during pre-operative staging and at 
post-treatment follow-up. 
2.4 Receptor imaging 
Another radiopharmaceutical category of potential interest for imaging breast lesions 
comprises substances with high affinity for receptors. Receptor imaging may be applied in 
the diagnosis, staging, restaging, response to therapy and prognosis of breast cancer 
patients. Radiolabelled estradiol has been under investigation in vivo by traditional 
scintiscan (with 16-a,17-b-iodo-estradiol- 123IE2) and by PET. In patients with suspected 
breast cancer, it has shown ≥66% sensitivity. Nevertheless, differential diagnosis of a lesion’s 
benign or malignant nature is difficult to be based solely on this technique, mainly because 
fibrocystic breast disease is also characterized by ER expression [Scheidauer et al., 1991, 
Rijks et al., 1996]. 
An interesting alternative approach utilizes radiolabelled somatostatin analogues, e.g. 111In-
pentetreotide. Upon investigating 52 breast cancer patients, somatostatin receptor 
expression has been reported to reach 85% in ductal and 56% in lobular histologies; a total of 
75% detection rate regarding the primary lesion, but only 30% sensitivity for axillary lymph 
node status. Overall, despite the in vivo breast cancer somatostatin receptor depiction, the 
method is inferior to the use of traditional 99mTc-labelled scintimammographic agents, 
owing to comparatively unfavorable dosimetry and cost-effectiveness [Van Eijck et al., 
1994]. 
2.5 Other molecular metabolic imaging modalities: positron emission tomography 
(PET) 
Initial PET studies on breast cancer were performed by Beany and colleagues in 1984. They 
demonstrated that breast tumors sustain higher perfusion than normal tissues and that 
despite the increased total oxygen consumption by the neoplastic tissue, oxygen extraction 
within the tumor is significantly decreased compared to normal tissues. Later on Mintun 
and colleagues described the visualization of primary tumors and a great percentage of 
lymh node invasion by the IV injection of steroid hormones labelled with positron-emitting 
nuclides, specifically 18F-16-a fluoroestradiol (FES). Hormone receptor imaging constitutes a 
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major functional approach of PET on breast cancer research. A subsequent study revealed 
93% sensitivity for 18F-a-FES in the detection of the primary tumor, metastases or relapse. At 
the same time, clearly decreased radiotracer lesion accumulation was observed in patients 
receiving anti-estrogen treatment. Thus, the ability to estimate and evaluate 18F-a-FES 
uptake highlights the important role of PET on assessing breast cancer patients’ response to 
endocrine treatment [Flanagan et al., 1996]. On the contrary, frustrating were the first 
attempts to depict progestin receptors (PgR) using fluoro-16a-ethyl-19-norprogesterone 
(FENP) labelled with 18F. According to Dehdashti and colleagues (1991), the inherent 
radiotracer disadvantage is its non-specific uptake resulting in background uptake to the 
skeleton, normal mammary tissue and blood circulation. Other interesting PET radiotracers 
that may eventually allow for in vivo breast tumor characterization, comprise carbon-11 
methionine (11C-MET) as a tumor protein metabolism indicator; 11C-thymidine or the most 
promising 18F-fluoro-L-thymidine (FLT) as markers for cellular proliferation; 64Cu-labelled 
peptide agonists of alphavbeta3 integrin as possible markers for angiogenesis; and 18F-
fluoromisonidazole as a marker for tumor hypoxia [Khalkhali et al., 2001, Chen et al., 2004]. 
PET studies retain the major advantage of true quantification of the radiotracer distribution. 
The most widely used radiopharmaceutical in clinical PET is 18F-FDG, a tracer focusing on 
the study of tumor glucose metabolism. Protocol guidelines indicate the IV administration 
of 370 MBq of the tracer to a fasting patient (blood Glu< 200mg/dL) with concurrent 
hydration and imaging after 60-180 min. 
18F-FDG-PET applications in breast cancer patients have attempted detection, staging, and 
monitoring treatment response. According to a large series, the sensitivity for detecting 
tumors less than 1 cm is reported to be 57%, compared to 91% for tumors larger than 1 cm 
[Avril N et al., 2000]. The sensitivity for detecting carcinoma in situ appears even lower at 
25%. A significantly higher false-negative rate has been observed in infiltrating lobular 
carcinoma (ILC) compared to IDC (65% vs 24%, respectively), possibly due to a higher 
metabolic activity associated with poor prognosis. The specificity of FDG-PET in 
differentiating benign from malignant lesions approaches 90% in most of the studies, with 
the false positive results mostly attributable to inflammatory conditions. Overall sensitivity 
in the detection of the primary tumor has been reported to reach 80%-100% and specificity 
75%-100%. The verified prognostic significance of FDG uptake in the primary tumor has yet 
to be clarified with reference to the driving biochemical mechanisms evoking enhanced 
glucose metabolism. Yet, based on various research reports, its proven accuracy in detecting 
the primary tumor and axillary staging, does not surpass its most important current clinical 
application, i.e. the detection and definition of the extent of recurrent or metastatic breast 
cancer and monitoring response to treatment. FDG-PET is complementary to conventional 
staging methods in terms of higher sensitivity in identifying metastatic nodal and lytic (or 
mixed) bone lesions (95% sensitivity and specificity vs. 93% sensitivity and 79% specificity 
by conventional imaging). Regarding distant metastases, PET appears to be more accurate 
compared to conventional staging modalities, with the exception of brain and osteoblastic 
bone metastases. Nevertheless, its sensitivity and specificity ranging from 57% to 100% and 
66% to 100%, respectively in various series, PET cannot be a substitute for traditional staging 
by computed tomography (CT) and bone scintigraphy [Eubank WB et al., 2005]. The 
evaluation and follow-up of the response of metastases and locally advanced disease to 
treatment consists the mainstay of clinical PET in breast cancer. Precocious metabolic 
response, as compared to the delayed tumor size reduction, is demonstrated by FDG-PET, 
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thus permitting earlier assessment of response to neo-adjuvant chemotherapy administered 
in locally advanced disease (after 1 or 2 cycles instead of 3 to 4 required by conventional 
morphological imaging modalities). This early metabolic amendment potentially indicates 
cancer cell resistance to apoptosis [Eubank et al., 2005]. 
2.6 Developing horizons 
Small tumor size is perhaps the most significant limiting factor of conventional planar 
scintimammography. The development of small field-of-view, dedicated breast γ-cameras 
with high-resolution CdZnTe (CZT) detectors seems to contribute greatly to increasing the 
diagnostic accuracy of the modality even for lesions below the 1-cm range [Spanu et al., 
2008, 2009]. 
Limitations of FDG uptake including small tumor size, increased breast density, more well-
differentiated histologic subtypes (tubular carcinoma and CIS) and lobular carcinomas, have 
urged for technological improvements. The spatial resolution has been further enhanced 
with the introduction of the hybrid PET/CT scanner, which shows higher sensitivity and 
specificity than either PET or CT used separately. 
Dynamic contrast-enhanced CT (DCECT) can measure the regional blood flow and volume 
along with mean transit time of blood through the capillaries and thus tumor perfusion. 
Combined FDG-PET/DCECT can assess not only tumor glucose metabolism, but also tumor 
vascularity. 
These two parameters can be used in the differential diagnosis between benign and 
malignant lesions, assessment of tumor aggressiveness and prognosis, localisation of 
residual disease, treatment selection and follow-up, assessment of response to treatment and 
radiotherapy planning. 
Furthermore, since PET using Η215O for tumor perfusion evaluation is not readily available, 
the method has not entered clinical practice. Contrast-enhanced dynamic MRI and FDG-PET 
may obtain similar results, which seem advantageous over DCECT due to the lack of 
ionizing radiation and possible reactions to the IV contrast media. 
In general, the coordination of multiple methods for breast imaging is expected to improve 
detection, diagnosis and clinical management of breast cancer patients. Detection and 
diagnosis of breast cancer may be based initially on mammography. Suspicious lesions 
should be elucidated by SPECT or PET and MRI, in order to avoid unnecessary biopsies. 
While PET differentiates malignant lesions by their most enhanced metabolic activity and 
thus intense imaging, MRI provides the exact morphologic information about lesion site, 
which is required for planning biopsy or radiotherapy [Baum, 2008]. In addition, maximal 
benefit from PET and MRI may be obtained by spatial alignment and fusion in a single 
image. Difficulties resulting from the soft and easily deformed tissue may be overcome by 
using identical patient positioning and fiducial skin markers visible in both PET and MRI, 
which should be taped to predetermined locations on the skin of the breast prior to image 
acquisition. By this technique, it is posssible to estimate marker and nodule motions based 
on surface and oncometric coefficients using specific software heat transfer module.  
Another approach towards a better PET/MRI image utilizes PET/CT scanner. Synchronized 
CT and PET acquisition may permit further accuracy in corresponding breast sites in 
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conjunction with MRI skin markers. Positron emission mammography (PEM) is conducted 
by concurrent acquisition using two planar detectors and a traditional mammographic 
system and its role in screening or diagnosis still constitutes a field under investigation, 
although it does sustain the potential capability of detecting smaller and less FDG-avid 
tumors than the conventional whole-body PET. 
Finally, other SPECT or PET assessments using proper tracers may determine selection of 
treatment for breast cancer patients through: a) quantification of the therapeutic target by 
receptor imaging, radioimmunoscintigraphy and 99mTc(V)-DMSA-depicted cell proliferation 
in a CGRP-related neo-angiogenic background, introducing e.g. the ER (tamoxifen and 
letrozole), HER2 (trastuzumab [Herceptin]), EGFR (gefitinib [Iressa]) and angiogenesis 
factors (bevacizumab [Avastin]), considering that tumor expression may also be examined 
in vitro on biopsy specimens, b) identification of resistance factors, i.e. anti-HER2 MAb-
depicted HER2 expression which evokes resistance to hormone therapy, 99mTc-sestamibi-
depicted P-glycoprotein expression which denotes resistance to chemotherapy (doxorubicin, 
taxanes) and c) measurement of early response to treatment, as indicated by reduction of cell 
proliferation shown by 99mTc(V)-DMSA or 18F-FLT.  
3. Conclusion 
In the era of rapidly developing technology, improvements in mammographic and 
molecular diagnostics appear promising, keeping up with the progress and corresponding 
demands raised by therapeutic oncology. The combination of multiple imaging methods 
(PET/CT, PET/MRI etc.) may concurrently evaluate both morphological and functional 
parameters and may directly influence the clinical management of patients bearing breast 
lesions, especially in recurrent or metastatic disease.  
Scintimammography on its own is a simple, safe, non-invasive and widely available 
conventional nuclear medicine technique, which provides valuable multilevel information 
in the clinical management of breast lesions. The method visualizes the lesion site and also 
reflects specific biological and functional lesion features, including perfusion, proliferative 
potential, metabolic activity and receptor status. Thus, scintimammography represents not 
only a complementary method, but also a study of choice by applying the proper 
radioligand in the corresponding clinical background. It is noteworthy that the whole-body 
absorbed radiation dose for scintimammography is equivalent with that of mammography. 
Current innovative scintimammographic findings using 99mTc(V)-DMSA and 99mTc-
sestamibi add to our understanding of the process of malignant transformation, tumor 
biology and further propound individualized treatment strategy by improving our ability to 
depict and possibly quantify the therapeutic target, identify drug remission and resistance 
factors, measure and predict early response and possibly apply novel therapeutics such as 
188Re(V)-DMSA or anti-CGRP peptides. 
Hence, the clinical impact of the recent scintimammographic findings could be of great 
value in terms of  preoperative evaluation –on a molecular basis– of the extent and the 
nature of a suspected breast lesion, i.e. extent of the DCIS component in a mixed DCIS+IDC, 
lesion multicentricity or lymph node involvement. Furthermore, possible 
chemoprophylactic treatment with tamoxifen, aromatase inhibitors or anti-CGRP peptides 
in pre-cancerous lesions, or even prophylactic administration of NSAIDs in florid 
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hyperplastic lesions could be considered in patients with diffuse breast uptake patterns on 
99mTc(V)-DMSA. Finally, treatment with 188Re(V)-DMSA in cases of advanced disease with 
osseous and soft tissue metastatic spread could be considered if these lesions are depicted 
by breast and whole-body 99mTc(V)-DMSA scintigraphy.  
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1. Introduction 
Full-field digital mammography has transformed mammography over the past decade. The 
technology has reached a level of maturity that has caused an increase in its utilization in 
hospitals and clinics world-wide. This chapter will discuss the advantages and 
disadvantages of the technology as compared to screen-film mammography, a discussion on 
the basic physics of digital mammography and the currently available detector technologies. 
In addition to the technical aspects, this chapter will explore the clinical trials published to 
date regarding the technology performed compared to screen-film mammography in both 
screening and diagnosis, and evaluate the various imaging process algorithms that have 
been applied to digital mammography.  Finally, digital mammography’s impact on daily 
clinical workflow will be discussed along with future directions for this technology. 
Digital mammography has become part of everyday clinical practice across much of the 
developed world. However, I find it interesting that most of the radiologists in training 
(residents and fellows) have no concept of what “film” is and was to our practice of 
mammography. They are used to the digital age of computers, personal electronic devices 
and electronic social networking through the internet. To the present generation, softcopy 
display in some form is a way of daily life. To others who have devoted their medical career 
in screening and in the diagnostic evaluation of women for breast cancer, it has and 
continues to be a learning and transitional process. In order to understand and fully 
appreciate the advances in mammography technology, it is important to understand the 
natural history of breast cancer and the challenges and changes that our specialty has 
undergone and how it continues to evolve. 
Cancer of the breast is not a new disease.  It has been present since ancient times and was 
documented by the early Egyptians, Greeks, Babylonians and Chinese (Bland, 1998).  If a 
woman presented to her local “healer/physician” with a lump in her breast, treatment may 
have stemmed from charms and chants to applied ointments or possibly intervention with a 
knife and hot irons for cauterization. For women, treatment for breast cancer was similar for 
centuries and prognosis was generally poor.  
It was not until 1913, when Albert Salomon, a German surgeon, evaluated 3,000 mastectomy 
specimens in a radiology-histological study on comparing the x-ray findings with 
microscopic pathology that it became evident to evaluate radiography technology for breast 
cancer detection. In the 1920’s and 30’s, several attempts to implement radiography for the 
diagnosis of breast abnormalities were done by O. Kleinschmit, W. Vogel, J. Goyanes, and 
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Gershon-Cohen; however, it was not until four decades later that the use of x-rays for the 
diagnosis of breast became more established (Picard, 1998). 
The modern era of mammography began in the late 1960’s as the technique was refined with 
dedicated equipment, such as that developed by the physicist C. Gros (Van Steen & Van 
Tiggelen, 2007). During this time, the film industry began to develop dedicated 
mammography film with high-quality images, reliable capture parameters and reduced 
radiation dose to the patient. Previously, a general x-ray tube with industrial film (low 
sensitivity) with high radiation exposure to the patient was used to image the breast. By the 
late 1970’s and 80’s, dedicated mammography was established, and mammography was 
identified as the most reproducible and cost effective modality to screen the general 
population. In clinical studies with follow-up of patients, it was shown that early detection 
of breast cancer has led to a reduction of the mortality rate (range 18-30%) (Elmore, 2005; 
Hendrick, 1997; Nystrom, 1993; Strax, 1973; Tabar, 2011).    
It is estimated that 1.38 million women were diagnosed with breast cancer worldwide in 
2008. This accounted for approximately a tenth (10.9%) of all the new cancers and 23% of all 
female cancers (Ferlay, 2010). Female breast cancer rates vary. The highest rates are in 
Europe and the United States and the lowest are currently in Africa and Asia. Currently, 
breast cancer is the second leading cause of death in the women of the United States (Center 
of Disease Control, 2010) and the United Kingdom (Ferlay, 2010). Because of these cancer-
related deaths and the continued incidence of the disease worldwide, further emphasis has 
been placed on using mammography as screening tool for early detection.  
2. Physics of digital mammography 
2.1 Comparison of screen film mammography 
Screen-film mammography (SFM) has been (and continues to be in some countries) the 
standard imaging modality for detecting suspicious lesions at an early stage in the breasts of 
asymptomatic women. Film is a very useful medium that has been optimized over the past 
50 years. SFM has a high sensitivity (100%) in detecting suspicious lesions in breasts 
composed primarily of fatty tissue (Dujm, 1997; Saarenmaa, 2000). However, that value is 
significantly decreased in breasts composed of dense glandular tissue because breast cancers 
are frequently similar in radiographic density to the fibroglandular tissue. Consequently, 10-
20% of breast cancers are not visualized (Burrell et al., 1996).  Also, part of this decrease in 
lesion conspicuity may be due to the film itself since it serves as the medium of image 
acquisition, display and storage. After the film is exposed and processed, the image cannot 
be significantly altered and portions of the mammogram may be displayed with suboptimal 
contrast. Only slight improvements can be made with a “hot light” or magnifying glass. If 
improvements cannot be made, the patient may need to undergo another mammographic 
image and consequently be exposed to more radiation dose.  
Another limitation of film is that different regions of the breast image are represented 
according to the characteristic response of the mammographic film. There is a trade-off 
between the dynamic range (latitude) and contrast resolution (gradient). This is illustrated 
in Figure 1 by the sigmoid Hurter and Driffield (H&D) curve that is characteristic for a given 
type of SFM system under specific conditions. The H&D curve demonstrates the 








Fig. 1. Hurter and Driffield (H&D) curve for a SFM system where Log E represents the 
relative exposure and OD is the optical density. 
With the limited range of soft-tissue densities in the breast, mammography requires high 
contrast. The fixed characteristics of an H&D curve mean that if high contrast is to be 
obtained in intermediate-density tissue, there must be lower contrast within the thicker, 
denser fibroglandular tissues represented at the toe of the curve and the fatty tissue 
represented at the shoulder of the curve (Feig & Yaffe, 1998). Consequently, mammographic 
film has a limited dynamic range. 
Digital mammography offers several advantages over SFM. The digital system separates the 
process of x-ray detection from image display and storage. Since image acquisition and 
display are separated, each can be optimized. Digital detectors have a wider dynamic range 
(linear response) compared to film as seen in Figure 2. Digital detectors have increased 
efficiency at a lower radiation dose in the detection and depiction of the x-ray photons 
compared to film (Pisano, 1998; Feig, 1996). In addition, digital detectors (even with a lower 
spatial resolution than film) also appear to improve lesion conspicuity through their 
improved efficiency of absorption of x-ray photons, a linear response over a wide range of 
radiation intensities and low system noise (Feig & Yaffe, 1998).  Plus, post-processing 
software can be utilized to assist the radiologist in evaluating the images for suspicious 
findings by altering contrast and brightness automatically or manually. With digital 
mammography, computer aided detection software can be utilized at a push of a button 
instead of waiting for someone to digitize the film images for each case. With digital 
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sensitivity) with high radiation exposure to the patient was used to image the breast. By the 
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of Disease Control, 2010) and the United Kingdom (Ferlay, 2010). Because of these cancer-
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image and consequently be exposed to more radiation dose.  
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between the dynamic range (latitude) and contrast resolution (gradient). This is illustrated 
in Figure 1 by the sigmoid Hurter and Driffield (H&D) curve that is characteristic for a given 
type of SFM system under specific conditions. The H&D curve demonstrates the 








Fig. 1. Hurter and Driffield (H&D) curve for a SFM system where Log E represents the 
relative exposure and OD is the optical density. 
With the limited range of soft-tissue densities in the breast, mammography requires high 
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film has a limited dynamic range. 
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spatial resolution than film) also appear to improve lesion conspicuity through their 
improved efficiency of absorption of x-ray photons, a linear response over a wide range of 
radiation intensities and low system noise (Feig & Yaffe, 1998).  Plus, post-processing 
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mammography, computer aided detection software can be utilized at a push of a button 
instead of waiting for someone to digitize the film images for each case. With digital 














Fig. 2. Digital detectors have a linear response and wide dynamic range compared to SFM. 
The digital response is seen as the diagonal line. Log E represents the relative exposure and 
OD is the optical density. 
2.2 Image acquisition 
To obtain a mammographic image, x-rays must be generated from a target. A metal filter in 
the system will remove the majority of non-desirable energies of the beam before it enters 
the patient. In a SFM system, the automatic exposure control (AEC) will end the film 
exposure when the tissue above the AEC has transmitted a suitable number of x-rays to 
expose the film where its gradient (slope of the H&D curve) will be near or at its maximum 
value and there will be acceptable image brightness (Yaffe, in Bick & Diekmann, 2010). 
However, other areas of the breast may be suboptimally exposed - dense areas 
underexposed. In the SFM system, the intensifying screen produces light that is 
proportional to the amount of energy deposited by the x-rays. The now exposed film will be 
chemically processed to produce the permanent mammographic image of the different 
optical densities. The mammographic film serves the three roles of image acquisition, 
display and storage. 
In digital mammography, a detector replaces the screen-film system. The detector will still 
be exposed to x-rays just as in a SFM system. The detector produces a signal that is linearly 
proportional to the intensity of the photons transmitted by the breast; therefore, it is possible 
to produce a better representation of the x-ray transmission of all parts of the breast (Feig & 
Yaffe, 1998). For digital mammography, AEC still plays a role. Unlike SFM where it was 
important in determining image contrast, in digital mammography the AEC aids in 
obtaining a predetermined signal-to-noise ratio and a reasonable radiation dose to the 













digitized and stored. With digital mammography, wet chemical processing is eliminated 
and the detector's only role is image acquisition. Another added benefit of a digital detector 
is the elimination of film granularity that adds noise to a system. 
2.3 Properties of digital images 
Spatial resolution in SFM is commonly based on the limiting resolution in terms of line-
pairs/mm from a bar pattern, Figure 3. This test can be very subjective. Therefore, in order 
to evaluate spatial resolution more quantitatively, it can be evaluated with the modulation 
transfer function (MTF). The MTF describes how well the entire imaging system or one of its 
components is performing in the form of a sinusoidal shape (Bunch, 1987; Pisano, 2004). The 
MTF describes how well each spatial frequency is transferred through a system. The MTF of 
a system is the product of the MTFs of the components of each system. As seen in Figure 4, 
at low spatial frequencies the MTF value is at or near the value of 1.0 and the MTF value 
decreases with increasing spatial frequency. The MTF of SFM extends beyond 20 cycles/mm 
and it is predominately the result of the screen since film has a very high MTF (Pisano et al., 
2004). In a digital system, the MTF will be based on the focal spot, patient motion, lateral 
spread of signal (light or electronic charges) in the detector, and spatial sampling.  
 
Fig. 3. Bar pattern of line-pairs/mm for determining spatial resolution for SFM. 
 
Fig. 4. Modulation Transfer Function (MTF) of a screen film system.  
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Spatial sampling is unique to digital mammography and affects resolution. The signal from 
each detector element (del) is averaged over the sensitive region or aperture (d). This will 
result in a decrease of the MTF of a detector (Pisano et al., 2004).  The size of the del will 
supply the information displayed in one pixel. Dels can range from ~ 44 to 100 μm (0.04-0.1 
mm). Dels are arranged with a specified center-to-center distance or pitch (p), Figure 5.  If 
the pitch is too large, information will be lost in the sampling process. 
 
Fig. 5. Example of a detector composed of detector elements (d) that contain a sensitive 
region called the aperture. The distance between the centers of dels is the pitch (p). 
2.4 Radiation dose   
The flexibility of digital with decoupling allows for decreased radiation dose compared to 
SFM. Several factors account for this decreased dose. First, image brightness (display) is 
now independent of acquisition. Since brightness is not dependent on the amount of x-ray 
exposure needed to produce the image, it allows the user to determine the dose selection. 
Secondly, digital detectors have higher detective quantum efficiency with decreased signal-
to-noise-ratios than a SFM image receptor (Pisano et al., 2004). Consequently, a more 
penetrating x-ray beam can be used with digital mammography, and this result in a lower 
patient dose. Currently, some digital mammography systems have dose reductions of 25-
30% compared with SFM (Heddson, 2007; Hendrick, 2010; Yaffe, in Bick & Diekmann, 2010). 
3. Digital mammography detectors 
The detector is one of the key components of a digital mammography system. It produces an 
electronic signal that represents the pattern of x-rays transmitted by the breast. Optimally, a 
detector should include the entire range of x-ray intensities transmitted by different areas of 
the breast without loss of information.  Besides the detector interacting with x-rays 
transmitted by the breast and absorption of the energy carried by the x-rays, it performs 
several other important functions. These other functions (in order) include: conversation of 
the transmitted and absorbed energy to a usable signal (light or electronic charge), collection 
of this signal, secondary conversion if needed (phosphor-based detectors), readout of the 





Bick & Diekmann, 2010). To provide high quality images, all of these steps need to be 
optimized. As a result, detectors are characterized by their quantum efficiency, sensitivity, 
spatial resolution, noise, dynamic range and linearity of response. 
3.1 Quantum efficiency & noise 
Quantum interaction efficiency describes the quantity of x-rays that reach the detector and 
interacts with it to produce signal. The quantum interaction efficiency of a detector can be 
increased by increasing the thickness of the detector. However, quantum interaction 
efficiency can be reduced by using higher energies since this will decrease the x-ray 
attenuation coefficient (Pisano et al., 2004). An exception to this is when the x-ray energy 
exceeds an absorption edge of the detector material, as in CsI. Thus, quantum detection 
efficiency will influence the sensitivity of detector. Detector sensitivity will also be 
dependent on the amount of energy required to produce an electron or light quantum to be 
measured¸ the efficiency of signal collection and measurement of the charge produced 
(Yaffe, in Bick & Diekmann, 2010).  
Quantum noise (or mottle) is the result of random fluctuation in the x-ray beam. It is 
independent of breast density composition. Quantum noise can be statistically described by 
the Poisson distribution (Pisano et al., 2004). To decrease the quantum noise of an image 
(increase the signal-to-noise ratio), the amount of x-rays absorbed by the detector have to be 
increased. This can be performed by using a detector with better quantum detection 
efficiency or by increasing exposure (mAs). 
Another source of fluctuation or noise that decreases image quality is structural noise. With 
the use of a detector, digital mammography has eliminated the structural noise of film 
granularity (random structure of the grains of silver halide) (Bunch, in Van Metter & Beutel, 
1997). However, in digital mammography there is some structural difference across the 
detector and this is associated with spatial variations in detector sensitivity. Because these 
differences may remain constant over time, they do no represent traditional noise. In digital 
mammography this is referred to as “fixed pattern noise” or “structural noise”.  Through the 
use of image correction with flat-fielding or gain correction this can be removed as seen in 
Figure 6. 
3.2 Detector systems 
There are two main types of digital mammography imaging systems.  One type uses a full-
field detector to be imaged, Figure 7. The detector in this system is stationary and the system 
may utilize a grid to remove x-ray scatter, thereby increasing the signal-to-noise ratio. The 
second major type of digital mammography system is a scanned-slot device that uses a 
detector rectangular in shape, Figure 8. The detector in this type of mammography system 
scans/moves across the inferior portion of the breast support at the same time a collimated 
x-ray beam moves during the image acquisition. The detector and the x-ray beam move in 
synchrony. In this latter type of system, no grid is needed since there is less scatter radiation 
from a narrower x-ray beam. Regardless of system type, it is important that the system is 
able to image as close to the chest wall as possible and for the system to accommodate all 
breasts sizes. 
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Fig. 6. Example of flat-field correction. a) Uncorrected image. b) Image after flat-field 
correction. Courtesy of Martin Yaffe, PhD; Sunnybrook Health Sciences Centre, Toronto, 
Canada.  (from Digital Mammography, eds. ED Pisano, MJ Yaffe, CM Kuzmiak. Lippincott, 
Williams & Wilkins, a Walters Kluwer Company, 2004. With permission.) 
 













Fig. 8. Example of a scanned-slot digital mammography system. a) Pictured is a Fisher 
SenoScan mammography unit. b) Image of the detector. 
3.3 Detector types 
Many different types of detectors are used for digital mammography and these will be 
briefly described in this section. The first four discussed are used in direct radiography (DR) 
mammography systems and the last one is used in a computed radiography (CR) system. 
3.3.1 Phosphor flat panel 
A phosphor flat panel detector, Figure 9, is constructed of a plate of amorphous silicon. 
Through solid-state manufacturing, a rectangular array of light-sensitive photodiodes with a 
layer of thallium-activated cesium iodide phosphor, CsI (Tl) are deposited onto the plate. 
The photodiodes are the dels of the detector. These dels will detect the light emitted by the 
phosphor and create and store an electric charge.  
Besides each del containing a photodiode, it also contains a thin film transistor (TFT) switch, 
and these are interconnected with an array of control and data lines.  A readout line is 
present along each column of the detector, and when a control line is activated it activates 
all the TFTs in that row (Yaffe, in Bick & Diekmann, 2010). The signal from the row of 
activated dels is then transferred to an amplifier and digitizer. The digitized information 
from one del will represent the information corresponding to a pixel of the image. 
b) a) 
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Fig. 9. Illustrations of a CsI-amorphous silicon photodiode flat panel detector. a) Generic 
detector. Courtesy of Martin Yaffe, PhD; Sunnybrook Health Sciences Centre, Toronto, 
Canada (from Digital Mammography, eds. ED Pisano, MJ Yaffe, CM Kuzmiak. Lippincott, 
Williams & Wilkins, a Walters Kluwer Company, 2004. With permission. b) Commercial 
detector. (Courtesy of General Electric Medical Systems, Milwaukee, WI). 
In this type of detector, CsI is used because of its crystal structure. These crystals can be 
commercially grown to form needle-like or columnar structures. Unlike granular phosphors 






to increased line-spread function in SFM, CsI crystals used in digital systems are more 
efficient at transferring the light produced (Pisano et al., 2004). This increase in efficiency is 
because the CsI crystals act as fiber optics. Consequently, the detector can be made thicker 
without loss of resolution. 
An example of a commercial system with this detector is produced by General Electric 
Medical Systems (Milwaukee, WI), Figure 7. The field size is 24 cm x 31 cm, the del pitch is 
100 μm, and the digitization is 14 bits (Ghetti et al., 2008).  Of interest, to correct for 
inhomogeneous areas in the detector, flat-fielding or gain correction requires that an offset 
value and a gain be measured for each del (Pisano et al., 2004).  
3.3.2 Phosphor-CCD system 
A phosphor-CCD system also uses CsI(Tl) as the material for x-ray absorption to light 
conversion in the detector. However, the CsI(Tl) is deposited on a rectangular fiber-optic 
coupling plate. The fibers conduct the light from the CsI to a charge-coupled device (CCD) 
array. The CCD is an electronic chip containing rows and columns of light-sensitive 
elements. The CCD converts the light into an electronic signal that is digitized.  
The phosphor-CCD system detector is long, narrow and rectangular in shape, 
approximately 1 cm x 24 cm as seen in Figure 8b. The x-ray beam is collimated into a narrow 
band since it and the detector scan across the breast in synchrony, Figure 10.  The charge 
created in the CCD is transferred down the columns from row to row at the same rate, but in 
opposite direction to the physical motion of the detector. The bundles of charges are 
integrated, collected and read out corresponding to x-ray transmission on the detector for 
each x-ray path through the breast (Pisano et al., 2004). This is known as time-delay 
integration.  
 
Fig. 10. Schematic of the path of detector travel in a scanned-slot detector system.  
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A major advantage of this scanned-slot system is the result of the x-ray beam being 
collimated and only part of the breast being imaged at a time. Consequently, the transmitted 
x-rays are not lost (scatter-to-primary ratio is reduced), resulting in a grid no longer being 
needed. Therefore, the dose should be reduced. A limitation of this type of system is that it 
requires a longer image acquisition time. 
A commercial unit like this was originally marketed by Fischer Imaging Inc (Denver, CO) as 
seen in Figure 8. It has dels of 54 μm with digitization performed at 12 bits. Of interest, over 
a small area of the detector, data could be read out at 27 μm to provide a high-resolution 
mode. 
3.3.3 Selenium Flat Panel 
A selenium detector utilizes a thin layer (100-200 μm) of amorphous selenium for x-ray 
absorption. When an x-ray is absorbed by this material, it causes some electrons in the 
selenium to be liberated. The now “freed electron” and its corresponding “hole” from its 
departure create an electron-hole pair. This electron-hole pair creates the signal (Pisano et 
al., 2004). When electrodes are placed above and below the selenium and an electric field is 
applied, this causes the charges to move toward the electrodes. The signal is collected by 
one of the electrodes that are composed of a large matrix of dels. The dels act as capacitors to 
store the charge. At the corner of each del is a TFT switch. The readout of the charge is 
performed in the same manner as for the phosphor flat panel detector. 
A detector of this kind is produced by Hologic (Danbury, CT). The Hologic detector dels are 
70 μm with 14-bit digitization. Anrad (St Laurent Quebec, Canada) produces another 
selenium flat-panel system with 85 μm dels. To increase the geometric efficiency of this type 
of detector and to have a del of 50 μm, Fujifilm Medical has developed an amorphous 
selenium detector that has two separate layers of selenium as seen in Figure 11. In the Fuji 
system, the upper layer of selenium absorbs the x-rays and produces the electron-hole pairs. 
The charge is then stored in each del. The lower selenium layer will transfer the stored 
charge to a set of readout lines and then it will be transferred to an amplifier and digitized 
(Yaffe, in Bick & Diekmann, 2010). The information from one del will be used to create the 
information corresponding to a pixel of the image. This system has a bit depth of 14. 
3.3.4 X-ray (Photon) Quantum Counting 
The x-ray quantum counting detector is another example of a direct radiography 
mammography system. However, unlike the other detectors described above, it functions 
on the principle that each individual x-ray quantum is counted regardless of its energy. The 
unique design and concept of this detector allows each del to produce an electronic pulse 
every time an x-ray interacts with it (Pisano et al., 2004). The pulses are then counted and 
will create the signal for that pixel. Advantages of this type of detector are that no noise is 
associated with energy conversion and no analog-to-digital converter is needed. 
Two quantum-counting systems have been developed. The detector in the Phillips Medical 
(Germany) [previously Sectra] system uses crystalline silicon in its multiple detectors. The 
detector and collimated x-ray beam move in synchrony across the breast. The x-rays are 
absorbed by the crystalline silicon. The electron-hole pairs are collected in an electric field 











Fig. 11. An illustration of the Fuji FFDM system that uses two layers of selenium. (Courtesy 
of Fujifilm Medical, Stamford, CT). 
system has a del size of 50 μm and a bit depth of 16.  In the system by XCounter (Stockholm, 
Sweden), it uses a set of multiple linear detectors and scans across the breast in synchrony 
with a collimated x-ray beam similar to the Sectra system. However, it uses a pressurized 
gas as the x-ray absorber. The pulses of ions generated by the gas form the signal (Thunberg, 
in Antonuk & Yaffe, 2002). The XCounter system has the same del size and bit depth as the 
Sectra. Neither system uses a grid. 
3.3.5 Photostimulable Phosphor (PSP) System 
The last detector to be discussed is the PSP system which is a computed radiography (CR) 
system. CR systems have been in use in general radiography for many years and are based 
on the principle of photostimulable luminescence. More recently they have been developed 
and used in mammography. The CR mammography systems utilize a phosphor screen. 
Energy from x-ray absorption causes electrons in the phosphor crystal to be liberated from 
the matrix and captured and stored in “traps” in the crystal lattice (Pisano et al., 2004), as 
seen in Figure 13. The number of traps filled is proportional to the amount of absorbed x-ray 
signal. 
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Fig. 12. X-ray (Photon) quantum counting detector. Schematic of a silicon based photon 
counting detector. (Courtesy of Phillips Medical, Germany) 
 
 
Fig. 13. Schematic demonstrating energy from x-ray absorption liberates electrons from the 





The CR image, which is analog, is then read out by placing the screen in a reading device. 
The reading device will scan it with a red laser beam in one dimension as it moves through 
the reader in the orthogonal direction. The red laser beam will free the electrons from the 
traps and cause them to return to their original resting state in the crystal lattice. As they 
return to their original state, the electrons will pass between energy levels created in the 
crystal with certain materials. The selected materials incorporated into the crystal typically 
emit blue light that is proportional to the x-ray energy absorbed by the phosphor (Yaffe, in 
Bick & Diekmann, 2010). The emitted blue light is measured with a light-collecting system 
composed of a photomultiplier tube, selected optical filter to eliminate the red light from 
interfering with the measurement, and a photomultiplier tube. Because the PSP is not 
composed of physical dels, spatial resolution of the system is the result of the size of the 
laser spot (del size) and the distance between sampling measurement (pitch) (Pisano et al., 
2004). To decrease scan time while increasing light collection efficiency, SNR and sensitivity, 
some PSP vendors utilize a double-sided (read from the top and bottom surface of the PSP) 
reading device as seen in Figure 14. 
 
 
Fig. 14. CR mammography dual optical collection system scanned with a red laser beam. 
(Courtesy of Fujifilm Medical, Stamford, CT) 
A system of this type was developed by Fujifilm Medical Systems (Stamford, CT). Its del 
size is 50 μm and has a bit depth of 12. There are other PSP systems developed and used 
throughout the world that have similar del and bit depths.  
Unlike the DR systems, the CR system uses removable cassettes that are placed into a bucky 
tray. This system can be a cost saver to some institutions since they may be able to convert 
their current SFM machine to CR. For work-flow, there may be little change in daily routine 
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for technologists. For some mammography technologists, CR systems have a similar “feel” 
as SFM. Cassettes with the PSP are still placed into the bucky tray, the patient is positioned 
and imaged the same, and then the plate is placed into a reading device without having to 
go into a darkroom. The mammographic image obtained can be printed to hard copy or 
displayed on softcopy just like the DR systems.  
3.4 Quality Control (QC)  
Mammography must be of high image quality in order for radiologists to detect the subtle 
changes of breast cancer. This can be difficult since breast cancer can present as a mass of the 
same density as normal breast parenchyma or be obscured by it. To ensure optimal 
performance from a system, the equipment must be properly set up and maintained. In the 
United States, the Mammography Quality Standards Act (MQSA) was established in 1992 to 
establish a federal mandated quality control program for screen film mammography. It now 
includes digital mammography. In Europe, as countries began to develop a breast cancer 
screening program, each began to develop their own national program. To standardize 
quality assurance and quality control, the European Commission published guidelines in 
2006. Now in its 4th edition, the published guidelines include digital mammography (Perry 
et al., 2006). However, there is no single international source on QC procedures. In the 
United States, it is required that users follow the manufacturers’ QC procedures for their 
systems. 
Digital imaging allows the decoupling of acquisition, processing and display. In order to 
have meaningful QC of a digital system, each of the components must be evaluated 
separately. To evaluate acquisition (detector, beam, scatter, and radiation dose), quantitative 
measures are performed on the “raw” or unprocessed images. The QC for image processing 
is still in its early stages. To evaluate image display, electronic test patterns are used. 
Image quality for mammography has been based on a test phantom, with objects imbedded 
within it. This test is subjective and prone to observer error. In the future, automated 
software may be useful for solving this problem (Young et al., 2008). Instead of a phantom, a 
more reliable measurement for verifying the consistency of image contrast in a digital 
system is the contrast-to-noise ratio (CNR). It is sensitive to changes in dose, object contrast 
and beam quality for each digital machine (Young, in Bick & Diekmann, 2010). The CNR 
object imaged is made of different materials that simulate the attenuation coefficient of 
breast tissue.  
As with SFM, digital mammography can have artifacts. The artifacts may arise from 
detector non-uniformities. Over time, there can be degradation of the homogeneity of the 
detector leading to image degradation. To correct for this, an algorithm can be applied to all 
the images. The procedure is called “flat-field” or “gain correction” and is based on the 
principle that the detector responds linearly to radiation exposure. The first step in this test 
is to record the receptor response for the same amount of time of an image, but without any 
x-ray exposure. The values from this “dark” image are stored in the dels. In a subsequent 
image acquired using x-rays, the values stored are subtracted from the measurement from 
each corresponding del resulting in an image where it appears that the dark signals from all 







Fig. 15. Digital mammogram a) before and b) after flat-filed correction. Courtesy of Martin 
Yaffe, PhD; Sunnybrook Health Sciences Centre, Toronto, Canada. (from Digital 
Mammography, eds. ED Pisano, MJ Yaffe, CM Kuzmiak. Lippincott, Williams & Wilkins, a 
Walters Kluwer Company, 2004. With permission.) 
 
Fig. 16. Ghost or lag artifact. a) Artifact seen on a detector. b) Another example of ghosting. 
c) Clinical image with the appearance of a second breast (arrows). (Images b & c are 
courtesy of Elizabeth Franklin of Carolinas Medical Center, Charlotte, North Carolina, USA) 
Other digital artifacts can be attributed to the digital detector. A single non-functioning pixel 
may not be noticed or even affect clinical images, but if the numbers of non-functioning 
pixels are too many it will impact clinical images. The non-functioning pixel can appear as a 
white dot and may simulate calcifications. If a pixel discharges too early it may result in a 
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bloom artifact, a white spot with a black halo secondary to the increase in charge of the 
neighboring dels (Van Ongeval, in Bick & Diekmann, 2010). If there is crystallization of the 
selenium of the detector, the images may become blurred over time (Marshall, 2006). Figure 
16 are examples of ghost or lag artifact and are the result of incorrect electron clearing. 
Electronic interference can result in a zigzag artifact as seen in this CR image, Figure 17.  
Artifacts can be the result of image processing in which there is significant edge artifact 
between dense and fatty tissue, Figure 18. Also, artifacts can be related to the patient, i.e. 
































Fig. 18. Processing artifact. Significant edge enhancement between the white breast tissue 
and black fat. This results in significant “blackness” of the image adjacent to the black white 
interface (arrow). 
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Fig. 19. Hair artifact. White swirling lines representing the patient’s hair are seen projecting 





4. Clinical trials 
4.1 United States 
In 1996 in the United States, the Federal Food and Drug Administration (FDA) published 
the Information for Manufacturers Seeking Marketing Clearance of Digital Mammography Systems 
(Food and Drug Administration, 1996; Pisano, 2004). For manufacturers of digital 
mammography equipment seeking FDA-approval through 510(k) or Premarket Approval, 
the document required that each manufacturer demonstrate through a designed clinical trial 
that digital mammography equipment was equivalent to SFM. However, this was not 
without some challenges. The original FDA guidelines required manufacturers to 
demonstrate a higher rate of inter-reader agreement with FFDM than was obtainable 
between readers of SFM when SFM was compared to itself (Beam, 1996; Elmore, 1992; 
Howard, 1993). There was no requirement that manufacturers determine the truth about the 
presence or absence of breast cancer, only that the mammogram interpretations agree. 
After an Advisory Panel met to discuss the “flawed” guidelines, the FDA released its 
revised guidelines on February 8, 1999. The guidelines now required approval trials to be 
based on breast cancer status truth. Consequently, sensitivity and specificity as measured by 
a Receiver Operating Characteristic (ROC) analysis was to be used with the goal of the 
studies to demonstrate that the difference in the areas under the ROC curve between digital 
and film was no greater than 0.1 (Pisano et al., 2004). This was now the FDA’s standard for 
proving “substantial equivalence” of the two technologies. 
Several minor clinical trials studies have been published in the US comparing digital 
mammography versus SFM, and these demonstrated promising results for digital 
mammography (Cole, 2001; Hendrick 2001; Pisano, 2004). One of the first major published 
clinical trials was the Colorado-Massachusetts Screening Trial (Lewin et al., 2001, 2002). The 
goal of this two-site study was to prospectively compare full-field digital mammography 
(FFDM) and SFM for cancer detection in a screening population. The design of the study 
was simple. All women at least 40 years old presenting for a screening mammogram were 
eligible to undergo both a SFM and a FFDM. A FFDM prototype system made by General 
Electric Medical (Milwaukee, WI) with a 18 cm x 23 cm amorphous silicon detector with a 
CsI crystal and a commercial SFM unit (DMR: General Electric Medical Systems, 
Milwaukee, WI) were used for imaging. A prototype softcopy display workstation was also 
used. 
Final results by Lewin et al. were published in 2002 (Lewin et al., 2002). A total of 6,736 
paired exams were performed on 4,521 women over a 30-month period. In these patients, 
2,048 findings were detected in 1,467 of the studies with film, digital, or both imaging 
modalities. Additional work-up of the findings led to 183 biopsies and 42 were positive for 
cancer. The cancer detection rate was not statistically significant (p > 0.1). The difference 
between the ROC area for digital (0.74) and SFM (0.80) were not significant (p > 0.1). FFDM 
had fewer recalls than SFM (p < 0.001); however, the positive predictive values of both 
modalities were similar (3.3% SFM, 3.4% FFDM) (Lewin et al., 2002). Although FFDM did 
not lead to a higher cancer detection rate, it did lead to fewer recalls with a study that used a 
prototype unit and display workstation. This study becomes the foundation for the next 
major screening clinical trial, Digital Mammography Imaging Screen Trial. 
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The Digital Mammography Imaging Screening Trial (DMIST) was sponsored by the 
American College of Radiology Imaging Network (ACRIN) and the National Cancer 
Institute (NCI) (Pisano et al., 2005). It was a cooperative venture by 33 sites in two counties 
led by Dr. Etta Pisano. A total of 49,528 asymptomatic women presenting for a screening 
mammogram underwent both a digital mammogram and SFM in a random order by the 
same technologist on the same day. A total of five digital systems were used: Senographe 
2000D (General Electric), SenoScan (Fischer Medical),  Selenium Full-Field Digital 
Mammography System (Hologic), Digital Mammography System (Hologic) and Computed 
Radiography System for Mammography (Fuji Medical). The images were read 
independently by radiologists, one radiologist for each exam. The radiologist scored each 
study on a 7-point malignancy scale for ROC analysis and a BIRADS (American College of 
Radiology, 2003) final impression to guide clinical work-up. The patient was recalled for 
additional diagnostic imaging whether the film, digital and/or both screening modalities 
demonstrated an abnormality. Standard work-up at each institution was performed that 
may have led to a biopsy. Breast cancer status was based on a breast biopsy within 15 
months of study entry or a follow-up mammogram acquired at least 10 months after study 
entry. 
Of the total patients recruited to DMIST over its 2-year accrual period, data was complete 
for 42,760 (86.3%) patients. A total of 335 breast cancers were diagnosed. Of these, 254 
(75.8%) were diagnosed within 365 days and 81 (24.2%) were diagnosed between 366 and 
455 days after study entry. The results demonstrate that for the entire population, the 
diagnostic accuracy of digital and film mammography was similar with a mean AUC of 
0.78+/-0.02 for digital and 0.74+/-0.02 for film (difference in AUC, 0.03; 95 percent 
confidence interval, -0.02 to 0.08;  P =  0.18). However, for certain subgroups, the accuracy of 
digital mammography was significantly higher than that of film mammography. The 
subgroups include women under the age of 50, women with heterogeneously dense or 
dense breasts, and premenopausal or perimenopausal women         (P values of P =0.002, P = 
0.003, P =0.002, respectively) (Pisano et al., 2005). Although the overall diagnostic accuracy 
of digital was similar to film, this large prospective, multicenter center study showed 
advantages for younger women with dense breasts.  
4.2 European clinical trials 
The first prospective digital screening study in Europe was performed in Norway in 2000 
(Skaane et al., 2003, 2005). The Oslo I trial was a prospective study to compare SFM and 
FFDM with soft-copy reading in a population-based screening program. By invitation from 
the Norwegian Breast Cancer Screening Program (NBCSP), women aged 50-69 years of age 
were invited to participate. The women who agreed to participate in the study underwent 
two standard views of each breast with each modality (similar to the US studies). The FFDM 
studies were performed with Senographe 2000D (General Electric Healthcare, Buc, France) 
and interpreted on a GE softcopy display system with 2K x 2.5K monitors. Eight radiologists 
performed independent double readings for both modalities and used a 5-point malignancy 
scale. All images deemed positive (score of 2 or higher) were reviewed in a consensus 
meeting for each technique used. It was the consensus conference that decided whether the 






The Oslo I study resulted in 3,683 women participating and a total of 31 cancers detected 
(detection rate 0.84%). Twenty-eight cancers were seen with SFM (detection rate 0.76%) and 
23 by FFDM (detection rate 0.62%). The cancer detection rates were not significant (P= 0.23). 
The PPV for SFM was 46% and FFDM 39%. The recall rate after the consensus meeting was 
3.5% (128 cases) for SFM and 4.6% (168 cases) for FFDM (Skaane et al., 2005). The recall rate 
was not significant. The authors concluded that there was no statistically significant 
difference in cancer detection rate; cancer conspicuity was equal between the modalities and 
soft-copy reading is comparable to SFM in a population based screening (Skaane et al., 
2005). 
Other data to come out of the Oslo I study was a retrospective review of the cancers (Skaane 
et al., 2003). In this retrospective review, a side-by-side feature analysis of conspicuity of the 
cancers was performed and there was no difference between the modalities. In 2005, Skaane 
et al. published follow-up information on the missed FFDM cancers from the Oslo I study 
(Skaane et al., 2005). They concluded that inexperience of the readers with softcopy, 
improper viewing conditions and rapid interpretations might have contributed to the lower 
detection rate. 
Within a few months after completion of the Oslo I trial, patient enrollment for the Oslo II 
screening trial began. The aims of this study were to prospectively compare cancer detection 
rates, recall rates and positive predictive values of SFM versus FFDM in a screening 
program in Norway (Skaane & Skjennald, 2004). Women 50-69 years old were invited to the 
NBCS and women 45-49 years old were invited to the Oslo screening program. The patients 
were randomized for age and residence to undergo SFM or FFDM. Due to the physical 
location of the mammography equipment, the study investigators decided to have 70% of 
the patients undergo SFM and the other 30% to undergo FFDM (Skaane & Skjennald, 2004). 
The same radiologists who participated in the Oslo I trial participated. All images were 
again independently double-read (now with appropriate viewing conditions in the room) 
and scored using a 5-point malignancy scale. The potential “call back” cases were again 
reviewed at a consensus conference. 
Results of the Oslo II study demonstrated a total of 64 cancers (cancer detection rate 0.38%) 
detected in 16,985 women who underwent SFM and 41 cancers (cancer detection rate 0.59%) 
in 6, 944 women who underwent FFDM (Skaane et al., 2007). The difference was in support 
of FFDM and was statistically significant (p = 0.03). The sensitivity was 77.4% for FFDM and 
61.5% for SFM (P =0.07).  The specificity was 96.5% and 97.9% respectively for the imaging 
modalities (P<0.005).  The PPV was 15.1% for SFM and 13.9% for FFDM and this difference 
was not significant. The recall rate for SFM was 2.5% and 4.2% for FFDM (P < 0.001) (Skaane 
et al., 2007). The higher recall rate of this study confirmed the higher recall rate in the Oslo I 
trial. However, it is important to know that recall was based on a consensus conference, and 
it was only at the conference where comparison mammograms were made available for 
review. The study concluded that FFDM with softcopy interpretation is well suited for 
breast cancer screening programs. 
Unlike the prior studies, the Swedish Helsingborg Study by Heddson et al. was a 
retrospective study that compared SFM, photon counting DR (PC-DR), and CR 
mammography from January 2000 to February 2005 (Heddson, et al., 2007). The goals were 
to evaluate cancer detection rates, recall rates, and PPV values in a screening population. A 
total of 52,172 screening mammograms were performed on 24,875 women during the study. 
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The Digital Mammography Imaging Screening Trial (DMIST) was sponsored by the 
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trial. However, it is important to know that recall was based on a consensus conference, and 
it was only at the conference where comparison mammograms were made available for 
review. The study concluded that FFDM with softcopy interpretation is well suited for 
breast cancer screening programs. 
Unlike the prior studies, the Swedish Helsingborg Study by Heddson et al. was a 
retrospective study that compared SFM, photon counting DR (PC-DR), and CR 
mammography from January 2000 to February 2005 (Heddson, et al., 2007). The goals were 
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Fifty percent of the studies were performed with SFM, 19% with photon counting DR 
system (Sectra, Sweden), and 31% with a CR system (Fujifilm, Japan). The age range of the 
patients was 46-74 years of age. Forty percent of the SFM cases and 65% of the FFDM cases 
were double read by two radiologists. Recall of the patient was based by consensus of the 
radiologists.  
Results of Helsingborg study demonstrated a statistically significant difference in the cancer 
detection rate for PC-DR versus SFM (P= 0.01) (Heddson et al., 2007). The cancer detection 
rates were 0.31% (81/25,901) for SFM, 0.49% (48/9841) for PC-DR, and 0.38% (63/16,430) for 
CR. In contrast to the Oslo studies, this study demonstrated a significantly higher recall rate 
for SFM than digital. The recall rate was for SFM, PC-DR, and CR were 1.4%, 1.0%, and 
1.0%. As a result of the higher cancer detection rate and lower recall rate, the PPV for digital 
was higher than film [(P< 0.001):  PC-DR = 47%, CR = 39% and film = 22%] (Heddson et al., 
2007). 
In addition to the above results, the Helsingborg Study demonstrated that digital 
mammography provided a dose reduction compared to film mammography as expected by 
its linear response to x-ray (Heddson et al., 2007).  PC-DR provided a 75% dose reduction 
and CR a 16% dose reduction. The average glandular dose was 0.28 mGy, 0.92 mGy, 1.1 
mGy, for PC-DR, CR, and SFM, respectively. The authors concluded that given the 


































Oslo I Prospective, paired 3,683 3,683 3.5 4.6 0.71 0.54 20.2 11.8 
Oslo II Prospective, randomized 16,985 6,944 2.5 4.2 0.38 0.59 15.1 13.9 
Helsingborg Retro-spective 25,901 9,841 1.4 1.0 0.31 0.49 21.8 47.1 
Florence Retro-spective 14,385 14,385 3.5 4.3 0.58 0.72 14.7 15.9 
Vestfold Retro-spective 324,763 18,239 4.2 4.1 0.65 0.77 15.1 18.5 
CELBSS Retro-spective 31,720 8,478 4.4 4.8 0.65 0.68 14.6 14.3 
Barcelona Retro-spective 12,958 6,074 5.5 4.2 0.42 0.41 7.5 9.7 
CELBSS = Central East London Breast Screening Service Study. 
 
Table 1. Published European studies comparing screen film mammography (SFM) and full 






Three of the European studies have been discussed above to give examples of designs and 
results. In total, there have been seven published European population-based screening 
studies comparing SFM and FFDM (Del Turco, 2007; Heddson, 2007; Sala, 2009; Skaane, 
2005, 2007; Vigeland, 2008; Vinnicombe, 2009). Table 1 compares the results. It is important 
to keep in mind when reviewing the data that each of the studies is of different design. Only 
the Oslo studies were prospective studies. The Oslo I was a paired-designed as were the US 
studies. Double reading was performed in the European studies followed by consensus or 
arbitration meetings for positive studies. In the US studies, each modality was interpreted 
using an independent reader blinded to the results of the other modality. The Colorado-
Massachusetts Screening Trial by Lewin et al. used a consensus conference, DMIST did not. 
In DMIST, if a single reader, regardless of modality, noted an abnormality then the patient 
was recalled. The recall rates reports vary in the studies; four of the European studies show 
a higher recall rate with digital (Del Turco, 2007; Skaane, 2005, 2007; Vinnicombe, 2009). In 
five of the studies, the cancer detection rate was greater for digital (Del Turco, 2007; 
Heddson, 2007; Skaane, 2007; Vigeland, 2008; Vinnicombe, 2009). Two were statistically 
significant: Oslo II and Helsingborg Study (Skaane, 2007; Heddson, 2007).  From these 
results, the utilization of digital screening mammography in the Western European 
Countries and the United States continues to increase.   
5. Image processing 
Image processing is the application of applying mathematical operations to the “raw” 
digital image with the aim to visualize subtle abnormalities so that they can be perceived by 
the radiologist as seen in Figure 20. Image processing should be robust and reproducible. 
The need for extra manipulation of the images should be none or very minimal for the 
radiologist. In addition, the radiologist should feel confident in reviewing the images. The 
unique property of digital is that each component of the system can be optimized.  A few of 
the basic methods used will be discussed. 
Intensity windowing algorithms are based on the principle that each acts on individual 
pixels in the image. A small portion of the full intensity range of the image is selected and 
then remapped to the full intensity range of the display (Pisano et al., 2000). With this 
process, it allows for the selection of specific intensity values of interest. Consequently, 
dense normal tissue and abnormal tissue values are exaggerated to accommodate for their 
small differences. This may result in increased lesion conspicuity. 
Manual Intensity Windowing (MIW) is one of the versions of intensity windowing. It is 
operator dependent. The radiologist manually windows and levels the images on a display 
system. Several examples are demonstrated in Figure 21. This can be quite variable 
depending on the radiologist’s image reading preference and experience. Another version is 
histogram-based. In this version, it allows the system to select a window to allow the full 
range of contrast across the part of the histogram representing any fatty, mixed, or dense 
portion. The advantage of HIW is that it can adapt to individual breast types. The third 
version is Mixture-Model Intensity Windowing (MMIW). It provides region-specific 
window settings: background, compressed and non-compressed fat, dense tissue, and 
muscle (Pisano et al., 2000). Examples of these are demonstrated in Figure 22. 
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process, it allows for the selection of specific intensity values of interest. Consequently, 
dense normal tissue and abnormal tissue values are exaggerated to accommodate for their 
small differences. This may result in increased lesion conspicuity. 
Manual Intensity Windowing (MIW) is one of the versions of intensity windowing. It is 
operator dependent. The radiologist manually windows and levels the images on a display 
system. Several examples are demonstrated in Figure 21. This can be quite variable 
depending on the radiologist’s image reading preference and experience. Another version is 
histogram-based. In this version, it allows the system to select a window to allow the full 
range of contrast across the part of the histogram representing any fatty, mixed, or dense 
portion. The advantage of HIW is that it can adapt to individual breast types. The third 
version is Mixture-Model Intensity Windowing (MMIW). It provides region-specific 
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muscle (Pisano et al., 2000). Examples of these are demonstrated in Figure 22. 
 




Fig. 20. Digital mammogram. a) Raw image. b) Processed image. (Courtesy of Fujifilm 
Medical, Stamford, CT) 
 
Fig. 21. Examples of different manual windowing and leveling of a digital mammogram that 






Fig. 22. Different post-processing algorithms (a) SFM of a cyst. (b-g) Photographic 
magnifications of a digital mammogram process with MIW (b), HIW (c), MMIW (d), 
CLAHE (e), unsharp masking (f), and peripheral equalization (g) (from RadioGraphics. 
Pisano et al. 2005. With permission). 
Adaptive Histogram Equalization (AHE) is a spatial enhancement method that changes 
pixel value based on spatial content. When applied to an image, there is enhancement of 
each pixel in relation to its local area. In doing so, all the gray values occur at an equal 
frequency in the image and consequently, the contrast of the background may be enhanced 
at the loss of contrast in the breast tissue (Karssemeijer, in Bick & Diekmann, 2010). In 
addition to the tissue contrast being increased in the image, so is noise. To limit noise, 
Contrast-Limited Adaptive Histogram Equalization (CLAHE) was developed. It limits the 
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maximum contrast adjustments by clipping and renormalizing the histogram (Pisano, 2000; 
Karssemeijer, 2010). 
Unsharp Masking (UM) is a post-processing technique that is created by subtracting a low-
pass filtered version of the original image from the original image (Chan et al., 1987). This 
process enhances high frequencies in the image such as calcifications and mass edges. A 
disadvantage of UM is that it also adds noise to the images. Also, it may falsely enhance a 
margin of a mass (i.e. an indistinct mass may appear more circumscribed and lead to 
inappropriate classification and follow-up of a mass instead of the need for a biopsy) 
(Pisano et al., 2000). 
Peripheral Equalization or Peripheral Enhancement (PE) is a post-processing technique 
developed to improve the visualization of the less compressed (and over penetrated) outer 
edges of the breast. A filter is used to obtain a blurred version of the mammogram 
representing tissue thickness. This blurred image “mask” is scaled from 0 to 1, and the 
mammogram is divided by means of the mask values on a pixel-by-pixel bases (Byng et al., 
1997). The applied algorithm acts on the pixels in the breast and where there is a thickness 
change. The result is that the pixels near the periphery are changed so the image becomes 
“flatter” across the mammogram and the periphery appears less black. 
Image processing is a vital component of digital mammography. We may find that it may 
take more than one algorithm and not necessarily “film-like display” to evaluate for masses, 
distortion and calcifications. Image processing algorithms are currently not assessed as part 
of QA protocols. However, they should be to ensure the image chain is working optimally. 
Automated systems may be of great importance for efficient use of technologist and 
physicist time in QA and QC. There is a great need to continue to develop and evaluate this 
area of digital mammography. 
6. Image display  
Image display of digital images can be performed with a laser printer onto hard copy “film-
like” medium or viewed on high-resolution computer monitors. Regardless of display type, 
it is important to know how the image is being seen relative to its full spatial resolution. 
Commercial laser printers for digital mammography can support spatial resolutions, grey 
scale and optical density similar to mammographic film.  If the images are printed with a 
laser printer, it may be done with 8, 10, or 12 bits per pixel displayed. If a digital 
mammography system uses larger bits than the printer, there will be loss of the dynamic 
range of digital image and the contrast scale will be compressed (Pisano et al., 2004). 
Consequently, not all the shades of grey can be displayed. If more than one version of the 
image is needed to display a finding, another image may need to be printed and this is a 
disadvantage. However, an advantage of laser-printed film is that it allows radiologists to 
use the same reading and workflow protocols as SFM.  
Softcopy display is performed with high-resolution mammography monitors that allow the 
flexibility of image display and contrast. An early study by Pisano et al. compared the speed 
and accuracy of the interpretation of Fischer digital mammograms on softcopy versus those 
on laser-printed film (Pisano et al., 2002). In the study, 8 radiologists interpreted 63 digital 
mammograms both on a prototype softcopy display system and on laser-printed film per 





radiologists read both conditions with at least one month between reads. Six cancers, 13 
biopsy-proven benign lesions, 23 probably benign findings and 20 normal cases were 
included. The results demonstrated that softcopy display interpretations tended to be faster 
than film: mean time 34 seconds versus 40.5 seconds. In contrast, the ROC curve and 
sensitivity favored film (0.67:0.71 for film and 0.65:0.69 for softcopy).  Specificity was slightly 
higher with softcopy (0.563 versus 0. 528), but not significant (Pisano et al., 2002). 
With specificity of softcopy as a concern, a retrospective study comparing the specificity for 
calcifications in digital mammograms using softcopy versus film was performed by Kim et 
al. in 2006 (Kim et al., 2006). Eight radiologists reviewed 130 biopsy-proven cases of 
calcifications on softcopy and screen film. For each condition, the radiologists were asked to 
rate the probability of malignancy on a 5-point scale. For film, the radiologists could use a 
magnifying glass for further evaluation of the images, and for softcopy they could “roam 
and zoom” to manually window for contrast. The study concluded that there was no 
statistically significant difference in specificity achievable using softcopy digital versus 
screen-film mammography. 
For radiologists using softcopy display for interpretations, appropriate room ergonomics 
and viewing conditions are absolutely necessary to minimize radiologist distractions and 
fatigue. Vendors need to continue developing hanging protocols and other tools that allow 
the radiologists to view all digital images with little manipulation of buttons or clicks of the 
mouse. 
7. Digital imaging and clinical workflow 
7.1 Clinical workflow 
Digital mammography has transformed our everyday working environment. For many, 
gone are the days of darkrooms with wet chemical processing and the challenges associated 
with them. Film screen mammography view boxes are being used less each day as softcopy 
display becomes more familiar to the radiologist. Digital mammography images can be 
viewed from anywhere, and the trend for comparisons to be on softcopy is becoming 
apparent. Also, with prior studies being in digital format, the number of lost or missing 
priors has decreased. Files rooms with overcrowded shelves and stacks of folders piled on 
the floor are starting to disappear as picture archiving systems (PACS) with electronic 
storage are used. 
Digital mammography has also had a large impact on patient throughput. Technologist 
image acquisition and processing time with direct radiography (DR) digital mammography 
has been significantly decreased in both screening and diagnostic mammography (Berns, 
2006; Kuzmiak, 2010). In the DR FFDM digital screening study by Berns et al., they studied 
the timed comparison of 183 hard-copy SFM cases and 181 FFDM softcopy display cases. 
Their results demonstrated a 7.5 min/case (35%) time savings over SFM (Berns et al., 2006).   
Results were similar in the diagnostic timed mammography study by Kuzmiak et al. 
(Kuzmiak et al., 2010).  This prospective study consisted of 3 phases: 1st Phase, 100 patients 
imaged with SFM; 2nd Phase, 100 patients imaged on DR FFDM and interpreted on a 
recently installed softcopy display mammography system; 3rd Phase, same as 2nd Phase but 
3-months after installation of the softcopy display system. Their results showed the 
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maximum contrast adjustments by clipping and renormalizing the histogram (Pisano, 2000; 
Karssemeijer, 2010). 
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margin of a mass (i.e. an indistinct mass may appear more circumscribed and lead to 
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Peripheral Equalization or Peripheral Enhancement (PE) is a post-processing technique 
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distortion and calcifications. Image processing algorithms are currently not assessed as part 
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it is important to know how the image is being seen relative to its full spatial resolution. 
Commercial laser printers for digital mammography can support spatial resolutions, grey 
scale and optical density similar to mammographic film.  If the images are printed with a 
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and accuracy of the interpretation of Fischer digital mammograms on softcopy versus those 
on laser-printed film (Pisano et al., 2002). In the study, 8 radiologists interpreted 63 digital 
mammograms both on a prototype softcopy display system and on laser-printed film per 
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higher with softcopy (0.563 versus 0. 528), but not significant (Pisano et al., 2002). 
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al. in 2006 (Kim et al., 2006). Eight radiologists reviewed 130 biopsy-proven cases of 
calcifications on softcopy and screen film. For each condition, the radiologists were asked to 
rate the probability of malignancy on a 5-point scale. For film, the radiologists could use a 
magnifying glass for further evaluation of the images, and for softcopy they could “roam 
and zoom” to manually window for contrast. The study concluded that there was no 
statistically significant difference in specificity achievable using softcopy digital versus 
screen-film mammography. 
For radiologists using softcopy display for interpretations, appropriate room ergonomics 
and viewing conditions are absolutely necessary to minimize radiologist distractions and 
fatigue. Vendors need to continue developing hanging protocols and other tools that allow 
the radiologists to view all digital images with little manipulation of buttons or clicks of the 
mouse. 
7. Digital imaging and clinical workflow 
7.1 Clinical workflow 
Digital mammography has transformed our everyday working environment. For many, 
gone are the days of darkrooms with wet chemical processing and the challenges associated 
with them. Film screen mammography view boxes are being used less each day as softcopy 
display becomes more familiar to the radiologist. Digital mammography images can be 
viewed from anywhere, and the trend for comparisons to be on softcopy is becoming 
apparent. Also, with prior studies being in digital format, the number of lost or missing 
priors has decreased. Files rooms with overcrowded shelves and stacks of folders piled on 
the floor are starting to disappear as picture archiving systems (PACS) with electronic 
storage are used. 
Digital mammography has also had a large impact on patient throughput. Technologist 
image acquisition and processing time with direct radiography (DR) digital mammography 
has been significantly decreased in both screening and diagnostic mammography (Berns, 
2006; Kuzmiak, 2010). In the DR FFDM digital screening study by Berns et al., they studied 
the timed comparison of 183 hard-copy SFM cases and 181 FFDM softcopy display cases. 
Their results demonstrated a 7.5 min/case (35%) time savings over SFM (Berns et al., 2006).   
Results were similar in the diagnostic timed mammography study by Kuzmiak et al. 
(Kuzmiak et al., 2010).  This prospective study consisted of 3 phases: 1st Phase, 100 patients 
imaged with SFM; 2nd Phase, 100 patients imaged on DR FFDM and interpreted on a 
recently installed softcopy display mammography system; 3rd Phase, same as 2nd Phase but 
3-months after installation of the softcopy display system. Their results showed the 
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diagnostic mammographic acquisition times with processing were 13.02 min/case for SFM 
(Phase 1), 8.16 min/case for digital (Phase 2), and 10.66 min/case for digital (Phase 3). All 
phases also included the measured time for additional imaging that was requested by the 
interpreting study radiologists. Compared to SFM, acquisition time for Phase 2 and 3 digital 
were significantly less (P < .001 and P < .0001, respectively). For Phase 2 & 3 digital, there 
was a 4.86 min/case (37.3%) and 2.36 min/case (18.1%) time savings compared to SFM 
(Kuzmiak et al., 2010).  
Regardless of reason for the mammogram, the main reason for the time savings is the 
elimination of processing time with DR mammography. The technologist no longer has to 
leave the exam room with SF cassettes to develop. With SFM, each film takes approximately 
90 seconds to develop. This time is now saved. The technologist now can review the images 
on a 1-megapixal monitor after exposure while the patient is still in the room. After initial 
review by the technologist for positioning and technique, the images are sent to PACS with 
a push of a button or touch of a screen. 
As part of the clinical workflow, there has been the concern of radiologist interpretation 
time with digital mammography. Berns et al. published average interpretation times, 
interpreted by seven radiologists, for their screening study of 1.2 minutes for SFM and 2.0 
minutes for DR FFDM (Berns et al., 2006). Study results by Haygood et al. showed similar 
results in longer interpretation times with digital (Haygood et al., 2009). Haygood’s study 
included 4 radiologists who were timed in clinical interpretation of 457 screening 
mammograms consisting of 189 SFM and 268 digital mammograms. They reported 
increased interpretation times for digital ranging from 1.27 to 3.37 minutes. The average 
interpretation time for all readers for SFM was 2.12 minutes and 4.0 minutes for digital 
(Haygood et al., 2009). 
In contrast to the above screening studies, Kuzmiak et al. found the radiologist 
interpretation time for digital mammography on softcopy display was not significantly 
different from that for film mammography in a diagnostic mammography setting (P = 
.2853 and P = .2893, respectively) (Kuzmiak et al., 2010). The mean interpretation times 
were 3.75 min/case for screen film (Phase 1), 2.14 min/case for digital (Phase 2), and 2.26 
min/case for digital (Phase 3).  The results provide support to radiologists for conversion 
to direct radiographic digital mammography for clinical use and that radiologists 
planning on using softcopy display systems must have appropriate training to optimize 
throughput. In addition, softcopy display manufacturers should continue to improve the 
functionality and ergonomics of their products to make softcopy interpretation more 
efficient. 
7.2 Electronically generated report 
With softcopy display systems an electronically generated reporting system can be 
integrated with it. Numerous vendors are available and each has different functions 
depending on radiologist preference. With these systems, mammograms and other imaging 
reports can be dictated (generated) and electronically signed off. Thus, it decreases the time 







Digital mammography decouples the process of image acquisition, processing and display 
so that each component can be optimized. The digital format has allowed the development 
of additional software to aid the radiologist in lesion detection – computed aided detection. 
We are now able to view mammography images and interpret them from other clinical sites 
in different parts of the city, state, or country through televideo. Other emerging 
technologies such as three dimensional tomosynthesis are now entering clinical use. Digital 
technology has changed mammography over the last decade, and it will continue to change 
it for decades to come. It will be interesting to see what the future holds for our patients and 
us. 
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diagnostic mammographic acquisition times with processing were 13.02 min/case for SFM 
(Phase 1), 8.16 min/case for digital (Phase 2), and 10.66 min/case for digital (Phase 3). All 
phases also included the measured time for additional imaging that was requested by the 
interpreting study radiologists. Compared to SFM, acquisition time for Phase 2 and 3 digital 
were significantly less (P < .001 and P < .0001, respectively). For Phase 2 & 3 digital, there 
was a 4.86 min/case (37.3%) and 2.36 min/case (18.1%) time savings compared to SFM 
(Kuzmiak et al., 2010).  
Regardless of reason for the mammogram, the main reason for the time savings is the 
elimination of processing time with DR mammography. The technologist no longer has to 
leave the exam room with SF cassettes to develop. With SFM, each film takes approximately 
90 seconds to develop. This time is now saved. The technologist now can review the images 
on a 1-megapixal monitor after exposure while the patient is still in the room. After initial 
review by the technologist for positioning and technique, the images are sent to PACS with 
a push of a button or touch of a screen. 
As part of the clinical workflow, there has been the concern of radiologist interpretation 
time with digital mammography. Berns et al. published average interpretation times, 
interpreted by seven radiologists, for their screening study of 1.2 minutes for SFM and 2.0 
minutes for DR FFDM (Berns et al., 2006). Study results by Haygood et al. showed similar 
results in longer interpretation times with digital (Haygood et al., 2009). Haygood’s study 
included 4 radiologists who were timed in clinical interpretation of 457 screening 
mammograms consisting of 189 SFM and 268 digital mammograms. They reported 
increased interpretation times for digital ranging from 1.27 to 3.37 minutes. The average 
interpretation time for all readers for SFM was 2.12 minutes and 4.0 minutes for digital 
(Haygood et al., 2009). 
In contrast to the above screening studies, Kuzmiak et al. found the radiologist 
interpretation time for digital mammography on softcopy display was not significantly 
different from that for film mammography in a diagnostic mammography setting (P = 
.2853 and P = .2893, respectively) (Kuzmiak et al., 2010). The mean interpretation times 
were 3.75 min/case for screen film (Phase 1), 2.14 min/case for digital (Phase 2), and 2.26 
min/case for digital (Phase 3).  The results provide support to radiologists for conversion 
to direct radiographic digital mammography for clinical use and that radiologists 
planning on using softcopy display systems must have appropriate training to optimize 
throughput. In addition, softcopy display manufacturers should continue to improve the 
functionality and ergonomics of their products to make softcopy interpretation more 
efficient. 
7.2 Electronically generated report 
With softcopy display systems an electronically generated reporting system can be 
integrated with it. Numerous vendors are available and each has different functions 
depending on radiologist preference. With these systems, mammograms and other imaging 
reports can be dictated (generated) and electronically signed off. Thus, it decreases the time 
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of additional software to aid the radiologist in lesion detection – computed aided detection. 
We are now able to view mammography images and interpret them from other clinical sites 
in different parts of the city, state, or country through televideo. Other emerging 
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1. Introduction  
Mammography is currently considered to be the best tool for early detection of breast 
cancer. The target groups of most of the population-based screening programmes are 
women aged between 50 and 65 years. A recent study has also shown mortality benefit in 
the age group 40-49 (Hellquist, et al, 2010). Screen-film mammography has been to date the 
traditional test for breast screening having been shown its efficacy in reducing breast cancer 
mortality in large randomised trials (Duffy, et al, 2006). The potential advantages of digital 
mammography over screen-film techniques have been the subject of several investigations 
which provides an improved diagnosis in dense breasts and an increase in breast cancer 
detection rate (Pisano et al, 2006; Hendrick et al, 2010).  
Breast screening using X-ray mammography only confers a benefit on the screened 
population if it is able to detect breast cancer at an early stage, whereby the prognosis is 
improved. This can only be achieved by having high quality breast images to assure as 
much as possible the detection of small and subtle lesions in the breast (Muller, 
1997;Karellas, 2004; Lewin, 2004; ICRU, 2009). High quality mammography must be 
achieved and maintained by applying rigorous and comprehensive quality assurance and 
control programmes. 
The quality of the breast images depends critically on the design and performance of the 
radiographic unit, the image receptor, and on how that equipment is used to acquire and 
process the mammogram. The type of display and the conditions under which the image is 
viewed have an important effect on the ability of the radiologist to extract the information 
recorded in the mammogram. The diagnostic information is integrally related to the quality 
of the image and higher image quality will result in more accurate diagnosis (Nishikawa, 
2004). The systematic monitoring of both image quality and radiation dose is needed to 
 
Imaging of the Breast – Technical Aspects and Clinical Implication 
 
114 
Tabar L, Vitak B, Chen T, et al. Swedish Two-County Trial: Impact of mammographic 
screening on breast cancer mortality during 3 decades. Radiology 2011; 206(3):658-
670. 
Thunberg S, Francke T, Egerstrom J, et al. Evaluation of a photon counting mammography 
system. In: Antonuk LE, Yaffe MJ (eds) Medical Imaging 2002: physics of medical 
imaging. Proceeding of SPIE vol 4682.  
Van Ongeval C, Jacobs J, Bosmans H. Classification of artifacts in clinical digital 
mammography. In Bick U, Diekmann F (eds), Digital Mammography. Springer, 
Berlin, 2010. 
Van Steen a, Van Tiggelen R. Short History of Mammography: A Belgian Perspective. JBR-
BTR 2007; 90:151-153. 
Vigeland E, Klaasen H, Klingen TA, et al. Full field digital mammography compared to 
screen film mammography in the prevalent round of a population-based screening 
program: the Vestfold County study. Eur Radiol 2008; 18:183-191. 
Vinnicombe S, Tinto Pereira SM, McCormack VA, et al. Full field digital versus screen film 
mammography: comparison within the UK breasts screening program and 
systematic review of published data. Radiology2009;251:347358. 
www.acr.org/SecondaryMainMenuCategories/quality_safety/BIRADSAtlas/BIRADSAtlas
excerptedtext/MammographyFourthEdition.aspx. Accessed August 2,2011. 
www.cdc.gov/cancer/breast/statistics/Accessed Aug 1, 2011. 
Yaffe MJ. Basic physics of digital mammography. In Bick U, Diekmann F (eds), Digital 
Mammography. Springer, Berlin, 2010. 
Yaffe MJ. Detectors for Digital Mammography. In Bick U, Diekmann F (eds), Digital 
Mammography. Springer, Berlin, 2010. 
Young KC, Alsager A, Oduko JM, et al. Evaluation of software for reading images of the 
CDMAM test object to assess digital mammography systems. Proc SPIE Med 
Imaging 2008; 69131C:1-11. 
Young KC. Quality control in digital mammography. In Bick U, Diekmann F (eds), Digital 
Mammography. Springer, Berlin, 2010. 
5 
Image Quality Requirements  
for Digital Mammography  
in Breast Cancer Screening 
Margarita Chevalier1, Fernando Leyton2,3, Maria Nogueira Tavares3,  
Marcio Oliveira3, Teogenes A. da Silva3 and João Emilio Peixoto4  
1Complutense University of Madrid 
2Diego Portales University 
3Centro de Desenvolvimento da Tecnologia Nuclear 




1. Introduction  
Mammography is currently considered to be the best tool for early detection of breast 
cancer. The target groups of most of the population-based screening programmes are 
women aged between 50 and 65 years. A recent study has also shown mortality benefit in 
the age group 40-49 (Hellquist, et al, 2010). Screen-film mammography has been to date the 
traditional test for breast screening having been shown its efficacy in reducing breast cancer 
mortality in large randomised trials (Duffy, et al, 2006). The potential advantages of digital 
mammography over screen-film techniques have been the subject of several investigations 
which provides an improved diagnosis in dense breasts and an increase in breast cancer 
detection rate (Pisano et al, 2006; Hendrick et al, 2010).  
Breast screening using X-ray mammography only confers a benefit on the screened 
population if it is able to detect breast cancer at an early stage, whereby the prognosis is 
improved. This can only be achieved by having high quality breast images to assure as 
much as possible the detection of small and subtle lesions in the breast (Muller, 
1997;Karellas, 2004; Lewin, 2004; ICRU, 2009). High quality mammography must be 
achieved and maintained by applying rigorous and comprehensive quality assurance and 
control programmes. 
The quality of the breast images depends critically on the design and performance of the 
radiographic unit, the image receptor, and on how that equipment is used to acquire and 
process the mammogram. The type of display and the conditions under which the image is 
viewed have an important effect on the ability of the radiologist to extract the information 
recorded in the mammogram. The diagnostic information is integrally related to the quality 
of the image and higher image quality will result in more accurate diagnosis (Nishikawa, 
2004). The systematic monitoring of both image quality and radiation dose is needed to 
 
Imaging of the Breast – Technical Aspects and Clinical Implication 
 
116 
guarantee a constant high quality of the mammography examination (ICRU, 2009; Ng, 
2005). Conventional film/screen mammography is being gradually substituted by digital 
technology in most countries. Consequently, there is an important activity related with 
developing quality control protocols adapted to this new digital technologies (CEC,2006; 
SEFM, 2008;NHSBSP, 2009; IAEA, 2011). 
Data retrieved from programmes in the Netherlands (Beckers, 2003), Sweden (Leitz, 2001), 
Norway (Pedersen, 2000) and the UK (NHSBSP, 2003) show that the levels of DG in screen-
film mammography range between 0.8 and 2.5 mGy for a 5.3 cm compressed breast 
thickness. Thus, several national and international protocols have established an accepted 
DG limit of 2.5 mGy for a 5.3 cm standard breast thickness. Data from a European survey 
(Report EUR 14821, 2001) on radiation doses developed in 56 mammography institutions 
showed DG values ranging from 1.0 to 3.0 mGy for 6.0 cm thick breasts. This value was 
established from measurements using an acrylic simulator. 
This chapter is devoted to describe the relevant parameters and procedures for the quality 
control of digital mammography systems making the necessary distinctions among the two 
technologies (computed radiography (CR) and flat panel detectors (DR)).  
2. Detectors for digital mammography 
2.1 Flat panel Systems – DR 
Flat panel systems (DR) have an active matrix of electronic detectors where each element 
absorbs the radiation transmitted through mammary tissue, producing an electrical signal 
proportional to the intensity of the X-rays.  
2.1.1 Indirect capture of an image 
In the indirect capture of an image, a flat screen scintillator, a photodiode circuitry layer, and a 
TFT array are used (Fig. 1). Caesium iodide crystals (CsI(Tl)) are the scintillators usually 
employed. CsI(Tl) crystals are structured in an array of thin needles that guide the light photon 
reducing the light diffusion within the scintillator layer. The light is captured by the elements 
of the photodiode matrix (amorphous silicon), which converts the light into electrical current. 
These amorphous silicon sensors (a-Si) are connected to a matrix of thin-film transistors (TFT) 
which store the information of each pixel up to the moment of its reading by the scan circuit in 
the detector (Vedantham, 2000; Suryanarayanan, 2004; Peixoto, 2009). 
2.1.2 Direct capture of an image 
In the direct capture mode, an amorphous selenium plate (a-Se) photoconductor is used to 
convert the incident X-ray photons into electron-hole pairs (Yaffe, 1997, Peixoto, 2009). Each 
charge of the electron-hole pair created is attracted by the corresponding electrode under the 
action of the strong electric field applied between the electrodes. The created charge is 
accumulated and stored by a TFT matrix (Fig. 2). 
2.2 Computed radiography system – CR 
Computed radiography (CR) is a process comparatively similar to the conventional screen-
film system. The film is replaced by a plate (IP) made up of photostimulable phosphorus  
 




Fig. 1. Indirect method of image acquisition with CsI(Tl)/a-Si. The CsI scintillators hold 
needle structures and work as channels which guide the light perpendicularly to the surface 
of the photodiodes (Peixoto, 2009). 
 
Fig. 2. Method of direct acquisition of an image with a-Se (Peixoto, 2009). 
(PSP) which is introduced into a cassette of similar characteristics than the one used with the 
film.  
Inside the cassette, the photostimulable phosphorus plate is used to absorb and store the 
energy of the X-ray transmitted through the breast, thus producing a ‘latent image’. The 
energy stored in the phosphorous plate is associated to the electrons raised to excited levels 
of energy in which they hold trapped (“F-centre”). This is the non-observable electronic 
latent image, where the number of electrons trapped is proportional to the number of 
incident X-ray photons (Marcelino V.A. Dantas., 2010). As follows, the cassette is inserted 
into the reading unit (Fig. 3). Inside this unit, the plate is scanned with a low energy intense 
laser light (~ 2 eV) which is highly focused. The electrons trapped in the phosphorus 
photostimulable matrix (PSP) are stimulated by the laser energy, and a significant fraction 
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returns to the lowest energy level with a simultaneous emission of a higher energy photo-
stimulated luminescence (PSL) (~ 3 eV). The intensity of the PSL, proportional to the 
number of electrons emitted, is captured by a light guide system near the IP (Fig. 4). A 
photomultiplier tube (PMT) at the output of the light guide amplifies and converts the PSL 
into a corresponding output voltage (Rowlands, 2002; Dantas, 2010). 
 
Fig. 3. Image digitiser for CR Systems (Alvarenga, 2008). 
 
Fig. 4. Image acquisition for the CR system: (a) single reading; (b) double reading (Peixoto, 
2009). 
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The residual latent image information is erased through an intense light which removes the 
electrons not released by the laser stimulation, and the IP returns to the cassette “reset” and 
ready to be reused. 
The diagram of the whole process involving the image acquisition with a CR system is 
shown in Fig. 5 (left).  
 
Fig. 5. Acquisition process, processing and visualisation of mammography images CR 
(Alvarenga, 2008).  
3. Parameters with the greatest impact on dose and image quality 
The objective of mammography is to provide the early detection of cancer, and therefore the 
image quality is a fundamental aspect. The image with a suitable diagnostic-quality has to 
be acquired with a radiation dose as low as possible. Nowadays, it is widely accepted that 
mean glandular dose (DG) is the best indicator to estimate the risk associated with breast 
irradiation in mammography (see definition in SectionV). Both factors, image quality and 
DG, are depending on breast characteristics (glandularity and thickness), exposure factors 
(beam quality, exposure time and compression force), detector features and mammography 
system performance (automatic exposure control) and characteristics (geometry, focal spot 
size). 
3.1 Characteristics of the breast  
Breast composition varies among women due to different proportion of glandular, fibrous 
and adipose tissue. The composition also changes with the age of the woman such that the 
proportion of adipose tissue increases with age.  
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Differences among the x-ray attenuation properties of the different breast tissues can be 
observed at the breast images. Glandular and fibrous tissues are visualised in mammography 
as radio-opaque whereas the adipose tissues are observed as radio-lucent (dark). Therefore, 
given the same compressed breast thickness a dense breast (having a higher proportion of 
glandular tissues) absorbs a higher amount of radiation than an adipose breast. 
The lesions of interest for diagnosis are microcalcifications, masses, asymmetries and 
distortions of the breast architecture. Microcalcifications are small (100 µm) and “easily” 
detected regardless of breast density. The masses tend to have low contrast, making it 
difficult to detect. Therefore, mammography must have - besides optimal resolution - good 
contrast, which makes visible those anatomic structures and pathological signs which have 
very similar densities. 
3.2 The compression system 
A proper compression of the breast is fundamental to provide a good quality image. Breast 
compression brings the structures close to the detector enhancing sharpness, prevents breast 
movement, reduces the breast thickness penetrated by X-rays and reduces the scattered 
radiation. All these factors improve the contrast and even reduce the absorbed dose 
(Karellas, 2004). In addition, the exposure factors in modern mammography systems are 
automatically selected in base of the compressed breast thickness. Quality control 
programmes have to include procedures to verify the compression force and the accuracy of 
the breast thickness determined by the system.  
3.3 Automatic exposure control 
In mammography, the automatic exposure control (AEC) (also known as “photo timer”) 
cuts off the exposure when arrives to the AEC radiation sensor, which lies below the anti-
scatter grid and the image receptor, the necessary dose resulting in optimum optical density 
or pixel value. The sensor can be placed at several positions (3 in most of the units) between 
the thorax and the nipple in depending of the breast size. 
Flat panel detectors of digital mammography units operate as AEC sensors. In this case, the 
information can be derived from the whole area of the detector or from predefined  
regions.  
The AEC of most modern mammography units uses the information associated with a pre-
exposure to determine the attenuation of the breast. This information along with the breast 
thickness automatically detected (compressor) determines all the exposure factors 
(anode/filter, kV, mAs).  
The AEC is committed to provide images with an appropriate optical density, 
independently from the beam quality and the characteristics of the breast. Thus, there is a 
guarantee that the information will be registered in the linear region of the characteristic 
curve of the film.  
In digital systems, the main role of the AEC is to assure that signal noise ratio (SNR) and 
contrast noise ratio (CNR) are adequate throughout the image and that the dose values 
comply with recommendations. 
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3.4 X-ray spectrum 
For both digital and screen-film detection techniques, the energy spectrum of the X-ray 
beam (including their filtering) is of a great concern when evaluating the performance of the 
mammographic systems, demanding careful and accurate quality controls in a clinical 
environment.  
 
Fig. 6. X-ray spectra for 30 kVp operating potential for Mo/Mo (a), Mo/Rh (b), Rh/Rh (c), 
and W/Rh (d) source/filter assemblies (NCRP 149, 2005). 
The attenuation coefficient of the glandular tissue is similar to that of the tumour tissue 
which makes difficult the visualization of smaller tumours; low energy X-ray beam is 
needed to demonstrate the subtle density differences between non-calcified normal and 
abnormal tissues. X-ray tubes of mammography systems are equipped with special 
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3.4 X-ray spectrum 
For both digital and screen-film detection techniques, the energy spectrum of the X-ray 
beam (including their filtering) is of a great concern when evaluating the performance of the 
mammographic systems, demanding careful and accurate quality controls in a clinical 
environment.  
 
Fig. 6. X-ray spectra for 30 kVp operating potential for Mo/Mo (a), Mo/Rh (b), Rh/Rh (c), 
and W/Rh (d) source/filter assemblies (NCRP 149, 2005). 
The attenuation coefficient of the glandular tissue is similar to that of the tumour tissue 
which makes difficult the visualization of smaller tumours; low energy X-ray beam is 
needed to demonstrate the subtle density differences between non-calcified normal and 
abnormal tissues. X-ray tubes of mammography systems are equipped with special 
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anode/filter combinations, such as Mo/Mo or Mo/Rh, operating in the 25-35 kVp range. 
The spectra of several anode/filter combinations (Fig. 6) show the important proportion of 
of X-rays characteristics (17.5 and 19.7 keV) from the molybdenum target and the strong 
suppression of the spectrum at energies >20 keV because of the k-shell absorption edge of 
the molybdenum filter (Fig. 6a) or else higher than 23 keV because of the Rh filter (Fig. 6b). 
The characteristics of the new digital detectors make it possible to use other anode/filter 
combinations such as Rh/Rh (Fig. 6c), W/Rh (Fig. 6d), W/Ag and W/Al which have some 
advantages for imaging dense or thick breasts. In addition, the breast doses associated with 
these combinations are lower than those delivered with Mo/Mo or Mo/Rh. 
The adequate selection of the spectrum (beam) may reduce the dose values above 20% 
(Young, 2006; Dance, 2000; Riabi, 2010). The threshold value for breast thickness where the 
spectrum is changed depends on the AEC calibration which is performed by technical 
services who install the equipment (which should be done together with those medical staff 
who use the equipment). The correct selection of the X-ray beam will strongly influence the 
dose and image quality. 
4. Image quality in mammography 
Image quality is a fundamental concept for the control and optimisation of mammography; it 
aims to improve the early detection of cancer and other pathological lesions  in the breasts. The 
image quality can be quantified by measuring the contrast noise ratio, the signal noise ratio, 
the modulation transfer function (MTF) (spatial resolution), the noise, the uniformity and 
various artefacts such as the ghost image. In order to assess these physical parameters, 
phantoms and more specific devices are needed to perform quality control in mammography. 
The current trend is to utilise a contrast-detail phantom (CDMAM) which permits the 
assessment of the image quality as a function of the contrast threshold associated with the 
circular objects of different diameters and thickness (SEFM, 2008). The “clinical ”assessment of 
the image quality is better performed by means of the receiver operating curve (ROC) 
methodology. Unfortunately, this type of analysis is far too complex and is time consuming. In 
addition, it is required a database with too many images, which makes its application difficult 
in the clinical practice of routine image quality control (NCRP, 2005). 
4.1 MTF 
The modulation transfer function (MTF) is a quantitative and objective measurement of the 
image quality that can be provided by a system. MTF gives information about the 
magnitude of the object contrast which is transferred to the image as a function of the spatial 
frequency. The low spatial frequencies correspond to rough details, whereas the high ones 
define the fine details or the edges of the structures. For example, an MTF with a value of 0.5 
for a determined frequency means that the inherent modulation (contrast) of the object will 
diminish at 50% given the limitations of the image system (ICRU, 2009) (Fig. 7). 
In practice, the MTF is determined through the Fourier transform of the line spread function 
(LSF), which is obtained through the differentiation of the edge response (ESF). 
Spatial resolution is expressed in terms of spatial frequency, which in turn is associated with 
a MTF value. 
 




Fig. 7. Modulation transfer function of mammography systems (ICRU, 2009). 
4.2 Noise  
The main component of noise in radiographic images is the quantum noise, which is 
associated with the statistical fluctuations in the photons’ fluence on the detector and with 
the random variations in the absorption. The simplest way to define the noise is through a 
measurement of the standard deviation (sd) of the number of photons absorbed (N) in a 
region of the detector. This figure complies with Poisson statistics, and therefore sd = N0.5 
(i.e., the sd is related to the square root of the Kerma) (Chevalier, 2010). 
The structural noise in the digital detectors emerges mainly from the lack of homogeneity in 
the sensitivity of the elementary detectors (i.e., from the fixed spatial variation of the image 
detecting structure), which means that it is also proportional to the dose. Moreover, this 
noise causes the appearance of a structured background in the image, which is usually 
removed through the flat field techniques. These techniques include the creation of a 
corrective mask from a direct and uniform image of the X-ray beams (Chevalier, 2010). 
In digital systems, what has to be added to these two types of noise is the electronic one, 
which emerges from the electronic readout outside the pixels and in the amplification of the 
signal and which does not depend on the dose. The electronic noise owes essentially to the 
dark noise in the detectors and decreases if the temperature of the surroundings is lowered 
or reduced. Therefore, the digital equipment has to operate in temperatures at intervals 
between 20-30 ºC. 
4.3 Uniformity 
The initial operation which usually occurs is a "flat-field", a correction of the uniformity of 
gain. The non-uniformity of the sensitivity of the detector is corrected through a gain map 
and is also used to correct all the images acquired. Moreover, if an element of a single (pixel) 
detector is defective its signal can be replaced with a reasonable combination of adjacent 
detector signals. This is acceptable if the defective detectors are isolated and only few of 
them are faulty. Detectors of the CR type presents a lack of uniformity due to the heal effect 
that is very depending on the X-ray unit. 
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Artefacts are undesirable characteristics which are not related to the mammary anatomic 
structures of a radiographic image. They can hinder the image by hiding or simulate a lesion 
on detection. 
Artefacts can be caused by the source of X-rays, the beam filter, the compression device, 
breast support, grid, and flaws in processing, amongst others. In digital mammography, 
besides the sources just cited, the non-uniformity in the response of the elemental detectors 
may also generate artefacts, owing to the results of an inadequate flat-fielding. Another 
drawback in the digital system is the presence of reminiscent images (ghost images), 
resulting from previous exposures (ICRU, 2009). The latest appears more often with CR 
systems or aSe based flat panel detectors. 
5. Dosimetry in mammography 
One of the pillars underpinning the analysis of the risks-benefits of mammography is the 
accurate knowledge of the imparted doses, since it is well-established that there is an 
association between breast dose and the increased incidence of breast cancer. Assessments 
of breast doses are particularly important in breast screening programmes in which large 
groups of asymptomatic women undergo mammographic examinations. As in other 
radiological examinations, dose values are indicative of the diagnostic adequacy of the 
mammography technique selected in clinical practice. In addition, knowledge of dose values 
is essential for optimisation strategies developed to minimise doses while maintaining the 
necessary image quality. 
The X-ray spectrum in mammography is of low energy and the depth dose within the breast 
decreases rapidly. Due to this, it is important to use a dosimetric quantity which gives a 
measure of the dose to the whole organ. Glandular tissue is the most vulnerable in the breast 
as compared to adipose, skin and areolar (nipple) tissues (Hammerstein et al., 1979). At 
present, it is widely accepted that mean glandular dose (DG) is the most appropriate 
dosimetric quantity to predict the risk of radiation carcinogenesis. Therefore, this quantity 
has been recommended by several national and international organisations (NCRP, 1986; 
IPSM, 1989; IAEA, 2007) and it is the quantity used in many national protocols for 
mammographic quality assessment (CEC, 1996, 2006; ACR, 1999; IAEA, 2007). The factors 
that affect DG are the X-ray beam quality and breast thickness and composition. These two 
latter parameters have a larger variability than the former, varying both within and between 
populations, and the latter with women’s age as well. Even when the average glandularity 
would be the same, its distribution is unpredictable and changes from breast to breast. 
Direct measurements of DG are not possible for individual breasts and, therefore, DG is 
derived from the entrance surface dose (or a related quantity) using adequate conversion 
factors (ICRU, 2005; NCRP, 2004). These factors were initially measured (Hamerstein, 1979; 
Stanton, 1984) and further calculated by means of Monte Carlo techniques (Rosenstein, 1980; 
Dance, 1990, 2000, 2009; Wu et al, 1991, 1994; Klein et al., 1997; Boone et al., 2002). This latter 
approach allows for the possibility of estimating conversion factors for a wide range of 
input spectra and breast features. Differences among the conversion factors (cG) obtained by 
several authors mainly arise from differences in breast model geometry, mammographic X-
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ray spectral data, photon interaction cross-sections and Monte Carlo codes. Other important 
factors affecting the calculations are the mammography system’s characteristics and the 
imaging system components and geometry. The differences in cG values quoted by different 
authors were as high as 15-16% (Klein, 1997; ICRU, 2005; Dance 2000).  
The breast model most commonly adopted (Fig. 8) has a central region consisting of a 
homogeneous mixture of adipose and glandular tissue surrounded by a layer at all sides, 
except for the one corresponding to the chest wall representing the skin. It is assumed that 
the breast is firmly compressed by a polycarbonate compression paddle. The percentage of 
breast glandularity is defined as the fraction by weight of glandular tissue at the central 
region (without skin). Most authors employ the elemental tissue composition published by 
Hammerstein et al. (1979).  
Initially, it was assumed that a 50:50 mixture of adipose and glandular tissues was 
representative of a typical breast (Hammerstein, 1979). On this basis, phantoms of several 
thicknesses were constructed assuming this “standard” composition with the aim of 
facilitating DG estimates in the practice. This assumption implied that the fraction of 
glandular tissue was independent of compressed breast thickness. On the basis of this data, 
the standard “phantom” was defined as a 4.5 cm thickness of PMMA, representing the 
“standard breast” (4 cm thick and 50%/50% glandular/adipose tissue) (IPEM, 1989; CEC, 
1996). Data indicating that the composition of the average compressed breast deviates from 
the 50:50 composition has been published (Geise, 1996; Klein et al., 1997; Young et al., 1998; 
Chevalier, 1998; Beckett, 2000; Zoetelief et al., 2006). In addition, it was found that breast 
glandularity decreases when the compressed breast thickness increases. In some of these 
works it is also determined that the equivalent thickness of PMMA gives the same incident 
air kerma at its upper surface as for that of a breast of a specified thickness and composition 
(Geise, 1996; Dance et al., 2000, 2009; Kruger, 2001; Argo, 2004).  
 
Fig. 8. Breast model geometry. The rectangular section represents a vertical cross-section 
through the breast coplanar with the focal spot of the X-ray tube. The D-shape section 
represents the breast in craniocaudal projection. The shaded and outer regions represent, 
respectively, the breast parenchyma and the skin (0.5 cm of adipose tissue). In the work of 
Dance (2009) it is used as a voxelised breast model. 
5.1 Practical issues 
DG is generally calculated through the following relationship (ICRU, 2005): 
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where Ka,i represents the incident air kerma (without backscatter) and cG is the appropriate 
conversion factor. The incident air kerma is the air kerma free in the air (without 
backscatter) at the central axis of the incident X-ray beam at the skin-entrance plane which 
yields the desired image optical density (screen-film mammography) or signal:noise ratio 
(digital mammography).  
5.1.1 Determination of the incident air kerma 
Two approaches have been used to determine the incident air kerma, Ka,i. In the European 
and IAEA approach (CEC, 1996, 2006; IAEA, 2007), this quantity is calculated from the 
measured value of the X-ray tube output, Y(d), in terms of air kerma per tube-current-
exposure-time product (mGy/mAs), measured at a distance d from the focal spot of the 
mammography unit. The value of Ka,i at the focus to surface distance for the phantom or for 
compressed breast (d’) is determined as follows:  
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Where Pit is the mAs employed for a given exposure of the compressed breast or phantom, 
which is determined from the AEC post-exposure readout. The tube output has to be 
measured using an ionisation chamber with a flat energy response (CEC, 1996; ICRU, 2009) 
and conveniently calibrated for the mammography beam qualities. The ionisation chamber 
is placed at 6 cm from the chest wall and laterally centre. The distance d is usually fixed at 
4.5 cm above the breast support. The compression plate should be about 10 cm above the 
chamber so as to avoid backscatter effects.  
 
 Wu, 1991 Wu, 1994 Dance, 1990 Dance, 2000 Dance, 2009 
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0% - 100% 
Homog. 
mixture 
0% - 100% 
Breast thickness 
(cm) 3 – 8 2 – 8 2 – 11 2 – 11 













(kV) 10 – 35 23 – 50 25, 26, 28, 30, 32 25 - 40 
Source image 
distance 60 cm 65 
Compressor In place compressing the breast
Grid ----- ----- In place In place 
Image receptor ----- Yes (screen) Yes (screen) Yes (screen) 
Table 1. Important parameters considered by Dance and Wu for the calculation of the 
conversion factors using Monte Carlo techniques.  
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In the ACR approach (ACR, 1999), Ka,i is directly measured by placing the ionisation 
chamber adjacent to the ACR phantom at the level of the entrance surface of the phantom. 
The chamber is positioned at 4 cm from the chest wall. The compressor plate is located 
above the phantom and the chamber. The exposure conditions are those used clinically for a 
4 cm compressed breast.  
Ka,i can be also measured using TLD dosimeters (ACR, 1999; CEC, 1996) placed on the 
entrance surface of the phantom or breast. The TLDs have to be calibrated in terms of air 
kerma free-in-air against a suitable ionisation chamber and dosimeter. Hence, the entrance 
dose measured by TLDs placed on the phantom or patient surface includes backscatter. 
Measurements performed with TLD dosimeters are influenced by many factors, including 
the performance of the instrument and those related to procedure of dosimeter preparation 
and handling. In addition, TLDs’ response dependence of scatter gives rise to 
underestimations of Ka,i in a magnitude that is dependent on the dosimeter's thickness and 
the relative amount of backscatter radiation (Dance at al., 1999). Another factor that limits 
the use of TLD dosimeters is related with its visibility in the breast image. It is 
recommended that they be positioned on the upper inner quadrant of the breast so as to 
minimise interference with breast tissues. 
5.1.1.1 Mean glandular dose (DG) estimates  
The ACR protocol adopted the cG values calculated by Wu (1991, 1994; Sobol, 1997). The 
European and the IAEA protocols (CEC, 1996, 2006; IAEA, 2007) recommended the use of 
the cG values from Dance (1990; 2000; 2009). Fig. 8 and Table 1 summarise the details used 
by both authors to perform the Monte Carlo calculations. The cG values depend on the beam 
quality (half value layer (HVL)), breast thickness and breast composition. It is important to 
measure HLV and compressed breast thickness with accuracy in order to minimise the 
errors in the DG estimate. Narrow beam geometry is recommended for HVL measurements 
with the aim of reducing the influence of scattered radiation (IPEM, 2005; IAEA, 2007). In 
addition, Al filters of high purity (>99%) should be used and the compressor plate should be 
in place during the measurements. Errors in the compressed breast thickness measurement 
are due to the compressor plate which can bend and deform considerably. Several authors 
have proposed methods to gain accuracy in these measurements (Burch, A, 1995; Maria S. 
Nogueira., 2011). 
DG values derived from phantom measurements are useful for 1) simplifying the follow-up 
of the mammography system’s performance, 2) comparing with references or limiting 
values allowing the checking of the compliance of the equipment with recommendations, 3) 
checking if the exposure factors selected by the mammography system are suitable in terms 
of radiation dose, 4) for developing optimisation strategies. 
The evaluation of the mean glandular dose with large patient’s samples enables a more 
direct evaluation of the risk of radiation induced cancer. However, it is difficult to know the 
composition of individual breasts needed to determine the conversion factors. A fairly 
widespread method is to determine the composition of the breast from its image. To avoid 
bias or subjective criteria the BI-RADS criteria are used (ACR, 1998) so that the individual 
breasts are classified by the radiologist into one of four possible groups according to its 
ascribed glandularity (0%, 25%, 75% and 100%).  
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Where Pit is the mAs employed for a given exposure of the compressed breast or phantom, 
which is determined from the AEC post-exposure readout. The tube output has to be 
measured using an ionisation chamber with a flat energy response (CEC, 1996; ICRU, 2009) 
and conveniently calibrated for the mammography beam qualities. The ionisation chamber 
is placed at 6 cm from the chest wall and laterally centre. The distance d is usually fixed at 
4.5 cm above the breast support. The compression plate should be about 10 cm above the 
chamber so as to avoid backscatter effects.  
 
 Wu, 1991 Wu, 1994 Dance, 1990 Dance, 2000 Dance, 2009 
cG DGN GD N  pg gcs gcs 












0% - 100% 
Homog. 
mixture 
0% - 100% 
Breast thickness 
(cm) 3 – 8 2 – 8 2 – 11 2 – 11 













(kV) 10 – 35 23 – 50 25, 26, 28, 30, 32 25 - 40 
Source image 
distance 60 cm 65 
Compressor In place compressing the breast
Grid ----- ----- In place In place 
Image receptor ----- Yes (screen) Yes (screen) Yes (screen) 
Table 1. Important parameters considered by Dance and Wu for the calculation of the 
conversion factors using Monte Carlo techniques.  
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In the ACR approach (ACR, 1999), Ka,i is directly measured by placing the ionisation 
chamber adjacent to the ACR phantom at the level of the entrance surface of the phantom. 
The chamber is positioned at 4 cm from the chest wall. The compressor plate is located 
above the phantom and the chamber. The exposure conditions are those used clinically for a 
4 cm compressed breast.  
Ka,i can be also measured using TLD dosimeters (ACR, 1999; CEC, 1996) placed on the 
entrance surface of the phantom or breast. The TLDs have to be calibrated in terms of air 
kerma free-in-air against a suitable ionisation chamber and dosimeter. Hence, the entrance 
dose measured by TLDs placed on the phantom or patient surface includes backscatter. 
Measurements performed with TLD dosimeters are influenced by many factors, including 
the performance of the instrument and those related to procedure of dosimeter preparation 
and handling. In addition, TLDs’ response dependence of scatter gives rise to 
underestimations of Ka,i in a magnitude that is dependent on the dosimeter's thickness and 
the relative amount of backscatter radiation (Dance at al., 1999). Another factor that limits 
the use of TLD dosimeters is related with its visibility in the breast image. It is 
recommended that they be positioned on the upper inner quadrant of the breast so as to 
minimise interference with breast tissues. 
5.1.1.1 Mean glandular dose (DG) estimates  
The ACR protocol adopted the cG values calculated by Wu (1991, 1994; Sobol, 1997). The 
European and the IAEA protocols (CEC, 1996, 2006; IAEA, 2007) recommended the use of 
the cG values from Dance (1990; 2000; 2009). Fig. 8 and Table 1 summarise the details used 
by both authors to perform the Monte Carlo calculations. The cG values depend on the beam 
quality (half value layer (HVL)), breast thickness and breast composition. It is important to 
measure HLV and compressed breast thickness with accuracy in order to minimise the 
errors in the DG estimate. Narrow beam geometry is recommended for HVL measurements 
with the aim of reducing the influence of scattered radiation (IPEM, 2005; IAEA, 2007). In 
addition, Al filters of high purity (>99%) should be used and the compressor plate should be 
in place during the measurements. Errors in the compressed breast thickness measurement 
are due to the compressor plate which can bend and deform considerably. Several authors 
have proposed methods to gain accuracy in these measurements (Burch, A, 1995; Maria S. 
Nogueira., 2011). 
DG values derived from phantom measurements are useful for 1) simplifying the follow-up 
of the mammography system’s performance, 2) comparing with references or limiting 
values allowing the checking of the compliance of the equipment with recommendations, 3) 
checking if the exposure factors selected by the mammography system are suitable in terms 
of radiation dose, 4) for developing optimisation strategies. 
The evaluation of the mean glandular dose with large patient’s samples enables a more 
direct evaluation of the risk of radiation induced cancer. However, it is difficult to know the 
composition of individual breasts needed to determine the conversion factors. A fairly 
widespread method is to determine the composition of the breast from its image. To avoid 
bias or subjective criteria the BI-RADS criteria are used (ACR, 1998) so that the individual 
breasts are classified by the radiologist into one of four possible groups according to its 
ascribed glandularity (0%, 25%, 75% and 100%).  
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5.1.1.2 The European and the IAEA approach: measurements of phantoms 
Dose assessment in mammography initially (CEC, 1996) relied on the estimation of DG for a 4.5 
cm thick standard breast model with 50% glandularity in a central region by using a 4.0 cm 
thickness PMMA phantom. DG was estimated using the cG from Dance (1990) given in Table 1. 
It was recommended that patient dosimetry be performed by recording the exposure data and 
compressed breast thickness of at least 50 patients. Ka,i and DG were calculated for each 
patient using the cG factors tabulated by Dance (1990) for the corresponding HVL value and 
compressed breast thickness. The main problem associated with this methodology was firstly 
due to the fact that the average compressed breast thickness of a typical population is 5.5 cm. 
Secondly, several works showed a breast composition for the standard breast different to that 
of 50% glandularity. In addition, modern X-ray systems select different spectra as a function of 
both breast thickness and composition. In order to take into account all these factors, Dance et 
al. (2000) modify the definition of cG according to the expression given in Table 1. In this 
expression, the g-factor (unchanged from that initially used) corresponds to a glandularity of 
50% and is tabulated for different breast thicknesses and HVL. The c-factor corrects for any 
difference in breast composition from 50% glandularity and is tabulated for different HVL, 
breast thicknesses and breast glandularities. The factor s makes a correction for the use of an X-
ray spectrum other than that for a Mo/Mo target–filter combination. The value for s depends 
only on the anode/filter combination, except in the case of W/Al which depends also on the 
kVp (Dance, 2009).  
The equivalence between a range of PMMA thickness (2 - 8 cm) and compressed breast 
thickness has also been determined (Dance, 2000). According to the resulting equivalences, 
Ka,i delivered for a 4.5 cm thick PMMA phantom is equivalent to that for a 5.3 cm thick 
breast with 29% glandularity. This result was deduced from a sample of women in the age 
range 50-64 (Young, 1998; Becket, 2000). The mean glandular dose for different PMMA 
thicknesses is estimated using the relationship: 
 DG, PT = K PT gCBT cCBTs       (3) 
K PT is the air kerma at the entrance surface of a phantom of PT thickness and the gCBT and 
cCBT factors are the values tabulated for the equivalent compressed breast thickness.  
The DG limits proposed by the European (CEC, 2006) and IAEA (2011) protocols are given in 
Table 2 for a range of PMMA thickness. These values have been derived from screen/film 
mammography, since the cost associated with the transition to digital mammography 
should not imply an increase in the doses. 
 






Acceptable level for 
DG 
to equivalent breast 
(mGy)
Achievable level for 
DG 
to equivalent breast 
(mGy) 
20 21 1.0 0.6 
30 32 1.5 1.0 
40 45 2.0 1.6 
45 53 2.5 2.0 
50 60 3.0 2.4 
60 75 4.5 3.6 
70 90 6.5 5.1 
Table 2. Acceptable and achievable limits for mean glandular dose (DG). 
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5.1.1.3 Measurements on patients  
The method followed for patient dosimetry relies on the results obtained in two studies 
(Young et al 1998; Beckett et al., 2000) that have each independently estimated the breast 
composition of women attending for screening. As a result, the average breast composition 
as a function of breast thickness was established for two age groups. One age group (aged 
50 to 64) corresponds to the ages of women currently invited for breast screening in most of 
the programmes. The second age group corresponds to women aged between 40 and 49. DG 
is calculated for each breast thickness by using the c-factors for the corresponding average 
composition of each age group.  
The impact of the new factors c and s on DG values obtained through the patients sample 
was analysed by recalculating the dose values obtained in previous studies (NHSBSP, 2003). 
It was found that, for the largest breasts (thickest on compression), the use of the c-factor 
increases doses by approximately 30%. For the smallest breasts, the dose estimates are 
decreased by 11%. The overall effect is to increase the average doses by about 11% for 
craniocaudal views and by about 14% for mediolateral oblique views.  
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1. Introduction 
To understand how we can optimize the spectrum of an X-ray beam to obtain the maximum 
contrast using the minimum dose for a given x-ray exam we need to know a little about how 
the X-rays are generated, how an x-ray tube works, how the energy spectrum of the output 
X-ray beam will look and how the X-rays interact with the human body and with the 
imager. 
A general X-ray tube has two electrodes, the cathode and the anode, with a high voltage 
applied between them. Electrons are generated at the cathode. After the electrons are 
emitted from the cathode they are accelerated by the high voltage toward the anode 
(positive) electrode. The high speed electrons hitting the anode material then generate 
invisible radiation i.e. X-rays. The energy spectrum of the output X-rays is dependent on the 
anode-cathode voltage difference and on the material of the anode and is measured in 
electronvolts. The energy spectrum is a so called Brehmstrahlung radiation meaning that it 
is continuous over a wide range of energies and has more photons emitted at the lowest 
energies. The photon flux decreases to zero at the anode-cathode voltage difference level.  
When the Brehmstrahlung radiation of the X-ray beam passes into the human body, some 
photons are absorbed while others pass through. The ones that have passed through are 
available for imaging.  Because the absorption of the human body is higher at lower energy 
X-rays, the beam exiting the body has a higher average energy than the beam had when it 
entered the body.  This effect is called beam hardening and it causes a decrease in the 
contrast of images and difficulties in CT reconstruction.  Furthermore, the dose the patient 
receives from the very low energy X-rays serves no purpose; it does not contribute to the 
final image in any way.   
Figure 1 demonstrates the difference between input and exit X-ray beams showing that the 
very low energy X-rays do not penetrate the human body at all and only add extra 
(unwanted) dose to the patient (Sutton 2009). Three cases are shown in the figure. The 
original input beam, an 80kVp X-ray beam from a W anode filtered through a 2 mm Al 
filter, is shown in blue and has the highest photon flux and widest energy spectrum. The red 
series shows the energy of the beam after having passed through simulated soft tissue 
(150 mm soft tissue and 50 mm water). This exit beam shows that only X-ray photons with 
>25keV energy will contribute to the image. The green series shows the energy of the beam 
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after having passed through simulated tissue and bone (150mm soft tissue + 50 mm water + 
30 mm bone). This exit beam now shows that only X-ray photons with >37 keV are available 
to contribute to the image. The very low energy input photons are completely absorbed in 
the body, adding extra patient dose, because there is no exit photon for imaging1. 
 
Fig. 1. Comparison of the ratio of the incident photons (original beam) to the exit photons 
after going through different body tissues including water. Only the exit photons contribute 
to the imaging. 
So, how can we optimize contrast of the x-ray image using the minimum dose?   
2. Using the right x-ray energy range 
Figure 1 implies that the spectrum of the input x-ray beam has to be optimized for each 
imaging modality for minimum patient dose. For instance, a thicker body part such as the 
pelvis, which contains lots of bony structures, absorbs most of the low energy X-ray beams 
below 30 keV so we need to use higher X-ray beam energies to get a reasonable number of 
exiting x-ray photons for imaging while avoiding overdosing the patient with low energy X-
rays which would be completely absorbed in the thick pelvis.  
By contrast, imaging of the breast, which is smaller (thinner) relative to the pelvis and does 
not contain any bony structure, requires much lower X-ray energy to get sufficient X-ray 
                                                                 
1 Note that some low energy X-rays are removed by the inherent filtration of the X-ray tube. In many 
cases the exit window of the X-ray tube is made of 2mm Aluminum which removes most of the X-ray 
radiation below 15 keV. 
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photons for good imaging. Figure 2 shows the contrast/dose relationship for 
mammography. From the diagram, the optimum X-ray energy for imaging the breast is in 
the range of 18-21 keV (mean energy).2 
 
Fig. 2. The general relationship of contrast and dose to photon energy in mammography 
(Sprawls). 
There are several methods for limiting the input X-rays to an optimum range.  They include 
dual energy imaging, monochromatic X-ray imaging, and quasi-monochromatic X-ray 
imaging. 
3. Dual energy imaging  
In many cases X-ray images must capture both hard (bony) structures and soft tissues, 
which may be overlapping, in the same picture. A method to separate two different tissues, 
and optimize the contrast between them, is to acquire two images at different x-ray energies 
and do a weighted subtraction. This is called dual energy imaging. Taking images at low 
and high energies and doing a subtraction can remove either the soft or the bony structure 
depending on the techniques used.  
3.1 Brief theory of dual energy imaging 
The data processing methods that make use of dual energy data are referred to as 
decomposition techniques and are divided into three classes based on the type of 
information returned by the technique. The three types of information about the object being 
imaged that may be returned by decomposition techniques are: (1) effective atomic number 
and density; (2) attenuation due to Compton scattering and electron density; or (3) the 
physical densities of two known components (Walter, Wu et al. 2004). 
                                                                
2 This range will vary depending on the size and density of the breast. 
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2 This range will vary depending on the size and density of the breast. 
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The ability to determine material composition from dual energy techniques fundamentally 
results from the fact that the linear attenuation coefficient of X-ray absorption, ((E)), for an 
element has a unique functional dependence on photon energy. Over the range of x-ray 
photon energies used, the attenuation coefficient is dominated by two major attenuation 
processes: the photoelectric effect and Compton scattering. A major simplifying factor of the 
analysis is that each of these two processes has a fixed and unique functional dependence on 
energy that can serve as a linear basis set for any material. That is, 
 μ(E) = xμ�(E) + yμ�(E) (1) 
where p(E) is the linear attenuation as a function of energy due to the photoelectric effect 
and c(E) is the linear attenuation as a function of energy due to the Compton scattering 
effect and x and y are material specific constants.  
A consequence of this relationship is that the energy dependence of any material’s 
attenuation coefficient can be expressed as the linear combination of any two other 
materials. Therefore, each material can be characterized by two density values, pA  pB, which 
are derived from the attenuation measured at two different kVp spectra, A(E), B(E). As in, 
 μ(E) = xμ�(E) + yμ�(E) = p�μ�(E) + p�μ��(E) (2) 
The important consequence for image formation is that these two material density values 
are available to encode the pixel values apart from or in combination with Hounsfield units 
in the case of CT imaging. Materials with similar density can now be differentiated based on 
average atomic number. Of particular interest is the use of contrast agents with atomic 
numbers significantly different from the usual materials present in the body as these agents 
will show up on images in high contrast to the normal materials of the body. Moreover, 
because the dual energy analysis makes explicit use of the energy dependence of the 
attenuation, the beam hardening artifacts are absent here, a distinct advantage over 
conventional CT. Also, in the dual energy technique as opposed to the conventional 
approach, the accuracy of the CT number associated with pixels is not affected by the beam 
hardening corrections which must approximate the energy dependent attenuation with data 
from a single energy value. 
3.2 Dual energy imaging applications 
Dual energy imaging was used in CT scanning as long ago as 1976 (Alvarez and Macovski 
1976) when it was also being used for the exact determination of the atomic number of 
elements (Rutherford, Pullan et al. 1976). It has been used for mammography as well. Johns 
et al. described the first applications of dual energy imaging to mammography (Johns, Drost 
et al. 1983).  Later work optimized the method to get the best SNR with minimum dose 
(Johns and Yaffe 1985). Since that time, several articles were published about optimization of 
parameters in dual energy breast imaging. Boone at al. (Boone, Shaber et al. 1990) analyzed 
detector parameters, effects of X-ray parameters and filtrations and the effect of scatter on 
the quality of the dual energy images. Kappadath et al. (Kappadath, Shaw et al. 2004) used 
digital subtraction techniques and a method they developed called DEDM (Dual Energy 
Digital Mammography) to improve the visibility of micro calcifications.  
Dual energy techniques have also been used to improve Computed Tomography (CT) 
imaging. While 3D CT scans and the use of Iodine (I) as a contrast agent have, on their own, 
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greatly improved the visibility of malignant cancerous tissues (Chen, Jing et al. 2006; 
Arvanitis, Royle et al. 2007; Puong, Bouchevreau et al. 2007), the combination of dual energy 
CT and Iodine contrast together offers yet more improvements to our ability to separate 
different tissues from one another in an image (Carton, Lindman et al. 2007), (Puong, 
Patoureaux et al. 2007; Saunders, Samei et al. 2008).   
Dual energy imaging is used in many fields of medical imaging, such as for lung imaging 
when we need to separate (or suppress) the overlapping rib shadows from the soft lung 
tissues to enhance visualization of lung nodules (Kashani, Varon et al. 2010), or, similarly, 
for digital angiography to visualize the heart behind the ribs (Ersahin, Molloi et al. 1994). In 
many cases dual energy angiography is used in combination with Iodine (I) or Gadolinium 
(Gd) contrast agents (Fiedler, Elleaume et al. 2000).  
Dual energy imaging is an important technique for performing bone densitometry tests 
(Shimura, Nakajima et al. 1993) and specialized systems have been developed and sold by 
GE  and Hologic (GE ; Hologic).  
3.3 Dual energy imaging methods 
Generally dual energy imaging is implemented by use of X-ray tube voltage switching to 
obtain two images; one at low and one at high kVp values. To avoid motion artifacts 
between the two images quick changes in tube voltage are necessary. 
Different methods and detectors have also been developed for dual energy imaging. Coello 
et al. (Coello, Dinten et al. 2007) built a system where, instead of switching voltages, a filter 
wheel containing multiple filter materials is rotated in front of the X-ray tube, providing 
different X-ray spectra. This paper also provides an excellent overview of the theory of dual 
energy imaging and its optimization for best signal to noise ratio and image contrast.  
4. Monochromatic X-ray imaging 
Beam hardening has a significantly deleterious effect on the precision of CT reconstruction. 
It can be avoided by using monochromatic X-ray beams. Furthermore, for each imaging 
object there is an ideal energy at which enough X-ray photons make it through the object to 
allow for low noise imaging while still using a low enough X-ray energy to provide the best 
contrast ratio. Synchrotrons are ideal sources of monochromatic beams of high flux. Some 
experiments on breast imaging with synchrotrons were made and compared to normal 
mammographic images (Fiedler and et al. 2004). A further advantage of monochromatic 
imaging is that it allows for phase contrast imaging, which greatly improves the contrast 
even between different soft tissues. However, the size and price of a synchrotron make it 
impractical for general radiographic use. X-ray tubes with monochromators can provide 
monochromatic x-ray beams but the flux is too low for practical applications (Donath, 
Pfeiffer et al. 2008). 
5. Quasi monochromatic X-ray beam imaging 
5.1 Generation of quasi monochromatic beams using diffraction 
Different methods have been developed to approximate monochromatic beams i.e. to 
provide quasi monochromatic beams, which consist of not a single X-ray energy but a 
narrow range of X-ray energies. 
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The ability to determine material composition from dual energy techniques fundamentally 
results from the fact that the linear attenuation coefficient of X-ray absorption, ((E)), for an 
element has a unique functional dependence on photon energy. Over the range of x-ray 
photon energies used, the attenuation coefficient is dominated by two major attenuation 
processes: the photoelectric effect and Compton scattering. A major simplifying factor of the 
analysis is that each of these two processes has a fixed and unique functional dependence on 
energy that can serve as a linear basis set for any material. That is, 
 μ(E) = xμ�(E) + yμ�(E) (1) 
where p(E) is the linear attenuation as a function of energy due to the photoelectric effect 
and c(E) is the linear attenuation as a function of energy due to the Compton scattering 
effect and x and y are material specific constants.  
A consequence of this relationship is that the energy dependence of any material’s 
attenuation coefficient can be expressed as the linear combination of any two other 
materials. Therefore, each material can be characterized by two density values, pA  pB, which 
are derived from the attenuation measured at two different kVp spectra, A(E), B(E). As in, 
 μ(E) = xμ�(E) + yμ�(E) = p�μ�(E) + p�μ��(E) (2) 
The important consequence for image formation is that these two material density values 
are available to encode the pixel values apart from or in combination with Hounsfield units 
in the case of CT imaging. Materials with similar density can now be differentiated based on 
average atomic number. Of particular interest is the use of contrast agents with atomic 
numbers significantly different from the usual materials present in the body as these agents 
will show up on images in high contrast to the normal materials of the body. Moreover, 
because the dual energy analysis makes explicit use of the energy dependence of the 
attenuation, the beam hardening artifacts are absent here, a distinct advantage over 
conventional CT. Also, in the dual energy technique as opposed to the conventional 
approach, the accuracy of the CT number associated with pixels is not affected by the beam 
hardening corrections which must approximate the energy dependent attenuation with data 
from a single energy value. 
3.2 Dual energy imaging applications 
Dual energy imaging was used in CT scanning as long ago as 1976 (Alvarez and Macovski 
1976) when it was also being used for the exact determination of the atomic number of 
elements (Rutherford, Pullan et al. 1976). It has been used for mammography as well. Johns 
et al. described the first applications of dual energy imaging to mammography (Johns, Drost 
et al. 1983).  Later work optimized the method to get the best SNR with minimum dose 
(Johns and Yaffe 1985). Since that time, several articles were published about optimization of 
parameters in dual energy breast imaging. Boone at al. (Boone, Shaber et al. 1990) analyzed 
detector parameters, effects of X-ray parameters and filtrations and the effect of scatter on 
the quality of the dual energy images. Kappadath et al. (Kappadath, Shaw et al. 2004) used 
digital subtraction techniques and a method they developed called DEDM (Dual Energy 
Digital Mammography) to improve the visibility of micro calcifications.  
Dual energy techniques have also been used to improve Computed Tomography (CT) 
imaging. While 3D CT scans and the use of Iodine (I) as a contrast agent have, on their own, 
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greatly improved the visibility of malignant cancerous tissues (Chen, Jing et al. 2006; 
Arvanitis, Royle et al. 2007; Puong, Bouchevreau et al. 2007), the combination of dual energy 
CT and Iodine contrast together offers yet more improvements to our ability to separate 
different tissues from one another in an image (Carton, Lindman et al. 2007), (Puong, 
Patoureaux et al. 2007; Saunders, Samei et al. 2008).   
Dual energy imaging is used in many fields of medical imaging, such as for lung imaging 
when we need to separate (or suppress) the overlapping rib shadows from the soft lung 
tissues to enhance visualization of lung nodules (Kashani, Varon et al. 2010), or, similarly, 
for digital angiography to visualize the heart behind the ribs (Ersahin, Molloi et al. 1994). In 
many cases dual energy angiography is used in combination with Iodine (I) or Gadolinium 
(Gd) contrast agents (Fiedler, Elleaume et al. 2000).  
Dual energy imaging is an important technique for performing bone densitometry tests 
(Shimura, Nakajima et al. 1993) and specialized systems have been developed and sold by 
GE  and Hologic (GE ; Hologic).  
3.3 Dual energy imaging methods 
Generally dual energy imaging is implemented by use of X-ray tube voltage switching to 
obtain two images; one at low and one at high kVp values. To avoid motion artifacts 
between the two images quick changes in tube voltage are necessary. 
Different methods and detectors have also been developed for dual energy imaging. Coello 
et al. (Coello, Dinten et al. 2007) built a system where, instead of switching voltages, a filter 
wheel containing multiple filter materials is rotated in front of the X-ray tube, providing 
different X-ray spectra. This paper also provides an excellent overview of the theory of dual 
energy imaging and its optimization for best signal to noise ratio and image contrast.  
4. Monochromatic X-ray imaging 
Beam hardening has a significantly deleterious effect on the precision of CT reconstruction. 
It can be avoided by using monochromatic X-ray beams. Furthermore, for each imaging 
object there is an ideal energy at which enough X-ray photons make it through the object to 
allow for low noise imaging while still using a low enough X-ray energy to provide the best 
contrast ratio. Synchrotrons are ideal sources of monochromatic beams of high flux. Some 
experiments on breast imaging with synchrotrons were made and compared to normal 
mammographic images (Fiedler and et al. 2004). A further advantage of monochromatic 
imaging is that it allows for phase contrast imaging, which greatly improves the contrast 
even between different soft tissues. However, the size and price of a synchrotron make it 
impractical for general radiographic use. X-ray tubes with monochromators can provide 
monochromatic x-ray beams but the flux is too low for practical applications (Donath, 
Pfeiffer et al. 2008). 
5. Quasi monochromatic X-ray beam imaging 
5.1 Generation of quasi monochromatic beams using diffraction 
Different methods have been developed to approximate monochromatic beams i.e. to 
provide quasi monochromatic beams, which consist of not a single X-ray energy but a 
narrow range of X-ray energies. 
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One method utilizes mosaic crystals to produce quasi-monochromatic X-ray beams. When 
an X-ray hits the crystalline structure of a material, constructive interference takes place in 
accordance with the Bragg equation: 
 2d × sinθ = λ × n (3) 
where,  is the exiting X-ray photon wavelength, d is the spacing between atomic planes of 
the crystal and  is the diffraction angle and n is an integer.  The d-spacings are substance-
specific and like the have an inverse relationship with the energy of the output beam.  At 
different , different X-ray energy photons are reflected back from the crystal. This is called 
Bragg reflection and this method was proposed by Baldelli et al. (Baldelli, Taibi et al. 2003) 
to generate monochromatic X-rays. However, this method has some drawbacks. First of all, 
because it is a Bragg reflection from a plain surface it provides only a monochromatic fan 
beam and not a cone beam; furthermore, the intensity of the diffracted beam is very low 
because only a very small portion of the total incoming X-ray spectrum is reflected back. 
Moreover, because of the variation of crystal angle in the mosaic crystal and the finite width 
of the slits the X-ray beam is only quasi monochromatic with an energy bandwidth of ~E.  
 
Fig. 3. Quasi monochromatic X-ray beam by X-ray diffraction. 
A prototype of a quasi monochromatic diffraction system has also been developed for 
mammography (Baldelli and et al. 2005). Advantages of the system are that it is tunable in 
the range of 18-24keV, and according to the authors, the dose can be decreased by half. 
Disadvantages are that it uses little of the available X-ray flux and requires scanning, as it 
produces only a sheet beam, so the scanning time is a few seconds long (possible motion 
blur). The resolution of the system is also lower than the best digital mammo systems can 
produce.  
5.2 Applications for quasi monochromatic beams 
A similar system to that of Baldelli’s (Baldelli and et al. 2005) was developed for a combined 
breast SPECT – CT system (Gambaccini, Fantini et al. 2001). It had the same advantages and 
disadvantages as the mammography system.  
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The spatial resolution of such a system was analyzed by Gambaccini et al. (Gambaccini, 
Tuffanelli et al. 2001) who found that along the direction perpendicular to the diffraction 
plane the resolution properties of the imaging system mainly depend on the x-ray tube focal 
spot size and position. Along the diffraction plane the spatial resolution depends on mosaic 
crystal characteristics and on the geometry of the setup. 
6. K edge filters 
6.1 Theory of K edge filters 
There is another method of generating small energy bandwidth X-ray radiation. It is known 
that in addition to the Brehmstrahlung radiation, materials bombarded with electrons 
produce characteristic radiation which increases the intensity of the X-ray radiation at 
energy levels specific to each material. For instance, a typical X-ray radiation spectrum for a 
Tungsten (W) anode using 100 kV anode-cathode potential and a 2 mm Al window is shown 
in Figure 4. As before, the lowest energy X-rays are absorbed by the Al output window. The 
sharp peeks in the X-ray spectrum are characteristic for the anode material. These peeks are 
the result of the electron structure of a given material and they show the energy differences 
between electron shells of the atomic structure.  
For example, W has 3 electron shells that play a role in its use as a K edge filter.  The 3 
innermost electron shells are designated “K”, “L”, “M”, where K is the innermost shell, and 
M the outermost.  For W, K has an energy of 70keV, L has an energy of 11keV, and M has an 
energy of 3keV.  The characteristic peaks for W will occur at “L minus K” and “M minus K” 
or at 59keV (designated the K peak) and 67keV (designated the K peak).  W also has a 
second electron in its K shell with a slightly different binding energy which explains the 
doublets in Figure 4.  
The same phenomenon works in the opposite way; materials absorb X-ray photons which 
are above their binding energy. This is the basis of the K edge filters. Generally at these 
(energy) levels the X-ray absorption of the material jumps (increases) when the material is 
used as an X-ray filter. Figure 5 shows the X-ray spectrum for the same W anode and the 
same X-ray tube voltage as in Figure 4 but with an added 0.2 mm W sheet as a filter. This 
 
Fig. 4. W anode spectra with low energy filter of 2 mm Al. 
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The spatial resolution of such a system was analyzed by Gambaccini et al. (Gambaccini, 
Tuffanelli et al. 2001) who found that along the direction perpendicular to the diffraction 
plane the resolution properties of the imaging system mainly depend on the x-ray tube focal 
spot size and position. Along the diffraction plane the spatial resolution depends on mosaic 
crystal characteristics and on the geometry of the setup. 
6. K edge filters 
6.1 Theory of K edge filters 
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that in addition to the Brehmstrahlung radiation, materials bombarded with electrons 
produce characteristic radiation which increases the intensity of the X-ray radiation at 
energy levels specific to each material. For instance, a typical X-ray radiation spectrum for a 
Tungsten (W) anode using 100 kV anode-cathode potential and a 2 mm Al window is shown 
in Figure 4. As before, the lowest energy X-rays are absorbed by the Al output window. The 
sharp peeks in the X-ray spectrum are characteristic for the anode material. These peeks are 
the result of the electron structure of a given material and they show the energy differences 
between electron shells of the atomic structure.  
For example, W has 3 electron shells that play a role in its use as a K edge filter.  The 3 
innermost electron shells are designated “K”, “L”, “M”, where K is the innermost shell, and 
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Fig. 4. W anode spectra with low energy filter of 2 mm Al. 
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added tungsten sheet filters out not only the low energy X-rays but the X-ray spectrum also 
shows a huge drop in intensity (the absorption increases dramatically) above the tungsten K 
edge. Please note that the total intensity decreased as well. The scale of Figure 5 is different 
from that of Figure 4 for better visibility. The total intensity after K edge filtering is always 
lower than without it for the same energy range but the characteristic K edge radiation 
peaks are still present. This example shows that material K edge absorption can be used to 
suppress both low and high energy portions of the original X-ray spectrum to produce 
narrow bandwidth X-ray radiation or so called quasi-monochromatic X-rays.  
 
Fig. 5. Tungsten (W) anode with 0.2 mm W (K edge) filter. 
The absorption spectra of K edge filters can be calculated. If there are no K-edge 
discontinuities, then the energy dependence of the linear attenuation coefficient μ(E, x� ) of 
materials can be described by a linear combination of the photo-electric and the Compton 
cross-sections ���(E) and ���(E)(Alvarez and Macovski 1976) 
 μ(E, x� ) 	= 	 a��(x� ) ��� 	+ 	a��(x� )f��(E/E�)  (4) 
Here Ee = 510.975 keV denotes the rest mass energy of the electron, and the vector x�  
describes the space dependence of the attenuation and 1/E3 approximates the energy 
dependence of the photoelectric interaction. The energy dependence of the Klein–Nishina 
cross-section (Compton scattering) is given by:  




� 	ln(1	 + 	2α)� 	+
�
�� 	ln(1 + 2α) 	−	
�	�	��
(�	�	��)� (5) 
Where 510.975 keV, and aph and FKN are given as: 
 a�� ≈ K� × �� × Z�											n ≈ 4 (6) 
 a�� ≈ K� × �� × Z (7) 
where K1 and K2 are constants, ρ is mass density, A is atomic weight and Z is atomic 
number. When a material with high atomic number Z is present, the above description of 
the attenuation properties of the matter has to be modified.  To correctly describe the 
attenuation of a sample containing a single element with K edge discontinuity inside the 
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relevant energy range, the decomposition (4) has to be extended by the energy dependent 
attenuation function of this particular element as a third component (Sukovic and 
Clinthorne 1999). The decomposition for a high Z element with K edge in the diagnostic 
energy range becomes:  
 μ(E, x� ) = 	 a��(x� ) ��� 	+ 	a��(x� )f�� �
�
��� +	a�(x� )f�(E) = ∑ a�
���� (x� )f�(E) (8) 
where the values a = 1, 2, 3 represent the photoelectric, Compton and the K edge 
components, respectively. In the above formula, aK(x� ) and fK(E) denote the local density and 
the mass attenuation coefficient of the K edge material. The latter includes the photoelectric 
effect, Compton effect and K edge contributions of the material.  
6.2 K edge materials, energies, and applications 
Table 1 provides a list of some K edge filters whose K edge energies (except for Al and Cu 
filters) fall into the region where they are or could be applied to X-ray imaging. From the 
table it is clear that the K edge energy increases with increasing atomic number. 
K edge filtering has been used for mammography for some time where different Rhodium 
(Rh) and Molybdenum (Mo) anode and filter combinations are used to generate energy 




Table 1. K edge energies for different materials already used or that can be used in K-edge 
X-ray imaging. 
As shown in Figure 6, at an anode voltage of 28 kV, a Mo anode – Mo filter combination 
gives a lower mean energy of 17.6 keV better suited for thinner, lower density breasts, while 
the Rh anode – Rh filter combination has a mean energy of 18.3 keV, which is better for 
thicker and denser breast imaging. Different Mo and Rh anode and filter combinations are 
used in some specialized mammography imagers and various anode voltages to fine tune 
the optimum energy spectrum to obtain maximum contrast at minimum dose for different 
breast types. Tungsten (W) anodes with higher anode voltages (40kV) and Silver (Ag) filters 
Material Aluminum Copper Molybdenum Rhodium Silver Tin Iodine
Chemical sign Al Cu Mo Rh Ag Sn I
Atomic number 13 29 42 45 47 50 53
K edge energy in keV 1.6 8.98 20 23.22 25.51 29.2 33.16
Material Barium Cerium Neodimium Europium Gadolinium Holmium
Chemical sign Ba Ce Nd Eu Gd Ho
Atomic number 56 58 60 63 64 67
K edge energy in keV 37.45 40.44 43.56 48.5 50.2 55.6
Material Erbium Ytterbium Tantalum Tungsten Gold Bismuth Uranium
Chemical sign Er Yb Ta W Au Bi U
Atomic number 68 70 73 74 79 83 92
K edge energy in keV 57.5 61.3 67.41 69.5 80.72 90.53 115.6
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relevant energy range, the decomposition (4) has to be extended by the energy dependent 
attenuation function of this particular element as a third component (Sukovic and 
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components, respectively. In the above formula, aK(x� ) and fK(E) denote the local density and 
the mass attenuation coefficient of the K edge material. The latter includes the photoelectric 
effect, Compton effect and K edge contributions of the material.  
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could also be used. This combination would be especially useful for imaging very large and 
dense breasts. 
Evaluation of different x-ray sources with varying anode voltages is given by Jennings et al. 
(Jennings, Quinn et al. 1993) and Venkatakrishnan (Venkatakrishnan, Yavuz et al. 1999). 
Optimization of spectral shape for digital mammography is given by Fahrig and Yaffe 
(Fahrig and Yaffe 1994). Dose versus image quality was also experimentally studied on a CsI 
flat panel mammo imaging system using Mo/Mo anode/filter combination.  (Huda W Fau - 
Sajewicz, Sajewicz Am Fau - Ogden et al.) Optimization of the anode-filter combination is 
provided by Varjonen et al. (Varjonen and Strommer 2008) and a very good Monte Carlo 
analysis of different combinations is provided by Dance et al. (Dance, Thilander et al. 2000) 
for both film and digital imaging.  Fahrig et al. (Fahrig, Rowlands et al. 1996) investigated 
the a-Se based digital imagers and found that the optimal x-ray spectra is similar to the 
indirect (scintillator + photodiode) based imagers.  
An X-ray tube at 30 kVp anode-cathode voltage does not provide enough flux for fast three 
dimensional breast imaging (breast CT). Generally higher tube voltage (60-80kVp) is applied 
(Boone, Nelson et al. 2001) to keep the imaging time within reasonable limits (breath 
withholding during the CT scan). However, it is known that the X-ray contrast decreases 
with increasing X-ray energies. However, in the following we will investigate how we can 
improve the visualization of tumors in X-ray CT images utilizing K edge filtering.  
 
Fig. 6. X-ray applications with K edge filtering. 
It is known that iodine has a high Z number which provides reasonable X-ray absorption. It 
dissolves in water and it has been used for intravenous injection to check blood flow in the 
body. It is common knowledge that most tumors have generally leaky blood vessels. Blood 
leaks from the vessels near tumors into the intercellular tissues and it generally takes a 
longer time to be re-circulated than blood that has not leaked out. So if we inject iodine into 
the blood stream, this iodine will also leak out in the tumor region and it will stay there for a 
period of time while the iodine in the rest of the vessels clears up more quickly. The 
presence of the iodine at the tumor will enhance the contrast of the image for several 
minutes following the iodine injection. 
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We know that Iodine has a K edge energy of 33.16 keV. To enhance the contrast of the iodine 
we have to use K edge filters which have K edges somewhat above the Iodine K edge. These 
materials are Cerium (Ce) Neodymium (Nd) And Europium (Eu). Figure 7 provides a 
comparison of the x-ray spectra using these different K edge filters for Iodine contrast 
enhancement.  
 
Fig. 7. Iodine (I) as a contrast agent and a few possible K edge filters: Cerium (Ce) 
Neodymium (ND) and Europium (Eu). 
Another contrast material, Gadolinium (Gd) has been extensively used in MRI due to its 
special magnetic properties. In the bloodstream it behaves similar to the Iodine; it also 
accumulates in the tumor region when injected in the blood and clears out slower from 
tumors than it clears from the bloodstream. However, it also has a K edge energy for X-rays 
at 50.2 keV versus the 33.16 keV K edge of Iodine. This makes Gd a contrast material 
candidate not so much for X-ray mammography but rather for general radiographic 
applications. To improve the visibility of Gd absorption, K edge filters with K edge energies 
slightly over that of the Gd can be used. Possible candidates are Holmium (Ho), Erbium 
(Er), Ytterbium (Yb) and Tantalum (Ta) or even Tungsten (W).  
Figure 8 gives a comparison of the X-ray spectrum of some K edge materials for Gd. It 
shows the spectra of Gd in red and a few possible K edge filters in other colors. Ta and W 
spectra have very similar shapes, both showing the W anode K edge spectra, but W has a 
higher K edge energy than Ta so it cuts off the spectra at higher keV. 
An interesting approach for K edge filtering is to use an X-ray tube target material made of 
K edge filter materials, as  was demonstrated by Sato et al (Sato, Tanaka et al. 2004) with 
Cerium and Samarium anodes (Sato, Tanaka et al. 2007). 
A further possibility is to combine dual energy imaging with K edge filters. Taking an image 
with a filter which has a K edge over the K edge of the contrast agent and one which has a K 
edge below and then using weighted subtraction can further improve the contrast. This is 
also seen from Table 4 in section 6.4.2. The Ce filter enhances the contrast while the Iodine 
filter decreases the Iodine contrast. So further contrast improvement can be obtained by 
weighted subtraction of the two spectra rather than by just using the Ce filter image alone 
(see also in Section 7).  
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could also be used. This combination would be especially useful for imaging very large and 
dense breasts. 
Evaluation of different x-ray sources with varying anode voltages is given by Jennings et al. 
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Optimization of spectral shape for digital mammography is given by Fahrig and Yaffe 
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Fig. 6. X-ray applications with K edge filtering. 
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We know that Iodine has a K edge energy of 33.16 keV. To enhance the contrast of the iodine 
we have to use K edge filters which have K edges somewhat above the Iodine K edge. These 
materials are Cerium (Ce) Neodymium (Nd) And Europium (Eu). Figure 7 provides a 
comparison of the x-ray spectra using these different K edge filters for Iodine contrast 
enhancement.  
 
Fig. 7. Iodine (I) as a contrast agent and a few possible K edge filters: Cerium (Ce) 
Neodymium (ND) and Europium (Eu). 
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Fig. 8. Gd spectrum is in red. To enhance the contrast, Er, Ta or W can serve as K edge 
filters, which have higher K edges as Gd. 
6.3 Experimental work with K edge filters 
This section describes some of the author’s own work on different K edge filters used for 
mammographic CT applications (Zentai 2011).  
For the CT tests, so called HU (Hounsfield Unit) Phantoms were prepared.  One set was 
made for HU calibration. This set consisted of small bottles filled with different water and 
alcohol solutions for densities less than water and also with water and glycerin mixtures for 
densities higher than water. The bottles were pushed into holes in a large polyethylene 
cylinder as shown in Figure 9. Polyethylene plugs were used for keeping the bottles in place 
and also for having the same material densities below and above the bottles. However, small 
holes were drilled in the center of the plugs for letting the extra air out when pushing the 
plugs in place. These holes contained air, so HU numbers for the air could also be evaluated 
by using the air pocket images of these holes. We found that for alcohol-water and glycerin-
water solutions the X-ray absorption is proportional to the density. So the numbers written 
over the bottles of Figure 9 represent the relative densities of the solutions in g/cm3. 
As we know, HU numbers are proportional to the absorption (densities) of these liquids; 
water has HU=0 and air has HU=-1000.  HU from 0 to 2000 represent liquids and solids 
denser than water. For instance, the density of pure alcohol is 0.782 and the approximate 
Hounsfield number for alcohol can be calculated (-1000 × 0.782) = -782.  Similarly, the 
density of pure glycerin is 1.14 and the Hounsfield number is then 114. So a set of five 
different solutions and air were used for calibrating the HU numbers for different X-ray 
tube voltages and different filters.  
To compare the HU numbers of different iodine solutions another fixture was designed as 
shown in Figure 10. The numbers in the figure give the relative density of the iodine 
solutions in mg/ml. 
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Fig. 9. Hounsfield unit CT phantoms. 
 
Fig. 10. Iodine solution phantoms. 
A rotational table was used to rotate the phantoms during CT image sequences. First it was 
verified that the center (focal spot) of the X-ray radiation was lined up with the center of the 
X-ray imager and that the imaginary line between these two points crossed the pivot-line of 
the rotation. This alignment was done with the help of a so called Isocal phantom. This 
phantom consists of a graphite cylinder with BBs, which are arranged in a spiral pattern 
alongside the perimeter. A detailed description of this method and the phantom is given by 
A. Jeung et al (Jeung, Sloutsky et al. 2005). We also processed a norm factor calibration when 
we used a cylindrical object of the same size and material as the bulk of the CT phantoms 
but without any holes in it. This calibration method is described in more details by Matsinos 
et al (Matsinos 2005).  
The rotational table was driven by a stepper motor for precision rotational speed. 625 
images were taken during one 360o rotation. The rotational speed and the imaging speed 
were synchronized. From these values the angles were calculated for each transmission 
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image required for the CT reconstruction. A modified Feldkamp back-projection (Feldkamp, 
Davis et al. 1984) algorithm was used for cone beam CT reconstruction developed by John 
Pavkovich at Varian (Pavkovich 1979; Pavkovich).  
Imaging was done on a Varian 4030CB CsI/photodiode flat panel imager. The readout 
ASICs of the imager were set to dynamic gain mode.  In this mode the readout ASICs can 
automatically switch from a high to a low gain mode during the integration time when the 
signal level exceeds a given limit. This mode provides about 16.5 bit resolution even when 
the A/D converter has only a 14 bit range. A detailed description of the functions of this 
readout ASIC is given in (Roos, Colbeth et al. 2004).  Imager calibrations were also 
performed to assure areas of the image where the gain is in transition still appear smooth 
and continuous. 
Different filters were used to evaluate the effect of filtering on the S/N (Signal to Noise) 
value of the reconstructed CT images and also for the contrast ratio in comparison to CT 
images without any beam filtering. Lists of the filters and their thicknesses and the 
corresponding K edges are given in Table 2.  
 
Table 2. Filters applied during the experiments and their consecutive K edge energies. 
The entrance doses for each imaging case were measured with a Radcal dose meter, which 
was placed in the center of the rotational table, where the geometrical center of the object 
was during the imaging data collection using the exact same conditions. 
It is clear that Al and Cu have K edges at very low energies and in this experiment these 
materials were used as beam hardening filters, filtering out the low energy X-rays. Cerium, 
Europium and Neodymium all have K edges slightly over the K edge of iodine so they 
could provide narrow bandwidth filtering for iodine imaging. For comparison we also used 
a 0.4 mm equivalent thickness iodine solution as a filter. For the K edge filter and no filter 
experiments we used 60 and 70 kVp X-ray tube anode voltage and 100 kVp for the Cu and 
Al filters for higher X-ray flux. 
6.4 Measurements, results and discussions 
6.4.1 Calculation and measurement of X-ray spectra  
Spectra of some K edge materials with the given thicknesses were calculated. The 
calculation was based on the Report 78 Spectrum Processor Program IPEM 1997 (Cranley, 
Gilmore et al. 1997). The original program contained only absorption spectra of a few 
materials so additional absorption spectra were obtained from the NIST XCOM website 
(NIST 2009). Some calculated spectra are given in  Figure 11, Figure 12, and in Figure 13. 
Figure 11 shows that the CsI scintillator used in the 4030CB flat panel detector has some 
















thickness 0.4 mm 0.71 mm 0.7 mm 1.0 mm 2.24 mm 0.5 mm 
K edge (in 
KeV) 33.16 40.44 43.56 48.50 1.56 8.98
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Fig. 11. Calculated 60kVp X-ray spectra with 0.4mm Iodine and 0.4 mm CsI filter.  
 
Fig. 12. 60 kVp spectra without any external filter and with 0.4 mm I filter are compared 
with 100 kVp spectra of 2.24 mm Al and 0.4 mm Cu filters. 
From Figure 12 it is clear that while Al effects only the low energy X-rays, copper shifts the 
mean energy to higher values and K edge filters (Figure 13) significantly decrease the total 
flux having only single transmission peaks about the K edge energy. 
The calculated and measured spectra of the K edge filter materials were compared.  Figure 
14 contrasts measured and calculated spectra of 0.71mm thick Ce filter. Very good 
agreement is shown in the 20 - 69 keV energy range. The flux drop of the measured spectra 
over 69 keV is attributed to the so called heel effect, which was simulated by Monte Carlo 
method and also measured  by Bhat et al (Bhat, Pattison et al. 1999). This effect refers to a 
falloff of intensity in the X-ray radiation when the electron beam from the cathode hits the 
anode at a small angle.  Because of the thick anode material, part of the X-ray generated 
deeper in the anode is also absorbed in the anode (in our case tungsten). This is practically 
the same filtering effect which is shown in Figure 5. It is especially significant above the 69.5 
keV K edge of the tungsten anode where this absorption sharply increases causing a sharp 
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image required for the CT reconstruction. A modified Feldkamp back-projection (Feldkamp, 
Davis et al. 1984) algorithm was used for cone beam CT reconstruction developed by John 
Pavkovich at Varian (Pavkovich 1979; Pavkovich).  
Imaging was done on a Varian 4030CB CsI/photodiode flat panel imager. The readout 
ASICs of the imager were set to dynamic gain mode.  In this mode the readout ASICs can 
automatically switch from a high to a low gain mode during the integration time when the 
signal level exceeds a given limit. This mode provides about 16.5 bit resolution even when 
the A/D converter has only a 14 bit range. A detailed description of the functions of this 
readout ASIC is given in (Roos, Colbeth et al. 2004).  Imager calibrations were also 
performed to assure areas of the image where the gain is in transition still appear smooth 
and continuous. 
Different filters were used to evaluate the effect of filtering on the S/N (Signal to Noise) 
value of the reconstructed CT images and also for the contrast ratio in comparison to CT 
images without any beam filtering. Lists of the filters and their thicknesses and the 
corresponding K edges are given in Table 2.  
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Fig. 11. Calculated 60kVp X-ray spectra with 0.4mm Iodine and 0.4 mm CsI filter.  
 
Fig. 12. 60 kVp spectra without any external filter and with 0.4 mm I filter are compared 
with 100 kVp spectra of 2.24 mm Al and 0.4 mm Cu filters. 
From Figure 12 it is clear that while Al effects only the low energy X-rays, copper shifts the 
mean energy to higher values and K edge filters (Figure 13) significantly decrease the total 
flux having only single transmission peaks about the K edge energy. 
The calculated and measured spectra of the K edge filter materials were compared.  Figure 
14 contrasts measured and calculated spectra of 0.71mm thick Ce filter. Very good 
agreement is shown in the 20 - 69 keV energy range. The flux drop of the measured spectra 
over 69 keV is attributed to the so called heel effect, which was simulated by Monte Carlo 
method and also measured  by Bhat et al (Bhat, Pattison et al. 1999). This effect refers to a 
falloff of intensity in the X-ray radiation when the electron beam from the cathode hits the 
anode at a small angle.  Because of the thick anode material, part of the X-ray generated 
deeper in the anode is also absorbed in the anode (in our case tungsten). This is practically 
the same filtering effect which is shown in Figure 5. It is especially significant above the 69.5 
keV K edge of the tungsten anode where this absorption sharply increases causing a sharp 
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decrease above this X-ray energy as can be seen in the measured spectra. However, this 
decrease would not affect the filter materials K edge behavior since those energies are much 
lower than the tungsten K edge as shown in Figure 13. Furthermore, most of the 
measurements with K edge filters were taken only at 60 or 70 kVp X-ray energies, the heel 
effect does not even show up at these low energies (below the tungsten K edge).  
 
 
Fig. 13. Simulated spectra for 70 kVp X-ray source and 0.71 mm Ce, 0.7 mm Nd, 1 mm Eu 
and 0.4 mm I filtering. 
Similarly, good agreement between the calculated and measured spectra for the Nd, I and 
Eu filters was found. Furthermore, our Ce, Nd and Eu spectra calculations and 
measurements are also very consistent with similar measurements taken by Crotty et al. 
(Crotty, McKinley et al. 2006). 
 
Fig. 14. Comparison of calculated and measured X-ray spectra after 0.71 mm Ce filter. Both 
the measured and the calculated spectra were normalized for the maximum flux value. 
 
Contrast Enhancement in Mammography Imaging Including K Edge Filtering 149 
6.4.2 Cone beam measurements 
After good agreement between the measured and calculated spectra was demonstrated, CT 
scans were carried out. It is noted that the K edge filtered X-ray scans require much longer 
exposure time per frame than scans with the non-filtered or Al and Cu filtered beams in 
order to get comparable dose results. 
CT scans were taken first with the HU phantoms (Figure 9). For each filter and at each kVp, 
CT reconstructions were carried out and the HU numbers were normalized with the help of 
the known densities of the HU phantoms. During the normalization an offset and a slope 
value had to be adjusted at the reconstructed numbers for the best match with the 
theoretical values.  
Next, CT scans were taken of the iodine samples of Figure 10 and the offset and slope 
calibration numbers from the HU phantom results were applied. A typical CT reconstructed 
axial view image of the iodine samples with Eu filter is shown in Figure 15.  The iodine 
content increases from top right clockwise.  
It is known that HU numbers depend on the energy and spectrum of the X-ray beam and 
that is why HU calibrations are always performed using the HU phantoms at each X-ray 
energy and with each filter. Furthermore, some comparisons were made of how much the 
HU numbers were different if the calibration values from the no filter case were applied 
instead of applying the calibration values for the proper energy and filter.  
 
Fig. 15. A CT reconstructed axial image slice of iodine bottles. Image sequence was taken at 
2 fr/s with 1.0 mm Eu filter at 70 kVp_20 mA continuous X-ray exposure. From top right to 
clockwise the iodine content of the bottles is 0, 0.5, 1.0, 4.0 and 16.0 mg/ml. 
Using the calibrated offset and gain numbers for the iodine samples, HU numbers were 
obtained for the same iodine filtering as shown in Figure 10. To double check the numbers 
the air and water (0.00 mg/ml) values were used, which should be close to the nominal   -
1000 and 0 HU numbers. In this case the largest error is for the air, where the difference 
between the nominal and reconstructed values was about 20 HU. 
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decrease above this X-ray energy as can be seen in the measured spectra. However, this 
decrease would not affect the filter materials K edge behavior since those energies are much 
lower than the tungsten K edge as shown in Figure 13. Furthermore, most of the 
measurements with K edge filters were taken only at 60 or 70 kVp X-ray energies, the heel 
effect does not even show up at these low energies (below the tungsten K edge).  
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2 fr/s with 1.0 mm Eu filter at 70 kVp_20 mA continuous X-ray exposure. From top right to 
clockwise the iodine content of the bottles is 0, 0.5, 1.0, 4.0 and 16.0 mg/ml. 
Using the calibrated offset and gain numbers for the iodine samples, HU numbers were 
obtained for the same iodine filtering as shown in Figure 10. To double check the numbers 
the air and water (0.00 mg/ml) values were used, which should be close to the nominal   -
1000 and 0 HU numbers. In this case the largest error is for the air, where the difference 
between the nominal and reconstructed values was about 20 HU. 
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Table 3. CT reconstruction (HU) values for iodine samples with iodine filter. 
Table 3 shows that the HU number increases with increasing iodine content, as expected.  
The HU slopes for iodine with different filters are plotted in Figure 16. It is shown that 
higher HU numbers were obtained (better iodine contrast) with Ce, Nd and Eu filters than 
without using any filter (No-filter case). The K edges all of these materials are above the K 
edge of iodine as shown in Figure 13. Furthermore, good HU linearity with iodine content 
was also observed for all cases. 
However, if an Iodine filter is used for the iodine samples, lower contrast is obtained than in 
the no filter case. It is also noticeable that using higher energy X-rays with Al and Cu filters, 
which filter out the low energy part of the X-ray spectra, the contrast (HU number) further 







Fig. 16. HU slope with different filters. 
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It is quite obvious that the Cerium filter at 60kVp energy significantly increased the HU 
number (increased the contrast) of iodine. It shows a 26% improvement. Eu and Nd filters also 
improved the contrast by 16 and 17% respectively. The Al and Cu filters made the X-ray beam 
harder, so the iodine contrast considerably decreased when these filters and higher X-ray 
energies were used. However, it is interesting to note that the iodine contrast enhancement 
with K edge filters drastically depends on the X-ray tube voltage. When the X- ray energies 
were increased from 60 kVp to 70 kVp, the Ce filter contrast enhancement effect had nearly 
gone and it gave about the same contrast as the no filter case (see Table 4). This means that to 
obtain the maximum HU (contrast) improvement with iodine, the right X-ray tube voltage has 
to be set for each filter material. Furthermore, the material of the imaged object also has an 





Table 4. HU number difference comparison between the 16 mg/ml iodine and 0 mg/ml 
(pure water) solutions and the relative HU change for different filters and X-ray energies. 
After the iodine contrast improvement, S/N (Signal–to-Noise) ratio was optimized. Dose 
per frame was varied to find the highest S/N. Generally the X-ray flux, after the filters were 
applied, was an order of magnitude lower than the flux in the no filter case or when the Al 
or Cu filters were used. To compensate for this effect the exposure time was increased by 
decreasing the framerate. However, the maximum exposure time per frame was also limited 
by the heat load limit of the X-ray tube because 625 frames had to be taken for CT 
reconstruction. Finally, the dose per frame numbers for the filter cases versus the no filter 
case was still about 2-3 times lower.  
The S/N ratios were measured at all sample positions and also inside the bulk polyethylene 
far from the samples. Finally these numbers were averaged for a given measurement to find 
the (S/N)filter. It is known that for the ideal case, when the electronics noise is negligible, the 
signal to noise (S/N) value is proportional to the square root of the number of incoming 
photons (flux). For equivalent image quality the S/N values have to be the same and so we 









[HU(16)-HU(0)] filter / 
[HU(16)-HU(0)] nofilter
No filter (60kVp) 866 1.00
Cu filter (100kVp) 501 0.58
Al filter (100kVp) 599 0.69
I filter (60kVp) 718 0.83
Ce filter (60kVp) 1093 1.26
Ce filter (70kVp) 874 1.01
Eu filter (70kVp)) 1007 1.16
Nd filter (70kVp) 1015 1.17
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without using any filter (No-filter case). The K edges all of these materials are above the K 
edge of iodine as shown in Figure 13. Furthermore, good HU linearity with iodine content 
was also observed for all cases. 
However, if an Iodine filter is used for the iodine samples, lower contrast is obtained than in 
the no filter case. It is also noticeable that using higher energy X-rays with Al and Cu filters, 
which filter out the low energy part of the X-ray spectra, the contrast (HU number) further 







Fig. 16. HU slope with different filters. 
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It is quite obvious that the Cerium filter at 60kVp energy significantly increased the HU 
number (increased the contrast) of iodine. It shows a 26% improvement. Eu and Nd filters also 
improved the contrast by 16 and 17% respectively. The Al and Cu filters made the X-ray beam 
harder, so the iodine contrast considerably decreased when these filters and higher X-ray 
energies were used. However, it is interesting to note that the iodine contrast enhancement 
with K edge filters drastically depends on the X-ray tube voltage. When the X- ray energies 
were increased from 60 kVp to 70 kVp, the Ce filter contrast enhancement effect had nearly 
gone and it gave about the same contrast as the no filter case (see Table 4). This means that to 
obtain the maximum HU (contrast) improvement with iodine, the right X-ray tube voltage has 
to be set for each filter material. Furthermore, the material of the imaged object also has an 





Table 4. HU number difference comparison between the 16 mg/ml iodine and 0 mg/ml 
(pure water) solutions and the relative HU change for different filters and X-ray energies. 
After the iodine contrast improvement, S/N (Signal–to-Noise) ratio was optimized. Dose 
per frame was varied to find the highest S/N. Generally the X-ray flux, after the filters were 
applied, was an order of magnitude lower than the flux in the no filter case or when the Al 
or Cu filters were used. To compensate for this effect the exposure time was increased by 
decreasing the framerate. However, the maximum exposure time per frame was also limited 
by the heat load limit of the X-ray tube because 625 frames had to be taken for CT 
reconstruction. Finally, the dose per frame numbers for the filter cases versus the no filter 
case was still about 2-3 times lower.  
The S/N ratios were measured at all sample positions and also inside the bulk polyethylene 
far from the samples. Finally these numbers were averaged for a given measurement to find 
the (S/N)filter. It is known that for the ideal case, when the electronics noise is negligible, the 
signal to noise (S/N) value is proportional to the square root of the number of incoming 
photons (flux). For equivalent image quality the S/N values have to be the same and so we 









[HU(16)-HU(0)] filter / 
[HU(16)-HU(0)] nofilter
No filter (60kVp) 866 1.00
Cu filter (100kVp) 501 0.58
Al filter (100kVp) 599 0.69
I filter (60kVp) 718 0.83
Ce filter (60kVp) 1093 1.26
Ce filter (70kVp) 874 1.01
Eu filter (70kVp)) 1007 1.16
Nd filter (70kVp) 1015 1.17
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Where Doseequivalent is the dose for the filter, which gives the same S/N ratio as the no filter 
case, and Dosefilter is the dose measured when a given filter was applied. (S/N)nofilter is the 
signal to noise ratio for the no filter case while (S/N)filter is for the filtered case. The dose per 
frame difference during the measurement was only 2-3 times lower for the filtered cases so 
we thought that the above approximation would not introduce significant error. This 
approximation was double checked with measurements and S/N evaluation at two 
different dose-rates and for 8 times dose difference the error using the above approximation 
was less than 10%.  
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After calculating the equivalent doses for each filter, these dose values were divided by the 
no filter case dose and dose equivalent S/N dose ratios were obtained. Both the equivalent 
doses and dose ratios are reported in Table 5. These numbers tell how much absolute and 
relative dose is needed when using these filters to get the same S/N value as the no filter 
case.  
Table 5 tells that practically all of the filter materials used in these experiments provide the 
same S/N ratio at lower dose as the no filter case. From the dose point of view a Cu filter 
gives nearly the same very low dose as a Eu filter. However, it is important not just to get 
lower dose but at the same time to provide better contrast resolution and therefore higher 





Table 5. Equivalent dose and dose rates. 
6.4.3 Some other applications of K edge filters 
In addition to mammography, Iodine and K edge filters are used for other medical x-ray 
imaging applications, such as lung tumor imaging and, frequently, angiography. (Nyman U 
Fau - Elmstahl, Elmstahl B Fau - Leander et al.), (Sato, Tanaka et al. 2004; Sato, Tanaka et al. 
2007), (Sato, Hayasi et al. 2006). 









No filter (60kVp) 1111 94.0 1111 1.00
Cu filter (100kVp) 569 114.3 385 0.35
Al filter (100kVp) 858 121.3 516 0.46
I filter (60kVp) 598 92.8 614 0.55
Ce filter (60kVp) 404 80.3 830 0.50
Ce filter (70kVp) 598 87.9 685 0.62
Eu filter (70kVp)) 648 121.4 389 0.35
Nd filter (70kVp) 627 98.5 571 0.51
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A further enhancement of K edge filters involves using these filers in combination with  
counting mode energy resolution detectors mostly in CT applications (Alvarez and 
Macovski 1976; Roessl, Brendel et al. 2008; Schlomka and et al. 2008; Watanabe, Sato et al. 
2008). 
It is interesting to note that K edge imaging is also used in NDT (non Destructive Testing) 
applications by Jensen et al (Technology ; Jensen, Aljundi et al. 1997), when they measure 
the total uranium content in reactor fuel plates using the K edge technique. A further 
interesting application of K edge imaging is in the analysis of paintings where researchers 
verify authenticity and hunt for paintings that have been painted over (Dik 2004). 
7. Conclusion 
This chapter presented different methods used in mammography to improve the contrast 
between adipose and glandular tissues but especially to find cancerous cells and regions.  
First of all the right energy range has to be determined for minimum patient dose with 
maximum contrast. Dual energy imaging, which uses two images taken at different 
energies, further enhances the contrast between different tissues and especially when 
contrast material is used. 
Monochromatic X-ray beams are ideal for getting high quality images with optimal dose 
level and avoiding beam hardening artifacts. Moreover, monochromatic imaging can 
provide phase contrast images with excellent soft tissue contrast. The major drawbacks are 
that the synchrotrons, which can provide monochromatic beams with enough flux for 
medical imaging, are very large and expensive sources of X-rays.  
Quasi monochromatic X-rays can be obtained by diffraction of X-rays emitted by an X-ray 
tube onto a mosaic crystal. The output beam has a limited bandwidth, low output flux, and 
has a fan beam shape. This limits its application only for scanning type imagers.  
Another method of generating quasi monochromatic beams uses K edge filters. These filter 
materials have K edge electrons with bonding energies in the diagnostic X-ray energy range. 
The material can absorb an X-ray photon, whose energy is equivalent to or slightly higher 
than the K edge energy, by releasing an electron. The material’s X-ray absorption level 
dramatically increases at or above this energy. As a result, x-rays higher than the K edge 
energy are suddenly cut off. Using these materials as X-ray filters, a narrow x-ray 
transmission energy range below the K edge energy can be obtained. One advantage of the 
K edge filters is that they provide cone beam shaped X-ray radiation rather than fan beam 
shaped radiation.  
Iodine and Gadolinium are contrast agents injected into the blood flow. They absorb the 
x-rays better than body tissues providing an x-ray shadow. They accumulate in the 
cancerous cells and remain there longer than they remain in the blood stream. This 
enhanced x-ray absorption provides extra contrast for better visibility of tumors. Using K 
edge filters X-ray image contrast of the I or Gd absorption can be further increased. I and 
Gd are frequently used as contrast agents for CT imaging. The experimental part of this 
paper describes evaluation of a few K edge filter materials using Iodine contrast material. 
These filters were compared to the non filtered case and also to Al and Cu filters, which 
provided only X-ray beam hardening. CT scans were performed and the HU numbers 
 
Imaging of the Breast – Technical Aspects and Clinical Implication 152 
Where Doseequivalent is the dose for the filter, which gives the same S/N ratio as the no filter 
case, and Dosefilter is the dose measured when a given filter was applied. (S/N)nofilter is the 
signal to noise ratio for the no filter case while (S/N)filter is for the filtered case. The dose per 
frame difference during the measurement was only 2-3 times lower for the filtered cases so 
we thought that the above approximation would not introduce significant error. This 
approximation was double checked with measurements and S/N evaluation at two 
different dose-rates and for 8 times dose difference the error using the above approximation 
was less than 10%.  
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case.  
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A further enhancement of K edge filters involves using these filers in combination with  
counting mode energy resolution detectors mostly in CT applications (Alvarez and 
Macovski 1976; Roessl, Brendel et al. 2008; Schlomka and et al. 2008; Watanabe, Sato et al. 
2008). 
It is interesting to note that K edge imaging is also used in NDT (non Destructive Testing) 
applications by Jensen et al (Technology ; Jensen, Aljundi et al. 1997), when they measure 
the total uranium content in reactor fuel plates using the K edge technique. A further 
interesting application of K edge imaging is in the analysis of paintings where researchers 
verify authenticity and hunt for paintings that have been painted over (Dik 2004). 
7. Conclusion 
This chapter presented different methods used in mammography to improve the contrast 
between adipose and glandular tissues but especially to find cancerous cells and regions.  
First of all the right energy range has to be determined for minimum patient dose with 
maximum contrast. Dual energy imaging, which uses two images taken at different 
energies, further enhances the contrast between different tissues and especially when 
contrast material is used. 
Monochromatic X-ray beams are ideal for getting high quality images with optimal dose 
level and avoiding beam hardening artifacts. Moreover, monochromatic imaging can 
provide phase contrast images with excellent soft tissue contrast. The major drawbacks are 
that the synchrotrons, which can provide monochromatic beams with enough flux for 
medical imaging, are very large and expensive sources of X-rays.  
Quasi monochromatic X-rays can be obtained by diffraction of X-rays emitted by an X-ray 
tube onto a mosaic crystal. The output beam has a limited bandwidth, low output flux, and 
has a fan beam shape. This limits its application only for scanning type imagers.  
Another method of generating quasi monochromatic beams uses K edge filters. These filter 
materials have K edge electrons with bonding energies in the diagnostic X-ray energy range. 
The material can absorb an X-ray photon, whose energy is equivalent to or slightly higher 
than the K edge energy, by releasing an electron. The material’s X-ray absorption level 
dramatically increases at or above this energy. As a result, x-rays higher than the K edge 
energy are suddenly cut off. Using these materials as X-ray filters, a narrow x-ray 
transmission energy range below the K edge energy can be obtained. One advantage of the 
K edge filters is that they provide cone beam shaped X-ray radiation rather than fan beam 
shaped radiation.  
Iodine and Gadolinium are contrast agents injected into the blood flow. They absorb the 
x-rays better than body tissues providing an x-ray shadow. They accumulate in the 
cancerous cells and remain there longer than they remain in the blood stream. This 
enhanced x-ray absorption provides extra contrast for better visibility of tumors. Using K 
edge filters X-ray image contrast of the I or Gd absorption can be further increased. I and 
Gd are frequently used as contrast agents for CT imaging. The experimental part of this 
paper describes evaluation of a few K edge filter materials using Iodine contrast material. 
These filters were compared to the non filtered case and also to Al and Cu filters, which 
provided only X-ray beam hardening. CT scans were performed and the HU numbers 
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were calculated for iodine contrast agents. It was found that the beam hardening Al and 
Cu filters and even the iodine filter decreased the iodine HU number, but the K edge 
filters, which have K edge energy slightly above the K edge of iodine, increased the HU 
number (increased iodine contrast). This increase can be as high as 26% for Ce filter at 60 
kVp. However, it is seen that using an Iodine filter for an Iodine contrast agent decreases 
the HU number to the no-filter case. That creates an option to further enhance the contrast 
by subtracting the Iodine filtered image from the Ce filtered one. This would provide an 
additional ~17% contrast enhancement of iodine. A drawback of this method is that we 
need two images (practically dual energy imaging), which increases the dose to the 
patient and increases noise.  
We also found that the increase of HU number is linearly proportional with the iodine 
content in water.  
Furthermore, the doses required for S/N number equivalent to the no filter case are lower 
for each filter material. However, we need not just lower dose but want to increase the 
iodine contrast (higher HU number for iodine). From this point of view Eu is a much better 
choice than Cu even if their dose improvement is nearly the same. The dose improvement is 
nearly 3 times for both filters but Cu decreased the HU number (the iodine visibility) nearly 
to half of the no filter case. So both the HU increase and the dose improvement have to be 
considered in parallel. From these considerations Ce, Eu and Nd are all promising 
candidates for iodine contrast imaging enhancement. Moreover, the HU contrast 
enhancement effect depends strongly on the X-ray tube voltage as seen in Table 4 for Ce and 
also on the object material, which contains the iodine, so careful optimization is required for 
getting the maximum HU improvement with a significantly decreased dose to the patient. 
Mc. Kinley et al investigated the effect of K edge filtering on breast CT and found dose 
reduction possibility up to 6 times while keeping the same contrast ratio (McKinley Iii, 
Tornai et al. 2007).  
Watanabe et al (Watanabe, Sato et al. 2008) and Roessl et al (Roessl, Brendel et al. 2008) also 
investigated how K edge imaging improves the signal to noise ratio but they used a photon 
counting CT method. S/N ratio improvement was demonstrated by using the K edge 
technique but the photon counting method is much more expensive and a slower process 
than multislice or cone beam CT with K edge filter. These drawbacks come from the high 
price of the large area pixellated energy resolution detectors and the counting speed is very 
limited. 
Finally, it is very important that for HU calibration we have to use the same kVp setting and 
filter that we use for scanning the CT object otherwise huge reconstruction errors could be 
introduced (Zentai 2011). 
We need to add that we used heavy K edge filtering of 200th value layer K edge filters for 
Ce, Eu and Nd. These thick filters significantly decreased the X-ray intensity even around 
the K edge. From our measurements and calculations we concluded that thinner filters may 
provide the same advantages that these thick filters without the large flux reduction. This 
could ease the tube flux requirement and so decrease the maximum heat load and/or 
increase the CT scanning speed. 
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Impedance Mammography  
Marina Korotkova and Alexander Karpov 
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Russia 
1. Introduction  
1.1 Imaging technique, employing feeble alternating current  
Currently, a variety of electrical impedance diagnostic systems is used both in academic 
studies and in clinical practice. A significant part of such systems employs electrodes which 
reside in a single array and two-dimensional mathematical conductivity reconstruction 
algorithms in the array of the electrodes. Electrical impedance mammograph belongs to 
the class of 3D tomography systems. Thus, all the measurements are made on the 
surface of the object under investigation. The change of surface potential difference 
(compared with the homogeneous case), as a rule, is caused by the presence of a local 
heterogeneous area in the object. It is mainly concentrated in the area which is a projection 
of the local heterogeneous area on the surface of the object. Therefore, the main objective of 
electrical impedance mammography is to visualize the reconstructed three-dimensional 
electrical conductivity distribution of the object basing on the results of electrical 
measurements on its surface. For this purpose various modifications of mathematical 
method of “back projection” are employed. Mathematical methods provide also cross-
sectional slices of conductivity. 
The usage of alternating current for this purpose is justified from several positions. 
Extreme complication of electrical conductivity measuring in biological systems at direct 
(i.e. unidirectional) current is conditioned by high degree of polarization of cellular 
membranes. Moreover, the flow of direct current through biological tissues is accompanied 
by irreversible chemical reactions at the electrodes, through which the object is connected 
with the external part of the circuit. Therefore, only alternating electric current of sufficiently 
high frequency is employed in medical diagnostics. 
1.2 Tissue-specific peculiarities of electrical conductivity 
In biological tissue, electric current affects the components and structures that have a net 
electric charge and / or an electric dipole moment. This influence is carried out in an 
environment characterized by the presence of numerous interface regions. An example of 
such interface regions are cell membranes. In the space, surrounding cell membranes from 
both sides, the changes are carried by electric charges, mainly in the form of ions and the 
sources of dipole moment in the form of polar water molecules and mobile polar 
 
Imaging of the Breast – Technical Aspects and Clinical Implication 158 
Venkatakrishnan, V., Yavuz, M., et al. (1999) Experimental and theoretical spectral optimization 
for digital mammography. SPIEVol. 3659, pp. 142-149. 
Walter, D.J., Wu, X., et al. (2004) Dual kVp material decomposition using flat-panel detectors. In, 
Medical Imaging 2004: Physics of Medical Imaging, SPIE, San Diego, CA, USA, Vol. 
5368, pp. 29-39. 
Watanabe, M., Sato, E., et al. (2008) Energy-discriminating K-edge x-ray computed tomography 
system. In, SPIE Penetrating Radiation Systems and Applications IX, SPIE, San 
Diego, California, Vol. 7080, pp. 70800B-1-5. 
Zentai, G. (2011) Signal-to-Noise and Contrast Ratio Enhancements by Quasi-Monochromatic 
Imaging. IEEE Transactions on Instrumentation and Measurement Vol. 60, 908-915. 
7 
Standards for Electrical  
Impedance Mammography  
Marina Korotkova and Alexander Karpov 
Clinical Hospital #9, Yaroslavl 
Russia 
1. Introduction  
1.1 Imaging technique, employing feeble alternating current  
Currently, a variety of electrical impedance diagnostic systems is used both in academic 
studies and in clinical practice. A significant part of such systems employs electrodes which 
reside in a single array and two-dimensional mathematical conductivity reconstruction 
algorithms in the array of the electrodes. Electrical impedance mammograph belongs to 
the class of 3D tomography systems. Thus, all the measurements are made on the 
surface of the object under investigation. The change of surface potential difference 
(compared with the homogeneous case), as a rule, is caused by the presence of a local 
heterogeneous area in the object. It is mainly concentrated in the area which is a projection 
of the local heterogeneous area on the surface of the object. Therefore, the main objective of 
electrical impedance mammography is to visualize the reconstructed three-dimensional 
electrical conductivity distribution of the object basing on the results of electrical 
measurements on its surface. For this purpose various modifications of mathematical 
method of “back projection” are employed. Mathematical methods provide also cross-
sectional slices of conductivity. 
The usage of alternating current for this purpose is justified from several positions. 
Extreme complication of electrical conductivity measuring in biological systems at direct 
(i.e. unidirectional) current is conditioned by high degree of polarization of cellular 
membranes. Moreover, the flow of direct current through biological tissues is accompanied 
by irreversible chemical reactions at the electrodes, through which the object is connected 
with the external part of the circuit. Therefore, only alternating electric current of sufficiently 
high frequency is employed in medical diagnostics. 
1.2 Tissue-specific peculiarities of electrical conductivity 
In biological tissue, electric current affects the components and structures that have a net 
electric charge and / or an electric dipole moment. This influence is carried out in an 
environment characterized by the presence of numerous interface regions. An example of 
such interface regions are cell membranes. In the space, surrounding cell membranes from 
both sides, the changes are carried by electric charges, mainly in the form of ions and the 
sources of dipole moment in the form of polar water molecules and mobile polar 
 
Imaging of the Breast – Technical Aspects and Clinical Implication 
 
160 
macromolecules. Moreover, the polarization ability of the cell membrane itself due to 
protein and lipid structures determines its exceptional electrical properties. Thus, the 
electrical properties of biological tissue as a colloid-disperse system in an alternating 
electric field are determined by the concentration and «the behaviour» of chemical 
compounds in it. 
2. Indications for application 
- Evaluation of palpable lesions of the mammary gland.  
- Evaluation of the impalpable changes which do not manifest clinically.  
- Formation of groups of people with heightened risk of breast cancer development, 
using the percentile curves of the age-related electrical conductivity. 
- Screening for oncopathology. 
- Additional examination of the dense tissue of the mammary gland.  
- Examination in the age group under 50, including adolescents.  
- Examination of pregnant and lactating women.  
- Monitoring during hormonal contraception and hormone replacement therapy.  
- Monitoring after pharmacotherapy or operative therapy. 
- Examination of the women after cosmetic surgery.  
3. Technical requirements and safety assurances for doctors and patients 
- Parameters of current employed: alternating current, frequency - 50 кHz, current 
intensity - 0.5 mA.  
- The abovementioned characteristics are allowed for medical use and are safe both for a 
doctor and a patient; also they are significantly lower than «threshold values», i.e. do 
not induce pain or other sensations.  
- Patient’s name/code, examination date, probing current characteristics and initial 
adjustments shall be displayed on the screen.  
- Examination results digital recording.  
- Penetration depth ≥ 4.0 cm.  
4. Examination quality criteria 
For high-quality diagnostic and continuity of work it is necessary that electrical impedance 
mammograms met specific quality criteria. 
- Appropriate visualization of mammary gland tissue:  the nipple shall be in the centre of 
the image.  
- If the mammary gland is not completely covered by the panel or if there are palpable 
lesions out of the electrodes panel area, the examination shall be carried out by 
segments, clockwise (upper – external – lower – internal segment of the mammary 
gland).  
- Proper designation: patient data, indication of the side and the date of the examination, 
physiological period, other features, for example, skin changes. 
- Sufficient compression: optimal number of good contacts. It is necessary to achieve the 
maximum possible number of good contacts, however, excessive compression of the 
breast shall be avoided. 
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- The absence of motion distortions and artifacts.  
- The absence of skin folds.  
- The images acquired using improper examination techniques are not accepted for 
interpretation. 
5. Types of mammary gland structure from the perspective of electrical 
impedance mammography 
Electrical conductivity index (IC), calculated during the electrical impedance examination, is 
a quantitative value, which characterizes the status of the breast. The results of 1,632 
electrical impedance mammograph examinations, obtained from healthy women from 
different age groups, were analyzed. The women were selected for the examination 
according to the following criteria: absence of complaints on the mammary glands, a normal 
menstrual cycle, uncomplicated perimenopausal period, absence of chronic somatic and 
gynaecological diseases and absence of hormonal contraceptives taking or hormone 
replacement therapy. The women were distributed by age in years as follows: 20-30 (380 
women), 31-40 (428), 41-50 (449) and 51-60 (375). All the examinations described in the 
chapter were carried out with the help of the electroimpedance computer mammograph 
“MEIK” v.5.6 (0.5 mА, 50 kHz), developed and manufactured by PKF "SIM-Technika", 
Russia.  
Fluctuations of electrical conductivity index in 1,632 studies were as follows: lower limit – 
0.01 conventional units, upper limit – 0.68 conventional units. In order to identify the 
structure of electrical impedance index distribution there were elaborated 8 ranges of 
criteria at a step of 0.09 and the quantity of studies was calculated in each range (Table 1). 
 
Electrical conductivity index Number of studies 
0.00 – 0.09 67 
0.10 – 0.19 279 
0.20 – 0.29 471 
0.30 – 0.39 435 
0.40 – 0.49 299 
0.50 – 0.59 75 
0.60 – 0.69 6 
Total 1632 
Table 1. Arrangement of electrical conductivity index frequencies. 
Fig. 1 shows the frequency histogram of electrical conductivity index data. Mean electrical 
conductivity index constituted 0.29, median value – 0.29 and mode - 0.26. 
Taking into consideration a bell-shaped curve, close mean, median and mode values one can 
speak about standard (Gauss) distribution of the quantitative value, in this case, of electrical 
conductivity index. Typically, mean value and standard deviation are used to describe 
standard distribution. More detailed data can be obtained using 3th, 10th, 25th, 40th, 75th, 
90th and 97th percentiles (Figure 2). In this case, the information on the shape of criterion 
distribution graph is not required.  
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Fig. 1. Frequency histogram of electrical conductivity index data. 
 
Fig. 2. Frequency histogram of electrical conductivity index data and percentile ranges. 
The following pattern was identified after the age-related characteristics of women 
belonging to the percentile ranges were analyzed. Women aged from 20 to 30, whose data 
fell to the ranges less than 3rd percentile (IC<0.09) and from 3rd to 10th percentile (IC=0.1-
1.4) constituted more than 50%. Women aged from 50 to 60, whose data fell to the ranges 
higher than 97th percentile (IC>0.53) and from 90th to 97th percentile (IC=0.47-0.52) 
constituted more than 50%. Age of the women whose data ranged between 25th and 75th 
percentiles (IC=0.21-0.39) distributed in a uniform manner, the percentage of each age- 
group constituted from 20 to 30% without any prevalence (Figure 3).   
 




Fig. 3. Age-related characteristics of percentile ranges. 
The low electrical conductivity index of the mammary glands typical for women aged from 
20 to 30 are conditioned by the peculiarities of breast’s anatomy. This group of women is 
characterized by the prevalence of ductal and acinar epithelium over connective tissue in the 
mammary gland structure. The phenomenon of low conductivity can be explained by the 
presence of a large number of membranes of epithelium cells in the mamma. It is known 
that cell membranes possess capacitance and act as a strong barrier for electrical current. 
Therefore, a large amount of lactiferous ducts and lobules in the mamma (implying the 
presence of a large number of cell membranes) conditions low electrical conductivity. The 
predominance of women in this age group is observed in two percentile ranges - less than 
3rd percentile and from 3rd to 10th percentile. Therefore, the status of mammary glands 
possessing electrical conductivity index lower than 0.14 cu, should be regarded as ductal 
and acinar type of the breast structure (Fig. 4). 
 
Fig. 4. EIM. Seven scan planes. A 21 years-old patient. Acinar/ductal type of  mammary 
gland structure. Low  values of electrical conductivity index (less than 10 pct). On the right - 
ultrasound image. 
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“Loss” of acinar/ductal epithelium in women aged from 50 to 60 is the reason for high 
electrical conductivity index of the mammary glands.  When progressive decrease of estradiol 
secretion occurs, terminal-duct secretory epithelium is substituted by connective tissue with a 
varied correlation of tissue elements. Intercellular substance includes the ground substance, 
which contains a large amount of mucopolysaccharides. Loose connective tissue, filling the 
space between bodies, blood vessels, nerves, muscles and other structures of the body, creates 
the internal environment, through which the delivery of nutrients to cells and the removal of 
the waste products of their metabolism are carried out. The major mucopolysaccharide of the 
ground substance of connective tissue is hyaluronic acid, which carries a large number of 
negative charges. Its ability to bind and retain water dipoles determines the electrical 
properties of amorphous substance of connective tissue, making it a good conductor. 
Therefore, the predominance of connective tissue in the breast should expect high electrical 
conductivity. The predominance of women in this age group is observed in two percentile 
ranges - more than 97th percentile and from 90th to 97th percentile. Therefore, the status of 
mammary glands possessing electrical conductivity index higher than 0.47 cu, should be 
regarded as amorphous type of the mammary gland structure (Fig. 5). 
 
Fig. 5. EIM. Seven scan planes. A 52 years-old patient. Amorphous type of mammary gland 
structure. High values of mean electrical conductivity index – (> 90 pct). On the right - X-ray 
mammogram. 
Different combinations of acinar/ductal components and connective tissue with adipocytes 
are the reasons for electrical conductivity index variations from 0.21-0.39 in women of all age 
groups. Therefore, the status of mammary glands possessing electrical conductivity index 
within the range from 0.21 to 0.39 cu, should be regarded as a mixed type of the mammary 
gland structure. Different combinations of the structures that determine the conductivity of 
tissues, define the wide range of the values of electrical conductivity index (Fig. 6). 
 
Fig. 6. EIM. Seven scan planes. Age 39 years. Mixed type of mammary gland structure. 
Mean electrical conductivity index – 25-75 pct. On the right - X-ray mammogram. 
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Within the ranges from 10th to 25th percentile and from 75 to 90th percentile the data of two 
age groups of women prevail. Therefore, the status of mammary glands possessing electrical 
conductivity index within these ranges, should be regarded as a mixed type of the 
mammary gland structure with prevalence of acinar/ductal or amorphous component 
respectively.  
Below the summary table of structure estimates for the breast in terms of electrical 











 Formulation Electrical conductivity Percentiles 
Type 
Iа 
Amorphous type of mammary gland 




Mixed type of mammary gland structure 
with amorphous component predominance. 0,40 – 0,46 75-90‰ 




Mixed type of mammary gland structure 
with acinar/ductal component 
predominance. High density of ductal 
component. 




Acinar/ductal type of mammary gland 
structure. 
Extremely high density of acinar/ductal 
component 
below 0.14 <10‰ 
 
 
Table 2. Types of mammary gland structure from the perspective of electrical impedance 
mammography. 
Thus the estimation of mammary gland structure from the perspective of electrical 
impedance mammography using electrical conductivity index is possible. It is known that 
the structure of the mammary gland determines their density. Thus, the defined ranges of 
electric conductivity correspond to different types of mammary gland “density”. Low 
values of electric conductivity correspond to “dense” breasts of the so-called combined 
ductal/lobular type. High values of electrical conductivity index are characteristics of the 
amorphous type of breasts, consisting mainly of fat and connective tissue. A distinctive 
feature of this method for evaluating structure of the breast is the expression of its 
anatomical and histological structure in numerical terms. Estimation of the density of 
mammary glands from the perspective of electrical impedance mammography using 
electrical conductivity index in ACR terms is provided below (Table 3). 
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 EIM classification ACR classification 
Type Iа Amorphous type of mammary gland structure. IC >90‰. Predominantly fat. Under 25% of 
tissue is represented by parenchyma Type 
Ib 
Mixed type of mammary gland 
structure with amorphous component 
predominance. IC=75-90‰. 
Type II 
Mixed type of mammary gland 
structure. 
IC=25-75‰. 
Fat with some fibroglandular tissue. 




Mixed type of mammary gland 
structure with acinar/ductal 
component predominance. High 
density of acinar/ductal component. 
IC=10-25‰. 
Heterogeneously dense. 




Acinar/ductal type of mammary gland 
structure. Extremely high density of 
acinar/ductal component. 
IC < 10‰. 
Extremely dense. 
75-100% of parenchyma tissue. 
Table 3. Mammary gland structure from the perspective of electrical impedance 
mammography execution and breast density types according to the classification of the 
American College of Radiology (ACR). 
6. System for description of mammary glands images  
6.1 Terminology 
 Electrical conductivity scale - electrical conductivity index values from 0 to 1.00, or in 
gray-scale - changes from black to white, respectively. 
 Hyperimpedance structure, lesion - electrical conductivity is lower than electrical 
conductivity of the surrounding tissue of the breast and corresponds to IC < 0.20. 
 Isoimpedance structure, lesion - electrical conductivity is approximately equal to the 
electrical conductivity of the surrounding tissue of the breast and corresponds to IC = 
0.3-0.5. 
 Hypoimpedance structure, lesion - electrical conductivity is higher than the electrical 
conductivity of the surrounding tissue of the breast and corresponds to IC = 0.6-0.8. 
 Animpedance structure, lesion - electrical conductivity is considerably higher than the 
electrical conductivity of the surrounding tissue of the breast and corresponds to IC > 
0.90. 
6.2 Normal signs in the electrical impedance mammogram 
6.2.1 The septa  
The septa (layers) consisting of delicate fibrillary tissue are going deep into the mass of the 
mammary gland from connective tissue capsule that surrounds it. The septa, radiating from 
the centre, which form the connective tissue stroma of the mammary gland are 
characterized by a hyperimpedance structure (Fig. 7). 
 




Fig. 7. EIM. Seven scan planes. Connective tissue septa, radiating from the areola (indicated 
with arrows). 
6.2.2 The parenchyma 
One distinguishes the parenchyma, which consists of alveolar-tubular glands, and the 
connective tissue stroma, which is represented by a small amount of cells, delicate fibres and 
ground intercellular substance. The parenchyma is characterized by an isoimpedance 
structure and is located between the septa.  (Fig. 8). 
 
Fig. 8. EIM. Seven scan planes. Parenchyma as isoimpedance areas located between the 
connective tissue septa (indicated with arrows). 
6.2.3 The lactiferous sinus zone 
Before reaching the nipple milk ducts gain in breadth and create a lactiferous sinus (sinus 
lactiferi) which accumulates secreta as well as the milk. There are about 15-25 sini in the 
retromammilary area. The lactiferous sinus zone is visualized as a vast hypoimpedance area 
located in the centre of the mammogram (fig. 9). 
 
Fig. 9. EIM. Seven scan planes. A hypoimpedance area in the centre of the mammogram 
corresponds to the location of the lactiferous sinus zone (indicated with arrows). 
6.2.4 The nipple 
The nipple consists of the excretory ducts of the breast lobes, surrounded by fibrous tissue 
and a large number of sebaceous glands. High electrical impedance of the nipple is 
determined by the absence of the excretory ducts of perspiratory glands in it. In the 
electrical impedance tomogram the nipple is visualized in the centre as a circular or linear 
hyperimpedance area, located closely to the lactiferous sinus zone (fig. 10). 
 
Imaging of the Breast – Technical Aspects and Clinical Implication 
 
166 
 EIM classification ACR classification 
Type Iа Amorphous type of mammary gland structure. IC >90‰. Predominantly fat. Under 25% of 
tissue is represented by parenchyma Type 
Ib 
Mixed type of mammary gland 
structure with amorphous component 
predominance. IC=75-90‰. 
Type II 
Mixed type of mammary gland 
structure. 
IC=25-75‰. 
Fat with some fibroglandular tissue. 




Mixed type of mammary gland 
structure with acinar/ductal 
component predominance. High 
density of acinar/ductal component. 
IC=10-25‰. 
Heterogeneously dense. 




Acinar/ductal type of mammary gland 
structure. Extremely high density of 
acinar/ductal component. 
IC < 10‰. 
Extremely dense. 
75-100% of parenchyma tissue. 
Table 3. Mammary gland structure from the perspective of electrical impedance 
mammography execution and breast density types according to the classification of the 
American College of Radiology (ACR). 
6. System for description of mammary glands images  
6.1 Terminology 
 Electrical conductivity scale - electrical conductivity index values from 0 to 1.00, or in 
gray-scale - changes from black to white, respectively. 
 Hyperimpedance structure, lesion - electrical conductivity is lower than electrical 
conductivity of the surrounding tissue of the breast and corresponds to IC < 0.20. 
 Isoimpedance structure, lesion - electrical conductivity is approximately equal to the 
electrical conductivity of the surrounding tissue of the breast and corresponds to IC = 
0.3-0.5. 
 Hypoimpedance structure, lesion - electrical conductivity is higher than the electrical 
conductivity of the surrounding tissue of the breast and corresponds to IC = 0.6-0.8. 
 Animpedance structure, lesion - electrical conductivity is considerably higher than the 
electrical conductivity of the surrounding tissue of the breast and corresponds to IC > 
0.90. 
6.2 Normal signs in the electrical impedance mammogram 
6.2.1 The septa  
The septa (layers) consisting of delicate fibrillary tissue are going deep into the mass of the 
mammary gland from connective tissue capsule that surrounds it. The septa, radiating from 
the centre, which form the connective tissue stroma of the mammary gland are 
characterized by a hyperimpedance structure (Fig. 7). 
 




Fig. 7. EIM. Seven scan planes. Connective tissue septa, radiating from the areola (indicated 
with arrows). 
6.2.2 The parenchyma 
One distinguishes the parenchyma, which consists of alveolar-tubular glands, and the 
connective tissue stroma, which is represented by a small amount of cells, delicate fibres and 
ground intercellular substance. The parenchyma is characterized by an isoimpedance 
structure and is located between the septa.  (Fig. 8). 
 
Fig. 8. EIM. Seven scan planes. Parenchyma as isoimpedance areas located between the 
connective tissue septa (indicated with arrows). 
6.2.3 The lactiferous sinus zone 
Before reaching the nipple milk ducts gain in breadth and create a lactiferous sinus (sinus 
lactiferi) which accumulates secreta as well as the milk. There are about 15-25 sini in the 
retromammilary area. The lactiferous sinus zone is visualized as a vast hypoimpedance area 
located in the centre of the mammogram (fig. 9). 
 
Fig. 9. EIM. Seven scan planes. A hypoimpedance area in the centre of the mammogram 
corresponds to the location of the lactiferous sinus zone (indicated with arrows). 
6.2.4 The nipple 
The nipple consists of the excretory ducts of the breast lobes, surrounded by fibrous tissue 
and a large number of sebaceous glands. High electrical impedance of the nipple is 
determined by the absence of the excretory ducts of perspiratory glands in it. In the 
electrical impedance tomogram the nipple is visualized in the centre as a circular or linear 
hyperimpedance area, located closely to the lactiferous sinus zone (fig. 10). 
 




Fig. 10. EIM. Seven scan planes. The nipple is visualized in the centre as a rounded 
hyperimpedance area (indicated with arrows). In the centre of the nipple there are excretory 
ducts which are characterized by hypoimpedance. Around the nipple there is the 
hypoimpedance area of the lactiferous sinus zone. 
6.2.5 The areola 
In the dermis of areola there are circular smooth muscle fibres, numerous sebaceous glands 
and a large number of pigment cells. Large sebaceous glands located on the periphery of the 
areola cause the formation of protrusions (Montgomery's tubercles). High electrical 
impedance of the areola, as well as that of the nipple, is determined by the absence of the 
excretory ducts of perspiratory glands in it. In the electrical impedance mammogram the 
areola is visualized as a circular hyperimpedance formation surrounding the lactiferous 
sinus zone (fig. 11). 
 
Fig. 11. EIM. Seven scan planes. A hyperimpedance area in the centre of the mammogram 
corresponds to the location of the areola (indicated with arrows). 
6.3 Volumetric lesion 
Volumetric lesion – a dimensional lesion, detected in several scan planes. The analysis of 
images includes assessment of the shape, contour, internal electrical structure and changes 
of the surrounding tissues. 
6.3.1 Assessment of volumetric lesion shape in accordance with the terms of BI-
RADS ACR 
a. Round – a lesion of a spherical, circular or spherical shape (Fig. 12). The size is determined 
by lesion’s diameter. Typical example – a cyst. 
 
Fig. 12. EIM. Seven scan planes. In the upper segment there can be visualized two lesions of 
rounded shape (indicated with arrows). 
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b. Oval – an ellipsoid or obovoid lesion (Fig. 13). The size is determined by longitudinal and 
lateral axes. Typical example – fibroadenoma, cancer.  
 
Fig. 13. EIM. Seven scan planes. The obovoid lesion is visualized at 9 on the clock dial 
(indicated with arrows). 
c. Lobular – a lesion with the undulated contour (Fig. 14). The size is determined by 
longitudinal and lateral axes. Typical example – fibroadenoma. 
 
Fig. 14. EIM. Seven scan planes. In the upper segment at 12 on the clock dial, there can be 
observed two round hypoimpedance lesions. 
d. Irregular - the shape of a lesion cannot be characterized and does not correspond to 
round, oval or lobular (Fig. 15). Typical example – breast cancer. 
 
Fig. 15. EIM. Seven scan planes. In the upper segment there can be visualized a lesion with a 
lobed contour (indicated with arrows). 
6.3.2 Assessment of volumetric lesion contours in accordance with the terms of BI-
RADS ACR 
a. Sharp (well defined or distinct) – the contours of a lesion are clearly observable. Abrupt 
junction of the lesion and surrounding tissues (Fig. 16). 
 
Fig. 16. EIM. Seven scan planes. The lesion with a sharp distinct contour is visualized at 9 on 
the clock dial (indicated with arrows). 
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6.3.2 Assessment of volumetric lesion contours in accordance with the terms of BI-
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a. Sharp (well defined or distinct) – the contours of a lesion are clearly observable. Abrupt 
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Fig. 16. EIM. Seven scan planes. The lesion with a sharp distinct contour is visualized at 9 on 
the clock dial (indicated with arrows). 
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b. Vague, indistinct (poorly observable) – the contours of a lesion are uneasy to define.  The 
transition between the lesion and surrounding tissues is gradual and indistinct (Fig. 17). 
Typical example of an invasive ductal carcinoma. 
 
Fig. 17. EIM. Seven scan planes. The irregular-shaped lesion with indistinct contours is 
visualized at 12-3 on the clock dial (indicated with arrows). 
c. Infiltrated - the contours of a lesion are clearly distinguishable and are characterized by 
hyperimpedance (Fig. 18). Typical example – breast cancer. 
 
Fig. 18. EIM. Seven scan planes. The obovoid lesion with hyperimpedance contours is 
visualized at 3 on the clock dial (indicated with arrows). 
6.3.3 Assessment of the internal electrical structure of a volumetric lesion 
Taken separately, the internal electrical structure of the lesion is not the criterion for judging 
on its possible malignancy. However, it is an important characteristic, especially in 
combination with other evaluation criteria. The increase of electrical conductivity is 
correlated with an increase of the probability of malignancy. 
a. Hyperimpedance - electrical conductivity of the lesion is lower than electrical 
conductivity than that of the surrounding tissue of the breast (Fig. 19). Typical example – 
mastitis in the stage of infiltration. 
 
 
Fig. 19. EIM. Seven scan planes. The obovoid lesion with hyperimpedance structure is 
visualized at 8 on the clock dial (indicated with arrows). 
b. Isoimpedance - electrical conductivity of the lesion corresponds to that of the surrounding 
tissue of the breast (Fig. 20). Typical examples – fibroadenoma, cancer. 
 




Fig. 20. EIM. Seven scan planes. The lesion with isoimpedance structure is visualized at 12 
on the clock dial (indicated with arrows). 
c. Hypoimpedance - electrical conductivity of the lesion is higher than that of the 
surrounding tissue of the breast (Fig. 21). Typical example – a cyst. 
 
Fig. 21. EIM. Seven scan planes. In the upper segment there can be visualized three 
hypoimpedance lesions of rounded shape (indicated with arrows). 
d. Animpedance - electrical conductivity of the lesion is considerably higher than that of the 
surrounding tissue of the breast (Fig. 22). Typical example – breast cancer.  
 
Fig. 22. EIM. Seven scan planes. In the upper segment, at 12 on the clock dial there is an 
irregular-shaped lesion with animpedance structure (highlighted in red and indicated with 
arrows). 
6.4 Assessment of volumetric lesion influence on the surrounding tissue in 
accordance with the terms of BI-RADS ACR 
a. Skin thickening – a significant one-sided hyperimpedance change of the contour around 
the mammary gland (Fig. 23). Typical example – mastitis-like carcinoma. 
 
Fig. 23. EIM. Seven scan planes. A pronounced hyperimpedance change of the contour 
around the mammary gland (indicated with arrows). 
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6.4 Assessment of volumetric lesion influence on the surrounding tissue in 
accordance with the terms of BI-RADS ACR 
a. Skin thickening – a significant one-sided hyperimpedance change of the contour around 
the mammary gland (Fig. 23). Typical example – mastitis-like carcinoma. 
 
Fig. 23. EIM. Seven scan planes. A pronounced hyperimpedance change of the contour 
around the mammary gland (indicated with arrows). 
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b. Skin extrusion or retraction – a local change of mammary gland contour: In case of the 
retraction – into the mamma, in case of extrusion – entoectad (Fig. 24, 25). Typical example – 
breast cancer, mastitis. 
 
Fig. 24. EIM. Seven scan planes. In the upper segment, a change of the contour (retraction) of 
the mammary gland (indicated with arrows) 
 
Fig. 25. EIM. Seven scan planes. At 7 on the clock dial, a change of the contour (extrusion) of 
the mammary gland (indicated with arrows). 
c. Skin or nipple infiltration – a local hyperimpedance change of the contour of a mammary 
gland or of a nipple (Fig. 26, 27). Typical example – breast cancer, Paget's cancer. 
 
Fig. 26 EIM. Seven scan planes. A unilateral local hyperimpedance change of the mammary 
gland contour (indicated with arrows). 
 
Fig. 27. EIM. Seven scan planes. A unilateral hyperimpedance change of the nipple contour 
(indicated with arrows). 
d. Alterations of the breast anatomy – focal disruption of the normal mammographic 
scheme. Alteration of the age-related electrical impedance structure (Fig. 28, 29). Typical 
example – mastitis, breast cancer. 
 




Fig. 28. EIM. Seven scan planes. Alteration of the normal mammographic scheme 
represented by a hyperimpedance lesion at 7 on the clock dial (indicated with arrows). 
 
Fig. 29. EIM. Seven scan planes. Total alteration of the age-related electrical impedance 
structure. 
6.5 Lactiferous sinus zone assessment 
The visualization of lactiferous sinus zone depends on the age and physiological period of a 
patient. In women of elder age during the postmenopause the lactiferous sinus zone is 
hardly visualized. An extensive round hypo- or animpedance area in the centre of the 
mammogram is typical for the lactation period (Fig. 30). When pathology, there can be 




Fig. 30. EIM. Seven scan planes. There is a vast undistorted hypoimpedance area in the 




Fig. 31. EIM. Seven scan planes. There is a divided hypoimpedance area in the centre of the 
mammogram, which corresponds to the location of the lactiferous sinus zone. It is 
highlighted in red. 
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6.6 Age-related and comparative electrical conductivity 
6.6.1 Age-related conductivity 
Age-related conductivity is the alteration of electrical conductivity of the breast with respect 
to age-related percentile curve of electrical conductivity (Fig. 32). The so-called percentile 
method as an approach to brief description of distributions is wide-spread in medical and 
biological research. This method does not require the data on distribution structure, i.e. it  is 
non-parametric. The assessment of the average electrical conductivity in healthy women of 
different ages allowed creating the percentile curves of age-related electrical conductivity.  
 
Fig. 32. Percentile curves of age-related electrical conductivity. 
According to these curves each age group corresponds to a certain range of electrical 
conductivity. In accordance with the proposed assessment rules, the values which are less 
than 5th percentile shall be considered as pronouncedly low, from 5 to 25 percentiles - as 
low,  from 25 to 75 percentiles - as medium, from 75 to 95 percentiles - as heightened and 
above 95 percentile – as pronouncedly heightened (Fig. 32). Formation of groups of people 
with heightened risk of breast cancer development can be performed using the percentile 
curves of the age-related electrical conductivity. 
6.6.2 Comparative conductivity 
Comparative conductivity is the alteration of electrical conductivity of one breast with 
respect to the other (Fig. 33). The histograms of the electrical conductivity distribution 
variance percent is chosen with the help of the Kolmogorov-Smirnov nonparametric test 
(more than 40%) and is highly informative (j>3.0 according to Kullback). Typical example – 
breast cancer, mastitis. 
 




Fig. 33. Upper row – EIM. Seven scan planes. Breast cancer. Bottom row - EIM. Seven scan 
planes. Healthy gland. The second row shows the divergence between the histograms of 
electrical conductivity distribution of the affected and healthy gland. 
7. Diagnostic criteria for electrical impedance mammography  
In order to sort out the diagnostic criteria the diagnostic chart was created, in which each 
criterion was measured in points (Table 4).  
Using the numerical score for evaluation of volumetric and non-volumetric lesions within 
the mammary gland in electrical impedance mammography allowed comparing this 
information to BI-RADS ACR categories (See Table 5). 
The above description of the system of images and diagnostic criteria for electrical 
impedance mammography provides diagnostics of various breast diseases, including 
neoplastic, inflammatory, dishormonal and other disorders. However, we believe the 
detection of breast cancer at early stages to be the high-priority of the method. The basic 
features of electrical impedance mammography in early diagnostics of breast cancer are the 
following. 
8. Early diagnostics of breast cancer 
If the method of diagnostics under examination permits to acquire a numerical result, the 
so-called "breaking point" (the value exceeding of which is considered as a sufficient cause 
for qualitative assessment) should be determined. In this case the estimation of diagnostic  
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Internal electrical structure 
hyperimpedance (IC <0.2) 
iso- and hypoimpedance (IC = 0.3-0.8) 






Comparative electrical conductivity 
divergence between the histograms < 30% 
divergence between the histograms 30-40 % 





Table 4. Diagnostic criteria for differentiating volumetric lesions in electrical impedance 
mammography. 
EIM ACR
Common scale BI-RADS categories
no score BI-RADS 0 poor image
0-1 BI-RADS 1 lesion is not defined
2-3 BI-RADS 2 benign tumours – routine mammography
4 BI-RADS 3 probably benign findings
5-7 BI-RADS 4 suspicious abnormality - biopsy
8-10 BI-RADS 5 highly suggestive of malignancy – treatment/biopsy 
Table 5. EIM numerical score allows for standardizing the description of volumetric lesions 
and for the usage of patient monitoring algorithm, developed by the American College of 
Radiology in electrical impedance mammography.  
technique efficiency may be limited to sensitivity and specificity assessment. The diagnostic 
criterion when screening for early stages of breast cancer is the following: high electrical 
conductivity areas (above 0.95 cu) outside the lactiferous sinus zone – the so-called 
animpedance areas, which differ markedly from electrical conductivity of healthy mamma’s 
areas (Fig. 34).  
It seems that membrane permeability increase is necessary in both directions to support vital 
activity of dedifferentiated cells during the intraductal stage of oncologic process. The 
membrane permeability of cancer cells during intraductal and early extraductal stage 
increases both for chemical compounds and electric charges. This process results in increase 
of electrical conductivity.  
 




Fig. 34. High electrical conductivity area (above 0.95 cu) outside the lactiferous sinus zone, 
which is highlighted with red (indicated with arrows). 
The example of electrical impedance diagnostic. Figure 35 represents the electrical 
impedance mammogram of a patient. There can be distinguished a focal lesion, in the form 
of animpedance area, highlighted with red, with electrical conductivity index over 0.95 
conditional units. This is the criterion for early diagnostics of breast cancer. Roentgenogram 
and US image of the same mammary gland are represented below (Fig. 36). 
 
Fig. 35. EIM. Amorphous type of mammary gland structure. In the outer segment of the left 
mammary gland, at 3 o’clock position there is observed an animpedance area, which is 
highlighted with red in the second scan plane, less than 10 mm in size. 
 
Fig. 36. Roentgenogram (left): fibro-fatty involution. In upper-outer segment there is observed 
a lesion up to 1 cm in size with a radiant contour. Ultrasound (right): The structure of 
parenchyma with adipose lobules and connective tissue layers. An inhomogeneous 8х7 mm 
lesion of irregular shape is located at 28 mm distance from the nipple and at 12 mm depth. 
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With such a breaking point the sensitivity and specificity of electrical impedance 
mammography are quite high: sensitivity is 84-93%, specificity – 87-99% (according to the 
data given by different authors). 
Impedance mammography is in the beginning of its development. The authors sincerely 
hope that their modest paper will help to arouse interest of a wide range of medical 
researchers. 
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1. Introduction 
Anatomic breast imaging techniques such as mammography and ultrasound are very useful 
in the detection of breast cancer, but can have limited sensitivity and positive predictive 
value, particularly in patients with dense breasts (Kolb et al., 2002). These limitations have 
provided the impetus for adjunctive technologies such as nuclear medicine and PET based 
diagnostic imaging procedures. The nuclear medicine based technique is referred to as 
Breast-Specific Gamma Imaging (BSGI) or molecular breast imaging (MBI) while the 
positron-emission tomography (PET) based technique is referred to as Positron Emission 
Mammography (PEM). Both have demonstrated good results in clinical studies and are 
increasingly being adopted into clinical practice. Although these imaging techniques have 
similarities, they are different in several aspects. This chapter is designed to provide an 
overview of these imaging technologies and their potential roles in patient management. 
2. Radiotracers 
Both BSGI/MBI and PEM are physiologic imaging modalities conducted through the 
injection of a pharmaceutical, called a tracer, which is tagged with a radioactive isotope and 
the resulting molecule is called a radiotracer. Each radiotracer is designed to bind to a 
specific target (organ, tissue, physiologic process, cell receptor or protein) while the isotope 
tag emits radiation that is detected by cameras placed near the patient. The cameras provide 
an image of the distribution of the radiotracer tracer and thus measure a specific physiologic 
process in the area being imaged.  
2.1 Isotopes 
There are two types of radioactive isotope tags used in medical imaging: single gamma 
emission isotopes and positron emission isotopes. Single gamma emission isotopes release a 
gamma ray from the nucleus.  There are a variety of single gamma isotopes used in nuclear 
medicine. The most common isotopes used in diagnostic imaging are referred to as low-
energy isotopes with gamma-ray energies ranging from 80 – 200 kiloelectron volts (keV). 
The gamma ray is a photon with sufficient energy to exit the body and be captured by 
specially designed detectors called gamma cameras. Positron emission isotopes emit a 
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positron, an antimatter particle with the same mass as an electron, but with a positive 
charge. This positron travels a short distance from the nucleus prior to colliding with an 
electron. Since the positron is a particle traveling through the tissue until this collision, the 
patient radiation dose associated with positron emission isotope studies is generally higher 
than that from single gamma emission isotope examinations. This collision results in 
annihilation of both particles converting the mass of the two particles into energy and  
producing a pair of 511 kiloelectron volt (keV) gamma rays traveling approximately 180 
from each other. In positron emission tomography imaging (PET) these gamma rays exit the 
body and are captured by a pair of opposed gamma cameras.    
The units for measuring the activity of radiotracer delivered to the patient are the Becquerel 
and the Curie. The Becquerel (symbol Bq) is the SI-derived unit of radioactivity. One Bq is 
defined as: one decay (emission) per second. The curie (symbol Ci) is a unit of radioactivity, 
defined as 3.7×1010 decays per second. In breast imaging, the megabecquerel (MBq) and 
millicurie (mCi) are the most common units used; one millicurie equals 37 Megabecquerel. 
These units only describe the number of decays per second for a given sample and are not to 
be confused with the units used to describe the radiation dose they deliver to a patient. A 
more detailed discussion of radiation dose is provided in Section 4.   
2.1.1 Pharmaceuticals for BSGI/MBI  
BSGI/MBI is a single photon imaging technique that has been conducted using a variety of 
imaging agents, but the most common is 99mTc-hexakis-2-methoxyisobutylisonitrile also 
referred to as 99mTc-Sestamibi or MIBI. MIBI is a 140 KeV gamma ray emitting isotope in a 
lipophilic cation molecule. It was originally cleared by the US FDA for use as a cardiac 
perfusion agent; breast imaging was subsequently added subsequently breast imaging was 
added as an indication following additional clinical studies to determine its efficacy in this 
application. It is injected intravenously and is retained in cells likely by electronegative 
cellular and mitochondrial membrane potentials (Piwnica-Worms et al., 1990). Studies show 
that its accumulation is roughly proportional to blood flow, desmoplastic activity and 
cellular proliferation and therefore it accumulates preferentially in breast cancers compared 
with surrounding tissues (Cutrone et al., 1998). It is a lipophilic substrate for the P-
glycoprotein (Pgp), a cellular efflux pump for various compounds (Ballinger et al., 1995). 
Therefore, Sestamibi exhibits rapid tumor wash-in (within about 2 minutes) followed by a 
slow tumor washout (over the course of several hours) (Sciuto et al., 2002). Based on these 
factors, imaging can begin within minutes after injection and can continue for up to about 90 
minutes post injection, providing ample time for all required views to be conducted before 
the washout cycle negatively impacts lesion-to-background tracer concentration ratio. In 
addition, since the level of Pgp expression correlates with tumor response to cytotoxic 
chemotherapy, a comparison of immediate and delayed images (4 hours post injection) may 
be used to quantify the radiotracer washout as a measure of Pgp expression and the 
probability of multi-drug resistance.  
There are no known contraindications for use. Reactions to Sestamibi are generally minor 
according to the Cardiolite drug data sheet. In the analysis of potential reactions, 3068 
patients (77% men, 22% women, and 0.7% not recorded) were documented from the cardiac 
clinical trials and 673 were recorded from the breast imaging trials. Of the 673 breast 
imaging patients, all of whom were women, the most common reported reaction was taste 
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perversion with most of those patients reporting a metallic taste at the time of injection. The 
other minor reactions are listed in table 1. More serious reactions were reported in less than 
0.5% of patients and included: signs and symptoms consistent with seizure occurring 
shortly after administration of the agent; transient arthritis, angioedema, arrythmia, 
dizziness, syncope, abdominal pain, vomiting, and severe hypersensitivity characterized by 
dyspnea, hypotension, bradycardia, asthenia, and vomiting within two hours after a second 
injection of Technetium Tc99m Sestamibi. However the list of serious reactions is from the 
total population of patients including men and women undergoing a cardiac stress test.   
 
Body System N = 673 
Body as a whole 21 (3.1%) 
Headache 11 (1.6%) 
Cardiovascular 9 (1.3%) 
Angina 0 (0%) 
ST segment changes 0 (0%) 
Digestive System 8 (1.2) 
Nausea 4 (0.6%) 
Special Senses 132 (19.6%) 
Taste Perversion 129 (19.2%) 
Parosmia 8 (1.2%) 
Table 1. Reactions to Sestamibi from 673 breast imaging patients. 
2.1.2 Pharmaceuticals for PEM 
PEM is a positron emission imaging technique conducted with 2-[fluorine-18] fluoro-2-
deoxy-D-glucose (FDG), a modified glucose molecule with a positron-emitting isotope. 
Breast cancers exhibit a greater uptake of FDG than the surrounding breast tissue due to 
their hyperglycolytic rate. For some malignant lesions, although they possess an elevated 
GLUT-1 transmembrane transport function, however this does not necessarily result in 
increased tracer uptake (Smith, 1999). Studies have established that the uptake of FDG is 
primarily dependent on blood flow, the type of breast malignancy and the microstructure of 
the lesion (nodular vs. diffuse) (Avril et al., 2001). For example, lobular carcinoma exhibits a 
roughly 30% lower uptake than ductal carcinoma (Avril et al., 2001). For the PEM 
procedure, patients must fast 4 – 6 hours prior to the injection of FDG. It is important to note 
that patients with compromised glucose metabolism should have their glucose level 
checked prior to the administration of FDG and at least one study reports that altered 
glucose metabolism can affect the sensitivity of this procedure (Berg et al., 2006). FDG is 
administered intravenously and imaging is conducted approximately 60-90 minutes post 
injection in order to allow sufficient time for glucose uptake into the tissue. Patients should 
be requested to sit quietly in a dark, calm room to avoid manipulating the distribution of 
FDG. A dual-phase imaging technique may be used to improve specificity of the study 
(imaging at both 60 and 90 minutes post injection).  
The emitted positron has a mean free path of approximately 1 mm in the breast tissue before 
annihilation with an electron resulting in the emission of two 511 KeV gamma rays. The 
random nature of the displacement between the positron and gamma ray points of origin 
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positron, an antimatter particle with the same mass as an electron, but with a positive 
charge. This positron travels a short distance from the nucleus prior to colliding with an 
electron. Since the positron is a particle traveling through the tissue until this collision, the 
patient radiation dose associated with positron emission isotope studies is generally higher 
than that from single gamma emission isotope examinations. This collision results in 
annihilation of both particles converting the mass of the two particles into energy and  
producing a pair of 511 kiloelectron volt (keV) gamma rays traveling approximately 180 
from each other. In positron emission tomography imaging (PET) these gamma rays exit the 
body and are captured by a pair of opposed gamma cameras.    
The units for measuring the activity of radiotracer delivered to the patient are the Becquerel 
and the Curie. The Becquerel (symbol Bq) is the SI-derived unit of radioactivity. One Bq is 
defined as: one decay (emission) per second. The curie (symbol Ci) is a unit of radioactivity, 
defined as 3.7×1010 decays per second. In breast imaging, the megabecquerel (MBq) and 
millicurie (mCi) are the most common units used; one millicurie equals 37 Megabecquerel. 
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more detailed discussion of radiation dose is provided in Section 4.   
2.1.1 Pharmaceuticals for BSGI/MBI  
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added as an indication following additional clinical studies to determine its efficacy in this 
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cellular and mitochondrial membrane potentials (Piwnica-Worms et al., 1990). Studies show 
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clinical trials and 673 were recorded from the breast imaging trials. Of the 673 breast 
imaging patients, all of whom were women, the most common reported reaction was taste 
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perversion with most of those patients reporting a metallic taste at the time of injection. The 
other minor reactions are listed in table 1. More serious reactions were reported in less than 
0.5% of patients and included: signs and symptoms consistent with seizure occurring 
shortly after administration of the agent; transient arthritis, angioedema, arrythmia, 
dizziness, syncope, abdominal pain, vomiting, and severe hypersensitivity characterized by 
dyspnea, hypotension, bradycardia, asthenia, and vomiting within two hours after a second 
injection of Technetium Tc99m Sestamibi. However the list of serious reactions is from the 
total population of patients including men and women undergoing a cardiac stress test.   
 
Body System N = 673 
Body as a whole 21 (3.1%) 
Headache 11 (1.6%) 
Cardiovascular 9 (1.3%) 
Angina 0 (0%) 
ST segment changes 0 (0%) 
Digestive System 8 (1.2) 
Nausea 4 (0.6%) 
Special Senses 132 (19.6%) 
Taste Perversion 129 (19.2%) 
Parosmia 8 (1.2%) 
Table 1. Reactions to Sestamibi from 673 breast imaging patients. 
2.1.2 Pharmaceuticals for PEM 
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deoxy-D-glucose (FDG), a modified glucose molecule with a positron-emitting isotope. 
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increased tracer uptake (Smith, 1999). Studies have established that the uptake of FDG is 
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roughly 30% lower uptake than ductal carcinoma (Avril et al., 2001). For the PEM 
procedure, patients must fast 4 – 6 hours prior to the injection of FDG. It is important to note 
that patients with compromised glucose metabolism should have their glucose level 
checked prior to the administration of FDG and at least one study reports that altered 
glucose metabolism can affect the sensitivity of this procedure (Berg et al., 2006). FDG is 
administered intravenously and imaging is conducted approximately 60-90 minutes post 
injection in order to allow sufficient time for glucose uptake into the tissue. Patients should 
be requested to sit quietly in a dark, calm room to avoid manipulating the distribution of 
FDG. A dual-phase imaging technique may be used to improve specificity of the study 
(imaging at both 60 and 90 minutes post injection).  
The emitted positron has a mean free path of approximately 1 mm in the breast tissue before 
annihilation with an electron resulting in the emission of two 511 KeV gamma rays. The 
random nature of the displacement between the positron and gamma ray points of origin 
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has some impact on the lower limit of spatial resolution in studies using positron-emitting 
isotopes (Turkington, 2001). 
2.2 Comparison of BSGI/MBI and PEM Radiotracers 
Both Sestamibi and FDG demonstrate increased accumulation in breast cancers, although 
the mechanism for this accumulation is better understood for FDG. In addition, although the 
breast tissue typically has a homogeneous uptake of both tracers, they can accumulate in 
normal glandular tissue resulting in a diffuse heterogeneous uptake pattern, especially in 
pre-menopausal women who are in the luteal phase of their menstrual cycle (Lin et al., 
2007). This is not surprising as it reflects the heterogeneous nature of the breast tissue and 
the impact of blood hormone levels on the breast parenchyma. This heterogeneity does not 
generally impact cancer detection, but may complicate interpretation. The intensity of this 
pattern can be reduced for both tracers by imaging outside of the luteal phase and several 
studies report that day 2 – 14 of the menstrual cycle is optimal. Neither tracer is linked to 
nephrogenic systemic fibrosis, a sometimes fatal condition that is associated with 
gadolinium contrast agents used in breast MRI. MIBI has some minor pharmacologic 
considerations and rare reactions occurring in less than 0.5%of patients.  FDG imaging 
requires fasting for a minimum of 4 hours prior to injection and as mentioned in the 
previous section, it is beneficial to check the blood glucose level prior to FDG administration 
as the tumor uptake of FDG is reduced in hyperglycemic states (Schelbert et al., 1999) and 
this results in some potential for complications and reduced sensitivity for the procedure in 
diabetic patients. In comparison, MIBI does not require fasting and imaging can be 
conducted within minutes of the injection.   
Some of the physical and clinical differences between FDG and MIBI imaging are 
summarized in Tables 2 and 3 respectively.  
 
 Energy of Emission photon 
Half Life 
(minutes) 
FDG 511 KeV 110 
MIBI 140 KeV 360 
Table 2. gamma-ray emission information for radiotracers. 
 
 Pre-study Fasting Injection to Imaging time 
Recommended 
Pre-procedural testing 
FDG 4 - 6 hours 60 – 90 minutes Blood glucose 
MIBI None 5 minutes None 
Table 3. Radiotracer administration and imaging considerations. 
3. Imaging systems 
Both the single gamma and positron isotopes described in section 2.1 ultimately emit 
gamma rays (the positron isotopes through the annihilation and the conversion of the 
positron) that exit the patient’s body and can be detected with external detectors. The goal of 
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these detector systems is to reconstruct the gamma ray emissions into an image that allows 
the physician to visualize the distribution of the radiotracer in the body. There are two 
modes of image reconstruction, plannar and tomographic. The planar method results in a 
single 2-dimensional image per acquisition, similar to the mammogram. Tomographic 
reconstruction provides a 3-dimensional reconstruction of the breast similar to MRI. The 
single gamma detector systems used for BSGI/MBI can be planar or tomographic and can 
be constructed of a single or multiple detectors. The positron imaging systems used for PEM 
by their design provide tomographic imaging only and since the detection of the pair of 
gamma rays is required for image reconstruction, positron systems must consist of either a 
pair of opposed detectors or a ring detector design.  
3.1 Gamma-ray imaging basics 
The detection of an abnormality in BSGI and PEM imaging is based on the ability of the 
imaging system to depict the variations of uptake in the tissue. Unlike anatomical imaging 
where high spatial resolution is needed to visualize the detailed morphology used to 
provide differential diagnosis, the molecular imaging system must provide sufficient image 
contrast in order to visualize the variations in radiotracer uptake; the contrast between 
radiotracer concentration in the tumor and the uptake of the surrounding breast tissue. 
While this is partially a function of resolution, there are several other factors impacting 
imaging. This contrast based imaging requires a careful balance between spatial resolution, 
image noise and photon sensitivity. Generally, as spatial resolution increases, image noise 
increases and photon sensitivity decreases proportionally to some degree thus if spatial 
resolution is increased to a level where the detector has poor photon sensitivity and the 
resulting image noise is too high, the ability of the system to visualize the contrasting tissue 
uptake is diminished. A detailed discussion of the balance between these factors is beyond 
the scope of this text, but it is important to realize that in molecular imaging is a contrast 
based imaging and spatial resolution is not the only parameter affecting the visualization of 
lesions. For example, it is possible to detect a 1 mm cancer using a system with a 4 mm 
spatial resolution if the uptake of that lesion is sufficiently enough higher than the 
background to overcome the partial volume effect. Conversely, a 40 mm cancer could be 
missed by the same imaging system if the lesion uptake is not sufficiently higher than the 
surrounding tissue. 
As an illustration, nearly all commercially available large field-of-view gamma cameras, 
typical to the nuclear medicine department, have a variable matrix setting, including 512 x 
512, 256 x 256 and 128 x 128. Although the 512 x 512 setting produces the highest spatial 
resolution, nearly all nuclear medicine studies are conducted on the 256 x 256 or 128 x 128 
settings because the resulting image noise at the 512 x 512 setting diminishes image quality 
for the majority of studies. 
System photon sensitivity is another important parameter in BSGI/MBI and PEM imaging. 
As photon sensitivity increases, the amount of radiotracer, the length of time the image is 
acquired, or some combination of both parameters can be decreased. For Example: a given 
detector system is providing good clinical images using a dose of 300 MBq and an 
acquisition time of 10 minutes. If the photon sensitivity of this system can be increased 50% 
the clinician would have three possible options. First, they could reduce the patient’s 
radiation exposure by reducing the amount of radiotracer delivered to the patient by 50%, to 
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has some impact on the lower limit of spatial resolution in studies using positron-emitting 
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these detector systems is to reconstruct the gamma ray emissions into an image that allows 
the physician to visualize the distribution of the radiotracer in the body. There are two 
modes of image reconstruction, plannar and tomographic. The planar method results in a 
single 2-dimensional image per acquisition, similar to the mammogram. Tomographic 
reconstruction provides a 3-dimensional reconstruction of the breast similar to MRI. The 
single gamma detector systems used for BSGI/MBI can be planar or tomographic and can 
be constructed of a single or multiple detectors. The positron imaging systems used for PEM 
by their design provide tomographic imaging only and since the detection of the pair of 
gamma rays is required for image reconstruction, positron systems must consist of either a 
pair of opposed detectors or a ring detector design.  
3.1 Gamma-ray imaging basics 
The detection of an abnormality in BSGI and PEM imaging is based on the ability of the 
imaging system to depict the variations of uptake in the tissue. Unlike anatomical imaging 
where high spatial resolution is needed to visualize the detailed morphology used to 
provide differential diagnosis, the molecular imaging system must provide sufficient image 
contrast in order to visualize the variations in radiotracer uptake; the contrast between 
radiotracer concentration in the tumor and the uptake of the surrounding breast tissue. 
While this is partially a function of resolution, there are several other factors impacting 
imaging. This contrast based imaging requires a careful balance between spatial resolution, 
image noise and photon sensitivity. Generally, as spatial resolution increases, image noise 
increases and photon sensitivity decreases proportionally to some degree thus if spatial 
resolution is increased to a level where the detector has poor photon sensitivity and the 
resulting image noise is too high, the ability of the system to visualize the contrasting tissue 
uptake is diminished. A detailed discussion of the balance between these factors is beyond 
the scope of this text, but it is important to realize that in molecular imaging is a contrast 
based imaging and spatial resolution is not the only parameter affecting the visualization of 
lesions. For example, it is possible to detect a 1 mm cancer using a system with a 4 mm 
spatial resolution if the uptake of that lesion is sufficiently enough higher than the 
background to overcome the partial volume effect. Conversely, a 40 mm cancer could be 
missed by the same imaging system if the lesion uptake is not sufficiently higher than the 
surrounding tissue. 
As an illustration, nearly all commercially available large field-of-view gamma cameras, 
typical to the nuclear medicine department, have a variable matrix setting, including 512 x 
512, 256 x 256 and 128 x 128. Although the 512 x 512 setting produces the highest spatial 
resolution, nearly all nuclear medicine studies are conducted on the 256 x 256 or 128 x 128 
settings because the resulting image noise at the 512 x 512 setting diminishes image quality 
for the majority of studies. 
System photon sensitivity is another important parameter in BSGI/MBI and PEM imaging. 
As photon sensitivity increases, the amount of radiotracer, the length of time the image is 
acquired, or some combination of both parameters can be decreased. For Example: a given 
detector system is providing good clinical images using a dose of 300 MBq and an 
acquisition time of 10 minutes. If the photon sensitivity of this system can be increased 50% 
the clinician would have three possible options. First, they could reduce the patient’s 
radiation exposure by reducing the amount of radiotracer delivered to the patient by 50%, to 
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150 MBq and maintain the same imaging time, 10 minutes. Second, they could reduce the 
imaging time by 50% to 5 minutes using a 300 MBq dose. Or third, they could reduce both 
the time and the dose by roughly 25% resulting in a dose of 225 MBq and an imaging time of 
7.5 minutes. It is important to remember that in molecular imaging techniques such as 
BSGI/MBI and PEM, the imaging time and the dose delivered can be manipulated, but 
reducing both to any large degree is not possible unless significant improvements in photon 
sensitivity are obtained.   
3.1.1 BSGI/MBI Imaging 
BSGI/MBI imaging is conducted with a single-head or dual-head detector system (see 
Figure 1). Only one detector equipped with a collimator is required for image 
reconstruction. Generally, gentle breast compression (normally less than 12 lbs or 53 
newtons) is used to provide breast immobilization. This compression is noticeably lower 
than that used in mammography for two reasons. First, the typical imaging time for a single 
BSGI/MBI image is significantly longer than that needed for a mammographic projection, 5 
– 10 minutes, thus lower pressures are better tolerated by patients and second, the 140keV 
gamma ray emitted in BSGI/MBI has sufficiently higher tissue penetration than the 8 – 35 
keV x-ray used in mammography therefore these images benefit less from higher 
compression. As shown in figure 1, in the single-head design a paddle is used to provide 
compression and in the dual-head system, the breast is compressed between the detectors. 
The compression paddle used in the single head system can be exchanged for a fenestrated 
paddle to allow biopsy. Biopsy is currently not available on the dual-head design. 
  
Fig. 1. A single and dual head imaging system for BSGI/MBI. 
3.1.2 BSGI/MBI detectors 
As mentioned in the previous section, there is generally an inverse relationship between 
photon sensitivity and spatial resolution however both are important to imaging. These 
parameters are determined by several aspects of the detector design, especially that of the 
collimator. The most commercially available systems have an extrinsic spatial resolution of 
between 1.9 and 3.3 mm at the surface of the detector however it is important to note that 
the spatial resolution of planar, single gamma imaging systems decreases with increasing 
source-to-collimator distance, thus the spatial resolution of a lesion near the detector is 
better than that of one deep in the breast tissue, relative to the detector face. For example, if 
the breast is being imaged in the cranio-caudal position (detector inferior to the breast 
tissue), lesions in the inferior portion of the breast tissue will be somewhat more visible than 
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those in the superior portion of the breast. This resolution loss is, at least in part, the driving 
logic behind the dual-head opposed detector design. In theory, if the breast is imaged using 
a dual-head system in the cranio-caudal position, the upper detector would maximize 
visualization of the superior portion of the breast while the lower detector optimizes 
visualization of inferior lesions.  
Although there is a theoretical benefit to the dual-head design, it is interesting to note that 
clinical data from the dual-head and single-head systems shows similar performance in 
terms of lesion sensitivity (see section 5 below). This is likely due to the two-view imaging 
protocol adopted from mammography that is standard in BSGI/MBI protocols.  Just as in 
mammography, the optimal coverage of breast tissue is obtained by acquiring an MLO and 
CC image of each breast and additional images are obtained as needed. Since all patients 
have a minimum of two views obtained, the likelihood of a lesion being deep to both 
projections is quite small. In addition, similar to mammography, when a lesion is seen in 
only one image, additional images are obtained in order to determine the location of the 
lesion in the breast tissue. As long as this two-view protocol remains the standard, it is 
unlikely that the dual-head system will result in significant improvements in the sensitivity 
of the detection of breast malignancies. However, provided the two detector images are 
fused properly, it may be possible to reduce either the injected dose or the acquisition time 
to facilitate low-dose imaging or higher throughput on the imaging system.  
Single photon emission computed tomography (SPECT) is a recent development in 
BSGI/MBI. Currently these devices are only available in the research setting (Williams et al., 
2010). Additional research is needed to determine if dual-head image combination 
techniques or the implementation of SPECT imaging will provide a clear benefit to 
BSGI/MBI in terms of breast cancer detection. Such studies are underway, but the data is 
not yet available for analysis.     
   
Fig. 2. Left and Center - a single-head BSGI/MBI system with a compression paddle used 
for positioning. The left image illustrates the cranio-caudal (CC) position and the center 
image illustrates the medial lateral oblique position (MLO). The right image illustrates the 
MLO position with the dual-head system where the compression paddle is replaced by a 
second detector. 
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Fig. 3. A typical 4-view BSGI study. 
3.1.3 Detectors for PEM  
PEM imaging is conducted with either a dual head or ring style gamma-ray detector. Both 
systems are designed to detect the coincident gamma rays which, are traveling 
approximately 180° from each other after the annihilation reaction (see figure 4). Unlike 
BSGI imaging devices, PEM devices do not use a collimator to help determine the location of 
each event. In PEM imaging, since there are two gamma-rays traveling 180° apart, the event 
location is calculated as a line of response between the location that each gamma-ray strikes 
the pair of opposed detectors. One advantage to PEM is that it does not have the same loss 
of resolution with distance that BSGI/MBI systems experience. As mentioned in the 
previous section, the mean free path of the 18F positron within the breast tissue is 
approximately 1 mm and commercially available PEM systems report an in-plane spatial 
resolution of about 2 mm. One limitation of the dual-head PEM detector design is that, due 
to the limited angle of acquisition, it has limited resolution in the Z-axis (depth).  Ring 
detectors do not suffer from this limitation as they provide a 360° acquisition for 
reconstruction however there is currently no biopsy capability on the ring detector systems. 
A needle biopsy localization device was recently introduced for the opposed dual-head 
detector system. 
    
Fig. 4. The left image provides an example of an opposed dual-head imaging system while 
the system on the right is an example of a ring detector system. 
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One limitation to PEM image reconstruction is that the detector photon sensitivity is not 
linear across the field-of-view with lower sensitivity along the detector edges. This causes a 
higher level of noise to be present in the breast images, along the chest wall. Figure 5 
provides a schematic representation of factors affecting the photon sensitivity in a PEM 
detector. The maximum angle of reconstruction (MAR) is a setting used in PEM software 
and it is defined as the maximum angle away from the detector normals (90 from the 
detector face) for which coincident gamma ray detections are included in tomographic 
image reconstruction. Larger MAR values yield greater overall photon sensitivity but with 
potential loss in spatial resolution due to the depth-of-interaction (DOI) blur. The blue lines 
in Figure 1 show the angular range over which gamma rays emitted from two points in the 
breast are accepted. Figure 1A shows a point near the nipple, and Figure 1B shows one near 
the chest. For events that occur in the center of the field-of-view (FOV), all of the events 
within the MAR are captured by the detector system. However a significant fraction of 
events occurring near the FOV edges go uncounted for because one of the paired gamma 
rays traveling outside the edges of the detector is not detected. As a recent study found, this 
loss of photon sensitivity along the edges limits the ability of the PEM system to detect 
lesions located near the chest wall (Rosen et al, 2005).  
 
Fig. 5. A and B: a schematic example of the maximum angle of reconstruction near the center 
of the detector field-of-view and then near the chest wall respectively. 
    
Fig. 6. a typical PEM study with multiple slice reconstruction for each projection. 
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PEM detectors are tomographic imaging devices, an example image from the opposed 
detector system is provided in Figure 6. Note the noise level along the chest wall and the  
Z-resolution affect is expressed as a blurry, low intensity focus in the reconstruction planes 
outside of the plane the lesion is located in. In this particular case, it is most noticeable in the 
MLO projection images. There is noticeable residual blur in the area of the largest lesion in 
all of the projections, including those outside of the lesion. 
4. Radiation dose 
As with all nuclear medicine procedures, the detector systems do not emit radiation. The 
radiation dose delivered to the patient in these procedures comes from the radiotracer and is 
dependent on both the activity of the radiotracer injected and the biologic distribution of the 
tracer in the organs. 
4.1 BSGI/MBI radiation dose 
Sestamibi (MIBI) was cleared by the US FDA in 1991 for cardiac perfusion studies. In 1997, 
breast imaging was added as an indication to the drug package insert following a clinical 
trial conducted with standard gamma cameras equipped with high-resolution collimators. 
According to the drug package insert, the patient whole-body radiation dose is 4.8 milligray 
at 1110 megabecquerels (0.5  rads at 30 millicuries), see Table 4. According to the Dosage 
and Administration section of the drug package insert, breast imaging is to be conducted 
using a dose of 740 – 1110 MBq (20 – 30 mCi).  
At the time of the US FDA approval, the breast imaging studies were being acquired with 
standard, large field-of-view gamma cameras, typical to a nuclear medicine department and 
the dose required for imaging was determined largely by the low photon sensitivity of these 
imaging systems when equipped with high-resolution collimators (Khalkhali et al., 2004) 
Since that time, several breast optimized gamma camera systems have been developed with 
significantly higher photon sensitivity and several studies indicate that it is possible to lower 
the injected dose of MIBI required for breast imaging with these systems.  
A recent clinical trial was conducted to examine breast tissue uptake as a function of 
injected dose. The results of this analysis indicate that breast tissue uptake of MIBI 
appears to be linear relative to the injected dose thus implying there is no physiologic 
limitation to using lower doses (Böhm-Vélez et al., 2011). According to additional studies, 
conducted by the Mayo Clinic, the new, breast optimized detector systems provide a 
photon sensitivity roughly 3 times higher than that of the older imaging systems (Hruska 
et al., 2008). 
From the available data, it is evident that these new detector technologies can reduce the 
dose required to conduct breast imaging with MIBI. Reducing the dose MIBI from 740 – 
1110 MBq (20 – 30 mCI) to 259 – 370 MBq (7 – 10 mCi) reduces patient radiation exposure by 
nearly a factor of 3. The radiation exposure from a 259 MBq injection of MIBI is 
approximately 2 millisieverts (mSv) and is approximately equivalent to the radiation dose 
diagnostic breast patients receive from the combination of screening and diagnostic 
mammograms (Hendrick, 2010; Valinten, 2007).  
 




Table 4. Radiation dosimetry of Sestamibi. 
 
Graph 1. The relative photon sensitivity of commercially available, breast-optimized 
imaging systems compared to that of the standard gamma camera. 
4.2 PEM radiation dose 
F-18 fluorodeoxy-D-glucose (FDG) was cleared by the US FDA in 2000 for a variety of uses 
including tumor localization. The total body radiation dose in FDG PET is 39 mrads per mCi 
injected activity (Table 5). According to the clinical literature, the typical FDG dose used for 
imaging with the standard whole body PET detectors ranges between is approximately 370 - 
740 MBq (10 - 20 mCi). 
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Table 5. Radiation dose for FDG based on 1 mCi injection. 
The dose of FDG used for PEM studies has generally followed the guidelines established 
with the lager systems, typically using approximately 444 MBq (12 mCi) (Berg et al, 2006). 
However, more recent studies have demonstrated that doses of 111 – 185 MBq (3 – 5 mCi) 
are possible with the breast-optimized imaging systems (MacDonald et al, 2010). The 
resulting radiation dose to the patient is 1.9 – 3.1 mSv using a low dose protocol, nearly 
identical to that of low dose BSGI/MBI (O’Connor et al., 2010).   
5. Clinical evidence 
There is a substantial history of clinical literature on imaging breast cancers with nuclear 
medicine techniques. One of the first reports of breast imaging using MIBI was provided by 
Campeau and his colleagues in 1992 while the first report of breast cancer imaging using 
FDG was reported by Wahl the previous year (Campeau et al., 1992; Wahl et al,. 1991) Since 
that time, hundreds of articles have been published on breast imaging using these 
radiotracers. However until recently, these imaging studies were conducted with large 
gamma cameras typical in the nuclear medicine department. The development of breast-
optimized detector systems used in BSGI/MBI and PEM is more recent and the primary 
advantage of these systems is that they provide higher sensitivity for the detection of breast 
lesions than their predecessors.  
5.1 Clinical evidence for BSGI/MBI  
There have been several clinical studies evaluating BSGI/MBI in breast cancer detection. In 
2008, the group from George Washington Medical University provided an overview of their 
experience using BSGI/MBI in 146 patients who participated in an IRB approved trial (Brem 
et al., 2008). Table 6 provides the reported sensitivity of BSGI for various subgroups from 
that analysis.  
 




Invasive Cancers 97% 
Sub-centimeter lesions 89% 
Lobular Carcinoma 93% 
DCIS 94% 
Table 6. The sensitivity of BSGI in various subgroups. 
Other, larger studies have provided evidence of high sensitivity and specificity for BSGI. 
The first of these larger studies was an analysis performed by Weigert and her associates in 
more than 500 women who had a BSGI scan performed as part of their routine diagnostic 
imaging following conventional imaging (Weigert et al., 2007). It is interesting to note that 
over half of the patients in this study had indeterminate findings following mammography 
and ultrasound. Two years later, Bertrand presented the results from a retrospective, 
multicenter study reporting that BSGI provided a higher sensitivity than diagnostic 
mammography in detection of breast cancer, especially in the high-risk and dense breast 
populations (Bertrand et al., 2009) Last, in 2011, Lee et al reported that BSGI had a higher 
sensitivity than mammography and higher specificity than ultrasound in their series of 622 
patients who had all three imaging modalities performed as part of their diagnostic 
examination (Lee et al., 2011).  In addition, this work found that there was no change in the 
sensitivity of BSGI between normally dense and heterogeneously or very dense breast 
tissue. 
 
 Bertrand, 2009 Lee, 2011 Weigert, 2007
Total Patients 1,042 662 512 
Sensitivity (%) 91 95 89 
Specificity (%) 77 88 90 
NPV (%) 96 97 98 
Table 7. The clinical performance of BSGI from several studies. 
5.2 Clinical evidence for PEM 
One of the earliest published studies on PEM containing a group of 77 patients examined 
the effectiveness of PEM in the detection of breast carcinoma (Berg et al., 2006). Table 8 
provides the sensitivity of PEM as determined by this work.  As expected, the sensitivity for 
lobular carcinoma was somewhat lower potentially due to the reduced glucose metabolism 
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Table 5. Radiation dose for FDG based on 1 mCi injection. 
The dose of FDG used for PEM studies has generally followed the guidelines established 
with the lager systems, typically using approximately 444 MBq (12 mCi) (Berg et al, 2006). 
However, more recent studies have demonstrated that doses of 111 – 185 MBq (3 – 5 mCi) 
are possible with the breast-optimized imaging systems (MacDonald et al, 2010). The 
resulting radiation dose to the patient is 1.9 – 3.1 mSv using a low dose protocol, nearly 
identical to that of low dose BSGI/MBI (O’Connor et al., 2010).   
5. Clinical evidence 
There is a substantial history of clinical literature on imaging breast cancers with nuclear 
medicine techniques. One of the first reports of breast imaging using MIBI was provided by 
Campeau and his colleagues in 1992 while the first report of breast cancer imaging using 
FDG was reported by Wahl the previous year (Campeau et al., 1992; Wahl et al,. 1991) Since 
that time, hundreds of articles have been published on breast imaging using these 
radiotracers. However until recently, these imaging studies were conducted with large 
gamma cameras typical in the nuclear medicine department. The development of breast-
optimized detector systems used in BSGI/MBI and PEM is more recent and the primary 
advantage of these systems is that they provide higher sensitivity for the detection of breast 
lesions than their predecessors.  
5.1 Clinical evidence for BSGI/MBI  
There have been several clinical studies evaluating BSGI/MBI in breast cancer detection. In 
2008, the group from George Washington Medical University provided an overview of their 
experience using BSGI/MBI in 146 patients who participated in an IRB approved trial (Brem 
et al., 2008). Table 6 provides the reported sensitivity of BSGI for various subgroups from 
that analysis.  
 




Invasive Cancers 97% 
Sub-centimeter lesions 89% 
Lobular Carcinoma 93% 
DCIS 94% 
Table 6. The sensitivity of BSGI in various subgroups. 
Other, larger studies have provided evidence of high sensitivity and specificity for BSGI. 
The first of these larger studies was an analysis performed by Weigert and her associates in 
more than 500 women who had a BSGI scan performed as part of their routine diagnostic 
imaging following conventional imaging (Weigert et al., 2007). It is interesting to note that 
over half of the patients in this study had indeterminate findings following mammography 
and ultrasound. Two years later, Bertrand presented the results from a retrospective, 
multicenter study reporting that BSGI provided a higher sensitivity than diagnostic 
mammography in detection of breast cancer, especially in the high-risk and dense breast 
populations (Bertrand et al., 2009) Last, in 2011, Lee et al reported that BSGI had a higher 
sensitivity than mammography and higher specificity than ultrasound in their series of 622 
patients who had all three imaging modalities performed as part of their diagnostic 
examination (Lee et al., 2011).  In addition, this work found that there was no change in the 
sensitivity of BSGI between normally dense and heterogeneously or very dense breast 
tissue. 
 
 Bertrand, 2009 Lee, 2011 Weigert, 2007
Total Patients 1,042 662 512 
Sensitivity (%) 91 95 89 
Specificity (%) 77 88 90 
NPV (%) 96 97 98 
Table 7. The clinical performance of BSGI from several studies. 
5.2 Clinical evidence for PEM 
One of the earliest published studies on PEM containing a group of 77 patients examined 
the effectiveness of PEM in the detection of breast carcinoma (Berg et al., 2006). Table 8 
provides the sensitivity of PEM as determined by this work.  As expected, the sensitivity for 
lobular carcinoma was somewhat lower potentially due to the reduced glucose metabolism 






Table 8. Sensitivity of PEM by sub-group. 
 
Imaging of the Breast – Technical Aspects and Clinical Implication 
 
192 
The overall sensitivity and specificity for PEM is very good, especially for DCIS. Table 9 lists 
for each of the four PEM studies cited, the total number enrolled, the sensitivity, specificity, 
and negative predictive value. 
 
 Berg, 2006 Tafra, 2005 Schilling, 2011
Total Patients 77 44 182 
Sensitivity (%) 90 89 85 
Specificity (%) 86 NR 74 
NPV (%) 88 NR NR 
Table 9. Clinical results of PEM imaging. NR = not reported. 
In clinical studies of BSGI/MBI and PEM, both of these metabolic imaging modalities 
provide improved sensitivity and specificity for the diagnosis of breast cancer compared to 
mammography alone. The sensitivity and specificity of BSGI and PEM are generally 
comparable with both modalities demonstrating the capability to visualize lesions as small 
as 1 – 2 mm. Both PEM and BSGI/MBI systems have biopsy guidance capabilities. 
6. Clinical considerations 
Both BSGI and PEM provide valuable clinical information in the detection and treatment of 
breast carcinoma. Like all imaging studies, each has distinct advantages and limitations. From 
the clinical data, it is evident that the performance of these modalities is quite comparable.  
The biggest differences between the procedures are logistical. First, in most areas, MIBI is 
more readily available and significantly less expensive than FDG. In addition, the shorter 
half-life of FDG puts tighter constraints on the clinical schedule. For example, if a patient 
arrives 1 hour late for a FDG injection, the dose has lost 32% of the intended activity where 
as a MIBI dose has lost 9%. Also, the use of FDG requires four hours of patient fasting prior 
to injection and MIBI does not have this constraint. FDG also requires a 1-hour post-injection 
delay for imaging where as MIBI imaging can begin immediately post injection. Based on 
the injection-to-imaging time considerations, total time required for a MIBI study is 
approximately 45 minutes compared to approximately 2 hours for an FDG study. 
7. Clinical indications 
Several indications for these technologies have been proposed in the medical literature. 
Generally speaking, BSGI/MBI has been examined as a diagnostic adjunct to 
mammography and ultrasound when these imaging modalities are inconclusive or 
discordant with other imaging studies and/or clinical signs and symptoms and there is a 
remaining diagnostic concern.  In addition, there is good data to suggest that it is also useful 
in pre-operative treatment planning for patients with known malignancy and in monitoring 
the response of the breast lesion(s) to neoadjuvant chemotherapy, see section 5.1. The 
majority of studies on PEM have examined its use as in preoperative treatment planning for 
patients with know malignancy and in monitoring the response of breast tumor(s) to 
neoadjuvant chemotherapy.  
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In June of 2009, an interdisciplinary committee established by the American College of 
Surgeons published a report to provide guidance on the use of imaging techniques in breast 
patients (Silverstein et al., 2009). This panel grouped BSGI/MBI and PEM together as 
molecular  imaging techniques and issued the following recommendation: 
- “The available information suggests that they (BSGI/MBI and PEM) may have 
equivalent sensitivity and improved specificity when compared with breast MRI. It is 
recommended that these adjunctive tools be used only after high-quality standard 
imaging is performed; their results should not prevent performing a biopsy 
recommended after conventional imaging. Either breast-specific gamma imaging or 
positron emission mammography may be used as an alternative to breast MRI when 
MRI is not available or is contraindicated in a particular patient. Both tools may be 
valuable in pre-operative surgical staging. Breast-specific gamma imaging may also be 
useful as an additional problem-solving tool in some situations.” 
7.1 Recognized BSGI/MBI indications 
In June 2009, the Society of Nuclear Medicine released the Procedural Guidelines for Breast 
Scintigraphy with Breast-Specific Gamma Cameras that included several proposed several 
indications for BSGI/MBI (Goldsmith et al., 2009). The indications are quite specific and 
echoed those set forth by the American College of Surgeons. The indications can be grouped 
into 4 primary categories.  
1. As a diagnostic adjunct for patients with indeterminate findings on conventional 
imaging (mammography, ultrasound and/or MRI) and remaining diagnostic concerns 
such as palpable mass, nipple discharge, pain, etc. 
2. Preoperative treatment planning in patients with a known cancer diagnosis to 
determine the extent of the primary lesion and to detect additional foci of disease. 
3. As an alterative to breast MRI for patients whom MRI is indicated, but not possible; 
ferromagnetic implants, compromised renal function, etc. 
4. Monitoring tumor response to chemotherapy.  
7.2 Recognized PEM indications 
There are no additional published guidelines for PEM other than those of the American 
College of Surgeons that essentially provided three indications: 
1. Pre-operative treatment planning in patients with a known cancer diagnosis to 
determine extent of the primary lesion and to detect additional foci of disease. 
2. To monitor the response of breast tumor(s) to neoadjuvant chemotherapy. 
3. As an alternative to breast MRI in patients for whom MRI is indicated, but not possible; 
ferromagnetic implants, compromised renal function, etc. 
8. Conclusion 
BSGI/MBI and PEM are adjunctive molecular breast imaging technologies which are 
becoming more common in the breast center and they provide very similar performance in 
terms of sensitivity and specificity. The radiation dose associated with these imaging 
techniques is similar to that patients receive from other diagnostic imaging procedures such 
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as CT, PET and nuclear medicine thus their use is currently limited to the diagnostic patient 
population. However, several studies are underway to reduce the radiation dose to the level 
of screening mammography which will likely increase their utility to breast cancer screening 
in the asymptomatic population. The BSGI/MBI procedure is a useful problem-solving tool 
for patients with dense or complex breast tissue and an unresolved diagnostic concern 
following anatomical imaging procedures such as mammography and ultrasound. Both 
BSGI/MBI and PEM are useful in breast cancer patients to detect the extent of disease 
(additional occult multifocal or muticentric disease) and to monitor tumor response to 
neoadjuvant chemotherapy. PEM has the advantage of tomographic reconstruction and 
uniform spatial resolution with increasing tumor depth. In addition, for the breast cancer 
patient undergoing a PET/CT scan for staging, it is possible to conduct the PEM study 
following the PET/CT without an additional administration of FDG. The advantages for 
BSGI/MBI are superior photon sensitivity along the chest wall, fewer patient restrictions 
and the wider availability of MIBI (see the considerations section above). 
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as CT, PET and nuclear medicine thus their use is currently limited to the diagnostic patient 
population. However, several studies are underway to reduce the radiation dose to the level 
of screening mammography which will likely increase their utility to breast cancer screening 
in the asymptomatic population. The BSGI/MBI procedure is a useful problem-solving tool 
for patients with dense or complex breast tissue and an unresolved diagnostic concern 
following anatomical imaging procedures such as mammography and ultrasound. Both 
BSGI/MBI and PEM are useful in breast cancer patients to detect the extent of disease 
(additional occult multifocal or muticentric disease) and to monitor tumor response to 
neoadjuvant chemotherapy. PEM has the advantage of tomographic reconstruction and 
uniform spatial resolution with increasing tumor depth. In addition, for the breast cancer 
patient undergoing a PET/CT scan for staging, it is possible to conduct the PEM study 
following the PET/CT without an additional administration of FDG. The advantages for 
BSGI/MBI are superior photon sensitivity along the chest wall, fewer patient restrictions 
and the wider availability of MIBI (see the considerations section above). 
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1. Introduction 
Nipple discharge (ND) is the third most common breast-related complaint after breast pain 
and breast mass, and accounts for nearly 7% of all breast symptoms (Hussain et al., 2006; 
Simmons et al., 2003 citing Leis et al., 1998).  
The diagnosis of ND begins with its characterization as either a physiological or 
pathological condition (Simmons et al., 2003). Physiological discharge, often a manifestation 
of breast manipulation, is usually bilateral, is white or green, and emanates from many 
ducts (Simmons et al., 2003). Possible causes of persistent physiological discharge include 
oral contraceptives, antihypertensives, tranquilizers, hypothyroidism, and pituitary 
adenoma (Simmons et al., 2003). Most NDs are physiological and are not associated with an 
underlying benign or malignant breast neoplasm (Sickles, 2000). A pathological discharge is 
generally unilateral, spontaneous, persistent, clear, watery, serous or bloody in appearance, 
and emanates from a single duct (Morrogh et al., 2007). Most of the common pathological 
causes of ND are benign (Hou et al., 2001; Hussain et al., 2006), and the most frequently 
encountered benign causes are intraductal papilloma, followed by ductal ectasia and 
fibrocystic disease (Hou et al., 2001; Morrogh et al., 2010; Sickles, 2000). The most important 
cause of pathological discharge is breast cancer. For single duct nipple discharges, the 
incidence of malignant or high-risk pathology is reported to be as high as 15% (Orel et al., 
2000 citing Carty et al., 1994; Fung et al., 1990; Leis et al., 1989; Piccoli et al., 1998; Tabar et 
al., 1983; Winchester et al., 1996). In some cases, ND is the only sign of carcinoma (Hou et al., 
2001). NDs that are bloody or serous in appearance, associated with a mass, and present in 
an elderly patient are more likely to be caused by malignant tumors (Das et al., 2001; El-Daly 
& Gudi, 2010; Pritt et al., 2004; Tabar, 1983; Tjalma, 2004 citing Seltzer et al., 1970). 
We defined suspicious ND as pathological ND, which is spontaneous, unilateral, and 
localized to a single duct, combined with at least one of the following characteristic findings 
associated a high risk of malignant disease: bloody or serous appearance, associated with a 
mass, and occurrence in elderly patients.  
If ND is multi-duct or bilateral, breast imaging is not required. However, single-duct ND is 
considered an indication for further investigation by mammography (MMG) and/or 
ultrasonography (US) (EUSOMA, 2010). 
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 In this chapter, we review several methods of diagnostic evaluation including MMG, US, 
conventional ductography (DG), ND cytology, fine needle aspiration (FNA) and 
histopathology. We also demonstrate how to use the findings of contrast-enhanced magnetic 
resonance imaging (CEMRI) studies, including direct and indirect MR ductography 
(MRDG), to localize the causative lesion and to differentiate malignant lesions from benign 
ones in cases of suspicious ND.  
2. Mammography (MMG)  
While MMG is considered the standard initial imaging examination and may reveal 
microcalcifications and other signs of malignancy, it rarely provides information about the 
etiology of ND (Rissanen et al., 2007 citing Cabioglu et al., 2003; Dillon et al., 2006; Funovics 
et al., 2003; Sardanelli et al., 1997; Tabar et al., 1983). In the study by Tabar et al. (1983), only 
half of the patients who presented with ND and were diagnosed with breast cancer had an 
abnormal mammogram. In the study by Morrogh et al. (2010), the sensitivity of MMG 
among all patients with pathological ND was 18%. Conversely, MMG had a high negative 
predictive value (NPV) and specificity (94%), suggesting that MMG can be used to select 
patients with physiological ND for whom clinical observation alone may be a reasonable 
management approach. 
3. Ultrasonography (US) 
Breast US is a non-invasive diagnostic method that has proven to be useful in the evaluation 
of patients with ND (Sakorafas, 2001). However, US has limitations with respect to depicting 
causative lesions of small masses and ductal carcinomas in situ (DCIS), especially those in 
peripheral regions without ductal dilatation or those in high adipose-containing breasts 
(Berg & Gilbreath., 2000; Nakahara et al., 2003 citing Chung et al., 1995).  
The most common sonographic features are duct dilatation, particularly in cases associated 
with solid internal echoes and duct wall thickening in generally central and/or subareolar 
areas (Ballesio et al., 2008). Berg & Gilbreath (2000) reported that US identified 45 of 48 
(94%) invasive tumor foci and 7 of 16 (44%) foci of DCIS while only 9 of 64 (14%) malignant 
foci were detected by US. Rissanen et al. (2007) reported that in 52 patients with unilateral 
nipple discharge, 80% of papillomatous lesions, 58% of other benign lesions, and 20% of 
malignant lesions were sonographically positive, and among the 6 cases in which duct 
dilatation was the only  sonographic finding, 3 (50%) were malignant lesions and the other 3 
(50%) were papillomas and other benign lesions. In a study of 55 patients with bloody ND, 
Nakahara et al. (2003) reported that of all findings, only the hypoechoic masses with smooth 
margins (NPV = 90.9%) and hypoechoic masses with irregular margins (positive predictive 
value (PPV) = 85.7%) were statistically significant. 
In addition to the patient’s clinical history and cytological evaluation of the ND, performing 
a US-guided FNA is fundamental for differentiating between malignant and benign lesions 
(Ballesio et al, 2008 citing Sardanelli et al., 1997). 
4. Nipple discharge (ND) cytology 
ND cytology is a simple and noninvasive method that includes simply touching the 
nipple, obtaining a smear of the fluid, or gently scraping the surface of a lesion. Breast 
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pumping, breast massage, or nipple aspiration may be attempted if the discharge does not 
occur spontaneously during collection of the samples (Gupta et al., 2004; Krishnamurthy, 
et al., 2003). Gupta et al. (2004) have suggested that the use of routine ND cytology is 
limited by the small samples obtained and that ND cytology cannot always distinguish 
between physiological processes, fibrocystic disease, and papillomas. However, studies 
based on a large number of cases suggest that ND cytology is a reasonable method for 
diagnosing malignant and suspicious cases (Das et al., 2001; El-Daly & Gudi, 2010; Gupta 
et al., 2004; Pritt et al., 2004). Cytological examination of ND is valuable mainly for 
detecting such cancers. The efficiency of ND cytology remains controversial, as an older 
study has demonstrated low sensitivity, for detection of malignancy, ranging from 11% to 
31.2%  (Dinkel et al., 2001). However, studies that are more recent have reported higher 
sensitivity of ND cytology. For example, Pritt et al. (2004) determined a sensitivity and 
specificity of 85% and 97%, respectively. Likewise, a sensitivity of 58.3% and 63% and a 
specificity of 100% and 100% were reported by Lee (2003) and El-Daly & Gudi (2010), 
respectively. Therefore, ND cytology can be useful in the diagnosis of malignant and 
suspicious cases. 
Foam cells are the predominant cytological feature in tissues being subjected to in 
inflammatory processes, mastopathy, or fibrocystic disease (Fig. 1a). Its secretion 
occasionally contains duct epithelial cells (Fig. 1b). Apocrine metaplasia of duct epithelial 
cells is sometimes seen. In intraductal papillomas, large, cohesive clusters of normal duct 
cells may be observed (Fig. 2). 
 
 
    
        (a)             (b) 
Fig. 1. Nipple discharge cytology of benign lesions. (a) Several foam cells are observed but 
no epithelial cells are present. (b) A number of clusters composed of duct cells forming a 
papillary structure can be seen. (Histological diagnosis, duct papillomatosis) 
Clusters of apocrine cells may also be seen. In some cases, papillary structures composed of 
spherical clusters of large duct cells with atypical features such as cytoplasmic vacuoles, 
enlarged nuclei, and visible nucleoli may be present. In ductal carcinoma, the clusters 
composed of atypical cells may be loosely structured and are sometimes thick or spherical. 
They may also form papillary structures. Necrosis is commonly seen in high-grade lesions 
(Fig. 3). 
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 In this chapter, we review several methods of diagnostic evaluation including MMG, US, 
conventional ductography (DG), ND cytology, fine needle aspiration (FNA) and 
histopathology. We also demonstrate how to use the findings of contrast-enhanced magnetic 
resonance imaging (CEMRI) studies, including direct and indirect MR ductography 
(MRDG), to localize the causative lesion and to differentiate malignant lesions from benign 
ones in cases of suspicious ND.  
2. Mammography (MMG)  
While MMG is considered the standard initial imaging examination and may reveal 
microcalcifications and other signs of malignancy, it rarely provides information about the 
etiology of ND (Rissanen et al., 2007 citing Cabioglu et al., 2003; Dillon et al., 2006; Funovics 
et al., 2003; Sardanelli et al., 1997; Tabar et al., 1983). In the study by Tabar et al. (1983), only 
half of the patients who presented with ND and were diagnosed with breast cancer had an 
abnormal mammogram. In the study by Morrogh et al. (2010), the sensitivity of MMG 
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predictive value (NPV) and specificity (94%), suggesting that MMG can be used to select 
patients with physiological ND for whom clinical observation alone may be a reasonable 
management approach. 
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of patients with ND (Sakorafas, 2001). However, US has limitations with respect to depicting 
causative lesions of small masses and ductal carcinomas in situ (DCIS), especially those in 
peripheral regions without ductal dilatation or those in high adipose-containing breasts 
(Berg & Gilbreath., 2000; Nakahara et al., 2003 citing Chung et al., 1995).  
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(Ballesio et al, 2008 citing Sardanelli et al., 1997). 
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nipple, obtaining a smear of the fluid, or gently scraping the surface of a lesion. Breast 
 
Suspicious Nipple Discharge Diagnostic Evaluation 
 
201 
pumping, breast massage, or nipple aspiration may be attempted if the discharge does not 
occur spontaneously during collection of the samples (Gupta et al., 2004; Krishnamurthy, 
et al., 2003). Gupta et al. (2004) have suggested that the use of routine ND cytology is 
limited by the small samples obtained and that ND cytology cannot always distinguish 
between physiological processes, fibrocystic disease, and papillomas. However, studies 
based on a large number of cases suggest that ND cytology is a reasonable method for 
diagnosing malignant and suspicious cases (Das et al., 2001; El-Daly & Gudi, 2010; Gupta 
et al., 2004; Pritt et al., 2004). Cytological examination of ND is valuable mainly for 
detecting such cancers. The efficiency of ND cytology remains controversial, as an older 
study has demonstrated low sensitivity, for detection of malignancy, ranging from 11% to 
31.2%  (Dinkel et al., 2001). However, studies that are more recent have reported higher 
sensitivity of ND cytology. For example, Pritt et al. (2004) determined a sensitivity and 
specificity of 85% and 97%, respectively. Likewise, a sensitivity of 58.3% and 63% and a 
specificity of 100% and 100% were reported by Lee (2003) and El-Daly & Gudi (2010), 
respectively. Therefore, ND cytology can be useful in the diagnosis of malignant and 
suspicious cases. 
Foam cells are the predominant cytological feature in tissues being subjected to in 
inflammatory processes, mastopathy, or fibrocystic disease (Fig. 1a). Its secretion 
occasionally contains duct epithelial cells (Fig. 1b). Apocrine metaplasia of duct epithelial 
cells is sometimes seen. In intraductal papillomas, large, cohesive clusters of normal duct 
cells may be observed (Fig. 2). 
 
 
    
        (a)             (b) 
Fig. 1. Nipple discharge cytology of benign lesions. (a) Several foam cells are observed but 
no epithelial cells are present. (b) A number of clusters composed of duct cells forming a 
papillary structure can be seen. (Histological diagnosis, duct papillomatosis) 
Clusters of apocrine cells may also be seen. In some cases, papillary structures composed of 
spherical clusters of large duct cells with atypical features such as cytoplasmic vacuoles, 
enlarged nuclei, and visible nucleoli may be present. In ductal carcinoma, the clusters 
composed of atypical cells may be loosely structured and are sometimes thick or spherical. 
They may also form papillary structures. Necrosis is commonly seen in high-grade lesions 
(Fig. 3). 
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          (a)             (b) 
Fig. 2. ND cytology of intraductal papilloma. (a, b) Cohesive clusters composed of benign 
duct cells. The histological diagnosis was intraductal papilloma (see Fig. 8) 
 
Fig. 3. ND cytology of a malignant lesion. The smear shows clusters of atypical cells with 
enlarged, irregular-shaped nuclei, and high nuclear cytoplasmic ratios. There are necrotic 
cells in the background. 
5. Fine needle aspiration (FNA) 
FNA cytology is now a popular widely used tool for assessing breast tumors. It has been 
reported that ND cytology is as specific as concomitant FNA cytology but slightly less 
sensitive for detecting papillomas or malignant lesions (Lee, 2003). However, ND samples 
are often inadequate. Gupta et al. (2004) showed that 492 of 1948 ND smears (25%) were 
inadequate for diagnosis. Lee (2003) reported that ND cytology was non-diagnostic in 43 of 
82 cases (52%), whereas FNA cytology was non-diagnostic in only 1 of 34 cases (2.9%). 
Therefore, ND cytology has little complementary diagnostic value. FNA cytology is a 
sensitive and effective method of diagnosing breast cancer.  
6. Ductography (DG, also called Galactography)  
DG is a diagnostic modality used for identification of the secreting duct, which is 
cannulated and injected with a sterile water-soluble contrast material. This is followed by 
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MMG (Sakorafas, 2001). DG is more sensitive than ND cytology and MMG in detecting 
intraductal lesions (Rongione et al., 1996; Chung et al., 1995; Orel et al., 2000). It was found 
that when a standard evaluation was negative for a lesion, the addition of DG localized 19 of 
25 (76%) otherwise occult malignant/high-risk lesions and 80 of 88 (91%) benign lesions 
(Morrogh et al., 2010). The incidence of malignancy, despite negative clinical breast 
examination and conventional imaging, was found to be as high as 10% (Morrogh et al., 
2008). Ductographic findings suggestive of carcinoma include irregular filling defects, ductal 
irregularities (distortion, displacement, complete obstruction of contrast flow, and non-
iatrogenic contrast extravasation), and a deeper position of the lesion (Cardenosa et al., 1994; 
Ciatto et al., 1998; Tabar et al., 1983). Smooth intraductal filling defects, complete ductal 
obstruction, ductal expansion with apparent distortion, and irregularity of the ductal wall 
are more common ductographic features obsreved for solitary papillomas (Cardenosa et al., 
1994; Nakahara et al., 2003). Unfortunately, evidence for a predictive role for DG is less 
convincing because a positive study does not differentiate between malignant and benign 
causes of discharge and a negative study does not exclude the presence of an underlying 
carcinoma. The PPV and NPVs of DG have been reported to be 19% and 63%, respectively 
(sensitivity, 76%; specificity, 11%); these values are consistent with those of other studies 
and confirm that DG is not effective in distinguishing between malignant and benign causes 
of nipple discharge (Morrogh et al., 2007). The routine use of DG in cases of suspicious ND 
remains controversial (Rongione et al., 1996; Chung et al., 1995; Orel et al., 2000). 
DG is invasive and time-consuming with potential complications including intense pain, 
mastitis, lymphatic opacification, and duct perforation (Cardenosa et al., 1994; Lorenzon et 
al., 2011; Tabar et al., 1983). The rate of incomplete and/or technically inadequate 
conventional DG has been reported to be as high as 10–15% (Morrogh et al., 2008; Sickles, 
2000). All of these technical difficulties may result in the failure to detect and surgically treat 
the lesion, as most cases of pathological ND have no detectable lump and negative or 
undefined ultrasonographic findings (Schwab et al., 2008). 
7. Contrast-Enhanced Magnetic Resonance Imaging (CEMRI) 
Negative or benign findings identified by physical examination, MMG, US, cytological 
analysis of discharge, and DG are not sufficient to rule out the presence of underlying 
malignant lesion (Rongione et al., 1996; Tabar et al., 1983), but the physician must still 
decide whether to manage expectantly or proceed to major duct excision (Morrogh et al., 
2010). CEMRI is increasingly being used as a diagnostic modality for breast cancer, with 
diagnostic sensitivities of 86–100% and 40–100% for invasive and intraductal cancers, 
respectively (Orel et al., 2001; Tjalma & Verslebers, 2004 citing Esserman et al., 1999; 
Vichweg et al., 2000). 
Preliminary research on the application of CEMRI for evaluation of patients with ND 
suggests that it is useful for the localization of otherwise occult diseases, identification of 
both benign and malignant causes of ND, and noninvasiveness relative to DG. However, the 
available data are limited (Nakahara et al., 2003; Orel et al., 2000; Tjalma & Verslebers, 2004). 
Therefore, the gold standard diagnostic and therapeutic approach for patients with 
pathological ND is surgical duct excision (Morrogh et al., 2010 citing Nelson & Hoehn, 
2006). However, a frequent criticism of this blind approach is that the pathologists may not 
always identify a discrete lesion responsible for the discharge. In addition, major duct 
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cells in the background. 
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inadequate for diagnosis. Lee (2003) reported that ND cytology was non-diagnostic in 43 of 
82 cases (52%), whereas FNA cytology was non-diagnostic in only 1 of 34 cases (2.9%). 
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MMG (Sakorafas, 2001). DG is more sensitive than ND cytology and MMG in detecting 
intraductal lesions (Rongione et al., 1996; Chung et al., 1995; Orel et al., 2000). It was found 
that when a standard evaluation was negative for a lesion, the addition of DG localized 19 of 
25 (76%) otherwise occult malignant/high-risk lesions and 80 of 88 (91%) benign lesions 
(Morrogh et al., 2010). The incidence of malignancy, despite negative clinical breast 
examination and conventional imaging, was found to be as high as 10% (Morrogh et al., 
2008). Ductographic findings suggestive of carcinoma include irregular filling defects, ductal 
irregularities (distortion, displacement, complete obstruction of contrast flow, and non-
iatrogenic contrast extravasation), and a deeper position of the lesion (Cardenosa et al., 1994; 
Ciatto et al., 1998; Tabar et al., 1983). Smooth intraductal filling defects, complete ductal 
obstruction, ductal expansion with apparent distortion, and irregularity of the ductal wall 
are more common ductographic features obsreved for solitary papillomas (Cardenosa et al., 
1994; Nakahara et al., 2003). Unfortunately, evidence for a predictive role for DG is less 
convincing because a positive study does not differentiate between malignant and benign 
causes of discharge and a negative study does not exclude the presence of an underlying 
carcinoma. The PPV and NPVs of DG have been reported to be 19% and 63%, respectively 
(sensitivity, 76%; specificity, 11%); these values are consistent with those of other studies 
and confirm that DG is not effective in distinguishing between malignant and benign causes 
of nipple discharge (Morrogh et al., 2007). The routine use of DG in cases of suspicious ND 
remains controversial (Rongione et al., 1996; Chung et al., 1995; Orel et al., 2000). 
DG is invasive and time-consuming with potential complications including intense pain, 
mastitis, lymphatic opacification, and duct perforation (Cardenosa et al., 1994; Lorenzon et 
al., 2011; Tabar et al., 1983). The rate of incomplete and/or technically inadequate 
conventional DG has been reported to be as high as 10–15% (Morrogh et al., 2008; Sickles, 
2000). All of these technical difficulties may result in the failure to detect and surgically treat 
the lesion, as most cases of pathological ND have no detectable lump and negative or 
undefined ultrasonographic findings (Schwab et al., 2008). 
7. Contrast-Enhanced Magnetic Resonance Imaging (CEMRI) 
Negative or benign findings identified by physical examination, MMG, US, cytological 
analysis of discharge, and DG are not sufficient to rule out the presence of underlying 
malignant lesion (Rongione et al., 1996; Tabar et al., 1983), but the physician must still 
decide whether to manage expectantly or proceed to major duct excision (Morrogh et al., 
2010). CEMRI is increasingly being used as a diagnostic modality for breast cancer, with 
diagnostic sensitivities of 86–100% and 40–100% for invasive and intraductal cancers, 
respectively (Orel et al., 2001; Tjalma & Verslebers, 2004 citing Esserman et al., 1999; 
Vichweg et al., 2000). 
Preliminary research on the application of CEMRI for evaluation of patients with ND 
suggests that it is useful for the localization of otherwise occult diseases, identification of 
both benign and malignant causes of ND, and noninvasiveness relative to DG. However, the 
available data are limited (Nakahara et al., 2003; Orel et al., 2000; Tjalma & Verslebers, 2004). 
Therefore, the gold standard diagnostic and therapeutic approach for patients with 
pathological ND is surgical duct excision (Morrogh et al., 2010 citing Nelson & Hoehn, 
2006). However, a frequent criticism of this blind approach is that the pathologists may not 
always identify a discrete lesion responsible for the discharge. In addition, major duct 
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excision is expected to be undesirable for a woman of childbearing age. Therefore, there is a 
need to develop more effective tools for localizing the lesions responsible for ND and for 
distinguishing between malignant and benign causes of ND, the 2 most important roles of 
imaging (Morrogh et al., 2007; Yau et al., 2011). 
7.1 Localization of the disease causing the ND 
There is evidence in the literatures that CEMRI offers high diagnostic performance for  
detecting lesions in patients with suspicious ND, even when no lesions are identified by 
conventional imaging and when DG is not feasible or inconclusive (Sardanelli et al., 2008 citing 
Daniel et al., 2003; Hirose et al., 2006; Nakahara et al., 2003; Orel et al., 2000). Lorenzon et al. 
(2011) found that CEMRI could identify 5/5 cancers (sensitivity = 100%) and 13/14 high-risk 
lesions (sensitivity = 92.9%) (overall sensitivity, 94.7%; overall specificity, 78.9%). In addition, it 
was found that 3 of 5 cancers (1 invasive, 1 in situ, 1 contralateral  invasive) and 2 of 14 high-
risk lesions could be detected only by CEMRI. CEMRI was significantly more sensitive than 
either MMG or US (p < 0.0001 and p = 0. 042, respectively). Morrogh et al. (2007) reported that 
the PPV and NPV of CEMRI for detection of the disease causing the ND were 56% and 87%, 
respectively (sensitivity, 83%; specificity, 62%), and CEMRI performed after negative standard 
evaluation detected 75% of otherwise occult malignant/high risk lesions. Nakahara et al. 
(2003) reported that CEMRI identified all malignant lesions (100%) including DCIS. Kramer et 
al. (Van Goethem et al., 2009 citing Kramer et al., 2000) used CEMRI alone and in combination 
with MMG and DG to assess 48 women with pathological ND. The sensitivity and specificity 
values of DG for detection of papillomas were 94% and 79%, respectively, whereas only 1 
carcinoma was detected by MMG/DG. CEMRI had a sensitivity of 89% (8/9) for malignant 
lesions. These authors have concluded that while MMG in combination with DG remains the 
primary diagnostic tool, the addition of CEMRI can demonstrate the location and distribution 
of lesions, especially in malignant cases, and therefore recommend performing a CEMRI to 
detect underlying lesions that may have been misdiagnosed by conventional imaging 
(Lorenzon et al., 2011; Van Goethem et al., 2009).  
7.2 Differentiation of malignant and benign lesions 
Predicting whether the causative lesion is malignant or benign is important because it 
affects the physician’s choice of clinical follow-up or surgical treatment.  
Nakahara et al. (2003) reported that segmental clumped enhancement (PPV = 100%), a focal 
mass with a smooth border (NPV = 91.7%), and diffuse or regional stippled enhancement 
(NPV = 94.1%) were statistically significant features that can be used for differentiating 
between malignant and benign lesions. Ballesio et al. (2008) reported that 5 papillomatosis 
lesions appeared as patchy, homogeneously enhanced areas, that among 15 intraductal 
papillomas, some had an oval appearance with well-defined margins, while other had areas 
of homogeneous enhancement with a linear shape at the periareolar or subareolar sites, 
moreover, they reported 2 cases of atypical ductal hyperplasias with diffuse nodular 
enhancement. One micropapillary DCIS, 1 papillary carcinoma, and 1 invasive ductal 
carcinoma were visualized as 2 segmental areas of enhancement and 1 mass-like 
enhancement with poorly defined margins. Morrogh et al. (2007) reported that MRI was use 
as the first-line test in 32/52 (63%) patients in whom it was performed and yielded a breast 
imaging reporting and data system (BI-RADS) MRI (American College of Radiology, 2003) ≥ 
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4 diagnosis in 11/32 (34%) patients. Seven of 11 (64%) patients proceeded directly to major 
duct excision and demonstrated 1 invasive cancer, 2 DCIS, 2 high-risk lesions, and 2 benign 
lesions. MRI was negative in 21 patients (BI-RADS MRI score, ≤3). Among this group, 4 
patients proceeded to major duct excision, yielding 1 invasive cancer and 3 benign lesions. 
Therefore, an evaluation based using only BI-RADS MRI descriptors has a limited ability to 
distinguish between malignant and benign lesions. 
We analyzed MRI findings in patients with suspicious ND using BI-RADS MRI descriptors 
and clustered ring enhancement criteria (Tokuda et al., 2009), and compared them with 
histopathological diagnoses to assess the accuracy of differentiating between malignant and 
benign lesions. Clustered ring enhancement is characterized by clusters of minute ring 
enhancements. The clusters include enhanced foci constituting enhanced ring-like patterns, 
and heterogeneous enhancement of minute internal ring patterns (Tozaki et al., 2006) (Fig. 
4). Breast CEMRI was performed on 47 patients to identify lesions causing suspicious ND. 
The 39 lesions for which histopathological diagnoses were obtained consisted of 17 
carcinomas and 22 benign lesions. The types of carcinoma identified included DCIS (n = 10), 
invasive ductal carcinoma (IDC) with intraductal components (n = 2), and IDC (n = 5). The 
benign lesions included fibrocystic disease (n = 11), intraductal papillomas (n = 5), duct 
papillomatosis (n = 2), fibrosis (n = 3), and a fibrous nodule (n = 1). Table 1 shows the 
frequencies of the BI-RADS MRI descriptors and the presence of clustered ring enhancement 
for benign and malignant lesions. Among the non-mass-like enhancement patterns, no 
distribution modifiers such as “linear,” ”regional,” or  “multiple regions” were observed, 
and no internal enhancements such as “reticular” enhancement were detected. Only 2 
lesions showing mass enhancement were not diagnosed by histopathology.  
    
       (a)            (b) 
Fig. 4. Images of the breast of a 54-year-old woman with suspicious microcalcifications 
observed by mammography. (a) Coronal first contrast-enhanced T1-weighted MR image of the 
left breast shows regional enhancement in the upper outer quadrant (arrow). The lesion 
demonstrates heterogeneous enhancement with interior clustered minute ring enhancements 
(clustered ring enhancement). (b) A photomicrograph of the histopathological specimen shows 
a ductal carcinoma in situ with intraluminal necrosis and microcalcifications. Clustered ring 
enhancement corresponds to periductal stroma. However, intraductal cancer cell involvement 
in the enhancement cannot be ruled out. Reprinted from Tozaki et al. (2006) 
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excision is expected to be undesirable for a woman of childbearing age. Therefore, there is a 
need to develop more effective tools for localizing the lesions responsible for ND and for 
distinguishing between malignant and benign causes of ND, the 2 most important roles of 
imaging (Morrogh et al., 2007; Yau et al., 2011). 
7.1 Localization of the disease causing the ND 
There is evidence in the literatures that CEMRI offers high diagnostic performance for  
detecting lesions in patients with suspicious ND, even when no lesions are identified by 
conventional imaging and when DG is not feasible or inconclusive (Sardanelli et al., 2008 citing 
Daniel et al., 2003; Hirose et al., 2006; Nakahara et al., 2003; Orel et al., 2000). Lorenzon et al. 
(2011) found that CEMRI could identify 5/5 cancers (sensitivity = 100%) and 13/14 high-risk 
lesions (sensitivity = 92.9%) (overall sensitivity, 94.7%; overall specificity, 78.9%). In addition, it 
was found that 3 of 5 cancers (1 invasive, 1 in situ, 1 contralateral  invasive) and 2 of 14 high-
risk lesions could be detected only by CEMRI. CEMRI was significantly more sensitive than 
either MMG or US (p < 0.0001 and p = 0. 042, respectively). Morrogh et al. (2007) reported that 
the PPV and NPV of CEMRI for detection of the disease causing the ND were 56% and 87%, 
respectively (sensitivity, 83%; specificity, 62%), and CEMRI performed after negative standard 
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with MMG and DG to assess 48 women with pathological ND. The sensitivity and specificity 
values of DG for detection of papillomas were 94% and 79%, respectively, whereas only 1 
carcinoma was detected by MMG/DG. CEMRI had a sensitivity of 89% (8/9) for malignant 
lesions. These authors have concluded that while MMG in combination with DG remains the 
primary diagnostic tool, the addition of CEMRI can demonstrate the location and distribution 
of lesions, especially in malignant cases, and therefore recommend performing a CEMRI to 
detect underlying lesions that may have been misdiagnosed by conventional imaging 
(Lorenzon et al., 2011; Van Goethem et al., 2009).  
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Predicting whether the causative lesion is malignant or benign is important because it 
affects the physician’s choice of clinical follow-up or surgical treatment.  
Nakahara et al. (2003) reported that segmental clumped enhancement (PPV = 100%), a focal 
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4 diagnosis in 11/32 (34%) patients. Seven of 11 (64%) patients proceeded directly to major 
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lesions. MRI was negative in 21 patients (BI-RADS MRI score, ≤3). Among this group, 4 
patients proceeded to major duct excision, yielding 1 invasive cancer and 3 benign lesions. 
Therefore, an evaluation based using only BI-RADS MRI descriptors has a limited ability to 
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benign lesions. Clustered ring enhancement is characterized by clusters of minute ring 
enhancements. The clusters include enhanced foci constituting enhanced ring-like patterns, 
and heterogeneous enhancement of minute internal ring patterns (Tozaki et al., 2006) (Fig. 
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The 39 lesions for which histopathological diagnoses were obtained consisted of 17 
carcinomas and 22 benign lesions. The types of carcinoma identified included DCIS (n = 10), 
invasive ductal carcinoma (IDC) with intraductal components (n = 2), and IDC (n = 5). The 
benign lesions included fibrocystic disease (n = 11), intraductal papillomas (n = 5), duct 
papillomatosis (n = 2), fibrosis (n = 3), and a fibrous nodule (n = 1). Table 1 shows the 
frequencies of the BI-RADS MRI descriptors and the presence of clustered ring enhancement 
for benign and malignant lesions. Among the non-mass-like enhancement patterns, no 
distribution modifiers such as “linear,” ”regional,” or  “multiple regions” were observed, 
and no internal enhancements such as “reticular” enhancement were detected. Only 2 
lesions showing mass enhancement were not diagnosed by histopathology.  
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Fig. 4. Images of the breast of a 54-year-old woman with suspicious microcalcifications 
observed by mammography. (a) Coronal first contrast-enhanced T1-weighted MR image of the 
left breast shows regional enhancement in the upper outer quadrant (arrow). The lesion 
demonstrates heterogeneous enhancement with interior clustered minute ring enhancements 
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enhancement corresponds to periductal stroma. However, intraductal cancer cell involvement 
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Non-mass-like enhancement    
Distribution modifiers    
Ductal 10 (45) 3 (18) NS 
Focal  1 (5) 1 (6) NS 
Regional 0 (0) 0 NS 
Segmental 8 (36) 10 (59) NS 
Diffuse 3 (14) 1 (6) NS 
No enhancement 0 2 (11) NS 
Internal enhancement    
Homogeneous 2 (9) 1 (7) NS 
Heterogeneous 9 (41) 9 (57) NS 
Stippled,punctuate 11 (50) 3 (22) NS 
Clumped 0 2 (14) NS 
Reticular 0 0 NS 
Clustered ring enhancement 2 9 0.002 
Numbers shown in parentheses indicate percentages.  
Masses were not diagnosed by histopathology were excluded from this table.  
*Fisher’s exact test was used. 
NS indicates not significant. 
Table 1. Frequency of MRI parameters in cases of suspicious nipple discharge. Reprinted 
from Tokuda et al. (Tokuda et al., 2009) 
The 22 benign and the 17 malignant lesions comprised 15 non-mass-like enhancements and 
2 non-enhanced lesions, which had DCIS foci measuring 2 and 2.5 mm in diameter without 
stromal changes.  
 The most common findings of the benign lesions were stippled (50%), ductal (45%), and 
heterogeneous (41%), whereas those of the malignant lesions were segmental (59%) and 
heterogeneous (57%). Both lesions (2/2) showing clumped internal enhancement were IDCs 
with an intraductal component. Clustered ring enhancement was observed in 60% (9/15) of 
the malignant enhancing lesions but in only 9% (2/22) of the benign lesions (p = 0.002). Of 
the 11 lesions showing clustered ring enhancement, 9 were malignant and 2 were benign. 
The highest PPVs for carcinoma were associated with the clumped (100% or 2/2), clustered 
ring enhancement (82% or 9/11), and segmental (56% or 10/18) descriptors. 
The specificity of clustered ring enhancement was 90% (20/22). Among the lesions showing 
clustered ring enhancement, 8 exhibited segmental distribution and 3 ductal enhancement. 
Both the malignant lesions with clumped enhancement (100% or 2/2) also showed clustered 
ring enhancement. Although the distribution pattern alone was not useful for differentiating 
between malignant and benign lesions, the combination of segmental distribution and 
clustered ring enhancement showed a significant association with breast cancer (p = 0.004). 
Twelve patients did not undergo a surgical procedure, and no histopathological diagnoses 
were obtained. We show cases with (Fig. 5) and without (Fig. 6) clustered ring enhancement. 
Images in Figures 5 and 6 are similar to images in Tokuda et al., (2009) but were obtained 
using a MRI device with a standard breast-dedicated coil. The most common kinetic pattern 
observed in the malignant lesions was the plateau pattern (40% or 6/15), and the most 
common kinetic pattern in the benign lesions was the persistent pattern (55% or 12/22). The 
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washout pattern had the highest PPV for carcinoma, 100% (p = 0.02). The highest PPVs for 
carcinoma were associated with a clumped internal enhancement (100%), clustered ring 
enhancement (82%), and a washout pattern (100%). 
Tozaki et al. (Tozaki et al, 2006) reported that clustered ring enhancement combined with 
the BI-RADS MRI descriptors appear to be useful in differentiating between benign and 
malignant lesions. Most of the lesions causing suspicious ND were observed to have non-
mass-like enhancement. Many DCISs have been reported to have non-mass-like 
enhancement and a segmental or ductal distribution and clumped internal enhancement 
(Liberman et al., 2002; Morakkabati-Spitz et al., 2005). Tozaki et al. (2006) reported that all 
lesions showing segmental distribution were malignant. In this study, of the lesions 
showing segmental distribution, 8 were benign and 10 were malignant. In addition, 
among the lesions showing ductal distribution, 10 and 3 were benign and malignant, 
respectively, and the difference was insignificant. The PPV of segmental distribution 
alone was 44%. Morakkabati-Spitz et al. reported that segmental distribution and linear 
enhancement were the most common features of DCIS on dynamic MRI. In that study, 13 
fibrocystic disease lesions showed segmental distribution. The PPV of segmental 
distribution in our study was similar to that reported by Morakkabati-Spitz et al. (2005), 
but was markedly lower than that of Tozaki et al. (2006). This may be due to different 
biases in patient selection for MRI. We analyzed lesions causing suspicious ND, 
Morakkabati-Spitz et al. (2005) examined lesions showing a segmental distribution and 
linear enhancement, and Tozaki et al. (2006) evaluated lesions showing non-mass- like 
enhancement. Similar to the results reported by Tozaki et al. (2006), the most common 
internal enhancement patterns was a heterogeneous pattern for the malignant lesions 
(59%) and a stippled/punctuate pattern for the benign lesions (45%); this difference was 
not significant. In this study, both the clumped internal enhanced lesions (2/2) were 
found to be malignant. Although the number of cases studied was small, Liberman et al. 
(2002) reported similar results (Liberman et al., 2002). 
All lesions (4/4) showing a washout kinetic pattern were malignant. Ten benign and 6 
malignant lesions showed a plateau pattern. Kuhl et al. (Kuhl et al., 1999) pointed out that 
segmental and ductal enhancements are the imaging hallmarks of DCIS in breast MRI and 
concluded that the sensitivity of breast MRI for the detection of DCIS can be increased by 
performing additional morphological analysis of the enhancement pattern. However, in this 
study, the combination of distribution modifiers and a washout pattern was not significant. 
The presence of clustered ring enhancement was useful for differentiating between 
malignant and benign lesions (p = 0.002) and had a high PPV (82%) for breast cancer. 
Although the distribution pattern alone was not useful for differentiating between 
malignant and benign lesions, the combination of segmental distribution and clustered ring 
enhancement showed a significant association with breast cancer (p = 0.004) and a high PPV 
(88%). This indicates that clustered ring enhancement is a useful parameter in CEMRI 
analysis.  
We conclude that the most common CEMRI finding in patients with suspicious ND is non-
mass-like enhancement. The combination of segmental distribution and clustered ring 
enhancement showed the highest PPV for malignancy, and MRI can provide clinically 
useful information for distinguishing between benign and malignant causes of suspicious 
ND.  
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Distribution modifiers    
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Focal  1 (5) 1 (6) NS 
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Table 1. Frequency of MRI parameters in cases of suspicious nipple discharge. Reprinted 
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ring enhancement (82% or 9/11), and segmental (56% or 10/18) descriptors. 
The specificity of clustered ring enhancement was 90% (20/22). Among the lesions showing 
clustered ring enhancement, 8 exhibited segmental distribution and 3 ductal enhancement. 
Both the malignant lesions with clumped enhancement (100% or 2/2) also showed clustered 
ring enhancement. Although the distribution pattern alone was not useful for differentiating 
between malignant and benign lesions, the combination of segmental distribution and 
clustered ring enhancement showed a significant association with breast cancer (p = 0.004). 
Twelve patients did not undergo a surgical procedure, and no histopathological diagnoses 
were obtained. We show cases with (Fig. 5) and without (Fig. 6) clustered ring enhancement. 
Images in Figures 5 and 6 are similar to images in Tokuda et al., (2009) but were obtained 
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washout pattern had the highest PPV for carcinoma, 100% (p = 0.02). The highest PPVs for 
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mass-like enhancement. Many DCISs have been reported to have non-mass-like 
enhancement and a segmental or ductal distribution and clumped internal enhancement 
(Liberman et al., 2002; Morakkabati-Spitz et al., 2005). Tozaki et al. (2006) reported that all 
lesions showing segmental distribution were malignant. In this study, of the lesions 
showing segmental distribution, 8 were benign and 10 were malignant. In addition, 
among the lesions showing ductal distribution, 10 and 3 were benign and malignant, 
respectively, and the difference was insignificant. The PPV of segmental distribution 
alone was 44%. Morakkabati-Spitz et al. reported that segmental distribution and linear 
enhancement were the most common features of DCIS on dynamic MRI. In that study, 13 
fibrocystic disease lesions showed segmental distribution. The PPV of segmental 
distribution in our study was similar to that reported by Morakkabati-Spitz et al. (2005), 
but was markedly lower than that of Tozaki et al. (2006). This may be due to different 
biases in patient selection for MRI. We analyzed lesions causing suspicious ND, 
Morakkabati-Spitz et al. (2005) examined lesions showing a segmental distribution and 
linear enhancement, and Tozaki et al. (2006) evaluated lesions showing non-mass- like 
enhancement. Similar to the results reported by Tozaki et al. (2006), the most common 
internal enhancement patterns was a heterogeneous pattern for the malignant lesions 
(59%) and a stippled/punctuate pattern for the benign lesions (45%); this difference was 
not significant. In this study, both the clumped internal enhanced lesions (2/2) were 
found to be malignant. Although the number of cases studied was small, Liberman et al. 
(2002) reported similar results (Liberman et al., 2002). 
All lesions (4/4) showing a washout kinetic pattern were malignant. Ten benign and 6 
malignant lesions showed a plateau pattern. Kuhl et al. (Kuhl et al., 1999) pointed out that 
segmental and ductal enhancements are the imaging hallmarks of DCIS in breast MRI and 
concluded that the sensitivity of breast MRI for the detection of DCIS can be increased by 
performing additional morphological analysis of the enhancement pattern. However, in this 
study, the combination of distribution modifiers and a washout pattern was not significant. 
The presence of clustered ring enhancement was useful for differentiating between 
malignant and benign lesions (p = 0.002) and had a high PPV (82%) for breast cancer. 
Although the distribution pattern alone was not useful for differentiating between 
malignant and benign lesions, the combination of segmental distribution and clustered ring 
enhancement showed a significant association with breast cancer (p = 0.004) and a high PPV 
(88%). This indicates that clustered ring enhancement is a useful parameter in CEMRI 
analysis.  
We conclude that the most common CEMRI finding in patients with suspicious ND is non-
mass-like enhancement. The combination of segmental distribution and clustered ring 
enhancement showed the highest PPV for malignancy, and MRI can provide clinically 
useful information for distinguishing between benign and malignant causes of suspicious 
ND.  
 















Fig. 5. Images of the breasts of a 70-year-old woman who presented with bloody discharge 
from the right nipple. (a) Pre-contrast enhanced fat-suppressed T1-weighted image showing 
intraductal high intensity corresponding to bloody discharge. (b) A fast short-tau inversion-
recovery (STIR) image showing peripheral duct ectasia and intraductal fluid accumulation. 
(c) Dynamic contrast-enhanced early phase image showing clumped enhancement with 
segmental distribution. (d) Post-contrast-enhanced sagittal image showing heterogeneous 
tramline-like and clustered ring enhancement. The histopathological diagnosis was invasive 
ductal carcinoma with predominant intraductal components. (e) Mapping of the lesion 
(green line area, ductal carcinoma in situ; red line area, invasive ductal carcinoma). 
 
Suspicious Nipple Discharge Diagnostic Evaluation 
 
209 
   
       (a)             (b) 
   
        (c)              (d) 
Fig. 6. Images of the breasts of a 49-year-old woman who presented with bloody discharge 
from the left nipple. (a) Pre-contrast fat-suppressed T1-weighted MR image showing no 
intraductal abnormal intensity. (b) STIR MR image showing duct ectasia and intraductal 
fluid accumulation. (c) A contrast-enhanced T1-weighted MR image showing homogeneous 
ductal enhancement. (d) Mapping of the lesion (green line area, intraductal papilloma.). 
MRI findings may improve patient selection and treatment planning. However, MRI should 
not be used as an alternative for a breast biopsy to determine whether a given lesion is 
malignant, and it should not replace major duct excision as the gold standard for ruling out 
malignancy in patients with ND and a negative evaluation (Morrogh et al., 2007; Bluemke et 
al., 2004).  
7.3 MR ductography (MRDG, also called MR galactography) 
Several approaches to MRI of the secreting breast have been suggested, including direct 
(Schwab, 2008; Wenkel, 2011) and indirect MRDG and fusion MR imaging of contrast-
enhanced and indirect ductography (Hirose et al., 2007).  
7.3.1 Direct MRDG (direct MR galactography) 
Direct MRDG is performed by filling the discharging duct with gadolinium-diethylene-
triamine-pentaacetic acid (Gd-DTPA) diluted in saline, using a DG needle as for the 
conventional DG procedure, and obtaining 3D MRI  sequences (Schwab et al., 2008). Schwab 
et al. (2008) reported findings in 23 patients with pathological discharge. Direct MRDG 
showed pathological findings in 82% of all findings, while indirect MRDG produced 
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Direct MRDG is performed by filling the discharging duct with gadolinium-diethylene-
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et al. (2008) reported findings in 23 patients with pathological discharge. Direct MRDG 
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pathological findings in 33% of all findings with significant (p < 0.01) differences in the 
detection of ductal disease between indirect MRDG and all direct MRDG sequences. Wenkel 
et al. (2011) reported observations of 30 women who underwent conventional DG and direct 
MRDG. There was no significant difference in sector localization between conventional DG 
and direct MRDG. It was concluded that because direct MRDG is more effective in 
identifying the disease than indirect MRDG, conventional DG, direct MRDG may have the 
potential to become an alternative to conventional DG. 
7.3.2 Indirect MRDG (indirect MR galactography)  
Intraductal fluid accumulation and duct ectasia can be detected in 40–73% with patients 
with pathological ND (Daniel et al., 2003; Orel et al., 2000; Schwab et al., 2008), just as MR 
hydrography can noninvasively depict fluid-fluid tubular structures such as the bile and 
pancreatic ducts, the ureters, and the semicircular canals (Jara et al., 1998). This method, 
known as indirect MRDG, can demonstrate the peripheral part of the duct of the point 
obstructed by an intraductal lesion (Hirose et al., 2006). Advantages to this technique are 
that it is noninvasive; uses no radiation or contrast material; and causes none of the potential 
complications associated with cannulation of the duct and injection of contrast medium, 
including duct perforation, extravasation, and mastitis (Hirose et al., 2007). 
The EUSOMA working group suggests that in countries where DG is considered a routine 
test for suspicious ND, non-contrast T2-weighted and CEMRI can be considered if DG fails 
for technical reasons or if the patient refuses the procedure. 
Indirect MRDG does not identify ducts that are not dilated, although conventional DG may 
show an undilated duct after cannulation. In some cases, the fluid within the duct has a high 
signal intensity on T1-weighted images and a low signal intensity on heavily T2-weighted 
images. This suggests either hemorrhage or the presence of proteins (Hirose et al., 2007). 
The single 3D fused image obtained by combining data from indirect MRDG and CEMRI  
not only demonstrates the existence of an intraductal abnormality but also reveals the shape, 
size, and extent of the lesion, and can clarify the relationship between the duct and the 
intraductal lesion (Hirose et al., 2006) (Fig.7). 
8. Histopathological diagnosis  
Most NDs are caused by benign lesions such as papillomas and duct ectasia. 
Microdochectomy or major duct excision is often performed on patients with ND to exclude 
the possibility of underlying ductal carcinoma. Morrogh et al. (2010) analyzed the 
histopathological findings in biopsies or surgical specimens obtained from patients with 
pathological ND and identified cancer in 65 of 287 (22%) cases. Among the 287 cases, 121 
(42%) were papillomas (Morrogh et al., 2010). Another report identified cancer in 9 of 211 
cases (4.3%). Among the 211 cases, 81 (38%) were papillomas (Dillon et al., 2006). A 
papilloma (Fig. 8a, b) consists of a proliferation of ductal epithelium supported by a 
fibrovascular stroma. The epithelium of the stromal supporting layer is composed of 
epithelial and myoepithelial cells. Many papillomas have a complex structure as a result of  
stromal overgrowth (Fig. 8c), epithelial hyperplasia, or a combination of both of these 
processes. Foci of apocrine metaplasia are often observed in papillomas (Fig. 8d). Ductal 
carcinoma (Fig. 9) shows various histopathological patterns. 
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Fig. 7. Images of an intraductal papilloma in a 75-year-old woman. (a) The conventional 
ductogram and (b) indirect MR ductogram (MIP image) both show a dilated duct with a 
filling or signal defect (arrow), which represents an intraductal papilloma. (c) The MR 
mammogram (MIP image) shows a well-circumscribed enhanced lesion (arrow) that 
indicates the presence of a tiny papilloma. (d) The 3D fusion image shows the dilated duct 
(green) and the intraductal lesion (red). Reprinted from Hirose et al. (2006). 
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pathological findings in 33% of all findings with significant (p < 0.01) differences in the 
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Fig. 8. Intraductal papilloma. (a) Low magnification. (b) Part of the papilloma in a cystically 
dilated duct. (c) Well-developed stromal sclerosis is present. (d) Apocrine metaplasia is 
observed. 
    
           (a)               (b) 
Fig. 9. Ductal carcinoma. (a) Ductal carcinoma in situ. Cystically dilated ducts contain 
hemorrhage. (b) Invasive ductal carcinoma. 
9. Conclusion 
MRI provides clinically useful information in patients with suspicious ND and negative 
standard evaluation. A larger prospective study to determine the use of MRI in the detection 
and differentiation of benign and malignant lesions causing ND is warranted. 
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1. Introduction 
Radiotherapy is widely used in breast cancer treatment, particularly in patients undergoing 
breast conserving surgery, principally in order to reduce risk of local recurrence (Liljegren et 
al. 1999; Fisher et al. 2002). Although radiation therapy has been observed in a major meta-
analysis to confer a net survival benefit (Clarke et al. 2005), it is not without side-effects. It 
has been observed to confer increased risks of cardiovascular events and lung tumours 
(Clarke et al. 2005; Darby et al. 2005). The fact that radiation therapy confers both benefits 
and harms raises issues pertinent to all treatments, i.e., the importance of selecting patient 
populations for which the balance of benefits to harms is optimised, and of excluding those 
patients who will not benefit from the treatment, or at least not sufficiently to outweigh the 
risk of adverse effects. Given the current lack of confidence that the prognostic indicators for 
such selection exist, conservative therapy includes post-surgical radiotherapy as a standard 
of care. 
It has been reported that patients with invasive breast tumours less than 15 mm in size 
have mammographic tumour features that are good indicators of prognosis, and in 
particular, good long term survival has been observed in stellate lesions of this size 
without accompanying calcifications or with only non-specific calcifications (Smith et al. 
2004; Tabar et al. 2000). The large majority of these patients did not receive adjuvant 
therapy other than radiotherapy, and since long-term survival was very high, the 
potential for modern adjuvant therapies to further improve upon the survival of these 
cases is very small. However, the extent to which these patients benefited from 
radiotherapy, in terms of reduction of risk of local recurrence, is not known. In this paper, 
we review the treatment and tumour features of 425 stellate invasive breast cancers of 
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maximum diameter less than 15 mm, with a view to developing an index of risk of local 
recurrence and possibly of identifying patient populations suitable and unsuitable for 
radiotherapy. The research was approved by the Ethics Committee of Falun Central 
Hospital. 
2. Patient data obtained for analysis  
Mammograms were retrieved of all tumours of pathological size less than 15 mm, 
diagnosed in women aged 40-69 between 1977 and 1998 in Falun Central Hospital, Sweden. 
Of these, 425 were identified to have stellate appearance and either no calcifications or non-
specific calcifications on the mammogram. Patient charts were retrieved and additional 
pathological information was obtained on exact tumor size in mm, node status, tumor grade 
and histological type. Treatment details with respect to surgery, adjuvant radiotherapy, 
chemotherapy and hormonal therapy were also retrieved. In addition, we recorded age, date 
of diagnosis, mode of detection (screening or symptomatic) and follow-up details including 
dates of local recurrence, death from breast cancer and death from other causes.  
There was an average follow-up of 10.4 years to recurrence, death or last known date alive 
and disease-free, and a maximum follow-up of 27.9 years. The most recent date of follow-up 
was 20th March 2006. Local recurrence was defined as the occurrence of a histologically 
confirmed in situ or invasive carcinoma in the ipsilateral breast after treatment of the first 
breast cancer was completed.  
3. Radiotherapy treatment regimens 
For women who had breast conserving surgery for an invasive breast cancer, radiotherapy 
was regarded as standard treatment and computer dose-planned photon beam (6 and/or 15 
MV) treatment was used. Care was taken not to treat the ipsilateral lung and, in the case of 
left-sided breast cancers, the heart. The whole breast parenchyma was defined as the target 
and 2 Gray per fraction times 25 was delivered over 5 weeks. If the patient was younger 
than age 45 yrs or if extensive DCIS (>25% of tumor) was present, additional photon-boost 
was used against the tumor bed. The boost-target was treated with 2 Gy per fraction to a 
total of 10 - 16 Gray.  If one or more lymph nodes were engaged with cancer, separate fields 
were directed to the ipsilateral axilla and supraclavicular fossa, 2 Gray per fraction x 25 was 
used. Treatment of the intramammary lymph nodes was considered if 4 or more of the 
axillary nodes were metastasized. 
Computer dose-planned radiotherapy was used also for some patients treated with a 
mastectomy. The thoracic wall was treated with opposed tangential photon fields if the 
tumor was > 30 mm or multifocal or N1. Regional lymph nodes were treated according the 
rules described above. Boost treatment was given only in the rare instances when surgical 
radicality could not be achieved. 
4. Multifactor score of risk of recurrence 
Data were analysed by stepwise Cox proportional hazards regression to build up a 
multifactor score of risk of recurrence. Analyses were adjusted for age and epoch of 
diagnosis, as radiotherapy practices depended on these factors. After exclusion of those 
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factors that were not statistically significant when adjusted for other variables, we used the 
final Cox regression model to estimate the absolute reductions in 15-year risk of recurrence 
(only 22% of subjects had follow-up in excess of 15 years). 
5. Recurrence rates in patients with small stellate breast cancers 
Survival in this group was generally excellent. Figure 1 shows survival by size group (1-9 
mm and 10-14 mm) and radiotherapy. In all four groups, long-term survival was 90% or 




























Fig. 1. Breast cancer specific survival of 425 1-14 mm stellate invasive breast cancers by size 
group and radiotherapy. 
Table 1 shows the study subjects and recurrence rates by tumour, host, diagnostic and 
treatment features. There were 70 local recurrences in 425 patients. Overall, the average rate 
of recurrence was 1.6% per annum. Notably high recurrence rates were observed in grade 3 
tumours and lobular carcinoma cases. Because 51% of the cases were diagnosed before 1990, 
the proportions of subjects treated with breast conserving surgery and with hormone 
therapy were considerably smaller than would be the case in tumours diagnosed at the 
present time.  
 
Imaging of the Breast – Technical Aspects and Clinical Implication 
 
218 
maximum diameter less than 15 mm, with a view to developing an index of risk of local 
recurrence and possibly of identifying patient populations suitable and unsuitable for 
radiotherapy. The research was approved by the Ethics Committee of Falun Central 
Hospital. 
2. Patient data obtained for analysis  
Mammograms were retrieved of all tumours of pathological size less than 15 mm, 
diagnosed in women aged 40-69 between 1977 and 1998 in Falun Central Hospital, Sweden. 
Of these, 425 were identified to have stellate appearance and either no calcifications or non-
specific calcifications on the mammogram. Patient charts were retrieved and additional 
pathological information was obtained on exact tumor size in mm, node status, tumor grade 
and histological type. Treatment details with respect to surgery, adjuvant radiotherapy, 
chemotherapy and hormonal therapy were also retrieved. In addition, we recorded age, date 
of diagnosis, mode of detection (screening or symptomatic) and follow-up details including 
dates of local recurrence, death from breast cancer and death from other causes.  
There was an average follow-up of 10.4 years to recurrence, death or last known date alive 
and disease-free, and a maximum follow-up of 27.9 years. The most recent date of follow-up 
was 20th March 2006. Local recurrence was defined as the occurrence of a histologically 
confirmed in situ or invasive carcinoma in the ipsilateral breast after treatment of the first 
breast cancer was completed.  
3. Radiotherapy treatment regimens 
For women who had breast conserving surgery for an invasive breast cancer, radiotherapy 
was regarded as standard treatment and computer dose-planned photon beam (6 and/or 15 
MV) treatment was used. Care was taken not to treat the ipsilateral lung and, in the case of 
left-sided breast cancers, the heart. The whole breast parenchyma was defined as the target 
and 2 Gray per fraction times 25 was delivered over 5 weeks. If the patient was younger 
than age 45 yrs or if extensive DCIS (>25% of tumor) was present, additional photon-boost 
was used against the tumor bed. The boost-target was treated with 2 Gy per fraction to a 
total of 10 - 16 Gray.  If one or more lymph nodes were engaged with cancer, separate fields 
were directed to the ipsilateral axilla and supraclavicular fossa, 2 Gray per fraction x 25 was 
used. Treatment of the intramammary lymph nodes was considered if 4 or more of the 
axillary nodes were metastasized. 
Computer dose-planned radiotherapy was used also for some patients treated with a 
mastectomy. The thoracic wall was treated with opposed tangential photon fields if the 
tumor was > 30 mm or multifocal or N1. Regional lymph nodes were treated according the 
rules described above. Boost treatment was given only in the rare instances when surgical 
radicality could not be achieved. 
4. Multifactor score of risk of recurrence 
Data were analysed by stepwise Cox proportional hazards regression to build up a 
multifactor score of risk of recurrence. Analyses were adjusted for age and epoch of 
diagnosis, as radiotherapy practices depended on these factors. After exclusion of those 
 
Radiotherapy After Surgery for Small Breast Cancers of Stellate Appearance 
 
219 
factors that were not statistically significant when adjusted for other variables, we used the 
final Cox regression model to estimate the absolute reductions in 15-year risk of recurrence 
(only 22% of subjects had follow-up in excess of 15 years). 
5. Recurrence rates in patients with small stellate breast cancers 
Survival in this group was generally excellent. Figure 1 shows survival by size group (1-9 
mm and 10-14 mm) and radiotherapy. In all four groups, long-term survival was 90% or 




























Fig. 1. Breast cancer specific survival of 425 1-14 mm stellate invasive breast cancers by size 
group and radiotherapy. 
Table 1 shows the study subjects and recurrence rates by tumour, host, diagnostic and 
treatment features. There were 70 local recurrences in 425 patients. Overall, the average rate 
of recurrence was 1.6% per annum. Notably high recurrence rates were observed in grade 3 
tumours and lobular carcinoma cases. Because 51% of the cases were diagnosed before 1990, 
the proportions of subjects treated with breast conserving surgery and with hormone 
therapy were considerably smaller than would be the case in tumours diagnosed at the 
present time.  
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1977-84 117 (28) 20 1.4 
1985-89 99 (23) 18 1.5 
1990-94 99 (23) 19 2.0 
1995-98 110 (26) 3 1.7 
Age group <55 142 (33) 26 1.5 
55+ 283 (67) 44 1.6 
Tumour size 
(mm) 
1-9 156 (37) 25 1.6 
10-14 269 (63) 45 1.6 
Node status Negative 341 (80) 55 1.5 
Positive 45 (11) 10 2.0 
Not examined 39 (9) 5 1.7 
Grade 1 204 (50) 24 1.1 
2 173 (42) 31 1.8 
3 34 (8) 10 2.9 
Unknown 14 5 4.1 
Surgery Mastectomy 136 (32) 21 1.3 
BCS* 289 (68) 49 1.7 
Radiotherapy No 168 (40) 31 1.7 
Yes 254 (60) 38 1.5 
Unknown 3 1 3.3 
Chemotherapy No 411 (97) 67 1.6 
Yes 12 (3) 3 2.9 
Unknown 2 0 0.0 
Hormone therapy No 391 (92) 64 1.5 
Yes 32 (8) 6 2.4 
Unknown 2 0 0.0 
Histological type Ductal 286 (67) 47 1.6 
Lobular 52 (12) 14 2.8 
Tubular 80 (19) 7 0.8 
Other 7 (2) 2 2.9 
Detection mode Symptomatic 102 (24) 22 2.0 
Screening 323 (76) 48 1.4 
* BCS=breast conserving surgery 
Table 1. Host, tumour and treatment characteristics, with the corresponding rates of local 
recurrence. 
Table 2 shows the final model from the stepwise Cox regression for prediction of recurrence. 
Age and epoch of diagnosis were included regardless of significance. A highly significant 
increase in risk of recurrence was noted with grade (HR=1.93, 95% CI 1.31-2.85, p=0.001, trend 
test). Although the main effect of radiotherapy was not significant, it had a significant 
interaction with age (p=0.03), associated with lower rates of recurrence in patients aged 55 and 
over (HR=0.26, 95% CI 0.07-0.88), but not in patients aged less than 55. It also had a borderline 
significant interaction with histological type (p=0.07) with a high rate of recurrence in lobular 
carcinoma cases treated with radiotherapy (HR=3.58, 95%CI 0.90-14.13). The effects of BCS 
(p=0.01) and histological type (p=0.04) were significant before adjustment for these 
interactions, so these factors were retained in the model. No other variables had significant 
effects on risk of recurrence after adjustment for the factors in Table 2. 
 
Radiotherapy After Surgery for Small Breast Cancers of Stellate Appearance 
 
221 
Factor Category Cox regression RR* 95% CI 
Age group <55 1.00 - 
55+ 2.53 0.93-6.87 
Epoch of 
diagnosis 
1977-84 1.00 - 
1985-89 1.19 0.55-2.53 
1990-94 2.15 0.95-4.82 
1995-98 1.42 0.55-3.04 
Surgery Mastectomy 1.00 - 
BCS 1.81 0.93-3.51 
Histology Ductal, other 1.00 - 
Lobular 0.92 0.31-2.76 
Grade Trend 1.93 1.31-2.85 
Radiotherapy No 1.00 - 
Yes 1.21 0.40-3.62 
Interaction Lobular AND radiotherapy 3.58 0.90-14.13 
Interaction Age 55+ AND radiotherapy 0.26 0.07-0.88 
* RR=rate ratio 
Table 2. Relative hazards and 95% confidence intervals from the final Cox regression model 
after stepwise regression. 
Table 3 shows the results from the final Cox regression model, in terms of estimated annual 
rates of recurrence in the absence of radiotherapy and absolute reductions in cumulative 15-
year recurrence associated with radiotherapy. Overall, absolute effects were small. For 
example, for grade 1, non-lobular tumours, in women aged 55 or older, treated with 
mastectomy, the absolute reduction in risk of local recurrence associated with radiotherapy 
was 1.87%. Substantial reductions in recurrence rates were observed only for cases aged 55 
or more at diagnosis, of grade 2 or 3 and of non-lobular histological type. For some 
combinations of factors, notably lobular carcinoma cases younger than age 55, the 
reductions were negative, i.e. showing increases in recurrence in those treated with 
radiotherapy. For lobular carcinoma cases age 55 or over, and for non-lobular cases younger 
than age 55, no substantial benefit of radiotherapy was observed. 
6. Expert commentary 
This study pertains to a very special subgroup of good prognosis tumours, i.e. stellate 
lesions less than 15 mm in size without calcifications. Within this group, our results suggest 
that radiotherapy was substantially beneficial only in terms of preventing local recurrence in 
women aged 55 and older diagnosed with non-lobular carcinoma grade 2 or 3, a subgroup 
constituting 31% of the subjects (131 out of 425). Of the remaining 294 cases, 183 (63%) 
received radiotherapy, and based on these results not only did not substantially benefit from 
it, but may indeed have had their risk of recurrence increased. It might be argued that in 
modern treatment practice, very few of the mastectomy cases would receive radiotherapy. 
Where margins are close, the NCCN recommends that radiotherapy should be considered 
(NCCN 2009).  However, also in modern therapeutic practice, a large proportion of these 
cases, being smaller than 15 mm, would receive wide local excision. 
Radiotherapy is primarily aimed at reducing the risk of local recurrence (Liljegren 2002). It 
has been suggested that radiotherapy might be dispensed with for low-risk patients (e.g.  
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Radiotherapy is primarily aimed at reducing the risk of local recurrence (Liljegren 2002). It 
has been suggested that radiotherapy might be dispensed with for low-risk patients (e.g.  
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Surgery Age Lobular 
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Mastectomy <55 No 1 0.5 -0.0007 
 2 0.9 -0.0026 
 3 1.7 -0.0115 
Yes 1 0.4 -0.0114 
 2 0.9 -0.0360 
 3 1.7 -0.0748 
55+ No 1 1.2 0.0187 
 2 2.3 0.0570 
 3 4.5 0.1470 
Yes 1 1.1 -0.0030 
 2 2.2 -0.0084 




<55 No 1 0.9 -0.0036 
 2 1.7 -0.0088 
 3 3.2 -0.0228 
Yes 1 0.8 -0.0319 
 2 1.6 -0.0882 
 3 3.0 -0.1800 
55+ No 1 2.2 0.0504 
 2 4.2 0.1363 
 3 8.3 0.2769 
Yes 1 2.0 -0.0078 
 2 3.9 -0.0220 
 3 7.6 -0.0340 
Table 3. Estimated recurrence rates in the absence of radiotherapy and absolute reduction in 
15-year risk of recurrence by surgery, age, histological type and grade of tumours, from the 
final Cox regression model. 
older patients with lower stage non-lobular tumours) (Liljegren 2002; Liljegren et al. 1997).  
One study has found risk of recurrence to be particularly low in those with non-dense breast 
tissue (Cil et al. 2009). The results here suggest that a significant proportion of patients with 
small stellate lesions can be considered at low risk, and that some higher risk patients, such 
as lobular carcinoma cases, may have high local recurrence rates despite radiotherapy. 
These results are observational, and need to be validated.  
Another observational study has found, contrary to our results, that radiotherapy is associated 
with substantially reduced risk of local recurrence in lobular carcinoma (Diepenmaat et al. 
2009). There was, however, a comparatively shorter follow up time (median of 7.2 years). 
Issues such as this may be resolved by delineating the tumour populations in radiotherapy 
trials which have already been conducted, or by carrying out new prospective trials.  
The point has already been made that small stellate lesions are a good candidate for less 
aggressive therapy (Smith et al. 2004; Alexander, Yankaskas, and Biesemier 2006). The 
potential to save almost 70% of patients in this group from the hazards of radiation therapy 
is a goal worth pursuing. 
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7. Five year view 
The results of this observational study suggest that contrary to standard practice, post-
operative radiotherapy may not be the ideal treatment for all breast cancers treated with 
breast conserving surgery, particularly those with good prognosis. This is not to deny the 
results of the randomised trials and meta-analyses. There is clear evidence from these that 
radiotherapy reduces local recurrence and improves survival. However, this does not 
necessarily imply that it is needed in all cases. There is potential for utilising patient and 
tumour information to assign treatment based on that which is appropriate for the 
subgroup. This tailored therapeutic approach uses simply obtained specifics, e.g patient age, 
radiological appearance and tumour histology/grade. It would enable a more accurate risk-
benefit analysis to be calculated before prescription of therapies with adverse side-effects 
such as radiotherapy. It is therefore attractive in comparison with universal provision of 
radiotherapy to all patients. Before such policies can be implemented, it is essential that we 
are certain of the risks:benefit ratio for each patient subgroup and therefore these findings 
must be validated. This approach of investigating the level of benefit to different patient 
populations may be useful for other cancer therapies with adverse side-effects, with the 
objective of identifying other areas for improvement as medical oncology progresses to an 
era of individually tailored treatments. 
8. Conclusion 
Radiotherapy is widely used to reduce the risk of local recurrence of breast cancer, 
particularly after breast conserving surgery. However, radiotherapy to the breast has 
adverse long-term side effects (risk of heart disease, lung cancer, angiosarcoma, 
deformation), and therefore it would be useful to identify subsets of patients for whom this 
treatment is unnecessary. Patients with stellate tumours of 1-14mm have a good prognosis 
and a high proportion of them might benefit from omitting radiotherapy. A Cox regression 
was applied to follow up data from 425 such patients and a comparison of local recurrence 
rates made for different patient groups/tumour stages receiving or not receiving 
radiotherapy post surgery. These observations suggest that the only group of patients 
within the 1-14 mm stellate lesions to benefit from radiotherapy are those aged 55 or more, 
with high grade (2 or 3) disease and non-lobular histology. Radiotherapy may not be 
beneficial to certain groups with higher risk of recurrence (e.g. younger women or lobular 
carcinoma) and some groups with low risk of recurrence (e.g. low grade tumours). Further 
validation using subgroup analyses of trials already performed would be useful. 
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